term,brd & ggp & panc,brd & ggp & kras-mapk,panc & ggp & kras-mapk,brd & ggp & kras-mapk & panc,panc & ggp & kras-mapk set,brd & ggp set,GGP & Panc connection,BRD & GGP connection,,,,,,,,,,,,,,,,,,,,,,,,,
p16,0,0,138,0,"{12727809, 25240578, 29660164, 20485640, 25724428, 36448271, 15958547, 28232723, 12718618, 11490843, 33406492, 26527777, 15940643, 34328099, 11382316, 10734643, 11115575, 21196348, 28190274, 25152585, 27256393, 12483152, 12063826, 24604757, 26899542, 21611096, 22722139, 21242978, 15578211, 22208613, 17198183, 25726061, 23555182, 15957615, 25911935, 11561601, 12021893, 12021894, 22049925, 10660490, 9443984, 24212630, 16251039, 10436775, 22116519, 30226601, 11102889, 37191859, 10781373, 34629822, 12520639, 20418756, 27233476, 10436811, 15367885, 16497872, 19443408, 25453266, 26884312, 26118878, 22113502, 32405728, 34001634, 22112488, 21235432, 10436842, 12094699, 10415855, 12802288, 12692724, 26646266, 11520255, 16146690, 23340292, 19351817, 22052106, 24858378, 18691340, 16585505, 19896100, 32891173, 35941161, 9841966, 18028855, 31417657, 28145465, 24474939, 16818496, 21279552, 23049538, 33347393, 11950919, 24445769, 25687883, 24976721, 14743890, 17659731, 27454293, 9807701, 21836633, 17546589, 22226782, 26725216, 21492076, 21075310, 32344944, 27865459, 31588223, 9792901, 8950667, 16940943, 12946833, 21734801, 18266003, 26408346, 9641882, 10950061, 29103024, 17804724, 25029561, 12120000, 27158978, 26753987, 17031113, 18541514, 17349581, 23376846, 16549325, 17667542, 21535200, 25360865, 23470568, 23774697, 17023981, 15052782, 21886451, 9219065, 23316479}","{36908321, 31727874, 25773539, 24185123, 34893510, 29600711, 11331592, 29755274, 26802028, 27102007, 34160250}", ,,rapamycin,,,,,,,pi3k,ctd,,,,,,,,,,,,,,,,
cancer development,0,1,102,0,"{21856775, 33051146, 25724428, 31548432, 32304665, 23980075, 36077614, 12094008, 21852217, 36379206, 12622410, 18349132, 9001550, 34320467, 27364947, 16489047, 22722139, 11526239, 27732578, 28886117, 31877753, 25797243, 20807812, 28755079, 29670543, 24799381, 24212630, 33946266, 26404002, 32900774, 29101736, 25623216, 25261239, 28742845, 22784710, 22797009, 17706193, 28374746, 26516699, 35189981, 29156578, 26178787, 24902898, 25127677, 19917056, 15202051, 25250570, 32368394, 28025100, 36715788, 15316751, 23761168, 29670173, 36617502, 21199651, 30100261, 25939753, 23712558, 19292977, 28971839, 21279552, 33127746, 29802314, 36660044, 28272465, 25100121, 32499547, 26716510, 19609950, 33716066, 25322341, 31988090, 19951995, 32582528, 31057295, 28892048, 21734801, 18266003, 22751123, 8893335, 34356634, 26617245, 11986336, 36139432, 21819318, 33344439, 34859959, 22565310, 22860230, 33670598, 28367822, 30213082, 23470560, 17911264, 24947179, 25604078, 22586351, 27889647, 26544625, 24395249, 16979953, 32017404}","{33757572, 28359301, 25512710, 34160902, 34548613, 30539410, 30833300, 31105558, 36544023, 30733722, 35530522, 35065514, 33712563, 34750516, 31680319, 30542529, 33161793, 32559427, 22334664, 35096137, 35969736, 28481868, 29725006, 27746255, 36674511, 34791636, 30715616, 37223910, 28002667, 30589164, 29777912, 26731131}", ,,#N/A,,,,,,,pi3k,lovastatin,HY-L025-74,G03,HY-N0504,Lovastatin,Mevinolin,75330-75-5,404.54,Autophagy; Ferroptosis; HMG-CoA Reductase (HMGCR),Apoptosis; Autophagy; Metabolic Enzyme/Protease,Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.,C24H36O5,DMSO : ≥ 100 mg/mL (247.19 mM),10mM,Cardiovascular Disease; Cancer,Launched,O=C([C@@H](C)CC)O[C@@H]1[C@@]([C@H]2CC[C@@H](OC3=O)C[C@H](C3)O)([H])C(C=C[C@@H]2C)=C[C@H](C)C1
trp53,0,2,88,0,"{23076356, 19880966, 25724428, 18374157, 21056012, 22157328, 36451859, 25719829, 32341020, 20018721, 26438692, 34009137, 26582596, 36379206, 25888329, 34484811, 31011408, 24953430, 31233118, 32368735, 26004068, 32360551, 36741230, 33073264, 32694385, 21289082, 27506299, 32580737, 29364867, 23689354, 31534224, 25003666, 17611415, 23963802, 26359451, 29249692, 30185628, 32233134, 33501895, 24803537, 27003603, 22158044, 28162272, 15894267, 24075515, 25127677, 29490942, 32909573, 27659014, 34001163, 33060108, 24607504, 30728464, 24278292, 20959520, 21199651, 27609895, 26946344, 32434991, 37169967, 28415794, 35428659, 23333712, 29363536, 24875860, 25875797, 25875801, 23989613, 21665147, 31780749, 26077591, 33509790, 30386596, 35247012, 27624879, 36351408, 16397237, 29903803, 27376576, 27248578, 36848578, 29604293, 27061193, 20534740, 26704357, 33483239, 20303350, 30975481}","{33705152, 33512458, 16204849, 34987057, 29880921, 33158843}", ,,#N/A,,,,,,,pi3k,fenofibrate,HY-L025-57,G03,HY-17356,Fenofibrate,,49562-28-9,360.83,Autophagy; Cytochrome P450; PPAR,Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.",C20H21ClO4,DMSO : 250 mg/mL (692.85 mM; Need ultrasonic),10mM,Cardiovascular Disease; Cancer,Launched,CC(C)(OC1=CC=C(C(C2=CC=C(Cl)C=C2)=O)C=C1)C(OC(C)C)=O
tumor development,0,1,72,0,"{30142336, 21673986, 31262852, 26477318, 27659014, 27308552, 29808009, 22752926, 27641742, 29970191, 35082384, 36741265, 23761168, 31548432, 28581520, 36912021, 8194712, 19208345, 29249692, 18832796, 33467038, 30626590, 16822304, 34805152, 28837246, 28891811, 30386596, 35247012, 21704226, 32200350, 36139432, 26416424, 32434991, 29596465, 27461042, 28415794, 31072439, 12082617, 34529467, 26137023, 34922945, 36453576, 26880586, 18541514, 31266893, 12483152, 24720336, 30372817, 27215184, 24850902, 16489047, 31076568, 30213082, 26118878, 17911264, 3009377, 11159909, 21589862, 24878567, 23162473, 25341034, 19631339, 20725998, 35261808, 24395249, 30296435, 23622131, 33997944, 22190076, 25127677, 31760766, 22900095}","{27536004, 31105558, 28714904, 30459933, 24632608, 29077030, 32157097, 33144118, 30610113, 30029633, 31901895, 30643017, 31780938, 30015945, 32741705, 27158366, 35049055, 24065765, 26623725, 29246957, 37075063, 35593209, 28484091, 26456956}", ,,#N/A,,,,,,,pi3k,umbralisib,HY-L025-24,G09,HY-12279C,Umbralisib (hydrochloride),TGR-1202 hydrochloride; RP5264 hydrochloride,1532533-78-0,608.01,Casein Kinase; PI3K,Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"Umbralisib (TGR-1202) hydrochloride is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib hydrochloride exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib hydrochloride can be used for haematological malignancies reseach[1][2][3][4].",C31H25ClF3N5O3,DMSO : ≥ 150 mg/mL (246.71 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,O=C1C(C2=CC=CC(F)=C2)=C([C@@H](N3N=C(C4=CC=C(OC(C)C)C(F)=C4)C5=C(N)N=CN=C53)C)OC6=CC=C(F)C=C16.[H]Cl
oncogenesis,0,2,51,0,"{9918209, 29364867, 25250570, 28025100, 25748236, 31548432, 23213974, 29748382, 12647072, 27539232, 25133484, 34805167, 27068336, 24240689, 21734707, 37210549, 35965494, 26790710, 31874105, 22790202, 30083262, 22056382, 31816384, 25216706, 22762308, 34347973, 30558665, 26929740, 36709325, 24694735, 24195024, 18089810, 20801877, 26590425, 26497117, 22462691, 21492076, 35538031, 15300592, 31227505, 11323507, 34903667, 32012917, 30514931, 23422836, 8759672, 20358644, 36882420, 8927612, 26052093, 29490942}","{30876800, 34201346, 30232453, 35836809, 28263307, 35105803, 24421395, 24952595, 32873880, 32240793, 32913560, 32624538, 27827996, 33711386, 24632608, 28729764, 36775461, 28468776, 26914985, 28630312, 28848040, 34563497, 23144621, 29467311, 36274096, 33562801, 25284786, 34729395, 34519605, 25961913, 30154425, 34615996, 26405693, 29931583, 27624132, 16122695, 25982285, 33594072, 35514200, 20676058, 11244510, 32094302, 24973920, 17425505, 36777828, 30921702, 30212584, 20581866, 36313707, 33849067, 25639793, 21652721, 37148657, 24571255, 24009722, 36711038}", ,,#N/A,,,,,,,pi3k,auy922,HY-L025-7,D09,HY-10215,Luminespib,VER-52296; AUY922; NVP-AUY922,747412-49-3,465.54,Apoptosis; Autophagy; HSP,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Luminespib (VER-52296) is a potent HSP90 inhibitor with IC50s of 7.8 and 21 nM for HSP90α and HSP90β, respectively[1].",C26H31N3O5,DMSO : ≥ 62 mg/mL (133.18 mM),10mM,Cancer,Phase 2,O=C(C1=NOC(C2=CC(C(C)C)=C(O)C=C2O)=C1C3=CC=C(CN4CCOCC4)C=C3)NCC
cancer cell growth,0,1,51,0,"{18758789, 35561222, 17363592, 11205897, 14521721, 24491405, 29670543, 9443985, 18949011, 32451092, 20428829, 34098465, 35166242, 35954337, 17096356, 22740901, 29440631, 20858281, 29791786, 23547054, 30341811, 27911862, 21999932, 31106493, 14978241, 30061636, 33200711, 36029643, 16688716, 23288781, 21207374, 34420045, 29321164, 22718289, 26138072, 22392697, 18346844, 19609950, 18769120, 24809702, 28381547, 28194669, 24518510, 21037555, 37108468, 11039477, 16604531, 9364215, 31088502, 26683769, 7809022}","{27259267, 35402244, 30308485, 35836809, 25999370, 30529546, 30996246, 33822745, 31253147, 29437725, 31250978, 36965420, 26586936, 31874106, 30933440, 32978368, 34353856, 36793283, 32522824, 26864203, 29133261, 35399501, 31934287, 23704919, 33257688, 35159127, 27158366, 34771678, 24391143, 35831279, 28137841}", ,,#N/A,,,,,,,pi3k,flavopiridol,HY-L025-1,C08,HY-10006,Flavopiridol (Hydrochloride),Alvocidib (Hydrochloride); L86-8275 (Hydrochloride); HMR-1275 (Hydrochloride),131740-09-5,438.3,Autophagy; CDK; HIV,Anti-infection; Autophagy; Cell Cycle/DNA Damage,"Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.",C21H21Cl2NO5,DMF : 7.69 mg/mL (17.55 mM; Need ultrasonic); DMSO : ≥ 20 mg/mL (45.63 mM); H2O : ≥ 20 mg/mL (45.63 mM),10mM,Cancer,Phase 2,O=C1C2=C(C=C(C([C@]3([H])[C@H](O)CN(C)CC3)=C2OC(C4=CC=CC=C4Cl)=C1)O)O.[H]Cl
nude,0,0,50,0,"{12105858, 23076356, 24308485, 17363592, 3778442, 26500238, 20675343, 30342032, 15580305, 18949011, 29158292, 21890455, 23232026, 20631070, 16707615, 8609057, 10757026, 1499946, 12850474, 15639340, 17487403, 18413748, 25304374, 9024823, 12960962, 26753987, 9361092, 14559813, 18349132, 16688716, 18089810, 20068565, 12806617, 15591514, 24894173, 22710877, 11526239, 18027870, 17911264, 22066019, 25305448, 21364589, 7641198, 10415855, 25050737, 10822130, 24561527, 26439801, 25434366, 22900095}","{34591491, 30308485, 31712391, 26067464, 31905936, 33407504, 34326687, 35720479, 35135529, 27256375, 32528891, 30933440, 37201092, 32099528, 37035213, 32640974, 26919247, 34586831, 31324754, 32992343, 28766687, 34876902, 27044328, 29246955, 33858423, 35831279, 33230453, 25065590, 30988278, 23374840, 31523195}", ,,#N/A,,,,,,,pi3k,sirolimus,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
notch,0,1,47,0,"{24875648, 21673986, 28141826, 21285251, 31276933, 26279302, 26909576, 33693707, 19028876, 25117068, 36686732, 32382352, 22751123, 25698580, 19208345, 33946266, 33268505, 35018527, 24216479, 27610015, 17591971, 23284900, 35279012, 26369833, 17982507, 19440048, 21819318, 20484026, 28551612, 30278076, 22056382, 25152585, 26185420, 25416148, 27764699, 22806240, 24878567, 35493099, 25050737, 26984178, 28981109, 19249398, 29414775, 22359542, 35242873, 34657147, 32424701}","{35215234, 24930440, 35943053, 28684431, 34540687, 27148573, 35196077, 36768307, 28820917, 26829750, 27322055, 36731467, 25369933, 34617061, 31059052, 31281517, 26115193, 26683772, 34415102}", ,,dapt,,,,,,,pi3k,a66,HY-L025-33,F04,HY-13261,A66,,1166227-08-2,393.53,PI3K,PI3K/Akt/mTOR,A66 is a highly specific and selective p110α inhibitor with an IC50 of 32 nM.,C17H23N5O2S2,DMSO : 50 mg/mL (127.06 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CC(C)(C1=NC(C2=C(N=C(S2)NC(N3[C@@H](CCC3)C(N)=O)=O)C)=CS1)C
tumour suppressor,0,2,42,0,"{29364867, 9438601, 10660490, 23598351, 31534224, 25596178, 18266003, 15051286, 24305049, 9641882, 10909469, 18525343, 31300513, 33099938, 12079267, 11169959, 32929194, 32778157, 7730480, 24280502, 16823993, 10436800, 36621763, 30061636, 34099908, 1964102, 34057028, 10505546, 34244683, 16549328, 14743890, 32541781, 31154393, 32010971, 37105116, 26497117, 23408353, 22699621, 10436842, 34039665, 36118392, 11520255}","{25119042, 27957794, 31929348, 30940648, 20228809, 26416749, 22864638, 32771023, 35869742, 36333293, 35132755, 28927100, 32355326, 29915391}", ,,#N/A,,,,,,,pi3k,odq,HY-L025-5,B07,HY-101255,ODQ,,41443-28-1,187.15,Apoptosis; Guanylate Cyclase,Apoptosis; GPCR/G Protein,"ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells[1].",C9H5N3O2,DMSO : 100 mg/mL (534.33 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1ON=C2N1C3=C(C=CC=C3)N=C2
d1,0,1,39,0,"{18805632, 16146690, 26947075, 12021893, 22118662, 15652748, 24520077, 23019409, 25698580, 20642839, 23308056, 20682659, 28961832, 11102889, 20858281, 22393391, 19639215, 19125423, 27624879, 24608432, 24389175, 11522750, 23237571, 17520196, 15572689, 29059158, 17667542, 17569628, 25632222, 16382049, 25632225, 24076388, 21084261, 11159909, 20717927, 11751405, 25050737, 20113529, 22287227}","{34974082, 32828291, 30308485, 27440272, 32774672, 30272279, 34236185, 16475162, 32975004, 32371868, 28663582, 29596834, 30135075, 34199844, 27858214, 19244327, 37197608, 32954665, 34634662, 28059436, 31114028, 32163373, 30529073, 31857841, 34519605, 18406326, 26586936, 32771387, 30933440, 22595521, 31531200, 32978368, 32678475, 29133261, 29725006, 17998543, 27572308, 25277525, 35007061, 36284375, 29866840, 32110043, 31036508, 33531996, 27520485, 29050985, 35472745, 35831279, 29545201, 32551032}", ,,flupenthixol,,,,,,,pi3k,sinomenine,HY-L025-49,E09,HY-15122,Sinomenine,,115-53-7,329.39,Apoptosis; Autophagy; NF-κB; Opioid Receptor,Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling; NF-κB,"Sinomenine, an alkaloid extracted from?Sinomenium acutum, is a blocker of the NF-κB activation[1]. Sinomenine also is an activator of μ-opioid receptor[2].",C19H23NO4,DMSO : 50 mg/mL (151.80 mM; Need ultrasonic); 1M HCl : 25 mg/mL (75.90 mM; ultrasonic and adjust pH to 1 with HCl),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,OC(C1=C2C[C@@]3([H])[C@](C=C4OC)([H])[C@@]1(CCN3C)CC4=O)=C(C=C2)OC
cyclin d1,0,1,37,0,"{18805632, 16146690, 12021893, 22118662, 15652748, 24520077, 23019409, 20642839, 23308056, 20682659, 11102889, 20858281, 22393391, 19125423, 27624879, 24608432, 24389175, 19029954, 23237571, 17520196, 15572689, 29059158, 17667542, 26138072, 17569628, 25632222, 16382049, 25632225, 24076388, 21084261, 11159909, 20717927, 24552806, 11751405, 25050737, 20113529, 22287227}","{32828291, 30308485, 27440272, 32774672, 30272279, 16475162, 32371868, 28663582, 29596834, 30135075, 34199844, 34634662, 19244327, 32954665, 28059436, 32163373, 30529073, 34519605, 18406326, 26586936, 32771387, 30933440, 22595521, 32978368, 32678475, 29133261, 29725006, 17998543, 27572308, 25277525, 36284375, 29866840, 32110043, 31036508, 33531996, 27520485, 29050985, 35472745, 35831279, 29545201, 32551032}", ,,icg 001,,,,,,,pi3k,tgr 1202,HY-L025-24,G08,HY-12279,Umbralisib,TGR-1202; RP5264,1532533-67-7,571.55,Casein Kinase; PI3K,Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib can be used for haematological malignancies reseach[1][2][3][4].",C31H24F3N5O3,DMSO : 25 mg/mL (43.74 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1C(C2=CC=CC(F)=C2)=C([C@@H](N3N=C(C4=CC=C(OC(C)C)C(F)=C4)C5=C(N)N=CN=C53)C)OC6=CC=C(F)C=C16
tumorigenicity,0,1,37,0,"{12105858, 26477314, 20179210, 31557131, 24520077, 20553613, 33034134, 27067801, 22752926, 31527715, 31174057, 35177646, 23227827, 18413748, 10554036, 36123703, 9024823, 31075266, 32029124, 15367885, 32988878, 12806617, 26590425, 9598810, 31233118, 24550494, 18769120, 21266529, 24409315, 25306215, 31526907, 28381547, 35893867, 26544625, 12447993, 25065594, 34657147}","{23137537, 35601153, 23686307, 37201092, 30232453, 35371302, 20228809, 32380205, 26919247, 24525235, 31076403, 33135348, 35902869, 34791636, 32913560, 30659195, 33850013, 24721791}", ,,#N/A,,,,,,,pi3k,su6656,HY-L025-69,E11,HY-B0789,SU6656,,330161-87-0,371.45,Akt; FAK; Src,PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK,"SU6656 is a Src family kinases inhibitor with IC50s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.",C19H21N3O3S,DMSO : 20 mg/mL (53.84 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=S(C1=CC2=C(NC(/C2=C\C(N3)=CC4=C3CCCC4)=O)C=C1)(N(C)C)=O
tumor suppressors,0,1,37,0,"{15929091, 29956741, 34395269, 25724428, 28581516, 34205964, 32949395, 12605716, 30342036, 26439702, 31832601, 12647072, 22222375, 36139432, 33574569, 28894253, 30504367, 23552700, 31780287, 36325577, 36096460, 21984975, 19443408, 36505808, 17659731, 26899542, 36765914, 31233118, 23407711, 33483239, 35399143, 28414320, 32012917, 14681207, 9219065, 26036346, 21665147}","{24632608, 33876771, 23325510, 30067623, 32071334, 35787399, 30087114, 24836559, 22231120, 32453591, 24794707, 35715442, 29383095, 34097087}", ,,#N/A,,,,,,,pi3k,zd1839,HY-L025-64,B06,HY-50895,Gefitinib,ZD1839,184475-35-2,446.9,Apoptosis; Autophagy; EGFR,Apoptosis; Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer [1][2][5].",C22H24ClFN4O3,DMSO : 125 mg/mL (279.70 mM; Need ultrasonic),10mM,Cancer,Launched,ClC1=C(C=CC(NC2=NC=NC3=C2C=C(C(OC)=C3)OCCCN4CCOCC4)=C1)F
vimentin,0,0,37,0,"{21285251, 35197444, 32081541, 17516553, 22083596, 31817229, 27914516, 26451606, 27067801, 23786654, 36788090, 35205666, 32747685, 19002021, 31963309, 26962861, 21683373, 33045679, 26770358, 30838710, 31920328, 31949640, 17879119, 9639120, 22291919, 7728976, 26609108, 26884312, 34150617, 26951514, 10069471, 22806240, 32896616, 22884073, 23803380, 28981109, 31988090}","{35403781, 34160902, 29237530, 33664670, 30618144, 34378541, 29997232, 32923445, 34519605, 34097087, 27297869, 25362514, 34175826, 25716692, 24655834, 34053984, 25466466, 36568944, 28545522}", ,,curcumin,,,,,,,raf,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
malignant transformation,0,1,36,0,"{30918400, 28445953, 9586823, 25461770, 25250570, 22384141, 11677475, 15040037, 19292977, 22078386, 34089011, 25905463, 25029561, 20067773, 28942143, 24386371, 21699781, 28188746, 21207374, 23887057, 18089810, 30283732, 31076568, 15591514, 22430298, 25248858, 26951514, 23408353, 29303908, 31341034, 24026351, 16979953, 23431158, 18549880, 9219065, 10415866}","{23137537, 30696633, 27520485, 33144329, 20581866, 32079723, 29246955, 25111821, 33835000, 26840085, 25065590, 33144118, 28213432, 29050361, 32992343}", ,,#N/A,,,,,,,raf,forskolin,HY-L025-51,G04,HY-15371,Forskolin,Coleonol; Colforsin; HL 362,66575-29-9,410.5,Adenylate Cyclase; Autophagy; FXR,Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease,"Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC50 of 41 nM and an EC50 of 0.5 μM for type I adenylyl cyclase[1]. Forskolin is also an inducer of intracellular cAMP formation[2]. Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR[3]. Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy[4][5].",C22H34O7,DMSO : 100 mg/mL (243.61 mM; Need ultrasonic),10mM,Cancer; Endocrinology; Metabolic Disease; Inflammation/Immunology,No Development Reported,O=C1[C@@]2(O)[C@]([C@@H](OC(C)=O)[C@@H](O)[C@@]3([H])C(C)(C)CC[C@H](O)[C@@]32C)(C)O[C@@](C)(C=C)C1
cancer initiation,0,0,35,0,"{27415425, 25623042, 27477511, 30533257, 36912021, 26451606, 30214681, 23639840, 24788257, 32900774, 36514219, 27215660, 23712558, 21951538, 35530290, 33824054, 33344439, 36325577, 30967626, 26929740, 23376846, 24694735, 24889936, 34547282, 27364947, 21738581, 31325400, 37250781, 27941872, 25452273, 35800049, 27402485, 26697077, 23431158, 26715642}","{34681760, 29393731, 29716963, 31142662, 36224430, 33143730, 26111795, 37162970, 26206333}", ,,#N/A,,,,,,,raf,tak 632,HY-L025-54,A08,HY-15767,TAK-632,,1228591-30-7,554.52,Aurora Kinase; Raf,Cell Cycle/DNA Damage; Epigenetics; MAPK/ERK Pathway,"TAK-632 is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAFV600E, BRAFWT, respectively.",C27H18F4N4O3S,DMSO : 100 mg/mL (180.34 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C(NC1=CC(OC2=CC=C3N=C(NC(C4CC4)=O)SC3=C2C#N)=CC=C1F)CC5=CC=CC(C(F)(F)F)=C5
dna methylation,0,1,34,0,"{30149376, 35864067, 25461770, 28581516, 33060108, 32520974, 34727952, 32949395, 18266003, 34944918, 35116442, 21472283, 26617245, 30226601, 26023084, 36353587, 26684859, 33505218, 36760387, 21573703, 33420235, 34198989, 24976721, 33521362, 32898003, 32576853, 21381080, 32457835, 33144687, 26544625, 21886451, 37108468, 36359417, 34508795}","{36839169, 29149060, 25512710, 28095495, 23566090, 33256844, 36934287, 36737807, 25621778, 31749139, 31075731, 37111316, 36385171, 27767195, 29534238, 34336926, 30719265, 32938017, 31080358, 25713319, 30672294, 34793513, 28035374, 33792558, 35052850, 23054645, 25575605, 26178744, 32246716, 36577469, 34070078, 32989249, 31164355, 20107077, 26812616, 33575113, 31780938, 26458440, 37173708, 31868237, 36674511, 28332497, 30582481, 33284950, 32762714, 28169463, 32526941, 34309725, 30719712, 37120098, 33190371, 27273316, 34617061, 25415526, 26618343, 26111464, 28279785, 31363048, 33605616, 18778484, 34830196, 35653238, 26814967, 35467128, 34715126, 16085498, 21321083, 27246590}", ,,#N/A,,,,,,,raf,bgb 283,HY-L025-60,G05,HY-18957,Lifirafenib,BGB-283,1446090-79-4,478.42,EGFR; Raf,JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Lifirafenib (BGB-283) is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively.",C25H17F3N4O3,DMSO : ≥ 100 mg/mL (209.02 mM),10mM,Cancer,Phase 2,O=C1NC2=NC=CC(OC3=CC=C(O[C@@]4([H])[C@]5([H])[C@@H]4C6=NC7=CC=C(C(F)(F)F)C=C7N6)C5=C3)=C2CC1
metabolic reprogramming,0,1,34,0,"{25595905, 31508487, 32046984, 34069772, 32816911, 37187730, 37021976, 34331036, 28647837, 35525794, 37152291, 36151074, 31611300, 24704294, 27461042, 33546421, 36123703, 27600832, 34398147, 33833413, 34660806, 24794439, 36408139, 30470748, 24743516, 33188080, 35261808, 26164081, 37108468, 30819189, 34398070, 34064761, 22541435, 31911550}","{35453346, 34579723, 34987057, 29764852, 35002741, 34503062, 36963289, 37162970, 30037819}", ,,#N/A,,,,,,,raf,dasatinib,HY-L025-6,D08,HY-10181B,Dasatinib (monohydrate),BMS-354825 (monohydrate),863127-77-9,506.02,Apoptosis; Autophagy; Bcr-Abl; Src,Apoptosis; Autophagy; Protein Tyrosine Kinase/RTK,"Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively.  Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively[1]. Dasatinib monohydrate also induces apoptosis and autophagy.",C22H28ClN7O3S,10 mM in DMSO,10mM,Cancer,Launched,O=C(C1=CN=C(NC2=NC(C)=NC(N3CCN(CCO)CC3)=C2)S1)NC4=C(C)C=CC=C4Cl.[H]O[H]
β catenin,0,2,33,0,"{24875648, 29956741, 26477318, 33279497, 23749643, 31330317, 32972302, 32774415, 23019409, 25003666, 31952541, 27655713, 29596326, 24067880, 32434991, 23303473, 29072694, 30142009, 30809277, 33839689, 23887057, 20814421, 31154393, 25593307, 26297056, 21084261, 26411367, 25305448, 26714478, 27889647, 30514931, 31988090, 22287227}","{32828291, 34160902, 36120591, 35499161, 30134175, 33957539, 29519268, 35135529, 32068780, 30661164, 35259053, 28187439, 35411247, 34763437, 34370992, 30876979, 26367796, 25961913, 33667649, 26983878, 29600711, 30643017, 35096137, 36567628, 27717711, 30829648, 27935314, 33158995, 35514200, 32046432, 24198243, 29716963, 31724259, 26833129, 33515627, 29507187}", ,,atra,,,,,,,raf,gsk2118436,HY-L025-46,C11,HY-14660,Dabrafenib,GSK2118436A; GSK2118436,1195765-45-7,519.56,Raf,MAPK/ERK Pathway,"Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively[4].",C23H20F3N5O2S2,DMSO : ≥ 33 mg/mL (63.52 mM),10mM,Cancer,Launched,CC(C)(C)C1=NC(C2=C(F)C(NS(C3=C(F)C=CC=C3F)(=O)=O)=CC=C2)=C(C4=CC=NC(N)=N4)S1
small interfering rna,0,0,33,0,"{17018633, 23689354, 25411978, 24403857, 17671195, 26616862, 27147553, 20682659, 15801000, 29486633, 25997867, 16357163, 30504367, 16166322, 23608755, 18413748, 22441145, 31413817, 26214202, 17974973, 17489984, 18349132, 25894862, 30315093, 29039574, 16046552, 18784349, 23427041, 24809702, 17114344, 17353198, 17942900, 26682870}","{29878401, 21900162, 34591491, 35787399, 16954381, 23596302, 36247184, 35902869, 24733848, 28848040, 31325480, 25961913, 32962745, 15507644, 23115324, 30206781, 23365439, 18480452, 26349765, 23128391, 28146632, 31868237, 28806224, 35006928, 23420887, 34392152, 28418907, 29321313, 28636389, 30062054, 22699752, 20926576, 36568944}", ,,#N/A,,,,,,,raf,ch5126766,HY-L025-59,H07,HY-18652,Avutometinib,Ro 5126766; CH5126766,946128-88-7,471.46,MEK; Raf,MAPK/ERK Pathway,"Avutometinib (Ro 5126766) is a first-in-class dual MEK/RAF inhibitor that allosterically inhibits BRAFV600E, CRAF, MEK, and BRAF  (IC50: 8.2, 56, 160 nM, and 190 nM, respectively).",C21H18FN5O5S,DMSO : 125 mg/mL (265.13 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=S(NC)(NC1=NC=CC(CC2=C(C)C3=CC=C(OC4=NC=CC=N4)C=C3OC2=O)=C1F)=O
rnai,0,2,33,0,"{22471946, 26009994, 25724428, 15652748, 18949011, 29108249, 27147553, 15801000, 36790955, 15682475, 21536687, 19671674, 24484537, 21385921, 22868929, 22086851, 19029954, 34578632, 31949640, 28389707, 32264398, 21207374, 16046552, 25143389, 23427041, 24552806, 32262384, 24395249, 24902898, 34998392, 21289082, 35819261, 34180478}","{34346116, 31000582, 26620551, 22493065, 24657164, 31551256, 27233051, 31253147, 33006750, 33907746, 34037670, 22623531, 35904816, 29148850, 26367798, 23479607, 21814200, 30057145, 32771387, 34084283, 17189189, 23249862, 28146632, 26253517, 32382029, 25242322, 24794707, 29078358, 27917784, 33310044, 30455393, 24349540, 28636389, 34593637, 30846826, 26139243, 32151278, 32042871, 27846392, 32793596}", ,,#N/A,,,,,,,raf,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
tumour growth,0,0,33,0,"{32913288, 31626255, 17582609, 33649045, 36991126, 24305049, 29533466, 15714203, 30038429, 37198494, 30007968, 36619305, 22393391, 33491761, 35428659, 37210549, 21970876, 35604033, 30061636, 25152585, 20978506, 35896270, 16052215, 25841238, 33230296, 21395550, 33126623, 26077929, 23535601, 28419443, 27402485, 26522614, 31088502}","{27292261, 24518598, 33536620, 31927213, 33080301, 30098223, 32771023, 32398865, 35568976, 31932756, 23828858, 28927100}", ,,#N/A,,,,,,,raf,rg7204,HY-L025-23,A02,HY-12057,Vemurafenib,PLX4032; RG7204; RO5185426,918504-65-1,489.92,Autophagy; Raf,Autophagy; MAPK/ERK Pathway,"Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].",C23H18ClF2N3O3S,DMSO : 50 mg/mL (102.06 mM; Need ultrasonic),10mM,Cancer,Launched,FC1=CC=C(C(F)=C1C(C2=CNC3=NC=C(C=C32)C4=CC=C(C=C4)Cl)=O)NS(CCC)(=O)=O
snail,0,1,33,0,"{21285251, 35197444, 35718922, 31817229, 23761168, 21304978, 26451606, 35205666, 19362090, 27624879, 37105075, 24389175, 24040120, 24330423, 19860666, 34859959, 24944064, 21288898, 22086851, 31920328, 24880079, 29367759, 27364947, 19179606, 34150617, 26951514, 19010789, 35838183, 28414315, 21364589, 22041584, 25050737, 36882420}","{36599264, 31908099, 33757572, 31114028, 34378541, 36120591, 36690674, 30529267, 36768307, 33006750, 32793596, 31653342, 31311807}", ,,curcumin,,,,,,,raf,pazopanib,HY-L025-22,B04,HY-12009,Pazopanib (Hydrochloride),GW786034 (Hydrochloride),635702-64-6,473.98,Autophagy; c-Fms; c-Kit; FGFR; PDGFR; VEGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.",C21H24ClN7O2S,DMSO : 10 mg/mL (21.10 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,CC1=CC=C(C=C1S(N)(=O)=O)NC2=NC=CC(N(C3=CC4=NN(C(C)=C4C=C3)C)C)=N2.Cl
killing,0,1,33,0,"{34331012, 35907592, 15580305, 33682329, 32862105, 28891811, 18430374, 25963558, 24282278, 23613993, 33008426, 12850474, 15890097, 16166322, 27323830, 27322423, 22347323, 33815107, 36760387, 31912905, 19062734, 29780561, 21836633, 26097885, 25632222, 33763295, 27096033, 35402225, 23475955, 23422836, 31456633, 21573499, 26052093}","{34782346, 31040907, 26658189, 35755278, 34696466, 33004947, 31653272, 36458010, 29228703, 35952671, 33420321, 33907746, 25049379, 33619107, 28766886, 28336808, 36711980, 32642733, 35904816, 28069687, 32196028, 31534014, 29636547, 36260688, 33741395, 35132755, 28765013, 35332309, 31937753, 32329693, 32575711, 35146591, 34753889, 30674532, 34215653, 34279931, 30824188, 30475902, 25793663}", ,,#N/A,,,,,,,raf,plx4032,HY-L025-23,A02,HY-12057,Vemurafenib,PLX4032; RG7204; RO5185426,918504-65-1,489.92,Autophagy; Raf,Autophagy; MAPK/ERK Pathway,"Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].",C23H18ClF2N3O3S,DMSO : 50 mg/mL (102.06 mM; Need ultrasonic),10mM,Cancer,Launched,FC1=CC=C(C(F)=C1C(C2=CNC3=NC=C(C=C32)C4=CC=C(C=C4)Cl)=O)NS(CCC)(=O)=O
wnt,0,2,32,0,"{24875648, 17956352, 28141826, 26909576, 23749643, 21734801, 19896093, 24216479, 29596326, 24067880, 17982507, 25855536, 18784821, 19860666, 15563452, 28551612, 31391551, 18310088, 27061193, 26185420, 24694735, 16042578, 20814421, 26590425, 29337182, 18725219, 26569573, 25305448, 29151594, 30410604, 27889647, 22900095}","{32828291, 19005066, 22829075, 35499161, 36121114, 33957539, 29519268, 35259053, 34763437, 34370992, 30876979, 26367796, 26367798, 34024119, 25961913, 33667649, 26983878, 29600711, 35681734, 30643017, 35096137, 36567628, 27717711, 30829648, 36252888, 21599968, 31900258, 31724259, 12941796, 36942693, 26833129, 29545201, 34344445}", ,,niclosamide,,,,,,,raf,lapatinib,HY-L025-64,B11,HY-50898B,Lapatinib (ditosylate monohydrate),GW572016 (ditosylate monohydrate); GW2016 (ditosylate monohydrate),388082-78-8,943.48,Autophagy; EGFR; Ferroptosis,Apoptosis; Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].",C43H44ClFN4O11S3,DMSO : 50 mg/mL (53.00 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=S(CCNCC1=CC=C(C2=CC3=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)N=CN=C3C=C2)O1)(C)=O.O=S(C6=CC=C(C)C=C6)(O)=O.O=S(C7=CC=C(C)C=C7)(O)=O.O
cdk4,0,2,32,0,"{33860102, 24858378, 34440587, 30271501, 26158861, 33472910, 30696953, 31745297, 20669973, 32234521, 28513565, 12055597, 19639215, 26770358, 9219065, 32109375, 33577028, 36719686, 36434634, 32626512, 12063826, 29059158, 34412631, 17569628, 37105116, 25219422, 34001634, 24076388, 11159909, 30254182, 32434425, 36346366}","{25053825, 31727874, 30308485, 11331592, 35249548, 35881485, 27440272, 25072021, 34954522, 28663582, 28042144, 37211680, 30135075, 27539364, 32393766, 27677740, 32793389, 33158576, 34385584, 36274096, 32694708, 36318650, 36755269, 36741704, 28604107, 30049486, 29725006, 27572308, 31226848, 27186656, 34942306, 26833129, 35149545, 26254443, 30057199, 28205554, 31160565, 30136059, 37252349}", ,,ly294002,,,,,,,raf,trametinib,HY-L025-14,D08,HY-10999A,Trametinib (DMSO solvate),GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate),1187431-43-1,693.53,Apoptosis; MEK,Apoptosis; MAPK/ERK Pathway,Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis[1][2].,C28H29FIN5O5S,DMSO : 69 mg/mL (99.49 mM; Need ultrasonic),10mM,Cancer,Launched,CN1C(C(C)=C(N(C(N(C2=O)C3CC3)=O)C4=CC=CC(NC(C)=O)=C4)C2=C1NC5=CC=C(C=C5F)I)=O.CS(C)=O
mtor,0,1,30,0,"{19107333, 21521159, 21078544, 23361300, 26451606, 25500057, 27595930, 23232026, 28513565, 28810144, 21678117, 22116519, 23980075, 26034349, 23563181, 24791855, 24231729, 26257206, 21840189, 21871555, 27694919, 25143389, 25632222, 26725216, 25632225, 25601637, 25736685, 24717934, 15313904, 28918901}","{32599680, 30305285, 25535366, 35308165, 24930440, 33051401, 36051080, 30232459, 34716294, 27865874, 30305939, 35390226, 26840085, 35850772, 28837371, 34805786, 29228703, 30136059, 37211680, 31250978, 28553123, 30824188, 30308518, 32982695, 28653353, 25623213, 33154093, 28187439, 33158576, 30926641, 27573426, 31957165, 30365111, 36341561, 36318650, 34533562, 28118076, 29172540, 31632060, 35593209, 30933440, 30606790, 27496136, 35633739, 33688653, 35031886, 31814736, 26536665, 34557659, 31036508, 25564254, 26058079, 31226848, 33393503, 27864418, 34565342, 35942238, 27494885, 25307878, 29475942, 36623719, 35472745, 25537515, 36883564, 30104685, 35831279, 32174193, 31139698, 36871542, 33835000, 26663801, 27935867, 30266108, 30382078}", ,"Here, we targeted bromodomain 4 (BRD4) in combination with another molecular metabolic tumor driver, the Akt/mTOR signaling pathway, to provide a highly effective treatment for this neoplasm (35472745)",everolimus,,,,,,,raf,cudc 907,HY-L025-36,A06,HY-13522,Fimepinostat,CUDC-907,1339928-25-4,508.55,Apoptosis; HDAC; PI3K,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR,"Fimepinostat (CUDC-907) potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes with an IC50 of  19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.",C23H24N8O4S,DMSO : 50 mg/mL (98.32 mM; Need ultrasonic); DMF : 5 mg/mL (9.83 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=CN=C(N(CC2=CC3=NC(C4=CC=C(OC)N=C4)=NC(N5CCOCC5)=C3S2)C)N=C1)NO
telomerase,0,0,28,0,"{34526722, 15753605, 12021894, 12021896, 24858378, 18266003, 9641882, 11490843, 35954337, 15112354, 19896100, 15084968, 10484017, 10734643, 28239030, 10436798, 18541514, 12483152, 17706193, 26899542, 26951514, 26118878, 21535200, 24919654, 32322667, 12094699, 10840305, 10822130}","{31900258, 21441348, 35385124, 34272171, 30661164, 34875179, 28854735, 32245330, 36332787, 32392533, 31549911, 34597402, 30419422}", ,,braco 19,,,,,,,raf,lovastatin,HY-L025-74,G03,HY-N0504,Lovastatin,Mevinolin,75330-75-5,404.54,Autophagy; Ferroptosis; HMG-CoA Reductase (HMGCR),Apoptosis; Autophagy; Metabolic Enzyme/Protease,Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.,C24H36O5,DMSO : ≥ 100 mg/mL (247.19 mM),10mM,Cardiovascular Disease; Cancer,Launched,O=C([C@@H](C)CC)O[C@@H]1[C@@]([C@H]2CC[C@@H](OC3=O)C[C@H](C3)O)([H])C(C=C[C@@H]2C)=C[C@H](C)C1
pi3k,0,1,27,0,"{20807812, 22975375, 21078544, 22751122, 26451606, 20642839, 25500057, 27595930, 28513565, 25348516, 21678117, 26257206, 23453624, 19860666, 10781373, 17043657, 21984975, 15073105, 27978579, 26725216, 22462691, 11034087, 24722280, 17353198, 15958516, 24478710, 26628860}","{33596421, 33596424, 34144267, 33509905, 29366803, 35850772, 36458010, 33713695, 37211680, 31215139, 37170211, 34020393, 33564720, 29792310, 31844420, 35633739, 27297869, 33688653, 36822097, 27572308, 31036508, 34524258, 35030628, 36599397, 29475942, 32782441, 30104685, 36448366, 32174193, 32599680, 28784769, 35855490, 34716294, 24930440, 36051080, 30481052, 33006750, 29228703, 31485609, 34638508, 31957165, 31862959, 34533562, 27601596, 34926269, 27496136, 30687956, 26536665, 34557659, 35513563, 34565342, 28750570, 26623725, 27250929, 33520370, 30136059, 30824188, 30266108, 34591491, 33051401, 31213835, 24657164, 30696721, 35390226, 34956562, 35740436, 34409758, 30991141, 36530982, 30537514, 32793389, 30926641, 36341561, 28881723, 31004990, 34688842, 35031886, 34730838, 35514200, 33310044, 35942238, 26058079, 34942306, 28137841, 31139698, 32827765, 31821686, 30479742, 30232459, 34751372, 37042063, 25072021, 34503062, 35173274, 36730269, 30134175, 32629664, 31043489, 36682147, 34634662, 35122599, 28848040, 33158576, 30269363, 32694708, 33712563, 35743155, 36318650, 30933440, 30606790, 33480647, 29133261, 24836559, 34038745, 28766687, 30554080, 24533473, 31226848, 32520674, 36524001, 26618343, 25537515, 31018997, 36139513}", ,,ctd,,,,,,,braf,dabrafenib,HY-L025-46,D02,HY-14660A,Dabrafenib (Mesylate),GSK2118436 Mesylate; GSK 2118436B,1195768-06-9,615.67,Raf,MAPK/ERK Pathway,"Dabrafenib Mesylate is a potent and selective Raf kinase inhibitor with IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively.",C24H24F3N5O5S3,DMSO : 20.83 mg/mL (33.83 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,CC(C)(C)C1=NC(C2=C(F)C(NS(C3=C(F)C=CC=C3F)(=O)=O)=CC=C2)=C(C4=CC=NC(N)=N4)S1.CS(=O)(O)=O
proto oncogene,0,0,27,0,"{20179210, 25431955, 12605716, 17591971, 12079267, 16133800, 16357163, 18693168, 19440048, 21951538, 30341811, 10449972, 30223034, 22056382, 21279552, 1964102, 29061961, 28108627, 22665051, 29320425, 2173932, 21364589, 18776302, 23431158, 25065594, 27591291, 15655549}","{36051080, 37059338, 34688663, 33668642, 28983590, 17406891, 34358447, 31516082, 25072693, 30154425, 29568956, 33664855, 29469144, 30333915, 11083868, 33987681, 32412527, 35866356, 35604347}", ,,#N/A,,,,,,,braf,everolimus,HY-L025-7,D10,HY-10218,Everolimus,RAD001; SDZ-RAD,159351-69-6,958.22,Apoptosis; Autophagy; Bacterial; FKBP; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; PI3K/Akt/mTOR,"Everolimus (RAD001) is a <a href=""/Rapamycin.html"" class=""link-product"" target=""_blank"">Rapamycin</a> (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].",C53H83NO14,DMSO : 50 mg/mL (52.18 mM; ultrasonic and warming and heat to 60°C); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](OCCO)CC4)OC)C)=O)=O
β1,0,0,27,0,"{32580737, 22118662, 34001163, 31817229, 34688654, 29222037, 25629724, 31852956, 27539232, 27655713, 22020907, 33045679, 23157946, 20424515, 27485764, 25841238, 29039574, 29229918, 27267807, 29261154, 21619683, 27089513, 22884073, 26915435, 22353526, 32636409, 33590779}","{33757572, 28063381, 33664670, 31079594, 28804523, 30124204, 36613933, 29782963, 33504568, 34926269, 31707348, 32544088, 35127386, 36244457, 34371697, 34146546, 35149305, 30106235, 34425215}", ,,propranolol,,,,,,,braf,chloroquine,HY-L025-58,G04,HY-17589A,Chloroquine,,54-05-7,319.87,Antibiotic; Autophagy; HIV; Parasite; SARS-CoV; Toll-like Receptor (TLR),Anti-infection; Autophagy; Immunology/Inflammation,Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].,C18H26ClN3,Ethanol : 100 mg/mL (312.63 mM; Need ultrasonic); DMSO : 50 mg/mL (156.31 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,CC(NC1=CC=NC2=CC(Cl)=CC=C12)CCCN(CC)CC
increased apoptosis,0,1,27,0,"{27659014, 17018633, 24403857, 26934555, 28535453, 19109152, 15801000, 24791855, 21536687, 34857016, 29798841, 24998203, 29903803, 27634878, 30083262, 29545922, 21622730, 23696215, 16046552, 37105116, 36384095, 24409315, 32572645, 32360551, 33216236, 35103981, 28242812}","{32764680, 30830987, 26851213, 29454094, 26224795, 28669341, 29567272, 31015208, 32380205, 35411247, 31708100, 35486664, 32632663, 29505757, 36599397, 25504753, 31623282, 35535987, 28504695, 35094142}", ,,#N/A,,,,,,,braf,lapatinib,HY-L025-64,B11,HY-50898B,Lapatinib (ditosylate monohydrate),GW572016 (ditosylate monohydrate); GW2016 (ditosylate monohydrate),388082-78-8,943.48,Autophagy; EGFR; Ferroptosis,Apoptosis; Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].",C43H44ClFN4O11S3,DMSO : 50 mg/mL (53.00 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=S(CCNCC1=CC=C(C2=CC3=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)N=CN=C3C=C2)O1)(C)=O.O=S(C6=CC=C(C)C=C6)(O)=O.O=S(C7=CC=C(C)C=C7)(O)=O.O
catenin,0,2,25,0,"{24875648, 16146690, 23749643, 23019409, 25003666, 16705170, 31952541, 29596326, 24067880, 19016747, 29072694, 15563452, 18310088, 18349132, 23887057, 20814421, 25593307, 20071774, 18725219, 21084261, 25305448, 27889647, 22041584, 30514931, 22287227}","{32828291, 34160902, 19005066, 36120591, 35499161, 30134175, 33957539, 29519268, 35135529, 32068780, 30661164, 35259053, 28187439, 35411247, 34763437, 34370992, 30876979, 26367796, 25961913, 33667649, 26983878, 29600711, 30643017, 35096137, 36567628, 27717711, 30829648, 27935314, 33158995, 35514200, 32046432, 24198243, 29716963, 12941796, 31724259, 26833129, 33515627, 29507187}", ,,icg 001,,,,,,,braf,bay 43 9006,HY-L025-7,A11,HY-10201A,Sorafenib (Tosylate),Bay 43-9006 (Tosylate),475207-59-1,637.03,Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR,Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator[1].",C28H24ClF3N4O6S,H2O : < 0.1 mg/mL (insoluble); DMSO : ≥ 31 mg/mL (48.66 mM),10mM,Cancer,Launched,O=S(C1=CC=C(C=C1)C)(O)=O.O=C(NC2=CC=C(C(C(F)(F)F)=C2)Cl)NC3=CC=C(OC4=CC(C(NC)=O)=NC=C4)C=C3
her2,0,0,25,0,"{32274564, 23340292, 11561610, 25896973, 29757973, 23213974, 25117978, 29670173, 26668065, 21723941, 33082167, 10830140, 12520639, 25992771, 24003140, 29986755, 12499914, 23076814, 14743890, 32057051, 27267807, 25360865, 23441129, 20103665, 28736628}","{36103824, 30696721, 37211680, 30952871, 34572840, 35260587, 33158576, 34385584, 32338867, 29792310, 33086530, 32161105, 33741018, 32848091, 33287516, 30524510, 27186656, 33617509, 33128042, 29298799, 27935867}", ,,lapatinib,,,,,,,braf,sorafenib,HY-L025-7,A11,HY-10201A,Sorafenib (Tosylate),Bay 43-9006 (Tosylate),475207-59-1,637.03,Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR,Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator[1].",C28H24ClF3N4O6S,H2O : < 0.1 mg/mL (insoluble); DMSO : ≥ 31 mg/mL (48.66 mM),10mM,Cancer,Launched,O=S(C1=CC=C(C=C1)C)(O)=O.O=C(NC2=CC=C(C(C(F)(F)F)=C2)Cl)NC3=CC=C(OC4=CC(C(NC)=O)=NC=C4)C=C3
cck,0,0,24,0,"{24177032, 32774415, 29970191, 35433491, 32304665, 31891232, 31922213, 22020907, 30913453, 31047726, 36614194, 34099637, 36367161, 25058882, 26929740, 9807701, 19570262, 9849431, 32141657, 33857498, 37138671, 33643376, 31889908, 33631610}","{34082824, 32314893, 32961679, 33407504, 32457617, 35842703, 35778964, 35883157, 28024472, 34387610, 33663517, 31632543, 35434025, 35981367, 15234110, 37201092, 25338565, 35096137, 35571403, 26304078, 27573714, 34730838, 24985178, 32100443, 35116642, 34876902, 36244457, 32812145, 28545522, 35494514, 36871542, 29783800, 32943995, 26456956, 34140798}", ,,diltiazem,,,,,,,braf,saha,HY-L025-7,E02,HY-10221,Vorinostat,SAHA; Suberoylanilide hydroxamic acid,149647-78-9,264.32,Apoptosis; Autophagy; Filovirus; HDAC; HPV; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].",C14H20N2O3,DMSO : ≥ 100 mg/mL (378.33 mM),10mM,Cancer; Infection,Launched,O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O
mtorc1,0,2,24,0,"{35254400, 33831427, 35477123, 35561222, 33294856, 22342683, 33388318, 23639840, 37236000, 26257206, 30142009, 34398147, 34420045, 26575954, 30865892, 35838183, 28591720, 31740775, 35814251, 32339950, 32101748, 28918901, 33804148, 31399545}","{32917124, 30308518, 33051401, 29127434, 28604107, 35472745, 35883603, 26840085, 31776981, 26536665, 36318650, 28805822}", ,,cc214 2,,,,,,,braf,ly3009120,HY-L025-27,G10,HY-12558,LY3009120,DP-4978,1454682-72-4,424.51,Autophagy; Raf,Autophagy; MAPK/ERK Pathway,"LY3009120 (DP-4978) is a pan RAF inhibitor which inhibits BRAFV600E, BRAFWT and CRAFWT with IC50s of 5.8, 9.1 and 15 nM, respectively.",C23H29FN6O,DMSO : ≥ 38 mg/mL (89.51 mM),10mM,Cancer,Phase 1,O=C(NC1=CC(C2=CC3=CN=C(NC)N=C3N=C2C)=C(C)C=C1F)NCCC(C)(C)C
biological processes,0,0,23,0,"{27904769, 28141826, 29358341, 17363592, 26572553, 16407822, 29290766, 30483731, 20642839, 30949406, 29748382, 33491761, 22078386, 33525943, 33344439, 28366542, 25658205, 28259298, 23774697, 33107691, 35488119, 26628860, 18393855}","{29149060, 30232453, 28626565, 32764680, 28723212, 36524430, 30977555, 34330905, 31253147, 26868508, 28743452, 32629664, 31570593, 29551266, 36077987, 34624676, 36077605, 28653353, 19880750, 30227759, 33469999, 29025975, 28045112, 37156794, 30387133, 35371325, 27056325, 32527308, 17998543, 30237520, 31037138, 35883603, 31707348, 36304339, 30633431, 12237408, 21599968, 32013155, 22509028, 25641834, 35650157, 33962228, 28656888, 33607295}", ,,#N/A,,,,,,,braf,plx 4720,HY-L025-64,D07,HY-51424,PLX-4720,,918505-84-7,413.83,Raf,MAPK/ERK Pathway,"PLX-4720 is a potent and selective inhibitor of?B-RafV600E?with?IC50?of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf.",C17H14ClF2N3O3S,DMSO : 100 mg/mL (241.65 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=S(NC1=CC=C(C(C(C2=CNC3=NC=C(C=C23)Cl)=O)=C1F)F)(CCC)=O
p27,0,0,23,0,"{16146690, 15811853, 23302291, 20642839, 23963802, 26416424, 20858281, 19125423, 14742320, 30003124, 11522750, 21871555, 34590153, 12499914, 15572689, 34412631, 25248858, 17569628, 25632222, 23470560, 25632225, 24552806, 24902898}","{28042144, 23950209, 33668642, 25773539, 30250532, 31272080, 25277525, 27256375, 28368473, 28281917, 26575167}", ,,ly294002,,,,,,,braf,encorafenib,HY-L025-53,A06,HY-15605,Encorafenib,LGX818,1269440-17-6,540.01,Raf,MAPK/ERK Pathway,Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM).,C22H27ClFN7O4S,DMSO : 50 mg/mL (92.59 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(OC)N[C@@H](C)CNC1=NC=CC(C2=CN(C(C)C)N=C2C3=CC(Cl)=CC(NS(=O)(C)=O)=C3F)=N1
hedgehog signaling,0,1,23,0,"{22099597, 22320912, 22232209, 17611415, 23786654, 21704226, 27862693, 17982507, 26199979, 35028532, 19860666, 23935937, 27003603, 30881497, 17114586, 22158044, 25024225, 25104358, 17353198, 19136624, 27573236, 27633013, 29414775}","{24973920, 35852097, 34333666, 26622824, 35167374, 31139698, 33711386, 37235835}", ,,#N/A,,,,,,,braf,cobimetinib,HY-L025-32,B04,HY-13078,Cobimetinib (racemate),GDC-0973 (racemate); XL518 (racemate),934662-91-6,531.31,MEK,MAPK/ERK Pathway,Cobimetinib racemate (GDC-0973 racemate; XL518 racemate) is the racemate of Cobimetinib. Cobimetinib is a potent and selective MEK inhibitor.,C21H21F3IN3O2,DMSO : ≥ 40 mg/mL (75.29 mM),10mM,Cancer,Launched,O=C(C1=CC=C(F)C(F)=C1NC2=CC=C(I)C=C2F)N3CC(C4NCCCC4)(O)C3
gli1,0,0,23,0,"{34046348, 23786654, 25632159, 27758883, 27862693, 28069799, 24737325, 27624879, 35028532, 31417657, 19860666, 22493246, 23935937, 23482563, 22086851, 18515410, 18829525, 30373214, 25104358, 17353198, 19136624, 23803380, 22900095}","{24973920, 33958721, 32999044, 27793034, 31114028, 31085420, 32380205, 25355313, 31292434, 34956562, 32913560, 31182587}", ,,salinomycin,,,,,,,braf,binimetinib,HY-L025-50,C11,HY-15202,Binimetinib,MEK162; ARRY-162; ARRY-438162,606143-89-9,441.23,Autophagy; MEK,Autophagy; MAPK/ERK Pathway,Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC50 of 12 nM.,C17H15BrF2N4O3,DMSO : 50 mg/mL (113.32 mM; Need ultrasonic),10mM,Cancer,Launched,BrC1=CC=C(C(F)=C1)NC2=C(C3=C(C=C2C(NOCCO)=O)N(C=N3)C)F
pi3k akt,0,0,22,0,"{30423298, 20807812, 21078544, 26451606, 26085527, 20642839, 25500057, 27595930, 30185628, 21678117, 26261555, 19860666, 22784710, 15073105, 27978579, 26725216, 24722280, 25736685, 17353198, 16163059, 15958516, 18393855}","{35855490, 34591491, 33596421, 24930440, 33051401, 36051080, 31213835, 33509905, 34956562, 29366803, 35740436, 25072021, 34503062, 36458010, 35173274, 30481052, 33006750, 29228703, 34409758, 33713695, 37211680, 31215139, 30824188, 30991141, 32629664, 37170211, 35122599, 31485609, 34020393, 31957165, 33158576, 30926641, 36341561, 36318650, 28881723, 34926269, 31004990, 30933440, 27496136, 34688842, 27297869, 35031886, 36822097, 27572308, 35514200, 34557659, 33310044, 35513563, 28766687, 30554080, 31226848, 36524001, 34524258, 34942306, 35030628, 32782441, 30104685, 36448366, 32174193, 31139698, 30266108}", ,,ly294002,,,,,,,braf,gsk2118436,HY-L025-46,C11,HY-14660,Dabrafenib,GSK2118436A; GSK2118436,1195765-45-7,519.56,Raf,MAPK/ERK Pathway,"Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively[4].",C23H20F3N5O2S2,DMSO : ≥ 33 mg/mL (63.52 mM),10mM,Cancer,Launched,CC(C)(C)C1=NC(C2=C(F)C(NS(C3=C(F)C=CC=C3F)(=O)=O)=CC=C2)=C(C4=CC=NC(N)=N4)S1
proteasome,0,0,22,0,"{30423298, 33178766, 21078544, 21698197, 29749405, 24362026, 20208558, 36975534, 35411249, 10554036, 33525943, 35604033, 23049538, 35116102, 35114566, 23288781, 33161807, 17488476, 19294695, 17203180, 30347501, 26052093}","{19787264, 36835328, 34520194, 32393731, 36273157, 37066758, 32134919, 24930440, 24189064, 33324552, 36577036, 37217935, 34494353, 32080280, 27989401, 31846298, 36656921, 29449372, 36940189, 36730269, 36046113, 34582690, 35371302, 31553577, 33596073, 32437546, 31114028, 33310889, 32582706, 30055346, 28154167, 23479607, 34583995, 30059709, 31059647, 30606790, 26254279, 33780296, 32224969, 26093901, 29725006, 33687890, 36577875, 32968148, 19211738, 31580635, 24448221, 35065444, 36623719, 36536188, 30975979, 34829934, 35600879, 32863216, 19038968, 26415225, 24220028, 37252349, 23241214, 24721791}", ,,geldanamycin,,,,,,,braf,trametinib,HY-L025-14,D08,HY-10999A,Trametinib (DMSO solvate),GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate),1187431-43-1,693.53,Apoptosis; MEK,Apoptosis; MAPK/ERK Pathway,Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis[1][2].,C28H29FIN5O5S,DMSO : 69 mg/mL (99.49 mM; Need ultrasonic),10mM,Cancer,Launched,CN1C(C(C)=C(N(C(N(C2=O)C3CC3)=O)C4=CC=CC(NC(C)=O)=C4)C2=C1NC5=CC=C(C=C5F)I)=O.CS(C)=O
hypermethylation,0,0,22,0,"{35864067, 34649604, 23912455, 26909576, 18848526, 32949395, 34944918, 21472283, 24471965, 30226601, 30227250, 33423164, 23552700, 33420235, 21792082, 17198183, 32457835, 12802288, 29626481, 33005298, 27602165, 34508795}","{30719712, 25743841, 30924611, 22120039, 28095495, 31514410, 36692427, 37173708, 21447565, 34597402, 32762714, 21321083, 30659195}", ,,#N/A,,,,,,,braf,sch772984,HY-L025-63,H09,HY-50846,SCH772984,,942183-80-4,587.67,ERK,MAPK/ERK Pathway; Stem Cell/Wnt,"SCH772984 is a highly selective and ATP-competitive ERK inhibitor, with IC50s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-na?ve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations[1].",C33H33N9O2,DMSO : 48 mg/mL (81.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C([C@H](CC1)CN1CC(N(CC2)CCN2C(C=C3)=CC=C3C4=NC=CC=N4)=O)NC5=CC6=C(C=C5)NN=C6C7=CC=NC=C7
adp ribose polymerase,0,1,22,0,"{19084933, 24308485, 34337294, 37201049, 23497499, 20619549, 12799645, 23404329, 12850474, 29802286, 26462257, 15375156, 35488448, 28246467, 24889936, 36399952, 15028947, 37197396, 26138072, 31856090, 28736628, 15003513}","{37211680, 33888130, 36227363, 29567272, 33512458, 36170346, 35442700, 29287727, 33532187, 34094834, 29533782, 32598582, 31523195, 34733788, 35958877, 31534014, 28473439}", ,,niraparib,,,,,,,braf,vemurafenib,HY-L025-23,A02,HY-12057,Vemurafenib,PLX4032; RG7204; RO5185426,918504-65-1,489.92,Autophagy; Raf,Autophagy; MAPK/ERK Pathway,"Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].",C23H18ClF2N3O3S,DMSO : 50 mg/mL (102.06 mM; Need ultrasonic),10mM,Cancer,Launched,FC1=CC=C(C(F)=C1C(C2=CNC3=NC=C(C=C32)C4=CC=C(C=C4)Cl)=O)NS(CCC)(=O)=O
poly adp ribose polymerase,0,1,22,0,"{19084933, 24308485, 34337294, 37201049, 23497499, 20619549, 12799645, 23404329, 12850474, 29802286, 26462257, 15375156, 35488448, 28246467, 24889936, 36399952, 15028947, 37197396, 26138072, 31856090, 28736628, 15003513}","{37211680, 33888130, 36227363, 29567272, 33512458, 36170346, 35442700, 29287727, 33532187, 34094834, 29533782, 32598582, 31523195, 34733788, 35958877, 31534014, 28473439}", ,,olaparib,,,,,,,pi3k akt,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
arid1a,0,1,22,0,"{32582528, 30014851, 30728464, 33350171, 28810144, 36980386, 29486633, 32967217, 28942143, 34659905, 29604291, 35302596, 30970447, 35231699, 30315093, 28188630, 29596894, 25714017, 34122731, 36999792, 30228219, 23103869}","{22442726, 26812616, 31913353, 29374058, 32005967, 34987057, 28426098, 35715442, 29760405, 36918265, 29296220, 33732255}", ,,mk 2206,,,,,,,pi3k akt,wortmannin,HY-L025-6,H04,HY-10197,Wortmannin,SL-2052; KY-12420,19545-26-7,428.43,Antibiotic; Autophagy; PI3K; Polo-like Kinase (PLK),Anti-infection; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively[1][2][3].",C23H24O8,DMSO : ≥ 50 mg/mL (116.71 mM),10mM,Cancer,No Development Reported,O=C1C([C@@](CC2)([H])[C@@]3(C)C2=O)=C([C@H](OC(C)=O)C3)[C@]4(C)C5=C1OC=C5C(O[C@@H]4COC)=O
1a,0,2,22,0,"{10473862, 32655498, 11819794, 35626644, 25632159, 29486633, 32967217, 13679043, 17520196, 11950919, 26397140, 17667542, 17114585, 24041692, 35838183, 32457835, 11751405, 14508142, 15957615, 12802288, 15720814, 30228219}","{30305285, 28095495, 24632969, 37111316, 35940372, 36656921, 27539364, 27390756, 35943085, 31516082, 28757943, 30765888, 25978433, 36190786, 25189880, 32927694, 36841551, 36477655, 33287516, 29374058, 35650157, 33726839, 29783800}", ,,#N/A,,,,,,,pi3k akt,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
non coding rnas,0,0,22,0,"{24469904, 29298720, 28810144, 33099938, 32727085, 28551612, 33577028, 25152585, 36586571, 26755660, 36612299, 23973710, 34859606, 30463064, 31747939, 30221677, 31452788, 33390837, 31562613, 32499447, 33997944, 33290747}","{35765893, 35011590, 36575377, 37111316, 27767195, 29534238, 32938017, 31837602, 31001132, 28187439, 34258104, 33575113, 35491403, 28981843, 29540837, 31200487, 35546353, 33962228, 30093685, 26799480}", ,,#N/A,,,,,,,3 kinase,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
zeb1,0,1,22,0,"{21285251, 26684803, 32838790, 22045191, 35718922, 26451606, 31952541, 26199979, 27624879, 34859959, 24389175, 24040120, 19860666, 33788731, 24880079, 32641744, 26609108, 25593307, 25305448, 28414315, 23918833, 29490942}","{31837602, 35403781, 31142662, 31075399, 27793799, 34378541, 28215221, 35002741, 32793596, 34344445}", ,,egcg,,,,,,,3 kinase,wortmannin,HY-L025-6,H04,HY-10197,Wortmannin,SL-2052; KY-12420,19545-26-7,428.43,Antibiotic; Autophagy; PI3K; Polo-like Kinase (PLK),Anti-infection; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively[1][2][3].",C23H24O8,DMSO : ≥ 50 mg/mL (116.71 mM),10mM,Cancer,No Development Reported,O=C1C([C@@](CC2)([H])[C@@]3(C)C2=O)=C([C@H](OC(C)=O)C3)[C@]4(C)C5=C1OC=C5C(O[C@@H]4COC)=O
fda,0,0,22,0,"{26745602, 29079305, 26500238, 36317327, 36835086, 36451861, 33509790, 32762399, 25136801, 33879459, 24648112, 36291766, 21970876, 35524675, 29852875, 23846731, 31492820, 20528225, 35812066, 36999792, 27689078, 37034616}","{32393731, 28807940, 31142662, 30529546, 35184394, 35881485, 28972303, 31973011, 36720918, 28978850, 34546978, 33310889, 32582706, 29792310, 29087414, 36318650, 33965371, 30079805, 30059709, 21447744, 35017665, 29907650, 33086530, 28176838, 32848091, 26351324, 37002845, 33811809, 26174566, 35348328, 28205554, 28847988, 30093685, 29764852, 31182587}", ,,#N/A,,,,,,,mtor,everolimus,HY-L025-7,D10,HY-10218,Everolimus,RAD001; SDZ-RAD,159351-69-6,958.22,Apoptosis; Autophagy; Bacterial; FKBP; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; PI3K/Akt/mTOR,"Everolimus (RAD001) is a <a href=""/Rapamycin.html"" class=""link-product"" target=""_blank"">Rapamycin</a> (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].",C53H83NO14,DMSO : 50 mg/mL (52.18 mM; ultrasonic and warming and heat to 60°C); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](OCCO)CC4)OC)C)=O)=O
phosphoinositide 3,0,0,21,0,"{21521159, 15549191, 18343945, 29670543, 21825040, 26091808, 26034349, 24130864, 23453624, 22628411, 25152578, 28454210, 29061961, 24445769, 21984975, 23918833, 20103665, 25311989, 26682870, 26735353, 26628860}","{25640480, 24533473, 37211680, 35385124, 36530982, 33480647, 34716294, 34020393, 34533562, 24657164, 33564720, 36341561, 12711674}", ,,#N/A,,,,,,,mtor,copanlisib,HY-L025-51,F09,HY-15346A,Copanlisib (dihydrochloride),BAY 80-6946 (dihydrochloride),1402152-13-9,553.44,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity[1].",C23H30Cl2N8O4,H2O : 20 mg/mL (36.14 mM; Need ultrasonic); DMSO : 5 mg/mL (9.03 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CN=C(N)N=C1)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C5=NCCN25.[H]Cl.[H]Cl
phosphoinositide 3 kinase,0,0,21,0,"{21521159, 18343945, 29670543, 21825040, 26091808, 26034349, 24130864, 23453624, 22628411, 25152578, 28454210, 29061961, 24445769, 21984975, 30226540, 23918833, 20103665, 25311989, 26682870, 26735353, 26628860}","{25640480, 24533473, 35385124, 36530982, 33480647, 34716294, 34020393, 34533562, 24657164, 33564720, 36341561, 12711674}", ,,wortmannin,,,,,,,mtor,nvp bkm120,HY-L025-64,F10,HY-70063,Buparlisib,BKM120; NVP-BKM120,944396-07-0,410.39,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.",C18H21F3N6O2,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : ≥ 100 mg/mL (243.67 mM),10mM,Cancer,Phase 3,FC(F)(C1=C(C2=CC(N3CCOCC3)=NC(N4CCOCC4)=N2)C=NC(N)=C1)F
target of rapamycin,0,0,21,0,"{21799944, 28705806, 22342683, 27200288, 29781033, 24791855, 24231729, 30142009, 24998203, 21840189, 26138072, 25143389, 25632222, 25632225, 30865892, 25601637, 31740775, 30226540, 24717934, 15313904, 26735353}","{30933440, 37211680, 32599680, 32917124, 29475942, 25307878, 30308518, 36623719, 36051080, 34716294, 27865874, 30365111, 36341561, 34533562, 28261211, 30136059}", ,,#N/A,,,,,,,mtor,hyperoside,HY-L025-74,E02,HY-N0452,Hyperoside,,482-36-0,464.38,Apoptosis; Fungal; Influenza Virus; NF-κB,Anti-infection; Apoptosis; NF-κB,"Hyperoside is a NF-κB inhibitor, found from Hypericum monogynum. Hyperoside shows anti-tumor, antifungal, anti-inflammatory, anti-viral, and anti-oxidative activities, and can induce  apoptosis[1][2].",C21H20O12,DMSO : 125 mg/mL (269.18 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,No Development Reported,OC1=CC(O)=C(C(C(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)=C(C3=CC=C(O)C(O)=C3)O4)=O)C4=C1
annexin,0,0,21,0,"{32707717, 21799944, 19801102, 35260176, 17671195, 30347681, 31930916, 18430374, 30372904, 35917363, 36076598, 25500542, 33922003, 25875797, 32110045, 20717927, 19631339, 33804148, 14521721, 9482108, 27878398}","{26878912, 29899872, 33888130, 36908321, 30308485, 23249862, 33597515, 29561307, 30552662, 28024472, 34097087, 12711674, 31523195, 34733788, 34565342, 32266878, 31632543}", ,,#N/A,,,,,,,mtor,cal 101,HY-L025-31,E11,HY-13026,Idelalisib,CAL-101; GS-1101,870281-82-6,415.42,Autophagy; PI3K,Autophagy; PI3K/Akt/mTOR,"Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable p110δ inhibitor with an IC50 of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.",C22H18FN7O,DMSO : ≥ 59.7 mg/mL (143.71 mM),10mM,Cancer,Launched,O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)CC)=NC5=C1C(F)=CC=C5
lncrnas,0,0,21,0,"{29389953, 29063045, 28860807, 29290766, 24469904, 29298720, 32727085, 22078386, 36612299, 26755660, 23662159, 36118868, 33061845, 34859606, 31325400, 31747939, 35547245, 30221677, 31562613, 32499447, 35433983}","{31914881, 25684227, 34976005, 35765893, 36575377, 31253147, 37004060, 31837602, 31514410, 31001132, 28187439, 33143730, 26111795, 33947836, 35486664, 33575113, 37035213, 36477655, 29133788, 31499747, 33844835, 35546353, 33962228, 30093685, 33500406}", ,,#N/A,,,,,,,mtor,bch,HY-L025-13,A06,HY-108540,LAT1-IN-1,BCH,20448-79-7,155.19,Apoptosis,Apoptosis,"LAT1-IN-1 (BCH) is a selective and competitive inhibitor of large neutral amino acid transporter 1 (LAT1) significantly inhibit cellular uptake of amino acids and mTOR phosphorylation, which induces the suppression of cancer growth and apoptosis[1][2][3].",C8H13NO2,H2O : 20 mg/mL (128.87 mM; ultrasonic and warming and heat to 60°C); DMSO : < 1 mg/mL (insoluble or slightly soluble),10mM,Cancer,No Development Reported,O=C(C1(N)C(C2)CCC2C1)O
sirnas,0,0,21,0,"{35804932, 28435453, 21698197, 36900379, 15682475, 35177646, 22868929, 33505218, 28389707, 17570131, 36581205, 23427041, 24809702, 26716649, 23205101, 36189421, 32262384, 29145206, 31088502, 35894141, 24041470}","{28681984, 29333921, 36352160, 29563491, 33622787, 36265509, 26099177, 32771387, 27008626, 29649811, 30786900, 35932692, 32339606, 28418907, 33310044, 21149631}", ,,#N/A,,,,,,,mtor,chidamide,HY-L025-13,E06,HY-109015,Tucidinostat,Chidamide; HBI-8000; CS 055,1616493-44-7,390.41,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Tucidinostat (Chidamide) is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC50s, 733 nM, 432 nM, respectively), and shows no effect on HDAC4/5/6/7/9[1].",C22H19FN4O2,DMSO : ≥ 50 mg/mL (128.07 mM),10mM,Cancer,Launched,O=C(C1=CC=C(CNC(/C=C/C2=CN=CC=C2)=O)C=C1)NC(C=CC(F)=C3)=C3N
hif,0,1,20,0,"{23857671, 32655498, 23749643, 32774415, 32179733, 23786654, 21320746, 33580614, 21573703, 33200711, 19097035, 26755660, 34320467, 33061845, 31076568, 25584484, 25305448, 16278378, 29693047, 19671674}","{31533472, 33298848, 33567268, 27292261, 34716294, 34415102, 26035625, 36343244, 29629903, 28187439, 33947836, 33287516, 29949369, 34255515, 28743452, 36139358}", ,,rapamycin,,,,,,,mtor,17 aag,HY-L025-7,D07,HY-10211,Tanespimycin,17-AAG; NSC 330507; CP 127374,75747-14-7,585.69,Antibiotic; Apoptosis; Autophagy; Bacterial; HSP; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90[1][5]. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression[3].",C31H43N3O8,DMSO : 50 mg/mL (85.37 mM; Need ultrasonic),10mM,Cancer; Infection,Phase 3,O=C(C(NC(/C(C)=C/C=C\[C@H](OC)[C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](C1)C)OC)O)C)OC(N)=O)=O)=CC2=O)C1=C2NCC=C
growth arrest,0,1,20,0,"{20452353, 25461770, 21225226, 20018721, 24282278, 30372904, 24240689, 30003124, 24040120, 33802809, 14613582, 17078869, 17569628, 11526239, 23408353, 34001634, 22127206, 21075310, 31310834, 22411900}","{26083714, 33945602, 35765893, 24584072, 28669341, 28026145, 23463074, 23154982, 36596519, 28805820, 23792448, 27864512, 30765888, 30924611, 28751557, 36741704, 29674704, 28408401, 31265875, 29246957, 37120495, 30451831, 33293694}", ,,#N/A,,,,,,,mtor,piceatannol,HY-L025-35,H10,HY-13518,Piceatannol,Astringenin; trans-Piceatannol,10083-24-6,244.24,Apoptosis; Autophagy; Endogenous Metabolite; Syk,Apoptosis; Autophagy; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI)[1]. Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties[2]. Piceatannol induces apoptosis in DLBCL cell lines[3]. Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells[4].,C14H12O4,DMSO : ≥ 31 mg/mL (126.92 mM); H2O : 1 mg/mL (4.09 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1O
wnt β catenin,0,2,20,0,"{24875648, 35254400, 26477318, 33279497, 31330317, 32774415, 36735511, 27655713, 35954337, 35229994, 33344439, 36367161, 33839689, 33662667, 34198989, 20814421, 26411367, 25305448, 26714478, 27889647}","{35499161, 31724259, 29519268, 33957539, 26983878, 29600711, 32828291, 26833129, 35096137, 36567628, 35259053, 34763437, 27717711, 30829648, 34370992, 30876979, 26367796, 25961913}", ,,wogonin,,,,,,,mtor,ribociclib,HY-L025-54,B07,HY-15777,Ribociclib,LEE011,1211441-98-3,434.54,CDK,Cell Cycle/DNA Damage,"Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[1].",C23H30N8O,DMSO : 20 mg/mL (46.03 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(N(C)C)C(N1C2CCCC2)=CC(C1=N3)=CN=C3NC(N=C4)=CC=C4N5CCNCC5
tumor regression,0,1,20,0,"{29259015, 29808009, 31492749, 37030295, 37162905, 25117978, 35247912, 12850474, 16171565, 36436020, 14767540, 34986552, 25888329, 32260561, 30283732, 36384095, 36216931, 32572645, 31046123, 28619758}","{32599680, 24045185, 35881485, 29472532, 28669341, 30824609, 31869746, 27764794, 30019901, 25299775, 27274052, 25564254, 26058079, 35198433, 25553514, 29208683, 26976114, 31346162, 33837043, 32371576, 28339196}", ,,#N/A,,,,,,,mtor,idelalisib,HY-L025-31,E11,HY-13026,Idelalisib,CAL-101; GS-1101,870281-82-6,415.42,Autophagy; PI3K,Autophagy; PI3K/Akt/mTOR,"Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable p110δ inhibitor with an IC50 of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.",C22H18FN7O,DMSO : ≥ 59.7 mg/mL (143.71 mM),10mM,Cancer,Launched,O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)CC)=NC5=C1C(F)=CC=C5
yap1,0,2,20,0,"{30142336, 33632898, 29364867, 31230347, 31557131, 31100813, 30214681, 24954535, 27215660, 31730860, 32434991, 35844783, 33501895, 34663879, 33146712, 33077732, 28381547, 35703534, 32203889, 34375670}","{31097696, 35601153, 33495462, 35705032, 31765738, 33115806, 32175692, 35399501, 33741710, 36378541, 29136404, 30205046, 34038745, 30382078}", ,,verteporfin,,,,,,,mtor,su11274,HY-L025-22,B11,HY-12014,SU11274,PKI-SU11274,658084-23-2,568.09,Apoptosis; Autophagy; c-Met/HGFR,Apoptosis; Autophagy; Protein Tyrosine Kinase/RTK,"SU11274 is a selective Met inhibitor with IC50 of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2.",C28H30ClN5O4S,DMSO : ≥ 100 mg/mL (176.03 mM),10mM,Cancer,No Development Reported,O=S(C1=CC2=C(C=C1)NC(/C2=C/C3=C(C(C(N4CCN(CC4)C)=O)=C(N3)C)C)=O)(N(C)C5=CC=CC(Cl)=C5)=O
ecm,0,2,19,0,"{31300513, 11590318, 16209712, 35428659, 33333043, 11522750, 36848578, 34262595, 35116738, 31797958, 33122631, 33580614, 36610378, 35405272, 30881497, 36408933, 23555182, 32660466, 32947833}","{31331201, 29878401, 34082824, 27409175, 18301994, 36613933, 28069687, 33504568, 30387133, 35571403, 34765643, 21251160, 34771678, 37120098, 36907496, 28846832, 32446320, 30529267, 35002741, 28182006, 32793596, 35782526}", ,,#N/A,,,,,,,mtor,punicalagin,HY-L025-72,A07,HY-N0063,Punicalagin,,65995-63-3,1084.72,HBV; SARS-CoV,Anti-infection,"Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive 3CLpro inhibitor and inhibits SARS-CoV-2 replication in vitro. Punicalagin is an anti-hepatitis B virus (HBV) agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19[1][2][3].",C48H28O30,DMSO : 50 mg/mL (46.09 mM; Need ultrasonic),10mM,Cancer; Infection; Metabolic Disease,Phase 4,O=C1C2=C(C3=C(O)C(O)=C2C4=C(O)C(O)=C(O)C=C4C(OC(C(OC5=O)C(C=O)OC(C6=C(C7=C5C=C(O)C(O)=C7O)C(O)=C(O)C(O)=C6)=O)C8O)=O)C9=C(C(O3)=O)C(C(C(O)=C(O)C(O)=C%10)=C%10C(OC8)=O)=C(O)C(O)=C9O1
tgf β1,0,0,19,0,"{35197444, 31817229, 34688654, 29222037, 31852956, 27539232, 37116704, 35279012, 34958892, 33045679, 23157946, 27485764, 29039574, 29229918, 27267807, 29261154, 21619683, 26915435, 35538031}","{33504568, 33757572, 36244457, 28804523, 30124204, 36613933, 34371697, 34146546, 29782963, 31707348, 28063381, 32544088, 35149305, 35127386, 30106235, 33664670, 34425215}", ,,hesperetin,,,,,,,mtor,tivantinib,HY-L025-63,G04,HY-50686,Tivantinib,ARQ 197,905854-02-6,369.42,Apoptosis; c-Met/HGFR,Apoptosis; Protein Tyrosine Kinase/RTK,Tivantinib is a highly selective c-Met tyrosine kinase inhibitor with a Ki of 355 nM.,C23H19N3O2,DMSO : 100 mg/mL (270.69 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(NC1=O)[C@@H](C2=CN3C4=C(C=CC=C42)CCC3)[C@@H]1C5=CNC6=C5C=CC=C6
cdk2,0,0,19,0,"{15811853, 32451092, 20669973, 35571489, 33879459, 34319912, 12055597, 9841966, 19639215, 24389175, 15930308, 15572689, 34412631, 24076388, 35103981, 25050737, 32434425, 22287227, 36346366}","{35198433, 27539364, 29540837, 25535366, 25553514, 36770891, 30971469, 33080301, 17942543, 24007471, 36284375, 29511348, 16940503}", ,,purvalanol a,,,,,,,mtor,pp2,HY-L025-40,B02,HY-13805,PP2,AGL 1879,172889-27-9,301.77,Src,Protein Tyrosine Kinase/RTK,"PP2 is a reversible and ATP-competitive Src family kinases inhibitor with IC50s of 4 and 5 nM for Lck and Fyn, respectively.",C15H16ClN5,DMSO : 50 mg/mL (165.69 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,No Development Reported,NC1=C2C(N(C(C)(C)C)N=C2C3=CC=C(Cl)C=C3)=NC=N1
malignant progression,0,1,19,0,"{21825040, 31534224, 37065746, 30569114, 35184157, 16585505, 15112354, 30614183, 28196015, 25058882, 18310088, 21738581, 31076568, 25376606, 30347501, 28842734, 30794864, 33005298, 31983610}","{30796033, 25222147, 36216804, 35765893, 26618343, 32157097, 26111795, 34415065}", ,,#N/A,,,,,,,src,n acetylcysteine,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
braf,0,1,18,0,"{28810144, 24978597, 29903880, 23846731, 19372556, 15367885, 16549325, 17353198, 25855536, 25266736, 25797243, 21734707, 30833748, 24604757, 25500057, 22628411, 22226782, 26732095}","{31696640, 23950209, 30353166, 25713167, 26087189, 24906137, 35177765, 36162600, 28108460, 30661164, 30192303, 28474232, 28820917, 28069687, 27169980, 33958721, 26983878, 33750776, 26284497, 35969744, 31932756, 29533782, 31549911, 31036508, 34771678, 31063649, 28576751, 23374840, 32898554, 29212027, 33781756, 29464061}", ,,dabrafenib,,,,,,,src,piceatannol,HY-L025-35,H10,HY-13518,Piceatannol,Astringenin; trans-Piceatannol,10083-24-6,244.24,Apoptosis; Autophagy; Endogenous Metabolite; Syk,Apoptosis; Autophagy; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI)[1]. Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties[2]. Piceatannol induces apoptosis in DLBCL cell lines[3]. Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells[4].,C14H12O4,DMSO : ≥ 31 mg/mL (126.92 mM); H2O : 1 mg/mL (4.09 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1O
pten,0,1,18,0,"{22462691, 20807812, 25601637, 24978597, 22784710, 24722280, 23390083, 29273451, 23169292, 24717934, 21984975, 24395249, 29059158, 26257206, 26380056, 15591514, 23316479, 24186143}","{30304769, 32934021, 33876771, 23521829, 30991141, 24444712, 27010857, 35135529, 29088303, 28881723, 27601596, 33158843, 26983878, 27572308, 30921702, 33339368, 33620092, 36753396, 29914872, 34403195, 30266108, 32355326, 25793663}", ,,melatonin,,,,,,,src,a 419259,HY-L025-54,A05,HY-15764A,A 419259 (trihydrochloride),RK 20449 trihydrochloride,1435934-25-0,592,Src,Protein Tyrosine Kinase/RTK,"A 419259 trihydrochloride is a Src family kinases inhibitor with IC50s of 9 nM, 3 nM and 3 nM for Src, Lck and Lyn, respectively.",C29H37Cl3N6O,H2O : ≥ 55 mg/mL (92.91 mM); DMSO : 1 mg/mL (1.69 mM; Need ultrasonic),10mM,Cancer,No Development Reported,NC1=C2C(N([C@H]3CC[C@H](N4CCN(C)CC4)CC3)C=C2C5=CC=C(OC6=CC=CC=C6)C=C5)=NC=N1.[H]Cl.[H]Cl.[H]Cl
matrix metalloproteinase,0,1,18,0,"{21288898, 20424515, 22234980, 14559813, 21856775, 19885545, 23588713, 11408348, 17487403, 26018318, 23555182, 23608755, 10554036, 23694968, 21558393, 22158044, 26381405, 20067773}","{24632608, 31331201, 29448097, 29878401, 30455393, 24520288, 28983590, 27477287, 26622824, 30872008, 16158187, 37043564, 32961679, 32774672, 35882867, 33504439, 29067128, 28237246}", ,,all trans retinoic acid,,,,,,,src,geldanamycin,HY-L025-50,F06,HY-15230,Geldanamycin,,30562-34-6,560.64,Antibiotic; Bacterial; HSP; Influenza Virus,Anti-infection; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,Geldanamycin is a Hsp90 inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.,C29H40N2O9,DMSO : 50 mg/mL (89.18 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,No Development Reported,COC(C(C=C1NC(/C(C)=C/C=C/[C@H](OC)[C@@H](OC(N)=O)/C(C)=C/[C@H](C)[C@H]2O)=O)=O)=C(C[C@H](C[C@@H]2OC)C)C1=O
xl,0,1,18,0,"{12021893, 26138072, 12850474, 28948203, 33687950, 33045679, 35260176, 23519249, 23302291, 23475955, 25875797, 34857016, 30142009, 23232026, 29670075, 17569628, 21840189, 20067773}","{31288832, 29709701, 35831302, 27406984, 32445837, 29440272, 30482844, 28663582, 33006750, 28042144, 32161312, 35385124, 33495462, 26397223, 35921705, 34875179, 27677740, 28059436, 32163373, 31862959, 36891574, 34959030, 31653826, 25338565, 28209615, 33741395, 34791636, 35332309, 29312470, 35315927, 33844952, 28418907, 28766941, 33945824, 34601571, 26254443, 30647404, 36332787, 23403638}", ,,quercetin,,,,,,,src,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
bcl xl,0,1,18,0,"{12021893, 26138072, 12850474, 28948203, 33687950, 33045679, 35260176, 23519249, 23302291, 23475955, 25875797, 34857016, 30142009, 23232026, 29670075, 17569628, 21840189, 20067773}","{31288832, 29709701, 27406984, 32445837, 29440272, 30482844, 28663582, 33006750, 28042144, 32161312, 33495462, 26397223, 35921705, 34875179, 27677740, 28059436, 32163373, 31862959, 36891574, 34959030, 31653826, 25338565, 28209615, 33741395, 34791636, 35332309, 29312470, 35315927, 33844952, 28418907, 28766941, 33945824, 34601571, 26254443, 30647404, 36332787, 23403638}", ,,betulinic acid,,,,,,,src,ibrutinib,HY-L025-14,D06,HY-10997A,Ibrutinib (Racemate),PCI-32765 (Racemate),936563-87-0,440.5,Btk,Protein Tyrosine Kinase/RTK,"Ibrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM.",C25H24N6O2,DMSO : 25 mg/mL (56.75 mM; Need ultrasonic),10mM,Cancer,Launched,C=CC(N1CC(N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C5=C(N)N=CN=C52)CCC1)=O
tumor suppression,0,0,18,0,"{30213082, 19029090, 31075266, 34070180, 31582374, 21056012, 19629168, 37140208, 22469842, 36102418, 23361300, 34040123, 33323382, 15300592, 8620534, 27454298, 22347323, 35894141}","{12237408, 28053089, 36352160, 27060168, 33214826, 22231120, 19731376, 36039890, 29366803, 20647772, 33798846}", ,,#N/A,,,,,,,src,selumetinib,HY-L025-63,G09,HY-50706A,Selumetinib (sulfate),AZD6244 (sulfate); ARRY-142886 (sulfate),943332-08-9,555.76,Apoptosis; MEK,Apoptosis; MAPK/ERK Pathway,"Selumetinib (AZD6244) is selective, non-ATP-competitive oral?MEK1/2?inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.",C17H17BrClFN4O7S,DMSO : 50 mg/mL (89.97 mM; Need ultrasonic); H2O : 1 mg/mL (1.80 mM; Need ultrasonic),10mM,Cancer,Launched,OCCONC(C(C=C1C(N=CN1C)=C2F)=C2NC3=C(C=C(Br)C=C3)Cl)=O.O=S(O)(O)=O
epcam,0,1,18,0,"{22806240, 29045505, 33127746, 31760766, 33744388, 23390083, 34100198, 33680936, 33693707, 24681997, 31963309, 29156783, 32641744, 22718289, 32162067, 24586805, 31106493, 24550494}","{32934021, 29997232, 31492561, 32166583, 27601596, 27835869}", ,,dapt,,,,,,,src,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
nf κb signaling,0,1,17,0,"{21673986, 27032419, 22056382, 23547054, 21536687, 26477488, 30563089, 31676721, 22751123, 27793842, 25237909, 33034134, 21819318, 23749528, 23447002, 32573499, 22752926}","{31331201, 26485762, 28724615, 24189064, 34782346, 30658190, 32961679, 32603665, 30300821, 31530390, 30321559, 29249691, 26225566, 33664670, 31570593, 31819043, 30253095, 36923307, 33603756, 31862959, 34974135, 29352508, 22645312, 27507649, 31330113, 33162822, 31707348, 35801173, 34392152, 30885979, 26668635, 35108062, 31115487, 34315876, 27520485, 26047594, 31975410, 35154163, 36364277, 24804860}", ,,#N/A,,,,,,,src,tirbanibulin,HY-L025-8,G07,HY-10340B,Tirbanibulin (Mesylate),KX2-391 (Mesylate); KX01 (Mesylate),1080645-95-9,527.63,Microtubule/Tubulin; Src,Cell Cycle/DNA Damage; Cytoskeleton; Protein Tyrosine Kinase/RTK,"Tirbanibulin Mesylate (KX2-391 Mesylate) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.",C27H33N3O6S,DMSO : 100 mg/mL (189.53 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NCC1=CC=CC=C1)CC2=NC=C(C3=CC=C(OCCN4CCOCC4)C=C3)C=C2.CS(=O)(O)=O
ubiquitination,0,0,17,0,"{35604033, 34978469, 25753158, 31935687, 18310088, 25939753, 24362026, 16278378, 30347501, 23288781, 31907951, 35844783, 36741265, 28765935, 34150617, 36624189, 26716510}","{19136002, 35402244, 24657799, 35906200, 31846298, 33596065, 23686307, 35371302, 31553577, 33596073, 36713387, 15666348, 30540463, 30227759, 32482868, 36438198, 11532602, 33024699, 28805820, 36719036, 26687678, 28805822, 36202813, 33086530, 35295813, 15744326, 30606790, 33780296, 28481868, 35559244, 22708559, 32820047, 28378579, 32559187, 32726616, 32110043, 34593637, 30940648, 30137962, 29581547, 33660782, 35987950, 29892083, 36606710, 28656888, 32893690, 24220028, 32355326, 31028095}", ,,#N/A,,,,,,,src,azm475271,HY-L025-36,E03,HY-13561,AZM475271,M475271,476159-98-5,442.94,Src,Protein Tyrosine Kinase/RTK,"AZM475271 is a potent and selective Src kinase inhibitor with IC50 of 5 nM; no inhibitory activity on Flt3, KDR, Tie-2.
IC50 value: 5 nM [1]
Target: Src inhibitor
in vitro: AZM475271 demonstrated strong dose-dependent inhibition of Src tyrosine kinase activity in the L3.6pl human pancreatic carcinoma cell line. Maximum reduction of Src kinase activity was observed after incubation for 4 hours with ≥5 μmol/L. The IC50 concentration of AZM475271 to inhibit the phosphorylation of c-src, lck, and c-yes was 0.01, 0.03, and 0.08 μmol/L, respectively, in comparison with an IC50 of 0.7 μmol/L AZM475271 to inhibit KDR [2].
in vivo: Tumors appeared to be palpable at day 14 after tumor cell injection in all animals except mice treated with both AZM475271 and gemcitabine, in which the earliest possible palpation of the tumors was at day 17 after tumor cell injection. Treatment with gemcitabine or AZM475271 alone did not significantly change animal weight [2].",C23H27ClN4O3,DMSO : ≥ 42 mg/mL (94.82 mM),10mM,Cancer,No Development Reported,CN1CCC(COC2=CC3=NC=NC(NC4=CC(OC)=CC=C4Cl)=C3C=C2OC)CC1
short hairpin rna,0,0,17,0,"{22160930, 24126434, 32434425, 19549704, 31456633, 27338794, 32972302, 24561527, 24240689, 28607485, 18413748, 30003124, 34412631, 31177911, 35884957, 26616862, 35433983}","{25053825, 25694599, 26055303, 19706770, 30272279, 27957794, 34763437, 30933440, 34893510, 33718091, 21907920, 32559187, 26324948, 31023702, 26622824, 36907496, 33128042, 22897906, 17626100, 20051959}", ,,#N/A,,,,,,,phosphatidylinositol 3,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
tumor cell growth,0,0,17,0,"{34901697, 36216931, 10624710, 23912455, 12649190, 25156550, 20675343, 24130864, 31725297, 19523441, 26373299, 10449972, 26715643, 22790202, 11054395, 37129853, 26979711}","{12237408, 32320642, 29540837, 30127528, 33380808, 33128042, 31934287, 29691442, 36690674, 34258104, 25249180}", ,,#N/A,,,,,,,phosphatidylinositol 3,wortmannin,HY-L025-6,H04,HY-10197,Wortmannin,SL-2052; KY-12420,19545-26-7,428.43,Antibiotic; Autophagy; PI3K; Polo-like Kinase (PLK),Anti-infection; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively[1][2][3].",C23H24O8,DMSO : ≥ 50 mg/mL (116.71 mM),10mM,Cancer,No Development Reported,O=C1C([C@@](CC2)([H])[C@@]3(C)C2=O)=C([C@H](OC(C)=O)C3)[C@]4(C)C5=C1OC=C5C(O[C@@H]4COC)=O
ferroptosis,0,0,17,0,"{33489473, 34955844, 35131878, 31822343, 35533575, 32368394, 35504235, 36443441, 33311482, 31920150, 36353142, 31456633, 30031610, 34331036, 26097885, 36499358, 33271455}","{33298848, 37066758, 36276071, 33008584, 36309482, 36873167, 32863216, 35645713, 32536370, 36539410, 35332309, 30988278, 33947836}", ,,#N/A,,,,,,,phosphatidylinositol 3 kinase,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
transdifferentiation,0,0,17,0,"{11358848, 25623042, 34526722, 23999170, 32891173, 30058725, 17230504, 28188746, 28639695, 24195024, 25698580, 26697077, 33932087, 14732924, 32709695, 21607102, 27610015}","{34624676, 36034982, 34520583, 29343723, 30476723, 28182006, 30106235, 35782526}", ,,#N/A,,,,,,,phosphatidylinositol 3 kinase,losartan,HY-L025-58,E05,HY-17512A,Losartan (potassium),DuP-753 (potassium),124750-99-8,461,Angiotensin Receptor,GPCR/G Protein,"Losartan potassium (DuP-753 potassium) is an angiotensin II receptor type 1 (AT1) antagonist, competing with the binding of angiotensin II to AT1 with an IC50 of 20 nM.",C22H22ClKN6O,DMSO : ≥ 110 mg/mL (238.61 mM); H2O : 50 mg/mL (108.46 mM; Need ultrasonic),10mM,Cardiovascular Disease; Endocrinology; Cancer,Launched,OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=N[N-]N=N4)C=C2.[K+]
master regulator,0,1,17,0,"{35604033, 28141826, 35477123, 30135074, 27862693, 26771140, 27477511, 35814251, 32434991, 31134896, 26117456, 26151762, 36882420, 36993718, 28867190, 36162331, 31911550}","{35694209, 25684227, 31142662, 33159815, 33296649, 36124682, 31697807, 34285329, 30996246, 36780189, 30350260, 30807094, 35871292, 35491403, 33809617, 21949397, 29603290, 22922464, 36187489, 33849067, 32151278, 33660782, 33234676, 36077302, 27846392}", ,,#N/A,,,,,,,phosphatidylinositol 3 kinase,amd3100,HY-L025-64,C10,HY-50912,Plerixafor (octahydrochloride),AMD3100 (octahydrochloride); JM3100 (octahydrochloride); SID791 (octahydrochloride),155148-31-5,794.47,CXCR; HIV; Virus Protease,Anti-infection; GPCR/G Protein; Immunology/Inflammation,Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC50 of 44 nM.,C28H62Cl8N8,H2O : 100 mg/mL (125.87 mM; Need ultrasonic); DMSO : < 1 mg/mL (insoluble or slightly soluble),10mM,Inflammation/Immunology; Endocrinology; Cancer,Launched,[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.N1(CCCNCCNCCCNCC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3
rapamycin,0,1,16,0,"{27200288, 25632225, 25601637, 31740775, 29781033, 24717934, 24791855, 15313904, 24231729, 24998203, 31177911, 21840189, 26735353, 22342683, 25143389, 25632222}","{32599680, 32917124, 34716294, 36051080, 27865874, 26840085, 37211680, 30308518, 30365111, 36341561, 35432890, 34533562, 25299775, 30933440, 28261211, 29475942, 25307878, 36623719, 30136059}", ,,#N/A,,,,,,,phosphatidylinositol 3 kinase,lovastatin,HY-L025-74,G03,HY-N0504,Lovastatin,Mevinolin,75330-75-5,404.54,Autophagy; Ferroptosis; HMG-CoA Reductase (HMGCR),Apoptosis; Autophagy; Metabolic Enzyme/Protease,Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.,C24H36O5,DMSO : ≥ 100 mg/mL (247.19 mM),10mM,Cardiovascular Disease; Cancer,Launched,O=C([C@@H](C)CC)O[C@@H]1[C@@]([C@H]2CC[C@@H](OC3=O)C[C@H](C3)O)([H])C(C=C[C@@H]2C)=C[C@H](C)C1
jak stat,0,1,16,0,"{24875648, 28253828, 29358341, 24809702, 33279497, 26572553, 30142155, 28496202, 21779469, 29808009, 25387567, 26575024, 32774415, 33037138, 26572242, 26682870}","{33705733, 31156620, 33469840, 32647323, 29249691, 36139421, 36100643, 35902886, 28653353, 32437546, 27677740, 25623213, 31927213, 28035374, 31875887, 27507649, 29316431, 30206163, 34397140, 25345375, 33987681, 32153186, 27250929, 34125178}", ,,tofacitinib,,,,,,,phosphatidylinositol 3 kinase,enzastaurin,HY-L025-8,G09,HY-10342,Enzastaurin,LY317615,170364-57-5,515.61,Apoptosis; Autophagy; PKC,Apoptosis; Autophagy; Epigenetics; TGF-beta/Smad,"Enzastaurin (LY317615) is a potent and selective PKCβ inhibitor with an IC50 of 6 nM, showing 6- to 20-fold selectivity over PKCα, PKCγ and PKCε[1].",C32H29N5O2,DMSO : 8.33 mg/mL (16.16 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C(C1=CN(C)C2=C1C=CC=C2)=C3C4=CN(C5CCN(CC6=NC=CC=C6)CC5)C7=C4C=CC=C7)NC3=O
activators,0,0,16,0,"{22509024, 17174914, 9641882, 20682659, 32912902, 26929740, 23076142, 31057295, 21825040, 12483152, 24713432, 30142009, 19860666, 9482108, 26118878, 33271455}","{34201346, 33723398, 16415879, 24296585, 10365964, 31726225, 18025106, 34696466, 25319830, 16512664, 27821592, 20493850, 34255515, 35906200, 33815322, 29437854, 17148447, 28248992, 29804834, 26569506, 23041316, 27388964, 34199844, 15312679, 35194019, 12419247, 33712563, 29212213, 16943289, 31922235, 29309117, 34097087, 36857796, 17023429, 20709061, 7898440, 30206163, 7565781, 17049045, 17030999, 27372760, 21749977, 28107481, 29343578, 36732631, 32559581, 33795806, 25345375, 31097696, 30413535, 9034338, 19828451, 20808803, 31294688, 35016035, 36826464, 27990121, 25263595, 21652721, 10567538, 35782526, 35740532, 36958711, 34581757, 31222014, 20505343}", ,,#N/A,,,,,,,phosphatidylinositol 3 kinase,nvp bkm120,HY-L025-64,F10,HY-70063,Buparlisib,BKM120; NVP-BKM120,944396-07-0,410.39,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.",C18H21F3N6O2,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : ≥ 100 mg/mL (243.67 mM),10mM,Cancer,Phase 3,FC(F)(C1=C(C2=CC(N3CCOCC3)=NC(N4CCOCC4)=N2)C=NC(N)=C1)F
methylated,0,0,16,0,"{30149376, 27904769, 33505218, 27758883, 31306149, 36969862, 23912455, 26023084, 22083596, 32520974, 29626481, 33005298, 36353587, 27602165, 32576853, 24852279}","{36300937, 21596426, 30369550, 27494802, 36385171, 34236185, 17687328, 32629664, 34793513, 11850414, 28341809, 25575605, 34039605, 26178744, 22498752, 30386240, 30634442, 31492561, 33664855, 32762714, 20538714, 18765789, 34865122, 27273316, 37120495, 15970672, 36098557}", ,,#N/A,,,,,,,phosphatidylinositol 3 kinase,copanlisib,HY-L025-51,F09,HY-15346A,Copanlisib (dihydrochloride),BAY 80-6946 (dihydrochloride),1402152-13-9,553.44,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity[1].",C23H30Cl2N8O4,H2O : 20 mg/mL (36.14 mM; Need ultrasonic); DMSO : 5 mg/mL (9.03 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CN=C(N)N=C1)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C5=NCCN25.[H]Cl.[H]Cl
utr,0,0,16,0,"{19818597, 22127206, 32626951, 36586571, 26755660, 22384141, 31047726, 32972302, 24608432, 30654191, 11439698, 35703534, 23973710, 29140695, 26036346, 30604411}","{32046432, 32938017, 28950657, 29777702, 26940039, 27425608, 22570411, 31059052, 32081805, 21608014, 32640974, 33686960, 29434197, 35127482, 31253147, 30481052, 30408638}", ,,#N/A,,,,,,,phosphatidylinositol 3 kinase,staurosporine,HY-L025-49,F07,HY-15141,Staurosporine,Antibiotic AM-2282; STS; AM-2282,62996-74-1,466.53,Antibiotic; Apoptosis; Bacterial; Fungal; PKA; PKC,Anti-infection; Apoptosis; Epigenetics; Stem Cell/Wnt; TGF-beta/Smad,"Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC50s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase respectively. Staurosporine also inhibits TAOK2 with an IC50 of 3 μM. Staurosporine is an apoptosis inducer[1][2][3][4][5].",C28H26N4O3,DMSO : 62.5 mg/mL (133.97 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C(NC1)C2=C1C3=C(C4=C2C5=C(C=CC=C5)N4[C@H]6C[C@@H](NC)[C@@H](OC)[C@]7(C)O6)N7C8=CC=CC=C83
growth suppression,0,0,16,0,"{26725216, 19712481, 12649190, 10766343, 17018633, 35201948, 36189421, 34688654, 15452878, 10911615, 14767540, 34921013, 16489047, 34852220, 21999932, 11526239}","{12237408, 27764802, 31250978, 31900258, 32999044, 34524279, 29142067, 21949397, 33858423, 34285087}", ,,#N/A,,,,,,,phosphatidylinositol 3 kinase,myricetin,HY-L025-49,D10,HY-15097,Myricetin,Cannabiscetin,529-44-2,318.24,Apoptosis; Autophagy; Endogenous Metabolite,Apoptosis; Autophagy; Metabolic Enzyme/Protease,"Myricetin is a common plant-derived flavonoid with a wide range of activities including strong anti-oxidant, anticancer, antidiabetic and anti-inflammatory activities.",C15H10O8,DMSO : ≥ 31 mg/mL (97.41 mM); Ethanol : 28.57 mg/mL (89.78 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC1=CC(O)=C(C(C(O)=C(C2=CC(O)=C(O)C(O)=C2)O3)=O)C3=C1
tumor associated macrophages,0,0,16,0,"{30463776, 31262852, 32572645, 34947972, 32809834, 35948109, 36741230, 24909166, 35346801, 31920150, 32611735, 34276760, 35156921, 32341020, 32070494, 30404927}","{31696640, 31819043, 35847495, 32184777, 32286255, 32603665, 35988145, 35755286, 35094142}", ,,#N/A,,,,,,,phosphatidylinositol 3 kinase,dactolisib,HY-L025-50,A09,HY-15174,Dactolisib (Tosylate),BEZ235 (Tosylate); NVP-BEZ 235 (Tosylate),1028385-32-1,641.74,Autophagy; mTOR; PI3K,Autophagy; PI3K/Akt/mTOR,"Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.",C37H31N5O4S,H2O : < 0.1 mg/mL (insoluble); DMSO : 34 mg/mL (52.98 mM; Need ultrasonic and warming),10mM,Cancer,Phase 3,CN(C1=C2C3=CC(C4=CC5=CC=CC=C5N=C4)=CC=C3N=C1)C(N2C6=CC=C(C=C6)C(C)(C#N)C)=O.CC7=CC=C(S(=O)(O)=O)C=C7
pik3ca,0,1,15,0,"{26091808, 19440799, 25714017, 22041919, 18343945, 26350096, 25797243, 23475955, 25311989, 28188630, 29059158, 18413752, 22628411, 30836094, 24186143}","{33876771, 35177765, 26983878, 33596424, 26771497, 34144267, 19706770, 31652979, 32877461, 35514200, 30584090, 34409758}", ,,ly294002,,,,,,,phosphatidylinositol 3 kinase,gs 1101,HY-L025-31,E11,HY-13026,Idelalisib,CAL-101; GS-1101,870281-82-6,415.42,Autophagy; PI3K,Autophagy; PI3K/Akt/mTOR,"Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable p110δ inhibitor with an IC50 of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.",C22H18FN7O,DMSO : ≥ 59.7 mg/mL (143.71 mM),10mM,Cancer,Launched,O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)CC)=NC5=C1C(F)=CC=C5
jak,0,1,15,0,"{24875648, 24809702, 30154150, 26572553, 26255562, 28496202, 27215660, 21779469, 29808009, 32350089, 27068336, 32266098, 26572242, 21321110, 26682870}","{34499329, 32977027, 33705733, 31156620, 33469840, 34168981, 35950489, 32647323, 29249691, 36139421, 28042144, 36100643, 35385124, 36164005, 35902886, 28653353, 32437546, 34272171, 27677740, 25623213, 31927213, 28035374, 31875887, 34875179, 36891574, 27507649, 37195585, 29316431, 32245330, 30206163, 34397140, 33844952, 25345375, 33987681, 32153186, 27250929, 36332787, 34125178}", ,,ag490,,,,,,,phosphatidylinositol 3 kinase,pterostilbene,HY-L025-76,F02,HY-N0828,Pterostilbene,,537-42-8,256.3,Autophagy,Autophagy,"Pterostilbene is a stilbenoid isolated from blueberries and Pterocarpus marsupium[1]. Shows anti-oxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and anti-obesity properties[1][4]. Pterostilbene blocks ROS production[3], also exhibits inhibitory activity against various free radicals such as DPPH, ABTS, hydroxyl, superoxide and hydrogen peroxide[4].",C16H16O3,DMSO : 110 mg/mL (429.18 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 3,OC1=CC=C(/C=C/C2=CC(OC)=CC(OC)=C2)C=C1
chemokine,0,0,15,0,"{21926469, 27659014, 22472349, 23712777, 25683115, 21996748, 16373424, 32453916, 26213494, 27737879, 18664506, 19509115, 32341020, 17546589, 29253566}","{35417091, 33159815, 33776776, 25606026, 25890327, 29448097, 36721187, 31080358, 25713319, 27517095, 29694891, 24924589, 27657907, 31874106, 36793283, 29593031, 28077651, 35007061, 30938974, 34315876, 32747750, 29208683, 29954928, 32868081, 37182455, 34336890, 30106235}", ,,quercetin,,,,,,,phosphatidylinositol 3 kinase,ag490,HY-L025-22,A04,HY-12000,AG490,Tyrphostin AG490; Tyrphostin B42,133550-30-8,294.3,Autophagy; EGFR; JAK; STAT,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.",C17H14N2O3,DMSO : ≥ 50 mg/mL (169.89 mM),10mM,Cancer,No Development Reported,O=C(NCC1=CC=CC=C1)/C(C#N)=C/C2=CC=C(O)C(O)=C2
receptor signaling,0,0,15,0,"{25934336, 20103639, 15549191, 23441129, 21779469, 22975375, 18693168, 30008881, 32194994, 26174103, 30881497, 20484026, 26262587, 32424701, 24186143}","{34568834, 29127434, 35850772, 26301565, 28434841, 25049379, 19318566, 37184294, 31862959, 33355184, 35743155, 33947836, 33980611, 33718091, 33531470, 27300431, 34074211, 30089714, 34160250, 35252219, 34581757}", ,,#N/A,,,,,,,wnt,niclosamide,HY-L025-68,E03,HY-B0497,Niclosamide,BAY2353,50-65-7,327.12,Antibiotic; Parasite; STAT,Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt,"Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells[2][3][5].",C13H8Cl2N2O4,DMSO : 4.55 mg/mL (13.91 mM; Need ultrasonic); DMF : 5 mg/mL (15.28 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Infection; Cancer,Launched,O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2O
cck 8,0,0,15,0,"{31891232, 33857498, 31922213, 22020907, 30913453, 31047726, 32774415, 33643376, 29970191, 35433491, 31889908, 34099637, 36367161, 32141657, 33631610}","{34082824, 32314893, 32961679, 33407504, 35842703, 35778964, 35883157, 28024472, 34387610, 33663517, 31632543, 35434025, 35981367, 37201092, 25338565, 35096137, 35571403, 26304078, 27573714, 34730838, 24985178, 32100443, 35116642, 34876902, 36244457, 32812145, 28545522, 35494514, 36871542, 29783800, 32943995, 26456956, 34140798}", ,,proglumide,,,,,,,wnt,iwp 4,HY-L025-30,D09,HY-12879,IWP-4,,686772-17-8,496.62,Wnt,Stem Cell/Wnt,IWP-4 is a small molecule Wnt inhibitor with an IC50 of 25 nM.,C23H20N4O3S3,DMSO : 1.3 mg/mL (2.62 mM; Need ultrasonic),2mM,Cancer,No Development Reported,O=C(NC1=NC2=CC=C(C)C=C2S1)CSC3=NC(CCS4)=C4C(N3C5=CC=CC=C5OC)=O
nfκb,0,2,15,0,"{24875648, 34098465, 31030752, 20424515, 35247012, 22118662, 23613993, 31174057, 28867179, 35346801, 26384530, 26182900, 33824054, 25875801, 24894173}","{33159815, 28515341, 33741710, 31195152, 28726418, 32331282, 29415456, 37184294, 30241450, 28951988, 28215221, 34765643, 33158995, 30712413, 26093279, 31692901, 26047594, 36706161, 35002741, 33348732, 30479742}", ,,wogonin,,,,,,,wnt,wogonin,HY-L025-74,B09,HY-N0400,Wogonin,,632-85-9,284.26,Apoptosis; Autophagy; CDK; Wnt,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Stem Cell/Wnt,"Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.",C16H12O5,DMSO : 62.5 mg/mL (219.87 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,No Development Reported,O=C1C=C(C2=CC=CC=C2)OC3=C(OC)C(O)=CC(O)=C13
pi3k mtor,0,1,15,0,"{23470560, 32371585, 21678117, 35674408, 28574828, 34198989, 29757973, 27435925, 26451606, 26257206, 30261145, 23232026, 31391551, 28513565, 18525343}","{32599680, 30606790, 29475942, 34716294, 33051401, 30232459, 25537515, 26536665, 36318650, 31036508, 34565342}", ,,bez235,,,,,,,wnt,nigericin,HY-L025-1,H07,HY-100381,Nigericin (sodium salt),,28643-80-3,746.94,Antibiotic; Bacterial; NOD-like Receptor (NLR); Potassium Channel,Anti-infection; Immunology/Inflammation; Membrane Transporter/Ion Channel,"Nigericin sodium salt is an antibiotic from Streptomyces hygroscopicus that works by acting as an H+, K+, and Pb2+ ionophore, a NLRP3 activator[1].",C40H67NaO11,Ethanol : ≥ 50 mg/mL (66.94 mM); DMSO : 11.76 mg/mL (15.74 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 60°C),10mM,Cancer; Infection,No Development Reported,C[C@H]1[C@](O[C@@H]2C[C@](CC[C@@H]3C)([H])O[C@@]3([H])[C@@H](C)C(O[Na])=O)([C@@H]([C@H](OC)C2)C)O[C@](C)([C@@]4([H])O[C@@](C)([C@@]5([H])O[C@@]([C@]([C@@H](C[C@@H]6C)C)([H])O[C@]6(O)CO)([H])C[C@H]5C)CC4)C1
apoptosis induction,0,1,15,0,"{19084933, 32707717, 36384095, 29757658, 36945130, 17487403, 26716649, 15580305, 11594773, 33076247, 30261145, 24215674, 35203351, 24028894, 30555743}","{27406984, 28415755, 32961679, 26051217, 28669341, 31015208, 30532520, 31104301, 31267379, 30037819, 36652476, 32978368, 34126285, 29312470, 35030628, 35600879, 34107377, 31523195, 24721791}", ,,#N/A,,,,,,,wnt,ncb 0846,HY-L025-3,H03,HY-100830,NCB-0846,,1792999-26-8,375.42,MAP4K; Wnt,MAPK/ERK Pathway; Stem Cell/Wnt,NCB-0846 is an orally available TNIK inhibitor with an IC50 of 21?nM.,C21H21N5O2,DMSO : ≥ 30 mg/mL (79.91 mM),10mM,Cancer,No Development Reported,O[C@@H](CC1)CC[C@@H]1OC2=CC=CC(C=N3)=C2N=C3NC4=CC=C(N=CN5)C5=C4
notch1,0,1,15,0,"{34659905, 35197444, 27381829, 23284900, 32699558, 27308552, 26279302, 24040120, 35664782, 24880079, 21304978, 34986552, 20484026, 34657147, 24216479}","{30304769, 24584072, 35943053, 25072021, 25948186, 35173274, 27148573, 26407966, 24394663, 29088303, 35852337, 36768307, 37213235, 28820917, 25369933, 34415065, 31226848, 31059052, 31281517, 29180399, 27651315, 33135348, 27531767, 34415102}", ,,pf 03084014,,,,,,,wnt,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
chronic inflammation,0,1,15,0,"{35563777, 31923844, 34955844, 7874278, 24058792, 22419113, 10328172, 34580018, 24212630, 31070039, 27991926, 27058937, 30250298, 34354940, 27413117}","{27491296, 31331201, 29273506, 32060899, 36711864, 37217935, 31195152, 23255218, 27008626, 27865874, 36176467, 32820150, 24759736, 28173625, 33616410, 35152859, 34791293}", ,,#N/A,,,,,,,wnt,propofol,HY-L025-69,B04,HY-B0649,Propofol,"2,6-Diisopropylphenol",2078-54-8,178.27,Endogenous Metabolite; GABA Receptor,Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling,Propofol potently and directly activates GABAA receptor and inhibits glutamate receptor mediated excitatory synaptic transmission. Propofol has antinociceptive properties and is used for sedation and hypnotic[1].,C12H18O,DMSO : 100 mg/mL (560.95 mM; Need ultrasonic); H2O : 0.5 mg/mL (2.80 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,OC1=C(C(C)C)C=CC=C1C(C)C
cdk4 6,0,1,15,0,"{34001634, 36719686, 30254182, 34440587, 30271501, 26158861, 33472910, 30696953, 31745297, 29059158, 32234521, 37105116, 28513565, 36346366, 32109375}","{25053825, 31727874, 35881485, 25072021, 34954522, 28663582, 28042144, 37211680, 30135075, 32393766, 27677740, 32793389, 33158576, 34385584, 36274096, 32694708, 36318650, 36755269, 36741704, 28604107, 30049486, 27186656, 34942306, 35149545, 26254443, 30057199, 30136059, 37252349}", ,,ly2835219,,,,,,,wnt,g007 lk,HY-L025-26,F03,HY-12438,G007-LK,,1380672-07-0,529.96,PARP,Cell Cycle/DNA Damage; Epigenetics,"G007-LK is a potent and selective inhibitor of TNKS1 and TNKS2, with IC50s of 46 nM and 25 nM, respectively.",C25H16ClN7O3S,DMSO : ≥ 30 mg/mL (56.61 mM),10mM,Cancer,No Development Reported,ClC1=C(C=CC=C1)N2C(/C=C/C3=NN=C(C4=CC=C(C#N)C=C4)O3)=NN=C2C5=CC=C(S(C)(=O)=O)C=N5
raf,0,0,14,0,"{26725216, 9918209, 15930308, 14559813, 24847881, 19372556, 17353198, 19501586, 21734707, 30833748, 15289335, 28513565, 22628411, 12799645}","{24194944, 31043489, 26620707, 24349540, 27496136, 36124682, 33154093, 35600879, 26284497, 26840085, 28069687, 27678457, 27158366}", ,,ly294002,,,,,,,wnt,chloroquine,HY-L025-58,G04,HY-17589A,Chloroquine,,54-05-7,319.87,Antibiotic; Autophagy; HIV; Parasite; SARS-CoV; Toll-like Receptor (TLR),Anti-infection; Autophagy; Immunology/Inflammation,Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].,C18H26ClN3,Ethanol : 100 mg/mL (312.63 mM; Need ultrasonic); DMSO : 50 mg/mL (156.31 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,CC(NC1=CC=NC2=CC(Cl)=CC=C12)CCCN(CC)CC
3 kinase,0,0,14,0,"{26725216, 22462691, 20807812, 14559813, 11034087, 17353198, 21984975, 15572689, 15073105, 15289335, 23453624, 26735353, 22628411, 17974973}","{32599680, 32917124, 33596421, 34716294, 33596424, 24657164, 34751372, 30134175, 25640480, 36682147, 35385124, 36530982, 34020393, 30537514, 34875179, 34638508, 33564720, 32694708, 36891574, 36341561, 34533562, 30933440, 26992199, 33480647, 34688842, 29133261, 24836559, 24533473, 17178852, 36599397, 29475942, 33520370, 12711674, 30136059}", ,,ly294002,,,,,,,wnt,bml 284,HY-L025-63,A03,HY-19987,BML-284,,853220-52-7,350.37,Wnt,Stem Cell/Wnt,BML-284 is a potent and cell-permeable Wnt signaling activator. BML-284 induces TCF-dependent transcriptional activity with an EC50?of 700 nM[1].,C19H18N4O3,DMSO : ≥ 100 mg/mL (285.41 mM),10mM,Cancer,No Development Reported,NC1=NC(C2=CC=CC(OC)=C2)=CC(NCC3=CC=C(OCO4)C4=C3)=N1
bax,0,0,14,0,"{16146690, 12021893, 22118662, 17569628, 12850474, 25997867, 22580602, 25050737, 23302291, 22532787, 24389175, 23963802, 28455228, 11526239}","{29878401, 29709701, 34995979, 32445837, 33407504, 31527063, 29353886, 32161312, 34634662, 29567272, 34959030, 25338565, 32249419, 35332309, 24985178, 33531996, 28391274, 30156013, 32551032, 27055867, 36157053}", ,BRD4 inhibitor regulates Bax proteins,astragaloside iv,,,,,,,wnt,dmat,HY-L025-52,G05,HY-15535,DMAT,CK2 Inhibitor; Casein kinase II Inhibitor,749234-11-5,476.79,Casein Kinase,Cell Cycle/DNA Damage; Stem Cell/Wnt,DMAT is a potent and specific CK2 inhibitor with an IC50 value of 130 nM.,C9H7Br4N3,DMSO : 50 mg/mL (104.87 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C)C1=NC2=C(Br)C(Br)=C(Br)C(Br)=C2N1
stat,0,1,14,0,"{24875648, 19712481, 21871555, 24809702, 31296870, 29808009, 26255562, 28496202, 21779469, 19288493, 27520560, 26682870, 20103639, 26628860}","{33705733, 31156620, 21271695, 33469840, 29249691, 32647323, 36139421, 36100643, 35902886, 28653353, 32437546, 27677740, 25623213, 31927213, 30943407, 28035374, 31875887, 27507649, 29316431, 30206163, 34397140, 18502747, 25345375, 33987681, 32153186, 30793699, 27250929, 34125178, 30266108}", ,,ag490,,,,,,,wnt,crocin,HY-L025-75,G08,HY-N0697,Crocin,Crocin I,42553-65-1,976.96,Endogenous Metabolite,Metabolic Enzyme/Protease,"Crocin (Crocin I) is a nutraceutical and the main constituent isolated from the stigmas of Crocus sativus with immense pharmacological properties as anti-inflammatory, anticancer, antidepressant and anticonvulsant[1].",C44H64O24,DMSO : 125 mg/mL (127.95 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,O[C@@H]([C@H](O)[C@H]1O)[C@H](O[C@H]1OC(/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C(O[C@@H]([C@@H]([C@@H](O)[C@@H]2O)O)O[C@@H]2CO[C@@H]([C@@H]([C@@H](O)[C@@H]3O)O)O[C@@H]3CO)=O)=O)CO[C@@H]([C@@H]([C@@H](O)[C@@H]4O)O)O[C@@H]4CO
nuclear translocation,0,0,14,0,"{21619683, 29059173, 21723941, 21856775, 27694919, 28069799, 29151594, 15811853, 24340014, 18829525, 30412725, 31177911, 17671195, 20067773}","{24859008, 33757572, 27793799, 24657164, 36120591, 32596881, 27957794, 28983590, 31325480, 36613933, 24799421, 30518851, 35646539, 24836559, 26324948, 35801173, 34392152, 36963289, 25891802, 30455393, 12941796, 36641892, 30062054, 35002741, 33781885, 33630975}", ,,#N/A,,,,,,,nras,trametinib,HY-L025-14,D08,HY-10999A,Trametinib (DMSO solvate),GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate),1187431-43-1,693.53,Apoptosis; MEK,Apoptosis; MAPK/ERK Pathway,Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis[1][2].,C28H29FIN5O5S,DMSO : 69 mg/mL (99.49 mM; Need ultrasonic),10mM,Cancer,Launched,CN1C(C(C)=C(N(C(N(C2=O)C3CC3)=O)C4=CC=CC(NC(C)=O)=C4)C2=C1NC5=CC=C(C=C5F)I)=O.CS(C)=O
ampk,0,0,14,0,"{31508487, 29322792, 28591720, 33689707, 32972302, 33161807, 33226737, 30833748, 30165365, 29440631, 30142009, 30038429, 26939902, 32762399}","{31914881, 27864418, 27010499, 29167426, 31250978, 28933601, 32917124, 32982695, 35308165, 28118076, 28525743, 31697807, 36568944, 31776981, 26036281, 29172540, 32787262, 33607295}"," Regulating cellular redox, targeting KRAS/AMPK signaling, or reversing metabolic reprogramming might be effective approaches to eliminate cancer stem cells (CSCs) and enhance chemosensitivity to GEM to improve the prognosis of PanCa patients.",BRD4 inhibitor induced phosphorylation of AMPKa; AMPKa knockdown attentuated autophagy induction and antiproliferation effect (31250978),staurosporine,,,,,,,pik3ca,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
cellular senescence,0,0,14,0,"{23408353, 34001634, 35477123, 30614183, 25461770, 28948203, 28892048, 19904754, 30003124, 33649045, 24583638, 31133044, 26904954, 32554750}","{23792448, 27081696, 36755269, 33495462, 32954665, 21889194, 34183849, 26802028, 30539410, 31265875, 36458010, 29434197, 34803511, 34160250}", ,,#N/A,,,,,,,pik3ca,aspirin,HY-L025-46,C07,HY-14654,Aspirin,Acetylsalicylic Acid; ASA,50-78-2,180.16,Apoptosis; Autophagy; Caspase; COX; Mitophagy; NF-κB; p38 MAPK; Virus Protease,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB,"Aspirin (Acetylsalicylic Acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis[1][2][3][4][5][6].",C9H8O4,DMSO : 400 mg/mL (2220.25 mM; Need ultrasonic); H2O : 0.1 mg/mL (0.56 mM; Need ultrasonic),10mM,Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease,Launched,OC(C1=C(OC(C)=O)C=CC=C1)=O
programmed cell death,0,1,14,0,"{32337408, 36311715, 36586571, 35948109, 31709456, 37065746, 32194994, 27402485, 34698902, 35581303, 23213974, 35222011, 26097885, 11526239}","{32630154, 36752907, 30696721, 36539410, 24952595, 33158814, 30824609, 32366754, 28270499, 36898211, 23728299, 32303673, 35127482, 31633227, 36873167, 31751121, 32726482, 35332309, 36799196, 32863216, 35289334, 34524279, 35918330, 30266108}", ,,#N/A,,,,,,,pik3ca,taselisib,HY-L025-41,C04,HY-13898,Taselisib,GDC-0032; RG-7604,1282512-48-4,460.53,PI3K,PI3K/Akt/mTOR,"Taselisib (GDC-0032) is a potent PI3K inhibitor targets PIK3CA mutations, with Kis of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.",C24H28N8O2,DMSO : 25 mg/mL (54.29 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,CC(C)N1C(C2=CN3C(C(C(OCC3)=C4)=CC=C4C5=CN(C(C)(C(N)=O)C)N=C5)=N2)=NC(C)=N1
retinoblastoma,0,0,14,0,"{20113529, 21699781, 25042889, 32655498, 15811853, 26904954, 32256815, 28892048, 27347121, 30003124, 36882420, 29059158, 32234521, 9641882}","{29914080, 9326598, 19244327, 11331592, 15548137, 31485609, 33515627, 36596519, 7523245, 21447565, 33080301, 36274096, 9016949, 37014264, 36318650, 20495359}", ,,#N/A,,,,,,,pik3ca,alpelisib,HY-L025-50,F10,HY-15244,Alpelisib,BYL-719,1217486-61-7,441.47,PI3K,PI3K/Akt/mTOR,"Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC50s of 5/250/290/1200 nM, respectively. Antineoplastic activity[1][2][3].",C19H22F3N5O2S,DMSO : 83.33 mg/mL (188.76 mM; Need ultrasonic),10mM,Cancer,Launched,CC(N=C(S1)NC(N2CCC[C@H]2C(N)=O)=O)=C1C3=CC(C(C)(C(F)(F)F)C)=NC=C3
cell cycle regulation,0,1,14,0,"{12647072, 30084546, 28825637, 24058792, 11382316, 17363501, 36975534, 34888306, 26384530, 23912084, 17078869, 12605716, 10935512, 8927612}","{23950209, 35765893, 30272279, 36193305, 30042400, 19244327, 19683497, 28653353, 25623213, 24924589, 34385584, 26378038, 34062779, 26303420, 28838216, 20032077, 30048594, 27081696, 19596781, 33086063, 24220028, 15112318}", ,,#N/A,,,,,,,bax,astragaloside iv,HY-L025-74,D03,HY-N0431,Astragaloside IV,,84687-43-4,784.97,ERK; JNK; MMP,MAPK/ERK Pathway; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.",C41H68O14,DMSO : ≥ 100 mg/mL (127.39 mM),10mM,Cancer,No Development Reported,O[C@H]1[C@H](O)[C@@H](O)[C@]([H])(O[C@@H]2C(C)(C)[C@@]([C@@H](O[C@]3([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C[C@]4([H])[C@@]56CC[C@@]7(C)[C@@]4(C)C[C@H](O)[C@]7([H])[C@]8(C)O[C@H](C(C)(O)C)CC8)([H])[C@]5(C6)CC2)OC1
splicing,0,0,14,0,"{26477314, 32355831, 34057028, 32814086, 23425895, 32559497, 22128300, 28167572, 33796221, 37098965, 29301749, 34857016, 23868061, 19609950}","{27536004, 9858827, 18513937, 33822745, 32624538, 31747612, 29312415, 26216992, 19301030, 15312679, 9649319, 22570411, 27129259, 35930668, 33792558, 28967088, 36968369, 34031359, 10841781, 15640247, 28069948, 24048450, 21441348, 18480452, 23128391, 33431496, 35426377, 35491403, 36343244, 21608014, 29555663, 31801551, 28783698, 29751762, 34470615, 24231520, 30568163, 34540900, 24065768, 36857449, 19629165, 36711789, 26551281, 31911672, 35636729, 12711674, 34344445, 23287038, 30527999}", ,,#N/A,,,,,,,bax,galangin,HY-L025-74,B04,HY-N0382,Galangin,"Norizalpinin; 3,5,7-Trihydroxyflavone",548-83-4,270.24,Autophagy; Cytochrome P450,Autophagy; Metabolic Enzyme/Protease,Galangin (Norizalpinin) is?an?agonist/antagonist?of the?arylhydrocarbon?receptor. Galangin (Norizalpinin) also shows inhibition of CYP1A1 activity.,C15H10O5,DMSO : 125 mg/mL (462.55 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C(O)=C(C2=CC=CC=C2)OC3=CC(O)=CC(O)=C13
antitumor immunity,0,1,14,0,"{35014625, 25416195, 33674596, 33509790, 32807942, 33747719, 33786412, 36158188, 27471630, 32194994, 33747255, 36878969, 36512410, 28837246}","{30182276, 34782346, 34365463, 32928920, 34508829, 28270499, 35953828, 35923111, 29493812, 32196028, 36370878, 33574085, 29670088, 32184777, 28408401, 31063649, 29208683, 27651309, 35618289, 28969075, 34524279}", ,,#N/A,,,,,,,bax,mdivi 1,HY-L025-54,G06,HY-15886,Mdivi-1,Mitochondrial division inhibitor 1,338967-87-6,353.22,Apoptosis; Autophagy; Dynamin; Mitophagy,Apoptosis; Autophagy; Cytoskeleton,Mdivi-1 is a selective dynamin-related protein 1 (Drp1) inhibitor. Mdivi-1 is a mitochondrial division/mitophagy inhibitor.,C15H10Cl2N2O2S,DMSO : 160 mg/mL (452.98 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1N(C2=C(Cl)C=C(Cl)C(OC)=C2)C(S)=NC3=C1C=CC=C3
pk,0,0,14,0,"{8063617, 30128034, 24831652, 21573703, 9252680, 30106154, 26505547, 35896270, 28449008, 18266003, 35920660, 15003513, 34508795, 31078621}","{31527168, 29657099, 25851940, 35859878, 36077617, 33643826, 33798846, 36709310, 9488450, 27682507, 34543572, 36914652, 28892380, 35816286, 28586718, 33955700, 34648693, 30879350, 28368119, 29541371}", ,,staurosporine,,,,,,,bax,cyclosporin a,HY-L025-68,H08,HY-B0579,Cyclosporin A,Cyclosporine A; Ciclosporin A; CsA,59865-13-3,1202.61,Antibiotic; Complement System; Molecular Glues; Phosphatase,Anti-infection; Immunology/Inflammation; Metabolic Enzyme/Protease; PROTAC,Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of calcineurin with an IC50 of 5 nM[3]. Cyclosporin A also inhibits CD11a/CD18 adhesion[8].,C62H111N11O12,Ethanol : 50 mg/mL (41.58 mM; Need ultrasonic); DMSO : 62.5 mg/mL (51.97 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Launched,C/C=C/C[C@H]([C@@H](O)[C@@]1(N(C)C([C@]([H])(C(C)C)N(C)C([C@H](CC(C)C)N(C)C([C@]([H])(CC(C)C)N(C)C([C@@H](C)NC([C@H](C)NC([C@@H](N(C([C@@]([H])(NC([C@@H](N(C(CN(C([C@@H](NC1=O)CC)=O)C)=O)C)CC(C)C)=O)C(C)C)=O)C)CC(C)C)=O)=O)=O)=O)=O)=O)[H])C
hh,0,0,14,0,"{25024225, 21704226, 22086851, 27758883, 30373214, 30128034, 32571902, 34046348, 17353198, 27573236, 18829525, 20814421, 26257206, 23786654}","{33958721, 34333666, 28593508, 34634662, 31114028, 32380205, 25355313, 33643826, 32913560, 30018745, 31182587}","inhibiting HH bad in PDAC? (32571902), seems good to combine w/ MEK inhibitor (30373214)"," Here, we identify a novel SOX2-BRD4 transcriptional complex driving the expression of GLI1, the final effector of the HH/GLI pathway (33958721); also 34634662",cyclopamine,,,,,,,bax,liquiritin,HY-L025-74,A11,HY-N0376,Liquiritin,,551-15-5,418.39,Reactive Oxygen Species,Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Liquiritin, a flavonoid isolated from Glycyrrhiza uralensis, is a potent and competitive AKR1C1 inhibitor with IC50s of 0.62 μM, 0.61 μM, and 3.72μM for AKR1C1, AKR1C2 and AKR1C3, respectively. Liquiritin efficiently inhibits progesterone metabolism mediated by AKR1C1 in vivo[1]. Liquiritin acts as an antioxidant and has neuroprotective, anti-cancer and anti-inflammatory activity[2].",C21H22O9,DMSO : 150 mg/mL (358.52 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Cancer; Inflammation/Immunology; Neurological Disease,No Development Reported,O=C1C[C@@H](C2=CC=C(O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O)C=C2)OC4=CC(O)=CC=C14
differentially expressed genes,0,1,13,0,"{26719042, 33505218, 26880586, 32235821, 33110094, 33753999, 23614574, 32660466, 30881497, 18784821, 28105175, 28198009, 33631610}","{33705733, 33412753, 36381331, 32626975, 27142060, 34539188, 34926268, 29568956, 32484798, 16008511, 33947836, 33893325, 32927694, 35685458, 32762714, 12705884, 35699165, 33476703, 31765738, 35349485, 27466232, 26582142}", ,,#N/A,,,,,,,bax,furosemide,HY-L025-66,E10,HY-B0135A,Furosemide (sodium),,41733-55-5,352.73,GABA Receptor; NKCC,Membrane Transporter/Ion Channel; Neuronal Signaling,"Furosemide sodium is a potent and orally active inhibitor of Na+/K+/2Cl-?(NKCC) cotransporter, NKCC1 and NKCC2[1].?Furosemide sodium is also a GABAA?receptors antagonist and displays 100-fold selectivity for?α6-containing receptors than?α1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema[2].",C12H10ClN2NaO5S,H2O : 100 mg/mL (283.50 mM; Need ultrasonic); DMSO : ≥ 150 mg/mL (425.25 mM),10mM,Cancer; Metabolic Disease,Launched,O=C(C1=CC(S(=O)(N)=O)=C(C=C1NCC2=CC=CO2)Cl)O[Na]
cell signaling,0,0,13,0,"{25714017, 28259298, 24978597, 24704294, 24878567, 31903112, 26915435, 24130864, 25253202, 28277619, 27087446, 30213082, 29279356}","{29415456, 24533473, 25623136, 28553123, 34160902, 23128391, 32354121, 19005066, 24796395, 36711980, 32582706, 34710325, 29050361, 37119804, 37131839}", ,,#N/A,,,,,,,ap 1,staurosporine,HY-L025-49,F07,HY-15141,Staurosporine,Antibiotic AM-2282; STS; AM-2282,62996-74-1,466.53,Antibiotic; Apoptosis; Bacterial; Fungal; PKA; PKC,Anti-infection; Apoptosis; Epigenetics; Stem Cell/Wnt; TGF-beta/Smad,"Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC50s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase respectively. Staurosporine also inhibits TAOK2 with an IC50 of 3 μM. Staurosporine is an apoptosis inducer[1][2][3][4][5].",C28H26N4O3,DMSO : 62.5 mg/mL (133.97 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C(NC1)C2=C1C3=C(C4=C2C5=C(C=CC=C5)N4[C@H]6C[C@@H](NC)[C@@H](OC)[C@]7(C)O6)N7C8=CC=CC=C83
protein interaction,0,1,13,0,"{26719042, 33505218, 36118824, 16278378, 25387567, 36261459, 30881497, 30594165, 32355831, 37201049, 30278585, 37151998, 35449823}","{31015424, 9699856, 7583761, 36305426, 34754068, 33616410, 34597402, 25758752, 36711980, 22137933, 33867857, 25849938, 28024402, 12032084, 16412250, 26702435, 35650157, 18539634, 37162611, 25974391, 32860796, 28726418, 22136469, 27465367, 24976024, 34982556, 29179037, 12359327, 25323695, 22788793, 27403962, 24623816, 34661079, 28365532, 31931101, 28766941, 11487468, 26358508, 28849908, 10716917, 19038968, 31920381, 23095041, 34995458, 31718149, 33705733, 34579723, 18495759, 24497428, 12198165, 30465816, 31815961, 36656921, 27390756, 35833124, 35371302, 34378541, 34152239, 24403256, 24048450, 28624199, 36378954, 22464331, 36180820, 32805211, 29567837, 28053347, 26552700, 19846528, 31914881, 27219844, 27673482, 22710155, 23752591, 10809234, 32080280, 35052443, 31364510, 29312415, 15994786, 25799074, 26858406, 30833074, 28757943, 27266999, 30387133, 32669118, 22498752, 36304339, 16940503, 25549280, 34073056, 26145250, 28300771, 9858534, 23576556, 26629616, 32149490}", ,,#N/A,,,,,,,ap 1,atorvastatin,HY-L025-57,H04,HY-17379,Atorvastatin (hemicalcium salt),CI-981; Atorvastatin hemicalcium,134523-03-8,577.67,Autophagy; Ferroptosis; HMG-CoA Reductase (HMGCR),Apoptosis; Autophagy; Metabolic Enzyme/Protease,"Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3].",C33H34Ca0.5FN2O5,DMSO : ≥ 50 mg/mL (86.55 mM); H2O : < 0.1 mg/mL (insoluble),10mM,Metabolic Disease; Inflammation/Immunology; Cancer,Launched,FC1=CC=C(C2=C(C3=CC=CC=C3)C(C(NC4=CC=CC=C4)=O)=C(C(C)C)N2CC[C@@H](O)C[C@@H](O)CC([O-])=O)C=C1.[0.5Ca2+]
protein protein interaction,0,1,13,0,"{26719042, 33505218, 36118824, 35707377, 36261459, 30881497, 30594165, 32355831, 37201049, 35449823, 30278585, 37151998, 36116415}","{23095041, 31914881, 34995458, 27219844, 31718149, 33705733, 27673482, 23752591, 9699856, 7583761, 10809234, 28726418, 24497428, 12198165, 22136469, 34754068, 30465816, 32080280, 33616410, 36656921, 35052443, 34982556, 31364510, 12359327, 25758752, 34597402, 15994786, 27390756, 35833124, 26858406, 35371302, 36305426, 36711980, 34378541, 34152239, 30833074, 28757943, 24403256, 22788793, 30387133, 32669118, 22498752, 32860796, 24048450, 36378954, 28024402, 36304339, 12032084, 36180820, 16940503, 16412250, 32805211, 28365532, 31931101, 29567837, 28766941, 25549280, 28053347, 28300771, 11487468, 35650157, 26629616, 37162611, 10716917, 19038968, 26552700, 31920381}", ,,#N/A,,,,,,,ap 1,sr 11302,HY-L025-54,F07,HY-15870,SR 11302,,160162-42-5,376.53,AP-1,Immunology/Inflammation,SR 11302 is an activator protein-1 (AP-1) transcription factor inhibitor. SR 11302 is a retinoid that specifically inhibits AP-1 activity without activating the transcription of retinoic acid response element (RARE)[1].,C26H32O2,DMSO : 25 mg/mL (66.40 mM; ultrasonic and warming and heat to 80°C),10mM,Cancer; Inflammation/Immunology,No Development Reported,O=C(O)/C=C(C)/C=C/C=C(C1=CC=C(C)C=C1)/C=C/C2=C(C)CCCC2(C)C
p akt,0,0,13,0,"{22784710, 27333990, 21799944, 22207048, 30894280, 26497549, 32256815, 26261555, 23561972, 32336215, 28679769, 23232026, 35116637}","{25053825, 34524258, 34591491, 34634662, 35472745, 29954928, 34956562, 36871542, 26663801, 34926269, 28766687}",inhibiting ITGA6 and RPSA weaken invation/metastasis via downregulating p-AKT and p-ERK1/2 (30894280),"Here, we targeted bromodomain 4 (BRD4) in combination with another molecular metabolic tumor driver, the Akt/mTOR signaling pathway, to provide a highly effective treatment for this neoplasm (35472745)",ly294002,,,,,,,ap 1,tsa,HY-L025-49,F10,HY-15144,Trichostatin A,TSA,58880-19-6,302.37,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].",C17H22N2O3,DMSO : 25 mg/mL (82.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
cdk,0,0,13,0,"{34001634, 33879459, 26530532, 26416424, 25305448, 35457227, 9841966, 19639215, 37030295, 9641882, 26934555, 37105116, 25931518}","{34633088, 23950209, 21900162, 31727874, 17942543, 32331282, 31067678, 33420321, 27539364, 36711980, 30227759, 28215221, 34062779, 28281917, 26627013, 35681734, 32012890, 31900258, 26254443, 30975979, 30104685, 32412527, 25944566}", ,,ly2835219,,,,,,,ap 1,indomethacin,HY-L025-43,G06,HY-14397A,Indomethacin (sodium hydrate),Indometacin (sodium hydrate),74252-25-8,433.82,Antibiotic; Bacterial; COX; Influenza Virus,Anti-infection; Immunology/Inflammation,"Indomethacin (Indometacin) sodium hydrateis a potent, orally active COX1/2  inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin sodium hydrateis has anticancer activity and anti-infective activity. Indomethacin sodium hydrateis can be used for cancer, inflammation and viral infection research[1][2][3].",C19H21ClNNaO7,DMSO : 12.5 mg/mL (28.81 mM; ultrasonic and warming and heat to 60°C); H2O : 25 mg/mL (57.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Launched,O=C(O[Na])CC1=C(C)N(C(C2=CC=C(Cl)C=C2)=O)C3=C1C=C(OC)C=C3.O.O.O
mdm2,0,2,13,0,"{30942624, 16818496, 23340292, 36243652, 19424582, 35131878, 25042889, 33178766, 26228206, 32531376, 24889936, 29153842, 16251039}","{28766886, 35371302, 11331592, 28604107, 34272171, 33154093, 30385614, 17369165, 33431824, 16204849, 32245330, 34875179, 35249548, 36862767, 33844952, 33034426, 31036508, 28766941}",inhibiting MDM2 reactivates TP53 tumor suppressor (36243652),,nutlin 3,,,,,,,ap 1,chrysin,HY-L025-45,F07,HY-14589,Chrysin,"5,7-Dihydroxyflavone",480-40-0,254.24,Estrogen Receptor/ERR,Vitamin D Related/Nuclear Receptor,Chrysin is one of the most well known estrogen blockers.,C15H10O4,DMSO : ≥ 100 mg/mL (393.33 mM),10mM,Cancer,No Development Reported,OC1=C2C(OC(C3=CC=CC=C3)=CC2=O)=CC(O)=C1
repressor,0,0,13,0,"{37116704, 33489473, 28178529, 29315556, 28664456, 31109321, 17114344, 20005451, 26416424, 19362090, 21734707, 26609108, 26716510}","{12489984, 12906115, 16315011, 18406149, 36287107, 31913353, 25606026, 16954381, 30658190, 28684431, 33431824, 28972303, 27865874, 32457617, 28837371, 32462489, 29529243, 31712669, 33732255, 35952671, 30824609, 27903272, 31467179, 11850414, 28525743, 36923952, 20542002, 29439026, 15834423, 16943289, 26910138, 36652476, 20098423, 17023429, 21478341, 28847821, 33344510, 21726812, 32407006, 33547232, 34523489, 32943995, 34540900, 34605158, 29018219, 18488044, 19883376, 35941107, 8626294, 8626295, 34283254, 34125178, 27055867, 33293694, 26289535}", ,,#N/A,,,,,,,p65,puerarin,HY-L025-72,F03,HY-N0145,Puerarin,,3681-99-0,416.38,5-HT Receptor,GPCR/G Protein; Neuronal Signaling,"Puerarin, an isoflavone extracted from Radix puerariae, is a 5-HT2C receptor antagonist.",C21H20O9,DMSO : 50 mg/mL (120.08 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Launched,O=C1C(C2=CC=C(O)C=C2)=COC3=C([C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)C(O)=CC=C13
mcl,0,1,13,0,"{35604033, 28160167, 19288493, 35884957, 28765935, 30142009, 19523441, 15956974, 25875797, 37030295, 30214681, 30261145, 35583805}","{28950657, 29709701, 26055303, 28415755, 30305939, 35041430, 31993368, 28663582, 32161312, 35921705, 33154093, 29287727, 34959030, 31882553, 34062779, 29156797, 31653826, 26627013, 35031886, 28024402, 35132755, 35332309, 34557659, 25564254, 33945824, 35261801, 35153769, 26254443, 32156781, 29290992, 29764852, 29914872, 24721791}",Mcl proteins are tumor protective/oncogenic (37030295),,#N/A,,,,,,,p65,costunolide,HY-L025-71,G09,HY-N0036,Costunolide,(+)-Costunolide; Costus lactone,553-21-9,232.32,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"Costunolide ((+)-Costunolide) is a naturally occurring sesquiterpene lactone, with antioxidative, anti-inflammatory, antiallergic, bone remodeling, neuroprotective, hair growth promoting, anticancer, and antidiabetic properties. Costunolide can induce cell cycle arrest and apoptosis on breast cancer cells[1][2][3].",C15H20O2,DMSO : ≥ 49 mg/mL (210.92 mM); Ethanol : 25 mg/mL (107.61 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,No Development Reported,O=C(O[C@@]1([H])[C@@]2([H])CC/C(C)=C/CC/C(C)=C/1)C2=C
ras raf,0,0,12,0,"{10871844, 21723941, 14559813, 26983463, 24847881, 23441129, 19288493, 15316751, 26257206, 15289335, 17569628, 28513565}","{26620707, 24349540, 27496136, 36124682, 33154093, 27158366}", ,,#N/A,,,,,,,p65,dioscin,HY-L025-72,E02,HY-N0124,Dioscin,Collettiside III; CCRIS 4123,19057-60-4,869.04,Apoptosis; Autophagy,Apoptosis; Autophagy,"Dioscin(CCRIS 4123; Collettiside III) is a natural steroid saponin derived from several plants, showing potent anti-cancer effect against a variety of tumor cell lines. 
IC50 value:
Target: Anticancer agent
in vitro: dioscin (1, 2 and 4 μmol/L) could significantly inhibit the viability of LNCaP cells in a time- and concentration-dependent manner. Flow cytometry revealed that the apoptosis rate was increased after treatment of LNCaP cells with dioscin for 24 h, indicating that apoptosis was an important mechanism by which dioscin inhibited cancer [1]. dioscin abrogated AKT phosphorylation, which subsequently impaired RANKL-induced nuclear factor-kappaB (NF-κB) signaling pathway and inhibited NFATc1 transcriptional activity. Moreover, in vivo studies further verified the bone protection activity of dioscin in osteolytic animal model [2]. Dioscin reduced cell death and lactate dehydrogenase (LDH) release in cells subjected to I/R. I/R induced apoptosis and cytochrome c release from mitochondria to the cytosol and this was prevented by dioscin. In support, dioscin decreased Bax but increased Bcl-2 mRNA expression. Dioscin prevented I/R induced dissipation of ΔΨm [3].",C45H72O16,DMSO : ≥ 100 mg/mL (115.07 mM),10mM,Cancer,Launched,O[C@@H]1[C@@H](O)[C@H](C)O[C@@]([H])(O[C@H]2[C@H](O)[C@@H](O[C@]3([H])O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@](O[C@@H]4CC5=CC[C@]([C@]([H])(C[C@@]6([H])[C@]7([H])[C@H](C)[C@]8(OC[C@H](C)CC8)O6)[C@]7(C)CC9)([H])[C@@]9([H])[C@@]5(C)CC4)([H])O[C@@H]2CO)[C@@H]1O
phosphatidylinositol 3 kinase,0,0,12,0,"{26725216, 22462691, 20807812, 14559813, 17974973, 11781836, 17353198, 15313904, 15572689, 15073105, 15289335, 10781373}","{32599680, 32917124, 33596421, 33596424, 34751372, 30134175, 36682147, 30537514, 34875179, 34638508, 32694708, 36891574, 30933440, 26992199, 34688842, 29133261, 24836559, 17178852, 29475942, 33520370, 30136059}", ,,ly294002,,,,,,,p65,budesonide,HY-L025-36,G05,HY-13580,Budesonide,,51333-22-3,430.53,Glucocorticoid Receptor,Immunology/Inflammation; Vitamin D Related/Nuclear Receptor,"Budesonide, an inhaled glucocortical steroid, is an orally active glucocorticoid receptor agonist. Budesonide decreases the size of lung tumors, reverses DNA hypomethylation and modulates mRNA expression of genes. Budesonide is an anti-inflammatory agent used for asthma[1][2][3].",C25H34O6,DMSO : 215 mg/mL (499.38 mM; Need ultrasonic and warming),10mM,Cancer; Inflammation/Immunology,Launched,O=C(C=C[C@@]12C)C=C1CC[C@@]([C@]2([H])[C@@H](O)C[C@@]34C)([H])[C@]3([H])C[C@]5([H])[C@@]4(C(CO)=O)OC(CCC)O5
receptor tyrosine kinases,0,2,12,0,"{31068384, 11034087, 20717927, 23441129, 12622410, 26597578, 31046123, 31492749, 25736685, 28608366, 32796566, 14521721}","{32599680, 31043489, 32393731, 36696581, 30630822, 30537514, 28108460, 31932756, 29792310, 28474232}", ,,sorafenib,,,,,,,p65,pristimerin,HY-L025-78,A07,HY-N1937,Pristimerin,Celastrol methyl ester,1258-84-0,464.64,Bacterial,Anti-infection,Pristimerin is a potent and reversible monoacylglycerol lipase (MGL) inhibitor with an IC50 of 93 nM.,C30H40O4,DMSO : 20 mg/mL (43.04 mM; Need ultrasonic); DMF : 25 mg/mL (53.81 mM; Need ultrasonic),10mM,Cancer,No Development Reported,C[C@](C1=CC=C(C(C)=C2O)C3=CC2=O)(CC[C@]4(C)[C@@]5([H])C[C@@](C(OC)=O)(C)CC4)[C@]5(CC[C@]13C)C
jak2,0,2,12,0,"{26404002, 26530532, 27345450, 26575024, 32583281, 24648112, 27003603, 21586612, 37210549, 26682870, 26227479, 32947833}","{27401345, 36051080, 35015307, 34365463, 32647323, 28042144, 34624676, 24584101, 28336808, 32437546, 34875179, 29088303, 24568369, 36702002, 31621555, 36891574, 36814396, 29907650, 30102854, 34290255, 31036508, 28586718, 22904298, 29914872, 29464061, 23929215}",CMap analysis suggests JAK2 as a target in PDAC (32947833),,sp600125,,,,,,,p65,garcinol,HY-L025-11,H08,HY-107569,Garcinol,,78824-30-3,602.8,Apoptosis; Cholinesterase (ChE); Endogenous Metabolite; Histone Acetyltransferase,Apoptosis; Epigenetics; Metabolic Enzyme/Protease; Neuronal Signaling,"Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards acetyl cholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50s of 0.66 μM and 7.39 μM, respectively[1]. Garcinol also inhibits histone acetyltransferases (HATs, IC50= 7 μM) and p300/CPB-associated factor (PCAF, IC50 = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity[2].",C38H50O6,DMSO : 50 mg/mL (82.95 mM; Need ultrasonic); Ethanol : 20 mg/mL (33.18 mM; Need ultrasonic and warming),10mM,Cancer; Inflammation/Immunology,No Development Reported,C/C(C)=C\C[C@@H](C[C@]12C([C@](C(C)([C@@H](C2)C/C=C(C)\C)C)(C/C=C(C)\C)C(C(C(C3=CC(O)=C(C=C3)O)=O)=C1O)=O)=O)C(C)=C
annexin v,0,0,12,0,"{30347681, 32707717, 18430374, 20717927, 21799944, 30372904, 19801102, 35260176, 25875797, 36076598, 32110045, 27878398}","{26878912, 29899872, 33888130, 36908321, 30308485, 23249862, 29561307, 30552662, 28024472, 34097087, 31523195, 34733788, 34565342, 32266878, 31632543}",annexin staining assay,,nac,,,,,,,p65,imd 0354,HY-L025-6,B09,HY-10172,IMD-0354,IKK2 Inhibitor V,978-62-1,383.67,IKK,NF-κB,IMD-0354 (IKK2 Inhibitor V) is a selective IKKβ inhibitor which inhibits NF-κB activity[1]. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC50 of 1.2 uM[2].,C15H8ClF6NO2,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : ≥ 100 mg/mL (260.64 mM),10mM,Cancer,No Development Reported,O=C(NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C2=CC(Cl)=CC=C2O
cell fate,0,0,12,0,"{25566081, 30014851, 22056382, 26909576, 28188746, 25894862, 31534224, 29452147, 28178232, 29289465, 17488476, 26716510}","{28626565, 30655386, 20493850, 26646171, 35264162, 34037670, 30227759, 30428346, 34293822, 26119999, 37059907, 34910919, 36256455, 34341073, 35799890, 33490899, 37108181, 37207130, 30139998, 25036774, 20181741, 33736688, 34146546, 26546038, 27651452}", ,,#N/A,,,,,,,p65,myricetin,HY-L025-49,D10,HY-15097,Myricetin,Cannabiscetin,529-44-2,318.24,Apoptosis; Autophagy; Endogenous Metabolite,Apoptosis; Autophagy; Metabolic Enzyme/Protease,"Myricetin is a common plant-derived flavonoid with a wide range of activities including strong anti-oxidant, anticancer, antidiabetic and anti-inflammatory activities.",C15H10O8,DMSO : ≥ 31 mg/mL (97.41 mM); Ethanol : 28.57 mg/mL (89.78 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC1=CC(O)=C(C(C(O)=C(C2=CC(O)=C(O)C(O)=C2)O3)=O)C3=C1
mcl 1,0,1,12,0,"{35604033, 28160167, 19288493, 15956974, 28765935, 30142009, 19523441, 25875797, 37030295, 30214681, 30261145, 35884957}","{28950657, 29709701, 28415755, 35041430, 31993368, 32161312, 35921705, 33154093, 29287727, 34959030, 34062779, 29156797, 31653826, 26627013, 28024402, 35132755, 35332309, 25564254, 33945824, 35261801, 35153769, 32156781, 29290992, 29764852, 29914872}","see ""mcl"" above",,at 101,,,,,,,p65,matrine,HY-L025-72,G08,HY-N0164,Matrine,Matridin-15-one; Vegard; α-Matrine,519-02-8,248.36,Apoptosis; Autophagy; Ferroptosis; Mitophagy; Opioid Receptor,Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling,"Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI)[1][2][3][4][5].",C15H24N2O,H2O : 20 mg/mL (80.53 mM; Need ultrasonic); DMSO : ≥ 50 mg/mL (201.32 mM),10mM,Cancer; Inflammation/Immunology,Launched,O=C1CCC[C@]2([H])[C@@]3([H])CCCN4[C@@]3([H])[C@](CCC4)([H])CN21
ccnd1,0,1,12,0,"{16382049, 33505218, 17233604, 35302596, 28860807, 35472201, 11751405, 32972302, 27919956, 20113529, 19860666, 22188669}","{32828291, 34199844, 36755269, 36530982, 24657799, 35969736, 31631721, 34586831, 27440272, 29545201, 19706770, 30305939, 31594641, 36923952, 34385584, 31036508}",CCND1 frequently mutated in PDAC (35302596),,resveratrol,,,,,,,stat,ag490,HY-L025-22,A04,HY-12000,AG490,Tyrphostin AG490; Tyrphostin B42,133550-30-8,294.3,Autophagy; EGFR; JAK; STAT,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.",C17H14N2O3,DMSO : ≥ 50 mg/mL (169.89 mM),10mM,Cancer,No Development Reported,O=C(NCC1=CC=CC=C1)/C(C#N)=C/C2=CC=C(O)C(O)=C2
akt2,0,1,12,0,"{23384775, 17018633, 23441129, 25748236, 15811853, 16549325, 25736685, 31907951, 18949011, 27919956, 27210037, 23232026}","{27297869, 29997232, 32877461, 33158843, 29931583, 25793663}","AKT2 is a common oncogene, similar to KRAS (31907951)",,ly294002,,,,,,,stat,wp1066,HY-L025-51,C07,HY-15312,WP1066,,857064-38-1,356.22,Apoptosis; JAK; STAT,Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"WP1066 is an inhibitor of JAK2 and STAT3, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3.",C17H14BrN3O,DMSO : ≥ 44 mg/mL (123.52 mM); Ethanol : 16.67 mg/mL (46.80 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(N[C@H](C1=CC=CC=C1)C)/C(C#N)=C/C2=NC(Br)=CC=C2
proliferative activity,0,1,12,0,"{37236000, 11950919, 26915435, 11180876, 14508142, 23915247, 12692724, 27878398, 8381655, 10909469, 29490942, 10626015}","{34995979, 27580186, 34175898, 32735909, 28653353, 35264812, 33575085, 34729902, 34816823, 32361153, 36500678, 35031886, 29434197, 31527644, 35569250, 30926312, 28750570, 33520370, 24009722}", ,,#N/A,,,,,,,stat,cyt387,HY-L025-14,B06,HY-10962,Momelotinib sulfate,CYT387 (sulfate salt),1056636-06-6,610.62,Apoptosis; Autophagy; JAK,Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC50=155 nM).",C23H26N6O10S2,DMSO : 220 mg/mL (360.29 mM; Need ultrasonic); H2O : 100 mg/mL (163.77 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(NCC#N)C(C=C1)=CC=C1C2=NC(NC(C=C3)=CC=C3N4CCOCC4)=NC=C2.O=S(O)(O)=O.O=S(O)(O)=O
cancer pathogenesis,0,0,12,0,"{33077732, 22860230, 24847881, 22020907, 21968429, 29452147, 12054612, 27911862, 35242873, 12878815, 26747707, 24518495}","{21164480, 35226658, 31420359, 33934351, 31801551, 36512624, 35568976, 29263030, 36227159, 27917784}", ,,#N/A,,,,,,,stat,piceatannol,HY-L025-35,H10,HY-13518,Piceatannol,Astringenin; trans-Piceatannol,10083-24-6,244.24,Apoptosis; Autophagy; Endogenous Metabolite; Syk,Apoptosis; Autophagy; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI)[1]. Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties[2]. Piceatannol induces apoptosis in DLBCL cell lines[3]. Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells[4].,C14H12O4,DMSO : ≥ 31 mg/mL (126.92 mM); H2O : 1 mg/mL (4.09 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1O
drug discovery,0,0,12,0,"{31816384, 25566081, 35167298, 34499267, 27248578, 31075266, 9383573, 23682805, 34558391, 33759222, 23698361, 36765914}","{30304769, 29657099, 30175757, 33616410, 35716125, 30165024, 33420321, 36711980, 36160045, 35084845, 33749556, 37083703, 35610180, 33780296, 32502863, 36841551, 36202064, 25849938, 28024402, 36577875, 30414936, 35020376, 35758684, 27890782, 33460833, 31246451, 31582847, 35266690, 32977027, 35357834, 30040205, 35041430, 36908700, 26924192, 28849824, 33922725, 28786345, 34520747, 35930799, 29148850, 22277300, 31059647, 30542529, 24751816, 37150933, 29068506, 28365532, 36695774, 29883107, 28714212, 34591474, 27193077, 29083896, 32893690, 23530754, 23566090, 30369550, 29581585, 28439316, 30421269, 35397401, 33685790, 27243809, 31776034, 34898210, 35324195, 36323630, 36053294, 35052850, 34816823, 31461688, 30289209, 30998845, 36202813, 34364223, 37142850, 30979914, 34232650, 30613330, 29864276, 30685526, 26707800, 27295577, 30938974, 25452384, 30327139, 26798447, 28939121, 34994556, 34791293, 36536188, 25559428, 34450309, 33513350, 34612618, 28195723, 26253201, 27559828, 29578648, 33333161, 27367338, 26396593, 32338867, 36215732, 36917685, 35432890, 22498752, 30634442, 28161994, 26869194, 30607314, 32968148, 31549911, 31580635, 26099177, 30378479, 26629616, 27806195, 36345338}", ,,#N/A,,,,,,,stat,methotrexate,HY-L025-44,G05,HY-14519A,Methotrexate (disodium),Amethopterin (disodium); CL14377 (disodium); WR19039 (disodium),7413-34-5,498.4,ADC Cytotoxin; Antifolate; Apoptosis; Bacterial; DNA/RNA Synthesis,Antibody-drug Conjugate/ADC Related; Anti-infection; Apoptosis; Cell Cycle/DNA Damage,"Methotrexate (Amethopterin) disodium, an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate disodium, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia)[1][2][3].",C20H20N8Na2O5,DMSO : 5 mg/mL (10.03 mM; ultrasonic and warming and adjust pH to 5 with HCl and heat to 60°C); H2O : 50 mg/mL (100.32 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Launched,NC1=NC(N)=C2C(N=CC(CN(C)C3=CC=C(C(N[C@@H](CCC(O[Na])=O)C(O[Na])=O)=O)C=C3)=N2)=N1
pluripotency,0,0,12,0,"{26199979, 27624879, 24880079, 21304978, 22469842, 26451606, 34859959, 24040120, 28445593, 25841238, 34657147, 23407711}","{25684227, 34520583, 30230537, 36161929, 34146702, 28026145, 28588073, 25146928, 31287992, 30428346, 37066171, 26405693, 25263550, 34293822, 30765888, 32989249, 25393219, 30924611, 26974661, 36332631, 29505757, 31235934, 29662175, 29662177, 34035299, 33190371, 25312495, 27498864, 35715442, 30510198, 36658808, 26847871}", ,,#N/A,,,,,,,stat,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
tumor maintenance,0,0,12,0,"{34117030, 27477511, 24954535, 22952903, 22232209, 23622131, 34531315, 34921013, 30470748, 22541435, 32341020, 35018527}","{23950209, 25553514, 32999044, 24065765}", ,,#N/A,,,,,,,stat,matrine,HY-L025-72,G08,HY-N0164,Matrine,Matridin-15-one; Vegard; α-Matrine,519-02-8,248.36,Apoptosis; Autophagy; Ferroptosis; Mitophagy; Opioid Receptor,Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling,"Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI)[1][2][3][4][5].",C15H24N2O,H2O : 20 mg/mL (80.53 mM; Need ultrasonic); DMSO : ≥ 50 mg/mL (201.32 mM),10mM,Cancer; Inflammation/Immunology,Launched,O=C1CCC[C@]2([H])[C@@]3([H])CCCN4[C@@]3([H])[C@](CCC4)([H])CN21
nanog,0,1,12,0,"{20173672, 28381547, 35103981, 24026351, 27624879, 24880079, 21304978, 29222037, 26451606, 34859959, 24040120, 26939902}","{36173569, 35264162, 25393219, 29505757, 29662175, 36539402, 25146928, 23374840, 30428346, 37066171, 27835869, 26847871}","nanog related to stem cells, an important cancer target (35103981)",,ly294002,,,,,,,stat,niclosamide,HY-L025-68,E03,HY-B0497,Niclosamide,BAY2353,50-65-7,327.12,Antibiotic; Parasite; STAT,Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt,"Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells[2][3][5].",C13H8Cl2N2O4,DMSO : 4.55 mg/mL (13.91 mM; Need ultrasonic); DMF : 5 mg/mL (15.28 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Infection; Cancer,Launched,O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2O
tumor immunity,0,0,12,0,"{35571489, 33316775, 15072584, 35154474, 37187730, 37191859, 32961746, 26182900, 23422836, 36319832, 30252570, 32424701}","{35517410, 28423491, 34865122, 35902886, 30958600, 35755278, 30943407, 27626654}", ,,#N/A,,,,,,,stat,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
pca,0,0,12,0,"{30007968, 36090050, 27779106, 15084968, 18693168, 23887057, 24469904, 26762195, 9821175, 26077591, 19896093, 32762399}","{26940039, 32657160, 27783056, 30272279, 31559706, 31253147, 34493733, 25908785, 35185589, 25432503, 33024699, 32333502, 32917955, 31901895, 33718091, 34323404, 29346775, 36963289, 27223260, 30565725, 30655838, 28636389, 30921702, 35349486, 27550065, 34403195}", ,,#N/A,,,,,,,stat,tofacitinib,HY-L025-63,D09,HY-40354A,Tofacitinib (citrate),Tasocitinib (citrate); CP-690550 (citrate),540737-29-9,504.49,Apoptosis; Bacterial; Fungal; Influenza Virus; JAK,Anti-infection; Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.",C22H28N6O8,DMSO : 28.57 mg/mL (56.63 mM; Need ultrasonic); H2O : 3.33 mg/mL (6.60 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O
phosphatidylinositol 3,0,0,11,0,"{26725216, 22462691, 20807812, 14559813, 17974973, 17353198, 15313904, 15572689, 15073105, 15289335, 10781373}","{32599680, 32917124, 33596421, 33596424, 34751372, 30134175, 36682147, 30537514, 34875179, 34638508, 32694708, 36891574, 30933440, 26992199, 34688842, 29133261, 24836559, 17178852, 29475942, 33520370, 30136059}", ,,ly294002,,,,,,,stat,ruxolitinib,HY-L025-64,A05,HY-50858,Ruxolitinib (phosphate),INCB018424 phosphate,1092939-17-7,404.36,Autophagy; JAK; Mitophagy,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.",C17H21N6O4P,DMSO : ≥ 31 mg/mL (76.66 mM); H2O : 10 mg/mL (24.73 mM; Need ultrasonic),10mM,Cancer,Launched,N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2.O=P(O)(O)O
p65,0,0,11,0,"{9918209, 20717927, 24340014, 12767057, 23302291, 26182900, 15375156, 24561527, 17671195, 29308316, 19896093}","{24859008, 29463681, 25606026, 34782346, 29440272, 27007123, 35501470, 27539364, 30991141, 33215396, 28983590, 29424686, 36702002, 26044852, 34974135, 24759736, 36711864, 37094074, 24608443, 31330113, 23624258, 34172737, 34949827, 33162822, 36176467, 26324948, 30455393, 36641892, 30528103, 29343723, 10567538, 31975410, 29366780, 33781885, 30479742}",p65 is a synonym of RELA,,puerarin,,,,,,,stat,parthenolide,HY-L025-72,E10,HY-N0141,Parthenolide,(-)-Parthenolide,20554-84-1,248.32,Apoptosis; Autophagy; Mitophagy; NF-κB,Apoptosis; Autophagy; NF-κB,Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting NF-κB activation; also inhibits HDAC1 protein without affecting other class I/II HDACs.,C15H20O3,H2O : < 0.1 mg/mL (insoluble); DMSO : ≥ 100 mg/mL (402.71 mM),10mM,Cancer,Phase 2,C/C1=C\CC[C@@](C)(O2)[C@H]2[C@@H](OC(C3=C)=O)[C@H]3CC1
protein protein,0,0,11,0,"{26719042, 33505218, 26823495, 22900040, 32235821, 30594165, 32355831, 30881497, 31568570, 30278585, 28742845}","{35867655, 31720974, 9699856, 7583761, 36305426, 34754068, 33616410, 34597402, 25758752, 14976033, 36711980, 35084845, 16204849, 32588860, 37131839, 36416071, 15822920, 21956175, 28024402, 27935314, 12032084, 16412250, 15839835, 35746919, 35650157, 18539634, 37162611, 31239290, 32860796, 31582847, 22924434, 28726418, 36988562, 22136469, 24954007, 34255515, 34982556, 12359327, 34582690, 26006698, 24664238, 33138352, 31857841, 22788793, 27403962, 11911891, 37150933, 34661079, 28365532, 31931101, 28766941, 24832227, 11487468, 10716917, 19038968, 31920381, 23095041, 34995458, 31718149, 33705733, 28864776, 35402505, 24497428, 12198165, 30465816, 36656921, 36824856, 34236185, 27106081, 27390756, 35833124, 35371302, 24467243, 34378541, 24007471, 34152239, 24403256, 37119804, 33438526, 21568322, 24048450, 36378954, 36180820, 32805211, 29567837, 25452384, 28053347, 34540900, 33592170, 31085420, 26552700, 31914881, 31273347, 27219844, 27673482, 17694091, 28195723, 23752591, 10809234, 32080280, 35052443, 31364510, 31521697, 15994786, 26858406, 30067623, 20871596, 27142060, 26596782, 11028911, 30833074, 28757943, 16362936, 34438075, 30387133, 32669118, 34536441, 22498752, 36304339, 16940503, 25549280, 28300771, 31581671, 26629616, 34490864, 28205554, 29892083, 23543289}", ,,#N/A,,,,,,,stat,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
antiapoptotic,0,1,11,0,"{26497549, 20208558, 15956974, 12767057, 15028947, 25875797, 21840189, 17671195, 11839677, 36346366, 30555743}","{28950657, 29709701, 35308165, 24657799, 27406984, 35787399, 26658189, 36001806, 35883157, 24906137, 32161312, 31661600, 28468776, 34875179, 36652476, 31409615, 29156698, 27078884, 35153769, 26254443, 23576556, 30647404, 33837043, 29735668, 29764852}", ,,#N/A,,,,,,,stat,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
akt1,0,1,11,0,"{24186143, 36118824, 37181515, 25748236, 19801102, 35707377, 27919956, 35457111, 18783292, 37151998, 28573215}","{31632060, 36500678, 35787399, 36051080, 32678475, 27297869, 32371868, 29464061, 20864510}", ,,kaempferol,,,,,,,catenin,icg 001,HY-L025-43,H10,HY-14428,ICG-001,,780757-88-2,548.63,Apoptosis; β-catenin,Apoptosis; Stem Cell/Wnt,ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.,C33H32N4O4,DMSO : ≥ 50 mg/mL (91.14 mM),10mM,Cancer,No Development Reported,O=C(NCC1=CC=CC=C1)N2CCC(N([C@@]2(CN(C3=O)CC4=C5C=CC=CC5=CC=C4)[H])[C@H]3CC6=CC=C(C=C6)O)=O
a kinase,0,0,11,0,"{37140994, 24003140, 24222664, 20473902, 21536687, 32193808, 33491761, 24880079, 15084597, 29039574, 16532023}","{37036970, 22623531, 26504077, 19297489, 28024402, 34107377, 14563639, 32318301, 32787262, 10783167}", ,,#N/A,,,,,,,pten,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
oncogenic transformation,0,1,11,0,"{24794439, 33051146, 31046123, 23201164, 28894253, 17353198, 31548432, 21750515, 25361845, 33949915, 26716510}","{34403195, 25525796, 30232453, 32395462, 10602503, 25478319, 31652979, 27600312, 34357401, 32060986, 27055867}", ,,#N/A,,,,,,,pten,mk 2206,HY-L025-9,B02,HY-10358,MK-2206 (dihydrochloride),MK-2206 (2HCl),1032350-13-2,480.39,Akt; Apoptosis; Autophagy,Apoptosis; Autophagy; PI3K/Akt/mTOR,"MK-2206 dihydrochloride (MK-2206 (2HCl)) is an orally active allosteric AKT inhibitor with IC50s of 5 nM, 12 nM, and 65 nM for AKT1, AKT2, and AKT3, respectively. MK-2206 dihydrochloride induces autophagy[1][3].",C25H23Cl2N5O,DMSO : 50 mg/mL (104.08 mM; ultrasonic and warming and heat to 60°C); H2O : 3.57 mg/mL (7.43 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=C1N2C(C3=CC(C4=CC=CC=C4)=C(N=C3C=C2)C5=CC=C(C6(N)CCC6)C=C5)=NN1.Cl.Cl
cell growth inhibition,0,0,11,0,"{18805632, 21871555, 27694919, 29683208, 17114344, 36029643, 33309163, 21692654, 15300592, 20103665, 8886038}","{28751557, 31969702, 31102023, 35836809, 28059436, 33638254, 32961679, 25989842, 31527063, 30015487}", ,,#N/A,,,,,,,pten,wortmannin,HY-L025-6,H04,HY-10197,Wortmannin,SL-2052; KY-12420,19545-26-7,428.43,Antibiotic; Autophagy; PI3K; Polo-like Kinase (PLK),Anti-infection; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively[1][2][3].",C23H24O8,DMSO : ≥ 50 mg/mL (116.71 mM),10mM,Cancer,No Development Reported,O=C1C([C@@](CC2)([H])[C@@]3(C)C2=O)=C([C@H](OC(C)=O)C3)[C@]4(C)C5=C1OC=C5C(O[C@@H]4COC)=O
long non coding rnas,0,0,11,0,"{29298720, 33099938, 31747939, 33577028, 36612299, 26755660, 32727085, 24469904, 33390837, 31562613, 32499447}","{31837602, 35765893, 33575113, 31001132, 28187439, 36575377, 35546353, 28981843, 33962228, 30093685}", ,,#N/A,,,,,,,pten,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
rna binding,0,0,11,0,"{37039106, 32355831, 32545414, 32814086, 29452455, 23425895, 36408139, 32727085, 35703534, 8893335, 28242812}","{26463137, 29563491, 27748806, 23241214, 31077320, 26099177, 28481226, 15822920, 29703820, 17898061, 35856391, 29176719, 11931765, 34715126, 22609015, 12915580, 28680062}", ,,#N/A,,,,,,,pten,celastrol,HY-L025-32,A08,HY-13067,Celastrol,Tripterine; Tripterin,34157-83-0,450.61,Apoptosis; Autophagy; Endogenous Metabolite; Mitophagy; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease,Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.,C29H38O4,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 33.33 mg/mL (73.97 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C(C2=CC=C3[C@](C)([C@]4(CC[C@]3(C2=CC1=O)C)C)CC[C@@]5(C)CC[C@@](C(O)=O)(C[C@]54[H])C)C
cancer cell survival,0,0,11,0,"{35785187, 35681705, 30061420, 28414320, 21586612, 30709910, 20103639, 34111513, 24201306, 30967003, 36233022}","{32200036, 19318566, 30846826, 30975979, 31927213, 22137933, 23704919, 33006750}", ,,#N/A,,,,,,,pten,kaempferol,HY-L025-45,F09,HY-14590,Kaempferol,Kempferol; Robigenin,520-18-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Estrogen Receptor/ERR; HIV; Mitophagy; Parasite,Anti-infection; Apoptosis; Autophagy; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer[1][2][3][4].",C15H10O6,DMSO : ≥ 32 mg/mL (111.79 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=C(O)C2=O)=CC(O)=C1
noncoding rnas,0,0,11,0,"{29063045, 28860807, 23774697, 29290766, 22078386, 27689078, 31325400, 23839098, 26747707, 21779484, 35433983}","{32320642, 25684227, 34976005, 25719566, 31253147, 25799074, 34056358, 31514410, 35052850, 26111795, 30502323, 30428346, 31868237, 36477655, 29133788, 33547232, 33844835, 33605616, 36166514}", ,,#N/A,,,,,,,pten,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
immune infiltration,0,0,11,0,"{34805152, 34279685, 34829830, 33714027, 34178637, 36353587, 35433491, 36118868, 36008214, 35488119, 32424701}","{30029633, 35833124, 36276071, 35434025, 36614001, 36933111, 37014264, 36458010, 35252219, 36711038}", ,,#N/A,,,,,,,pten,rosiglitazone,HY-L025-57,H08,HY-17386,Rosiglitazone,BRL 49653,122320-73-4,357.43,Apoptosis; Autophagy; Ferroptosis; PPAR; TRP Channel,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel; Neuronal Signaling; Vitamin D Related/Nuclear Receptor,"Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer[1][2][4][7].",C18H19N3O3S,DMSO : 250 mg/mL (699.44 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic) (insoluble); Ethanol : 2 mg/mL (5.60 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease,Launched,O=C(N1)SC(CC2=CC=C(OCCN(C)C3=NC=CC=C3)C=C2)C1=O
tumor suppressor p53,0,0,11,0,"{28162272, 19029954, 9209954, 23226501, 21699781, 19424582, 16540233, 11561610, 32322667, 19501586, 33824054}","{31314496, 21513889, 30385614, 21271695, 33431824, 16426974}", ,,#N/A,,,,,,,pten,gw9662,HY-L025-56,D09,HY-16578,GW9662,,22978-25-2,276.68,PPAR,Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor,"GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively.",C13H9ClN2O3,DMSO : ≥ 100 mg/mL (361.43 mM),10mM,Cancer,No Development Reported,O=C(NC1=CC=CC=C1)C2=CC([N+]([O-])=O)=CC=C2Cl
drug response,0,0,11,0,"{31572675, 34249445, 34210825, 31262731, 34011980, 18374157, 36761421, 34663758, 34916338, 33804148, 21738581}","{31527074, 29563491, 30339013, 29795241, 26658189, 30104685, 32412527, 36103824, 35959629, 30093685, 30674677, 35273398, 29303513, 36458010, 22451422}", ,,#N/A,,,,,,,pten,azd5363,HY-L025-51,H10,HY-15431,Capivasertib,AZD5363,1143532-39-1,428.92,Akt; Autophagy,Autophagy; PI3K/Akt/mTOR,"Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1,Akt2 and Akt3, respectively.",C21H25ClN6O2,DMSO : 125 mg/mL (291.43 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(C1(N)CCN(C2=C3C(NC=C3)=NC=N2)CC1)N[C@H](C4=CC=C(Cl)C=C4)CCO
decipher,0,0,11,0,"{18805632, 24520096, 37140101, 33483239, 32727085, 19629168, 21044336, 35402225, 31375828, 33390837, 33824054}","{30160288, 34279939, 29619268, 29233295, 29997232, 35423696, 35754900, 36918265, 27827996, 29795359}", ,,#N/A,,,,,,,pten,cilostazol,HY-L025-58,C05,HY-17464,Cilostazol,OPC 13013,73963-72-1,369.46,Autophagy; Phosphodiesterase (PDE),Autophagy; Metabolic Enzyme/Protease,"Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1][2].",C20H27N5O2,DMSO : 50 mg/mL (135.33 mM; Need ultrasonic),10mM,Cardiovascular Disease; Cancer,Launched,O=C1NC2=C(C=C(OCCCCC3=NN=NN3C4CCCCC4)C=C2)CC1
cell killing,0,0,11,0,"{27096033, 34331012, 18430374, 23613993, 35402225, 23475955, 23422836, 21836633, 33682329, 26052093, 25632222}","{29636547, 34215653, 28766886, 28336808, 36711980, 35332309, 35146591, 28069687, 31653272, 32196028, 25793663}", ,,#N/A,,,,,,,jak,ag490,HY-L025-22,A04,HY-12000,AG490,Tyrphostin AG490; Tyrphostin B42,133550-30-8,294.3,Autophagy; EGFR; JAK; STAT,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.",C17H14N2O3,DMSO : ≥ 50 mg/mL (169.89 mM),10mM,Cancer,No Development Reported,O=C(NCC1=CC=CC=C1)/C(C#N)=C/C2=CC=C(O)C(O)=C2
nras,0,2,10,0,"{29229669, 24791855, 29103024, 30194290, 30833748, 24604757, 29059158, 31746520, 25797243, 19440799}","{23950209, 33958721, 24065765, 27406984, 36162600, 32307821, 30226831, 35969744, 29650805, 26367798, 24906137, 33781756}", ,,trametinib,,,,,,,jak,itacitinib,HY-L025-57,E05,HY-16997,Itacitinib,INCB039110,1334298-90-6,553.51,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Itacitinib (INCB039110) is an orally active and selective inhibitor of JAK1 with an IC50 of 2 nM for human JAK1. Itacitinib shows >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis[1][2].,C26H23F4N9O,DMSO : ≥ 30 mg/mL (54.20 mM),10mM,Cancer,Phase 3,N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(C5CCN(C(C6=C(F)C(C(F)(F)F)=NC=C6)=O)CC5)C1
ap 1,0,0,10,0,"{10720480, 20424515, 24282278, 16407822, 27520560, 19904754, 12185592, 10348828, 22264792, 23552700}","{35890145, 16921027, 34880227, 27477287, 31444232, 31097419, 32708494, 21652721, 26727473, 26908627, 32765266, 27240956, 35401533}",inhibiting AP1 would probably promote PDAC (23552700),,staurosporine,,,,,,,jak,ibrutinib,HY-L025-14,D06,HY-10997A,Ibrutinib (Racemate),PCI-32765 (Racemate),936563-87-0,440.5,Btk,Protein Tyrosine Kinase/RTK,"Ibrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM.",C25H24N6O2,DMSO : 25 mg/mL (56.75 mM; Need ultrasonic),10mM,Cancer,Launched,C=CC(N1CC(N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C5=C(N)N=CN=C52)CCC1)=O
nuclear factor kappa,0,0,10,0,"{9918209, 30084546, 18049840, 30563089, 15073105, 31288851, 20068565, 17671195, 22190076, 22752926}","{37211680, 27539364, 25778533, 33159815, 34199719, 24632969, 29886474, 25263595, 31097419, 32708494, 33490899, 26324948, 31530390, 34050937, 24804860, 24799421, 36100190}", ,,#N/A,,,,,,,jak,tofa,HY-L025-4,E11,HY-101068,TOFA,RMI14514; MDL14514,54857-86-2,324.45,Acetyl-CoA Carboxylase,Metabolic Enzyme/Protease,TOFA (RMI14514;MDL14514) is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA ).,C19H32O4,DMSO : 11.36 mg/mL (35.01 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C(C1=CC=C(OCCCCCCCCCCCCCC)O1)O
cellular processes,0,1,10,0,"{26416424, 31780749, 29780561, 23519249, 34089011, 31452788, 27461042, 26735353, 27595930, 30377341}","{31015424, 28549889, 26472704, 19136002, 35745664, 34633088, 32486024, 32162442, 36247184, 33616410, 34791964, 28410781, 33685790, 36898211, 19244327, 35930668, 32356653, 34763437, 34152239, 28630323, 32482868, 17293877, 26329395, 28154167, 26500280, 17334841, 28805820, 26303420, 24616510, 29568956, 30386240, 32165310, 24939842, 29393731, 34298819, 23667654, 22334664, 11997514, 31780938, 34326347, 30841549, 31801551, 27746255, 11911891, 36470106, 34386523, 36285148, 21599968, 26702435, 27250788, 37207401, 20581866, 27757418, 30589164, 35754730, 28426098, 34403450, 27055867, 32992509, 32355326, 31028095}", ,,#N/A,,,,,,,jak,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
nuclear factor κb,0,1,10,0,"{20424515, 25473891, 22699205, 32047557, 25683115, 23598351, 24561527, 25875801, 26628860, 25500542}","{29463681, 21900162, 24189064, 28695816, 30321559, 33529752, 32550554, 29249691, 28663582, 35501470, 29448097, 31570593, 28983590, 29694891, 26044852, 28215221, 34493364, 27507649, 36260688, 31707348, 31114581, 25891802, 34075610, 35108062, 22649058, 33798633, 29208683, 31975410, 29067128}", ,,eicosapentaenoic acid,,,,,,,jak,cyt387,HY-L025-14,B06,HY-10962,Momelotinib sulfate,CYT387 (sulfate salt),1056636-06-6,610.62,Apoptosis; Autophagy; JAK,Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC50=155 nM).",C23H26N6O10S2,DMSO : 220 mg/mL (360.29 mM; Need ultrasonic); H2O : 100 mg/mL (163.77 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(NCC#N)C(C=C1)=CC=C1C2=NC(NC(C=C3)=CC=C3N4CCOCC4)=NC=C2.O=S(O)(O)=O.O=S(O)(O)=O
chemokines,0,1,10,0,"{26771140, 21926469, 27659014, 25531332, 27435400, 33034134, 27546622, 29798841, 19509115, 25500542}","{22645123, 33256844, 25890327, 29748248, 32203421, 33664670, 31533472, 31080358, 29694891, 35743155, 34949827, 33574085, 33893325, 31114581, 31186006, 30938974, 33476703, 21599968, 34315876, 26047594, 29208683, 35094142, 35986286, 27710838, 37182455, 35761277, 26582142}", ,,dexamethasone,,,,,,,jak,filgotinib,HY-L025-59,C07,HY-18300,Filgotinib,GLPG0634,1206161-97-8,425.5,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Filgotinib (GLPG0634) is a selective and orally active JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.",C21H23N5O3S,DMSO : 25 mg/mL (58.75 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,O=C(C1CC1)NC2=NN3C(C4=CC=C(CN5CCS(CC5)(=O)=O)C=C4)=CC=CC3=N2
ppi,0,1,10,0,"{35707970, 36690307, 33505218, 36118824, 22108522, 35493099, 36261459, 30881497, 30278585, 35449823}","{31914881, 27219844, 33705733, 36656921, 35833124, 36711980, 34378541, 30910254, 28757943, 30387133, 33438526, 33867857, 36304339, 28365532, 27009761, 31499747, 35650157, 28205554, 32860796, 31920381}", ,,#N/A,,,,,,,jak,piceatannol,HY-L025-35,H10,HY-13518,Piceatannol,Astringenin; trans-Piceatannol,10083-24-6,244.24,Apoptosis; Autophagy; Endogenous Metabolite; Syk,Apoptosis; Autophagy; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI)[1]. Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties[2]. Piceatannol induces apoptosis in DLBCL cell lines[3]. Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells[4].,C14H12O4,DMSO : ≥ 31 mg/mL (126.92 mM); H2O : 1 mg/mL (4.09 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1O
janus,0,0,10,0,"{26530532, 35948109, 23614574, 32947833, 27003603, 36451861, 26682870, 30142009, 33509790, 32762399}","{27507649, 33980611, 35385124, 34272171, 27677740, 31875887, 36702002, 30206163, 36332787, 36881782, 35499161, 32647323, 34791293, 23929215}", ,,#N/A,,,,,,,jak,cucurbitacin b,HY-L025-74,C06,HY-N0416,Cucurbitacin B,,6199-67-3,558.7,Apoptosis; Autophagy; Endogenous Metabolite; Integrin,Apoptosis; Autophagy; Cytoskeleton; Metabolic Enzyme/Protease,"Cucurbitacin B belongs to a class of highly oxidized tetracyclic triterpenoids; could repress cancer cell progression.
IC50 value:
Target: anticancer natural compound
in vitro: Cucurbitacin-B inhibited growth and modulated expression of cell-cycle regulators in SHSY5Y cells. At the molecular level, we found that Cucurbitacin-B inhibited AKT signaling activation through up-regulation of PTEN [1]. CuB induced apoptosis of A549 cells in a -concentration-dependent manner, as determined by fluorescence microscopy, flow cytometry and transmission electron microscopy. CuB dose-dependently inhibited lung cancer cell proliferation, with cell cycle inhibition and cyclin B1 downregulation. Apoptosis induced by CuB was shown to be associated with cytochrome c release, B-cell lymphoma 2 downregulation and signal transducer and activator of transcription 3 pathway inhibition [2]. CuB inhibited ITGA6 and ITGB4 (integrin α6 and integrin β4), which are overexpressed in breast cancer. Furthermore, CuB also induced the expression of major ITGB1and ITGB3, which are known to cause integrin-mediated cell death [3]. Cuc B treatment caused DNA double-strand breaks (DSBs) without affecting the signal transducer and activator of transcription 3 (STAT3), the potential molecular target for Cuc B. Cuc B triggers ATM-activated Chk1-Cdc25C-Cdk1, which could be reversed by both ATM siRNA and Chk1 siRNA. Cuc B also triggers ATM-activated p53-14-3-3-σ pathways, which could be reversed by ATM siRNA [4].
in vivo: Efficacy of CuB was tested in vivo using two different orthotopic models of breast cancer. MDA-MB-231 and 4T-1 cells were injected orthotopically in the mammary fat pad of female athymic nude mice or BALB/c mice respectively. Our results showed that CuB administration inhibited MDA-MB-231 orthotopic tumors by 55%, and 4T-1 tumors by 40%. The 4T-1 cells represent stage IV breast cancer and form very aggressive tumors [3].",C32H46O8,DMSO : ≥ 100 mg/mL (178.99 mM); H2O : 1 mg/mL (1.79 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O[C@H](C1)[C@@]([C@@](C)(O)C(/C=C/C(OC(C)=O)(C)C)=O)([H])[C@](C2)(C)[C@]1(C)[C@]3([H])CC=C4C(C)(C)C([C@@H](O)C[C@@]4([H])[C@]3(C)C2=O)=O
sp1,0,0,10,0,"{29389953, 14604996, 28402278, 29259015, 28352075, 18481199, 27835861, 26041879, 33146712, 25143389}","{36793283, 29453316, 20107077, 24632969, 24763052, 10567538, 18778484, 7565781, 16792505, 19111069}",seems to be involved with PKCl/YAP1 to promote tumorigenesis (33146712),,sp600125,,,,,,,jak,methotrexate,HY-L025-44,G05,HY-14519A,Methotrexate (disodium),Amethopterin (disodium); CL14377 (disodium); WR19039 (disodium),7413-34-5,498.4,ADC Cytotoxin; Antifolate; Apoptosis; Bacterial; DNA/RNA Synthesis,Antibody-drug Conjugate/ADC Related; Anti-infection; Apoptosis; Cell Cycle/DNA Damage,"Methotrexate (Amethopterin) disodium, an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate disodium, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia)[1][2][3].",C20H20N8Na2O5,DMSO : 5 mg/mL (10.03 mM; ultrasonic and warming and adjust pH to 5 with HCl and heat to 60°C); H2O : 50 mg/mL (100.32 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Launched,NC1=NC(N)=C2C(N=CC(CN(C)C3=CC=C(C(N[C@@H](CCC(O[Na])=O)C(O[Na])=O)=O)C=C3)=N2)=N1
nuclear antigen,0,0,10,0,"{21084261, 19631339, 23019409, 26182900, 25237909, 35322742, 23308056, 30569114, 8539259, 11522750}","{27864512, 16940503, 27291650, 32900933, 32820070, 33193257, 27129259, 31875566, 24040311, 29467311, 16227282, 36728436, 24146614, 11967287, 17267510, 24146618, 15507644, 16928766}", ,,#N/A,,,,,,,jak,ly2784544,HY-L025-31,G02,HY-13034,Gandotinib,LY2784544,1229236-86-5,469.94,FGFR; FLT3; JAK; VEGFR,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC50 of 4, 25, 32, 44, and 95 nM.",C23H25ClFN7O,DMSO : ≥ 50 mg/mL (106.40 mM),10mM,Cancer,Phase 2,CC1=NNC(NC2=NN3C(C(CN4CCOCC4)=C2)=NC(C)=C3CC5=CC=C(C=C5F)Cl)=C1
cyclin dependent kinases,0,2,10,0,"{25632225, 34001634, 35728737, 35457227, 32256815, 19639215, 29059158, 9219065, 9641882, 25931518}","{35198433, 31900258, 27539364, 31200487, 16893449, 26731470, 17942543, 24007471, 29511348, 32694708, 31527063, 36139513, 31067678}", ,,honokiol,,,,,,,jak,cerdulatinib,HY-L025-55,C03,HY-15999A,Cerdulatinib (hydrochloride),PRT062070 (hydrochloride); PRT2070 (hydrochloride),1369761-01-2,482,JAK; Syk,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC50s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies[1][2].",C20H28ClN7O3S,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 20 mg/mL (41.49 mM; ultrasonic and warming and heat to 80°C),10mM,Cancer,Phase 3,O=S(N(CC1)CCN1C2=CC=C(NC3=NC=C(C(N)=O)C(NC4CC4)=N3)C=C2)(CC)=O.Cl
cdk6,0,0,10,0,"{26530532, 32256815, 33251215, 32626512, 25050737, 20669973, 24389175, 17569628, 36346366, 32109375}","{31226848, 27764802, 30518851, 27539364, 25338565, 36755269, 34568834, 26254443, 30647404, 29730189, 33080301, 35264812, 34385584, 26304078, 31160565, 28024472, 24985178, 32860796}",seems to be upregulated and part of cell cycle progression (32256815),,apigenin,,,,,,,jak,kaempferol,HY-L025-45,F09,HY-14590,Kaempferol,Kempferol; Robigenin,520-18-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Estrogen Receptor/ERR; HIV; Mitophagy; Parasite,Anti-infection; Apoptosis; Autophagy; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer[1][2][3][4].",C15H10O6,DMSO : ≥ 32 mg/mL (111.79 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=C(O)C2=O)=CC(O)=C1
cxcl1,0,0,10,0,"{32882403, 25531332, 35948109, 36453584, 27454293, 35803738, 27454298, 23102107, 30693981, 36946782}","{30872008, 25606026, 28951988, 29748248, 35761277, 30938974, 35108062}",MEK+STAT3 inhibition reduces CXCL1 expression and seems to change it from cancer-associated to tumor-fighting (35948109),,sp600125,,,,,,,jak,wortmannin,HY-L025-6,H04,HY-10197,Wortmannin,SL-2052; KY-12420,19545-26-7,428.43,Antibiotic; Autophagy; PI3K; Polo-like Kinase (PLK),Anti-infection; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively[1][2][3].",C23H24O8,DMSO : ≥ 50 mg/mL (116.71 mM),10mM,Cancer,No Development Reported,O=C1C([C@@](CC2)([H])[C@@]3(C)C2=O)=C([C@H](OC(C)=O)C3)[C@]4(C)C5=C1OC=C5C(O[C@@H]4COC)=O
smoothened,0,0,10,0,"{26527777, 30373214, 27624879, 19136624, 18515410, 27633013, 26451606, 31417657, 19860666, 23786654}","{24973920, 33958721, 32380205, 25355313, 33643826, 32913560, 31182587}", ,We have recently demonstrated that the BET inhibitor effectively suppresses SMOi-resistant Hh-driven cancers [also mentions CDK7] (31182587),sonidegib,,,,,,,jak,vorinostat,HY-L025-7,E02,HY-10221,Vorinostat,SAHA; Suberoylanilide hydroxamic acid,149647-78-9,264.32,Apoptosis; Autophagy; Filovirus; HDAC; HPV; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].",C14H20N2O3,DMSO : ≥ 100 mg/mL (378.33 mM),10mM,Cancer; Infection,Launched,O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O
src,0,0,9,0,"{21266529, 30423298, 20682659, 20067773, 12750255, 20303350, 22589274, 17974973, 18393855}","{32599680, 36051080, 10809234, 33006750, 27980063, 25865888, 28983590, 28069687, 32416067, 36500678, 17998543, 34586831, 33664855, 35513563, 30455393, 20855524, 28846832, 36512624, 28474232, 29212027, 32793596}", ,BRD4 and SRC/MAPK knockdown synergistic in prostate cancer (35513563),n acetylcysteine,,,,,,,tyrosine kinases,tt 232,HY-L025-10,E06,HY-105172,TT-232,CAP-232; TLN-232,147159-51-1,947.13,Somatostatin Receptor,GPCR/G Protein; Neuronal Signaling,"TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent[1][2][4].",C45H58N10O9S2,10 mM in DMSO,10mM,Cancer; Inflammation/Immunology,Phase 2,O=C(N[C@H](C(N[C@@H]1C(N[C@H](C(N)=O)[C@H](O)C)=O)=O)CCCCN)[C@H](NC([C@@H](NC([C@H](CSSC1)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC(C=C3)=CC=C3O)=O)CC4=CNC5=CC=CC=C45
gene transcription,0,1,9,0,"{27758883, 21441955, 26569573, 12622410, 29321164, 17203180, 23839098, 17706193, 27454298}","{25140737, 27291650, 29453316, 33172487, 28572168, 35867655, 36124682, 29657099, 10365964, 16954381, 27769357, 31110158, 27769356, 34722316, 35072011, 31421967, 35850772, 34754068, 24759320, 36193305, 31067678, 29372961, 33907746, 32821285, 24686119, 32217639, 17023018, 26733615, 19736624, 29439026, 25740345, 24248379, 23115324, 29605436, 27911230, 27443262, 30518851, 28235844, 28648518, 36538950, 31780938, 36015180, 20032077, 30593613, 21956175, 35685458, 22136404, 31311960, 35758684, 27890782, 30139998, 31629407, 26702435, 28265070, 26137204, 31239290, 18493054, 31582847, 35855490, 16135811, 33159815, 33776776, 24632969, 29653131, 26911376, 18025106, 30539410, 22136469, 33057942, 24954007, 24733848, 33142427, 27626654, 34448544, 21513889, 34199719, 27063977, 24000170, 24333487, 30012592, 29087414, 33504439, 22788793, 30428346, 27403962, 34944697, 37094074, 18223296, 32361153, 35694272, 27056325, 31266503, 32927435, 34223822, 35982031, 33809617, 27372760, 35513563, 27965149, 32219359, 32575711, 32203489, 22649058, 35157728, 26833129, 15943913, 34280171, 25017071, 8910577, 36690674, 28689146, 32893690, 20505343, 30796039, 26855180, 33431820, 29139214, 36577036, 28322577, 25621778, 24952595, 12198165, 33125143, 31551256, 29863194, 33711386, 27827996, 26868508, 17687328, 27243809, 33820450, 27402533, 35264812, 11082032, 35904816, 35745584, 24361270, 26405693, 19218239, 27084101, 23086925, 24979794, 30606676, 26542424, 35975005, 20368734, 25345375, 36513631, 34540900, 37207401, 25788266, 19581291, 33214826, 35619690, 26798447, 10567538, 35215234, 35650434, 27259270, 35836809, 27673482, 17694091, 30830987, 35191694, 33469840, 28314513, 36372880, 19812244, 25547156, 25535892, 27900832, 29448097, 25799074, 29333921, 36898211, 31969702, 30672294, 35462054, 35276206, 11028911, 21851057, 35185589, 36323253, 27266999, 18400184, 27600312, 26303420, 26631615, 25512383, 16265664, 21804994, 16921027, 26220994, 27010499, 25097667, 20126658, 30872008, 27748806, 28974538, 33380808, 34298819, 35423696, 30607314, 21949397, 23420887, 19211738, 25891802, 35198433, 26145250, 28300771, 35890145, 35687908, 31581671, 25941994, 35401196, 35349485, 36905966, 36142573, 34139120, 31346162, 31018997, 30150647, 28339196, 33344510}", ,,#N/A,,,,,,,tyrosine kinases,piceatannol,HY-L025-35,H10,HY-13518,Piceatannol,Astringenin; trans-Piceatannol,10083-24-6,244.24,Apoptosis; Autophagy; Endogenous Metabolite; Syk,Apoptosis; Autophagy; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI)[1]. Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties[2]. Piceatannol induces apoptosis in DLBCL cell lines[3]. Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells[4].,C14H12O4,DMSO : ≥ 31 mg/mL (126.92 mM); H2O : 1 mg/mL (4.09 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1O
cellular functions,0,1,9,0,"{19609950, 30378057, 20858281, 27061193, 29303405, 29543440, 30229043, 37105075, 36617502}","{34201346, 32714883, 27494802, 25621778, 35786907, 31533472, 25120803, 34563497, 26596782, 27600312, 18815416, 34062779, 28237246, 36690761, 28847823, 21949397, 20676058, 22699752, 19581291, 29050361}", ,,#N/A,,,,,,,tyrosine kinases,staurosporine,HY-L025-49,F07,HY-15141,Staurosporine,Antibiotic AM-2282; STS; AM-2282,62996-74-1,466.53,Antibiotic; Apoptosis; Bacterial; Fungal; PKA; PKC,Anti-infection; Apoptosis; Epigenetics; Stem Cell/Wnt; TGF-beta/Smad,"Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC50s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase respectively. Staurosporine also inhibits TAOK2 with an IC50 of 3 μM. Staurosporine is an apoptosis inducer[1][2][3][4][5].",C28H26N4O3,DMSO : 62.5 mg/mL (133.97 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C(NC1)C2=C1C3=C(C4=C2C5=C(C=CC=C5)N4[C@H]6C[C@@H](NC)[C@@H](OC)[C@]7(C)O6)N7C8=CC=CC=C83
ets,0,1,9,0,"{23530240, 28178529, 21441955, 27318148, 27659014, 36612299, 18848526, 18481199, 27520560}","{17425505, 14976033, 36194562, 31000582, 27259270, 29991720, 37059338, 16158187, 32220972, 26623725, 27707886, 33469999, 32398865, 29898995, 28474232, 32012890, 11083868}", ,BRD/BET proteins interact with ETS proteins to induce senescence (37059338),yk 4 279,,,,,,,tyrosine kinases,regorafenib,HY-L025-34,C03,HY-13308,Regorafenib (Hydrochloride),BAY 73-4506 (hydrochloride),835621-07-3,519.28,Autophagy; PDGFR; Raf; RET; VEGFR,Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[1].",C21H16Cl2F4N4O3,DMSO : ≥ 5.6 mg/mL (10.78 mM); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,ClC1=C(C(F)(F)F)C=C(NC(NC2=C(F)C=C(OC3=CC=NC(C(NC)=O)=C3)C=C2)=O)C=C1.Cl
nf kb,0,0,9,0,"{33200711, 23302291, 26373299, 18823380, 33804148, 30463064, 33631610, 29308316, 19896093}","{27539364, 32249419, 24924589, 29424686, 32708494, 31934287, 25288306, 36629431, 28173625, 32647323, 28743452, 36139421}", ,BRD4 interacts with acetylated NFKB; BRD4 inhibitors inhibit this interaction (30386303),paeonol,,,,,,,tyrosine kinases,sti571,HY-L025-64,D06,HY-50946,Imatinib (Mesylate),STI571 (Mesylate); CGP-57148B (Mesylate),220127-57-1,589.71,Autophagy; Bcr-Abl; c-Kit; PDGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.",C30H35N7O4S,DMSO : 125 mg/mL (211.97 mM; Need ultrasonic); H2O : ≥ 50 mg/mL (84.79 mM),10mM,Cancer,Launched,O=S(O)(C)=O.O=C(NC1=CC=C(C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)C)C4=CC=C(CN5CCN(CC5)C)C=C4
survival pathways,0,1,9,0,"{21871555, 31138768, 26373299, 18393855, 26439702, 28178232, 29998364, 12799645, 23467612}","{29914080, 23872705, 28035374, 32885168, 34533562, 33795806}", ,,#N/A,,,,,,,tyrosine kinases,crizotinib,HY-L025-64,B03,HY-50878A,Crizotinib (hydrochloride),PF-02341066 hydrochloride,1415560-69-8,486.8,Anaplastic lymphoma kinase (ALK); Autophagy; c-Met/HGFR; ROS Kinase,Autophagy; Protein Tyrosine Kinase/RTK,"Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition[1][2][3].",C21H23Cl3FN5O,DMSO : ≥ 4.9 mg/mL (10.07 mM); H2O : 50 mg/mL (102.71 mM; Need ultrasonic),10mM,Cancer,Launched,ClC1=C(F)C=CC(Cl)=C1[C@H](OC2=CC(C3=CN(N=C3)C4CCNCC4)=CN=C2N)C.[H]Cl
hif 1α,0,1,9,0,"{25584484, 33580614, 25305448, 21320746, 26755660, 34320467, 36371988, 31076568, 23786654}","{31533472, 33298848, 33567268, 34716294, 26035625, 36343244, 29629903, 29949369, 34255515, 33287516, 36139358}", ,BRD4 inhibition inhibits induction of HIF-1a and decreases downstream targets (36139358),fg 4592,,,,,,,tyrosine kinases,pd98059,HY-L025-22,E02,HY-12028,PD98059,,167869-21-8,267.28,Aryl Hydrocarbon Receptor; Autophagy; ERK; MEK,Autophagy; Immunology/Inflammation; MAPK/ERK Pathway; Stem Cell/Wnt,"PD98059 is a potent and selective MEK inhibitor with an IC50 of 5 μM. PD98059 binds to the inactive form of MEK, thereby preventing the activation of MEK1 (IC50 of 2-7 μM) and MEK2 (IC50 of 50 μM) by upstream kinases. PD98059 is a ERK1/2 signaling inhibitor. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC50 of 4 μM) and AHR transformation (IC50 of 1 μM). PD98059 also inhibits Mycobacterium bovis Bacillus CalmetteGuerin (BCG)-induced autophagy[1][2][3].",C16H13NO3,DMSO : 33.33 mg/mL (124.70 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,No Development Reported,O=C1C=C(OC2=CC=CC=C21)C3=CC=CC(OC)=C3N
cell cycle control,0,0,9,0,"{22833572, 12021893, 35302596, 32489450, 30003124, 33862582, 21836633, 23552700, 30538111}","{17166848, 30618144, 16921027, 25120803, 36252888, 31514410, 11487468, 16512664, 28059436, 30012592, 32582706, 17329240, 14966270, 23365439}", ,,#N/A,,,,,,,tyrosine kinases,wortmannin,HY-L025-6,H04,HY-10197,Wortmannin,SL-2052; KY-12420,19545-26-7,428.43,Antibiotic; Autophagy; PI3K; Polo-like Kinase (PLK),Anti-infection; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively[1][2][3].",C23H24O8,DMSO : ≥ 50 mg/mL (116.71 mM),10mM,Cancer,No Development Reported,O=C1C([C@@](CC2)([H])[C@@]3(C)C2=O)=C([C@H](OC(C)=O)C3)[C@]4(C)C5=C1OC=C5C(O[C@@H]4COC)=O
epigenetic changes,0,0,9,0,"{24670819, 17198183, 31109321, 23774697, 34198989, 15316751, 26754001, 23467612, 24471965}","{36839169, 25512710, 34661254, 34459400, 33256844, 28684431, 31749139, 25547156, 24906137, 35902886, 36245290, 35869742, 35247919, 36224430, 33504568, 34913726, 28971711, 33155139, 33575113, 29476043, 36112085, 20538714, 29296220, 34309725, 31653342, 37120098, 32636391, 25788266, 36614001, 28169463, 33163263}", ,,#N/A,,,,,,,tyrosine kinases,sodium orthovanadate,HY-L025-71,D10,HY-D0852,Sodium orthovanadate,,13721-39-6,183.91,Phosphatase,Metabolic Enzyme/Protease,"Sodium orthovanadate is an inhibitor of protein tyrosine phosphatases, alkaline phosphatases and a number of ATPases, most likely acting as a phosphate analogue.",Na3O4V,H2O : 8.33 mg/mL (45.29 mM; Need ultrasonic); DMSO : < 1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble or slightly soluble),10mM,Cancer,No Development Reported,[O].[Na].[V]
myofibroblasts,0,0,9,0,"{32388866, 21856775, 23076142, 22291919, 35346801, 30167093, 32453916, 29490942, 33846527}","{34624676, 30062054, 36034982, 36907496, 26644586, 31119153, 32331282, 35799890, 36648754, 35002741, 28182006, 30153047, 30106235, 33384604, 32626975}", ,,#N/A,,,,,,,tyrosine kinases,lenvatinib,HY-L025-14,C05,HY-10981A,Lenvatinib (mesylate),E7080 (mesylate),857890-39-2,522.96,c-Kit; FGFR; PDGFR; RET; VEGFR,Protein Tyrosine Kinase/RTK,"Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows  potent antitumor activities[1][2].",C22H23ClN4O7S,DMSO : 7.35 mg/mL (14.05 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=C(OC)C=C2N=CC=C(OC3=CC=C(NC(NC4CC4)=O)C(Cl)=C3)C2=C1)N.OS(=O)(C)=O
nuclear receptor,0,0,9,0,"{23049538, 33079429, 35562376, 33074669, 33448017, 28445593, 29289465, 22056382, 33271455}","{33298848, 31254363, 35011590, 9858827, 19909775, 10809234, 34503062, 15322135, 29348827, 33113340, 12384511}", ,,#N/A,,,,,,,tyrosine kinases,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
taz,0,1,9,0,"{31262852, 34395269, 32900774, 32912902, 31912905, 28381547, 27215660, 31057295, 34680275}","{36781122, 31406246, 36162600, 35705032, 31281517, 27717711, 30224758, 32203417, 34597402, 34508829}", ,TAZ seems part of a complex that upregulate CCBE1; this seems to be disrupted by BRD4 inhibitors (36781122),dasatinib,,,,,,,tyrosine kinases,tyrphostin 23,HY-L025-53,B08,HY-15644,Tyrphostin 23,Tyrphostin A23; RG-50810; AG 18,118409-57-7,186.17,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Tyrphostin 23 (Tyrphostin A23) is an EGFR inhibitor with an IC50 and Kiof 35 and 11 μM, respectively.",C10H6N2O2,DMSO : 100 mg/mL (537.14 mM; Need ultrasonic),10mM,Cancer,No Development Reported,N#C/C(C#N)=C/C1=CC=C(O)C(O)=C1
ddr,0,0,9,0,"{34659905, 29545922, 34247626, 37139665, 35231699, 24583638, 35392854, 34852220, 36923647}","{29636547, 29393731, 34548613, 28847823, 30237520, 33607295, 33208498, 26119999, 29490263, 28881656, 25593309, 28669341, 27631103}", ,DDA = DNA damage response,minocycline,,,,,,,tyrosine kinases,sorafenib,HY-L025-7,A11,HY-10201A,Sorafenib (Tosylate),Bay 43-9006 (Tosylate),475207-59-1,637.03,Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR,Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator[1].",C28H24ClF3N4O6S,H2O : < 0.1 mg/mL (insoluble); DMSO : ≥ 31 mg/mL (48.66 mM),10mM,Cancer,Launched,O=S(C1=CC=C(C=C1)C)(O)=O.O=C(NC2=CC=C(C(C(F)(F)F)=C2)Cl)NC3=CC=C(OC4=CC(C(NC)=O)=NC=C4)C=C3
cancer metabolism,0,0,9,0,"{29702208, 22589701, 24704294, 23535601, 31225458, 28350132, 37108468, 24743516, 28647837}","{35847495, 25762632, 25111821, 29725006, 36512624, 33143730, 35778964}", ,,#N/A,,,,,,,tyrosine kinases,nintedanib,HY-L025-64,C04,HY-50904,Nintedanib,BIBF 1120,656247-17-5,539.62,FGFR; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.",C31H33N5O4,DMSO : 11.5 mg/mL (21.31 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1NC2=CC(C(OC)=O)=CC=C2/C1=C(NC3=CC=C(N(C(CN4CCN(C)CC4)=O)C)C=C3)\C5=CC=CC=C5
foxp3,0,0,9,0,"{19752775, 23989613, 26575024, 24607504, 37191859, 36705749, 33082167, 37201049, 33682329}","{28039300, 34910919, 36256455, 27799308, 30124204, 32632663, 28408401, 36719036, 27710838, 30807094, 30733722, 37072347, 28892380}",potential PDAC target (37201049),,melatonin,,,,,,,d1,flupenthixol,HY-L025-54,E09,HY-15856B,Flupentixol (dihydrochloride),Flupenthixol (dihydrochloride),2413-38-9,507.44,Apoptosis; Dopamine Receptor; PI3K,Apoptosis; GPCR/G Protein; Neuronal Signaling; PI3K/Akt/mTOR,"Flupentixol is an orally active D1/D2 dopamine receptor antagonist and new PI3K inhibitor (PI3Kα IC50=127 nM). Flupentixol shows anti-proliferative activity to cancer cells and induces apoptosis. Flupentixol can also be used in schizophrenia, anxiolytic and depressive research[1][2][3].",C23H27Cl2F3N2OS,H2O : 100 mg/mL (197.07 mM; Need ultrasonic); DMSO : 33.33 mg/mL (65.68 mM; Need ultrasonic),10mM,Cancer; Neurological Disease,Launched,OCCN1CCN(CC/C=C2C3=C(SC4=C/2C=CC=C4)C=CC(C(F)(F)F)=C3)CC1.[H]Cl.[H]Cl
nuclear factor kappa b,0,0,8,0,"{9918209, 18049840, 15073105, 33804148, 20068565, 17671195, 22190076, 22752926}","{37211680, 27539364, 25778533, 33159815, 34199719, 29886474, 25263595, 32708494, 26324948, 31530390, 34050937, 24799421, 36100190}", ,,bay 11 7082,,,,,,,d1,flupentixol,HY-L025-54,E09,HY-15856B,Flupentixol (dihydrochloride),Flupenthixol (dihydrochloride),2413-38-9,507.44,Apoptosis; Dopamine Receptor; PI3K,Apoptosis; GPCR/G Protein; Neuronal Signaling; PI3K/Akt/mTOR,"Flupentixol is an orally active D1/D2 dopamine receptor antagonist and new PI3K inhibitor (PI3Kα IC50=127 nM). Flupentixol shows anti-proliferative activity to cancer cells and induces apoptosis. Flupentixol can also be used in schizophrenia, anxiolytic and depressive research[1][2][3].",C23H27Cl2F3N2OS,H2O : 100 mg/mL (197.07 mM; Need ultrasonic); DMSO : 33.33 mg/mL (65.68 mM; Need ultrasonic),10mM,Cancer; Neurological Disease,Launched,OCCN1CCN(CC/C=C2C3=C(SC4=C/2C=CC=C4)C=CC(C(F)(F)F)=C3)CC1.[H]Cl.[H]Cl
factor 2,0,0,8,0,"{17956352, 19885545, 26915435, 21996748, 26117456, 26397140, 12359775, 28971839}","{29878401, 19136002, 29767555, 35550209, 35184394, 29703820, 33811350, 24733848, 32938017, 11025449, 34497070, 31119153, 29025975, 9436983, 25232960, 30610113, 32730819, 31707348, 35180281, 33662680, 25891802, 24065768, 29246955, 32868081, 31003769}", ,,#N/A,,,,,,,d1,olanzapine,HY-L025-45,A07,HY-14541,Olanzapine,LY170053,132539-06-1,312.43,5-HT Receptor; Adrenergic Receptor; Apoptosis; Autophagy; Dopamine Receptor; mAChR; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling,"Olanzapine (LY170053) is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (Ki=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (Ki=11 to 31 nM), muscarinic M1-5 (Ki=1.9-25 nM), and adrenergic  α1 receptor (Ki=19  nM). Olanzapine is an atypical antipsychotic[1][2].",C17H20N4S,DMSO : 20 mg/mL (64.01 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,CC1=CC(C(N2CCN(C)CC2)=N3)=C(S1)NC4=C3C=CC=C4
janus kinase,0,0,8,0,"{26530532, 35948109, 23614574, 32947833, 27003603, 30142009, 33509790, 32762399}","{27507649, 33980611, 34272171, 27677740, 31875887, 36702002, 30206163, 36332787, 36881782, 35499161, 32647323, 23929215}",Targeting the Janus Kinase (JAK)/STAT signaling pathway using the FDA-approved drug ruxolitinib overcame these tumor-protective responses,Early growth response gene (EGR1) is a transcription factor known to be a downstream effector of B-cell receptor signaling and Janus kinase 1 (JAK1) signaling in diffuse large B-cell lymphoma (DLBCL)… Genetic and pharmacologic inhibition of EGR1 synergizes with the BRD4 inhibitor JQ1  (33980611),tofacitinib,,,,,,,d1,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
ikk,0,1,8,0,"{20959520, 23547054, 21078544, 27068336, 12767057, 22751123, 24555417, 32573499}","{31330113, 22649058, 25049379, 34400879, 30300821, 35002741, 30479742}", ,IKK-NFkB pathway regulates BRD4,curcumin,,,,,,,d1,dim,HY-L025-54,A02,HY-15758,"3,3'-Diindolylmethane",DIM; Arundine; HB 236,5/4/68,246.31,Androgen Receptor; Autophagy,Autophagy; Vitamin D Related/Nuclear Receptor,"3,3'-Diindolylmethane is a strong, pure androgen receptor (AR) antagonist.",C17H14N2,DMSO : ≥ 100 mg/mL (405.99 mM),10mM,Cancer,Phase 4,C1(CC2=CNC3=C2C=CC=C3)=CNC4=C1C=CC=C4
binding protein 1,0,0,8,0,"{21622730, 23563181, 24791855, 35800049, 37187730, 22427155, 29748382, 32762399}","{35694209, 27957794, 24215362, 36623719, 29127434, 33125143, 36711789, 24836559, 23479607, 27767195, 12915580}", ,,#N/A,,,,,,,d1,haloperidol,HY-L025-44,H11,HY-14538,Haloperidol,,52-86-8,375.86,Dopamine Receptor,GPCR/G Protein; Neuronal Signaling,"Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.",C21H23ClFNO2,DMSO : 100 mg/mL (266.06 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,ClC(C=C1)=CC=C1C2(O)CCN(CCCC(C3=CC=C(F)C=C3)=O)CC2
gene amplification,0,2,8,0,"{37094468, 23169292, 20553613, 15190415, 23808822, 18413752, 36900379, 32010971}","{26455392, 35299072, 27764802, 25956709, 30127528, 29941483, 33536620, 31110158, 19706770, 34819668, 32600791, 35513563, 33713695}", ,,#N/A,,,,,,,matrix metalloproteinase,all trans retinoic acid,HY-L025-46,C02,HY-14649,Retinoic acid,Vitamin A acid; all-trans-Retinoic acid; ATRA,302-79-4,300.44,Autophagy; Endogenous Metabolite; PPAR; RAR/RXR,Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.",C20H28O2,DMSO : 50 mg/mL (166.42 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,CC1(C)C(/C=C/C(C)=C/C=C/C(C)=C/C(O)=O)=C(C)CCC1
g1 arrest,0,2,8,0,"{23237571, 25894862, 29749405, 17906614, 29059158, 37105116, 21840189, 11522750}","{28593508, 9326598, 31712391, 29581547, 35408939, 25009295, 30417424, 32800944, 27276402, 26840085, 28714904, 34508829}", ,,#N/A,,,,,,,matrix metalloproteinase,ptx,HY-L025-69,C09,HY-B0715,Pentoxifylline,BL-191; PTX; Oxpentifylline,5/6/93,278.31,Autophagy; HIV; Phosphodiesterase (PDE),Anti-infection; Autophagy; Metabolic Enzyme/Protease,"Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].",C13H18N4O3,DMSO : ≥ 2.8 mg/mL (10.06 mM); H2O : 93.3 mg/mL (335.24 mM; Need ultrasonic and warming),10mM,Cardiovascular Disease; Cancer,Launched,O=C(N1CCCCC(C)=O)N(C)C2=C(N(C)C=N2)C1=O
cyclin a,0,0,8,0,"{24076388, 33137095, 30372904, 15811853, 27223122, 20669973, 20113529, 11522750}","{17166848, 18329849, 15548137, 29366803, 14563639, 16512664, 24319289, 16546331}", ,,apigenin,,,,,,,matrix metalloproteinase,naringin,HY-L025-72,F11,HY-N0153,Naringin,Naringoside,10236-47-2,580.53,Autophagy; Cytochrome P450; Endogenous Metabolite; Mitophagy,Autophagy; Metabolic Enzyme/Protease,"Naringin is a major flavanone glycoside obtained from tomatoes, grapefruits, and many other citrus fruits. Naringin exhibits biological properties such as antioxidant, anti-inflammatory, and antiapoptotic activities.",C27H32O14,DMSO : 125 mg/mL (215.32 mM; Need ultrasonic); H2O : 1 mg/mL (1.72 mM; ultrasonic and warming and heat to 80°C); Ethanol : < 1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble),10mM,Inflammation/Immunology; Cancer,No Development Reported,O=C1C[C@@H](C2=CC=C(O)C=C2)OC3=CC(O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O[C@@]5([H])[C@@H]([C@@H]([C@H]([C@H](C)O5)O)O)O)=CC(O)=C13
rela,0,1,8,0,"{9918209, 19880966, 24340014, 12767057, 35402225, 35707377, 27454293, 27454298}","{21900162, 19103749, 27793799, 24189064, 28695816, 33741710, 29440272, 31195152, 28726418, 30321559, 33006750, 29415456, 23686307, 33462181, 29694891, 34378541, 29467311, 27436852, 28215221, 36711864, 29352508, 29776834, 27084101, 23667654, 29593031, 34765643, 28077651, 30153047, 34392152, 30712413, 35108062, 31115487, 25778533, 27292648, 26254443, 33620209, 30386303}", ,RelA is part of NFKB complex,bortezomib,,,,,,,matrix metalloproteinase,genistein,HY-L025-45,H04,HY-14596,Genistein,NPI 031L,446-72-0,270.24,Apoptosis; Autophagy; EGFR; Endogenous Metabolite,Apoptosis; Autophagy; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,"Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.",C15H10O5,DMSO : ≥ 100 mg/mL (370.04 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 4,OC1=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=CC(O)=C1
pd 1 pd l1,0,1,8,0,"{32337408, 36100320, 34239621, 33115526, 34440587, 34349003, 27402485, 30377341}","{30824609, 35083874, 32683685, 30958600, 32184777, 28249162, 32630154, 33658927, 37148657, 32339606, 35918330, 35547739, 30266108}", ,,#N/A,,,,,,,matrix metalloproteinase,osthole,HY-L025-71,H11,HY-N0054,Osthole,Osthol; NSC 31868,484-12-8,244.29,Apoptosis; HBV; Histamine Receptor; Parasite,Anti-infection; Apoptosis; GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling,Osthole (Osthol) is a natural antihistamine alternative. Osthole may be a potential inhibitor of histamine H1 receptor activity. Osthole also suppresses the secretion of HBV in cells.,C15H16O3,DMSO : ≥ 100 mg/mL (409.35 mM),10mM,Cancer; Infection; Endocrinology; Inflammation/Immunology; Cardiovascular Disease,No Development Reported,O=C1C=CC2=CC=C(OC)C(C/C=C(C)\C)=C2O1
proteasomal degradation,0,1,8,0,"{25753158, 35131878, 18310088, 31988076, 34909679, 36581205, 36162331, 36624189}","{35299072, 30918020, 32134919, 30175757, 30369550, 31026449, 27233051, 25877301, 28154167, 30037819, 28805822, 31311807, 31059647, 33086530, 33780296, 34688842, 28378579, 19211738, 24448221, 29581547, 34700270, 23706739, 36606710, 26415225, 36536188, 32355326}", ,,#N/A,,,,,,,matrix metalloproteinase,honokiol,HY-L025-71,F02,HY-N0003,Honokiol,NSC 293100,35354-74-6,266.33,Akt; Autophagy; ERK; HCV,Anti-infection; Autophagy; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt,"Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt. Honokiol can readily cross the blood brain barrier[1][2][3][4].",C18H18O2,DMSO : ≥ 50 mg/mL (187.74 mM),10mM,Cancer,Phase 3,OC1=C(CC=C)C=C(C2=CC(CC=C)=CC=C2O)C=C1
long noncoding rnas,0,0,8,0,"{29063045, 28860807, 29290766, 22078386, 27689078, 31325400, 23839098, 35433983}","{33547232, 25684227, 33844835, 34976005, 31514410, 36166514, 26111795, 36477655, 30428346, 31253147, 29133788}", ,,#N/A,,,,,,,matrix metalloproteinase,dexamethasone,HY-L025-46,B10,HY-14648,Dexamethasone,Hexadecadrol; Prednisolone F,50-02-2,392.46,Antibiotic; Autophagy; Bacterial; Complement System; Glucocorticoid Receptor; Mitophagy; SARS-CoV,Anti-infection; Autophagy; Immunology/Inflammation; Vitamin D Related/Nuclear Receptor,"Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.",C22H29FO5,DMSO : 250 mg/mL (637.01 mM; ultrasonic and warming and heat to 60°C); Ethanol : 8.33 mg/mL (21.23 mM; Need ultrasonic),10mM,Cancer; Infection; Endocrinology; Inflammation/Immunology,Launched,O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@@]4(C(CO)=O)O)=C1
cell phenotype,0,0,8,0,"{22806240, 25042889, 22471946, 33178766, 33188080, 35897809, 36055991, 27315162}","{34232599, 34037670, 33792558, 33658703, 34697072, 35799890, 34956562, 30807094, 32166583, 31423932}", ,,#N/A,,,,,,,matrix metalloproteinase,pioglitazone,HY-L025-45,H09,HY-14601,Pioglitazone (hydrochloride),U 72107A; AD 4833,112529-15-4,392.9,Ferroptosis; PPAR,Apoptosis; Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor,"Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.",C19H21ClN2O3S,DMSO : 100 mg/mL (254.52 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer; Metabolic Disease,Launched,CCC1=CN=C(CCOC2=CC=C(CC3C(NC(S3)=O)=O)C=C2)C=C1.Cl
aurka,0,0,8,0,"{16367914, 36161420, 28220783, 32193808, 33491761, 16532023, 32571902, 36116415}","{27650498, 32735909, 32954665, 35249548, 32885168, 30153557}", ,CDK9/AURKA + BRD4 synergistic? (35249548),mln8054,,,,,,,matrix metalloproteinase,cordycepin,HY-L025-73,E07,HY-N0262,Cordycepin,3'-Deoxyadenosine,73-03-0,251.24,Antibiotic; Autophagy; Bacterial; MMP,Anti-infection; Autophagy; Metabolic Enzyme/Protease,Cordycepin (3'-Deoxyadenosine) is a nucleoside derivative and inhibits IL-1β-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts (RASFs) in a dose-dependent manner[1]. Cordycepin kills Mycobacterium tuberculosis through hijacking the bacterial adenosine kinase[2].,C10H13N5O3,DMSO : 33.33 mg/mL (132.66 mM; Need ultrasonic); H2O : 2 mg/mL (7.96 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Infection; Inflammation/Immunology,Phase 2,OC[C@@H]1C[C@@H](O)[C@H](N2C=NC3=C2N=CN=C3N)O1
klf4,0,0,8,0,"{33127746, 24880079, 22751123, 36090038, 34859959, 24040120, 26977883, 34657147}","{33190371, 30135075, 26974661, 36691621, 25312495, 35831279, 36332631, 29662175}", ,KLF4 is a BRD4 dependent gene (35831279) and seems to be a cell reprogramming factor (36691621),kenpaullone,,,,,,,matrix metalloproteinase,tetracycline,HY-L025-68,D09,HY-B0474,Tetracycline (hydrochloride),,64-75-5,480.9,Antibiotic; Bacterial,Anti-infection,"Tetracycline (hydrochloride) is a broad-spectrum antibiotic, exhibiting activity against a wide range of gram-positive and gram-negative bacteria.",C22H25ClN2O8,DMSO : 62.5 mg/mL (129.96 mM; Need ultrasonic); H2O : 50 mg/mL (103.97 mM; Need ultrasonic),10mM,Infection; Cancer,Launched,O[C@@]1(C(C(C(N)=O)=C2O)=O)[C@@]([C@@H]2N(C)C)([H])C[C@@]([C@](O)(C3=CC=C4)C)([H])C(C(C3=C4O)=O)=C1O.Cl
pou5f1,0,1,8,0,"{34657147, 20173672, 28381547, 35103981, 24880079, 27624879, 24040120, 33788731}","{25393219, 25684227, 30962627, 33574085, 33190371, 36691621, 31516082, 30428346, 37066171, 25263550, 26847871}", ,these don't contain pou5f1? Confused,#N/A,,,,,,,matrix metalloproteinase,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
tams,0,0,8,0,"{34279685, 32809834, 36741230, 24909166, 28419443, 31920150, 35156921, 32070494}","{31819043, 32184777, 32286255, 35988145, 32603665, 35755286, 35094142}", ,tams = tumor associated microenvironment,#N/A,,,,,,,matrix metalloproteinase,emodin,HY-L025-43,G03,HY-14393,Emodin,Frangula emodin,518-82-1,270.24,11β-HSD; Autophagy; Casein Kinase; SARS-CoV,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively.  Emodin ameliorates metabolic disorder in diet-induced obese mice[3].",C15H10O5,Acetone : 10.87 mg/mL (40.22 mM; Need ultrasonic); DMSO : 5.41 mg/mL (20.02 mM; Need ultrasonic); Ethanol : 10.87 mg/mL (40.22 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C(C=C(C)C=C2O)C(C3=CC(O)=CC(O)=C31)=O
kappa b,0,0,7,0,"{9918209, 18049840, 15073105, 20068565, 17671195, 22190076, 22493246}","{37211680, 27539364, 25778533, 23667654, 33159815, 34199719, 29886474, 25263595, 32708494, 36247184, 26324948, 31530390, 34050937, 24799421, 36100190}", ,,#N/A,,,,,,,matrix metalloproteinase,decursin,HY-L025-60,H09,HY-18981,Decursin,(+)-Decursin,5928-25-6,328.36,Apoptosis; CXCR; PKC,Apoptosis; Epigenetics; GPCR/G Protein; Immunology/Inflammation; TGF-beta/Smad,"Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of  CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities[1][2][3][4].",C19H20O5,DMSO : 50 mg/mL (152.27 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,No Development Reported,C/C(C)=C\C(O[C@H](C(C)(C)O1)CC2=C1C=C(O3)C(C=CC3=O)=C2)=O
tyrosine kinases,0,0,7,0,"{31068384, 11034087, 23441129, 26597578, 25736685, 27595930, 12359775}","{25865888, 17425505, 31043489, 29899872, 32393731, 32599680, 15744326, 30630822, 28336808, 36696581, 30537514, 28108460, 31932756, 29792310, 34499862, 28474232, 29212027}", ,,tt 232,,,,,,,il 8,colchicine,HY-L025-56,D07,HY-16569,Colchicine,,64-86-8,399.44,Apoptosis; Autophagy; Microtubule/Tubulin,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton,Colchicine is a tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM[1][2][3]. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs)[4].,C22H25NO6,DMSO : ≥ 48 mg/mL (120.17 mM); H2O : ≥ 33.33 mg/mL (83.44 mM),10mM,Cancer,Launched,CC(N[C@H](C1=C2)CCC3=CC(OC)=C(OC)C(OC)=C3C1=CC=C(OC)C2=O)=O
il 8,0,0,7,0,"{16146690, 21462088, 30558665, 25050737, 16192891, 24389175, 29670075}","{36482051, 33172487, 34082824, 32708494, 29649811, 34236185, 25467295, 27106081, 36721187, 30253095, 24924589, 34378541, 24759736, 22645312, 29649741, 30652495, 26324948, 35007061, 33408470, 33854310}", ,IL8 and BRD4 synergy? Not sure… (36721187),colchicine,,,,,,,il 8,auranofin,HY-L025-70,B02,HY-B1123,Auranofin,SKF-39162,34031-32-8,680.5,Bacterial; SARS-CoV,Anti-infection,"Auranofin (SKF-39162) is a thioredoxin reductase (TrxR) inhibitor with an IC50 of 0.2 μM. Auranofin exhibits antiviral activity against SARS-CoV21, with a CC50 of 4.2?μM for monkey kidney Vero E6 cells.",C20H36AuO9PS,DMSO : 50 mg/mL (73.48 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,CC(O[C@@H]1[C@@H](OC(C)=O)[C@H]([SH-][Au+]P(CC)(CC)CC)O[C@H](COC(C)=O)[C@H]1OC(C)=O)=O
nf κb p65,0,0,7,0,"{29956741, 20717927, 34046348, 24561527, 34356340, 25237909, 34412631}","{31330113, 34172737, 33215396, 30528103, 25606026, 29343723, 29440272, 27007123, 34974135, 24608443}", ,,tudca,,,,,,,il 8,e2,HY-L025-66,F04,HY-B0141,Estradiol,β-Estradiol; E2; 17β-Estradiol; 17β-Oestradiol,50-28-2,272.38,Bacterial; Endogenous Metabolite; Estrogen Receptor/ERR,Anti-infection; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Estradiol (β-Estradiol) is a steroid hormone and the major female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering[1][2].",C18H24O2,DMSO : 62.5 mg/mL (229.46 mM; ultrasonic and warming and heat to 60°C); Ethanol : 20 mg/mL (73.43 mM; Need ultrasonic),10mM,Endocrinology; Cancer,Launched,C[C@@]1([C@H]2O)[C@](CC2)([H])[C@@](CCC3=C4C=CC(O)=C3)([H])[C@]4([H])CC1
iκb,0,1,7,0,"{20959520, 32004866, 28069799, 23547054, 27068336, 27991926, 24752990}","{30455393, 22649058, 25049379, 28983590, 36702002, 26324948, 35002741, 30321559, 34791293, 30479742}", ,,bay 11 7082,,,,,,,il 8,tsa,HY-L025-49,F10,HY-15144,Trichostatin A,TSA,58880-19-6,302.37,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].",C17H22N2O3,DMSO : 25 mg/mL (82.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
bcl2,0,1,7,0,"{23613993, 22384141, 17616686, 21078544, 23475955, 33649045, 19860666}","{31288832, 25053825, 28784769, 36287107, 32917124, 34568834, 27185926, 24657799, 24584072, 32246150, 35787399, 35105803, 35249548, 30417424, 31594641, 26327698, 29353886, 28663582, 33006750, 31527074, 30592293, 28468776, 29795241, 30107177, 32437546, 33154093, 28035374, 28653617, 30055346, 30323893, 33148342, 26586936, 30018745, 33654205, 32693114, 31311807, 29931583, 31844420, 35610180, 35114569, 26759243, 32249419, 36731467, 35281876, 33531996, 31226848, 33945824, 30568163, 34601571, 27520485, 31631721, 28391274, 26254443, 30647404, 30104685, 33515627, 25639793, 24435446, 31821686, 26077433, 24009722, 27055867, 33781756, 34581757, 33148670}", ,,metformin,,,,,,,il 8,pge1,HY-L025-66,E06,HY-B0131,Prostaglandin E1,Alprostadil; PGE1,745-65-3,354.48,Endogenous Metabolite; Prostaglandin Receptor,GPCR/G Protein; Metabolic Enzyme/Protease,"Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases[1][2][3].",C20H34O5,Ethanol : 100 mg/mL (282.10 mM; Need ultrasonic); DMSO : 100 mg/mL (282.10 mM; Need ultrasonic),10mM,Endocrinology; Cardiovascular Disease; Cancer,Launched,CCCCC[C@H](O)/C=C/[C@@H]1[C@H](C(C[C@H]1O)=O)CCCCCCC(O)=O
stat1,0,0,7,0,"{33505218, 36690307, 32242147, 27435400, 32200350, 21321110, 33509790}","{36918560, 34983841, 30793699, 36100643, 28035374, 26654227, 34365463, 34503062, 35289334, 33529752, 33630975}", ,,myricetin,,,,,,,il 8,catalpol,HY-L025-76,E08,HY-N0820,Catalpol,Catalpinoside,2415-24-9,362.33,HBV,Anti-infection,"Catalpol (Catalpinoside), an iridoid glycoside found in Rehmannia glutinosa. Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-HBV effects[1][2][3].",C15H22O10,DMSO : ≥ 30 mg/mL (82.80 mM); H2O : 7.14 mg/mL (19.71 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Infection; Inflammation/Immunology; Neurological Disease,No Development Reported,OC[C@@]12[C@]([C@@H]3O[C@]([C@@H]([C@@H](O)[C@@H]4O)O)([H])O[C@@H]4CO)([H])[C@](C=CO3)([H])[C@H](O)[C@@H]1O2
smad3,0,0,7,0,"{21288898, 34439202, 19010789, 17114344, 21225226, 26915435, 31817656}","{30106235, 33757572, 29343723, 32678475, 36250963, 28063381, 28182006, 27270427, 33664670}", ,smad3 activation seems to activate brd4? (36250963),kaempferol,,,,,,,chemokine,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
retinoic acid,0,0,7,0,"{37236000, 25531332, 27061193, 18789834, 24909166, 22440084, 30250298}","{28549889, 28039300, 32917124, 26055303, 31570593, 9436983, 8695863, 29699387, 29593031, 27581642, 23762261, 30552662, 31580635, 8208605, 26149470, 34829934, 10022127, 30602479, 26469117}", ,,#N/A,,,,,,,cyclin d1,icg 001,HY-L025-43,H10,HY-14428,ICG-001,,780757-88-2,548.63,Apoptosis; β-catenin,Apoptosis; Stem Cell/Wnt,ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.,C33H32N4O4,DMSO : ≥ 50 mg/mL (91.14 mM),10mM,Cancer,No Development Reported,O=C(NCC1=CC=CC=C1)N2CCC(N([C@@]2(CN(C3=O)CC4=C5C=CC=CC5=CC=C4)[H])[C@H]3CC6=CC=C(C=C6)O)=O
meki,0,2,7,0,"{34001634, 35771494, 30154150, 35806187, 35948109, 32194992, 32358491}","{31043489, 30353166, 31272080, 35969744, 31932756, 33087508}", ,meki = mek inhibitor; BRD4 inhibition resensitizes MEKi-resistant melanoma (35969744),pd98059,,,,,,,cyclin d1,decursin,HY-L025-60,H09,HY-18981,Decursin,(+)-Decursin,5928-25-6,328.36,Apoptosis; CXCR; PKC,Apoptosis; Epigenetics; GPCR/G Protein; Immunology/Inflammation; TGF-beta/Smad,"Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of  CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities[1][2][3][4].",C19H20O5,DMSO : 50 mg/mL (152.27 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,No Development Reported,C/C(C)=C\C(O[C@H](C(C)(C)O1)CC2=C1C=C(O3)C(C=CC3=O)=C2)=O
keap1,0,0,7,0,"{31822343, 26117456, 29240881, 21734707, 33672789, 26497117, 28971839}","{32938017, 35453346, 34520194, 29545928, 31325480, 24763052, 28012209, 33094643, 32968148, 32877461, 35883157, 31003769, 27233051}", ,keap1 activation reverses BRD4 inhibition effects (33094643),egcg,,,,,,,cyclin d1,lycorine,HY-L025-73,G02,HY-N0289,Lycorine (hydrochloride),,2188-68-3,323.77,Autophagy; Bacterial; Virus Protease,Anti-infection; Autophagy,Lycorine hydrochloride is the main active ingredient of the herbal medicine derived from Lycoris radiata (L’Her.) Herb. and  is also a melanoma vasculogenic inhibitor and has anti-tumor activity[1]. Lycorine hydrochloride effectively inhibits mitotic proliferation of Hey1B cells (IC50 of 1.2 μM)[2].,C16H18ClNO4,DMSO : 25 mg/mL (77.22 mM; Need ultrasonic); H2O : 16.67 mg/mL (51.49 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,No Development Reported,O[C@@H]1[C@@H](O)C=C(CC2)[C@@]3([H])N2CC4=C([C@@]31[H])C=C(OCO5)C5=C4.Cl
cell cycle distribution,0,1,7,0,"{26668065, 22977607, 22020907, 9841966, 35896270, 8539259, 21970876}","{35480096, 35046638, 33407504, 27573714, 28545522, 34387610, 32100443, 27607580, 28669341}", ,,#N/A,,,,,,,cyclin d1,embelin,HY-L025-58,C09,HY-17473,Embelin,Embelic acid; Emberine; NSC 91874,550-24-3,294.39,Apoptosis; Autophagy; IAP; NF-κB,Apoptosis; Autophagy; NF-κB,"Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC50=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells[1][2][3].",C17H26O4,DMSO : ≥ 50 mg/mL (169.84 mM),10mM,Cancer,No Development Reported,O=C1C(O)=C(CCCCCCCCCCC)C(C(O)=C1)=O
dna methyltransferase,0,0,7,0,"{12420225, 19294695, 21573703, 30226601, 32457835, 34727952, 29626481}","{25623136, 30824609, 31521697, 31164355, 32917124, 30386240, 30672294, 33945824, 28838216, 26111464, 28943305, 8917104, 31075731, 37111316, 31549911, 24403256, 19099580, 36513631}", ,,vorinostat,,,,,,,cyclin d1,gemcitabine,HY-L025-65,H10,HY-B0003,Gemcitabine (hydrochloride),LY 188011 (hydrochloride),122111-03-9,299.66,Apoptosis; Autophagy; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog,Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[1][2].",C9H12ClF2N3O4,H2O : 33.33 mg/mL (111.23 mM; Need ultrasonic); DMSO : 25 mg/mL (83.43 mM; ultrasonic and warming and heat to 60°C); DMF : 2.5 mg/mL (8.34 mM; Need ultrasonic),10mM,Cancer,Launched,O[C@H]1C(F)(F)[C@H](N2C(N=C(N)C=C2)=O)O[C@@H]1CO.Cl
high mobility group,0,2,7,0,"{33747719, 22898640, 34698902, 19179606, 33682329, 28374746, 25632159}","{17081121, 33603756, 24040311, 11313457, 31600692, 10330133, 35740436, 11967287, 28844955, 29366780}", ,,#N/A,,,,,,,cyclin d1,eupatilin,HY-L025-76,C11,HY-N0783,Eupatilin,,22368-21-4,344.32,Autophagy; PPAR,Autophagy; Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor,"Eupatilin, a lipophilic flavonoid isolated from Artemisia argyi Lévl. et Van., is a PPARα agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.",C18H16O7,DMSO : 33.33 mg/mL (96.80 mM; Need ultrasonic),10mM,Inflammation/Immunology; Neurological Disease; Cancer,Launched,O=C1C=C(C2=CC=C(OC)C(OC)=C2)OC3=CC(O)=C(OC)C(O)=C13
zinc finger,0,2,7,0,"{35098656, 26684803, 32355831, 25997867, 32179733, 29414775, 23471001}","{25367296, 17694082, 10925700, 29453316, 11331592, 28864776, 29249292, 16954381, 9699856, 7583761, 10940561, 36292752, 36381331, 35940372, 32355326, 34232599, 24258712, 22095101, 23831576, 21880731, 31999386, 34597402, 9828126, 28837921, 28055972, 36077605, 25920810, 31001132, 24333487, 25533489, 28341809, 28215221, 24633655, 25568313, 31882553, 36341561, 19099580, 26061247, 35843263, 24215362, 20923973, 23667654, 11230151, 29981437, 35666761, 36692427, 15467469, 29629903, 17507796, 7565781, 33554132, 31964889, 30139738, 32848091, 25593309, 33721694, 26942307, 17178852, 34889443, 34680936, 34979305, 33517164, 35650157, 36147311, 8910577, 30266865, 18794358, 30150647, 36938998, 34715126, 21923194, 21555453, 28680062}", ,,#N/A,,,,,,,cyclin d1,galangin,HY-L025-74,B04,HY-N0382,Galangin,"Norizalpinin; 3,5,7-Trihydroxyflavone",548-83-4,270.24,Autophagy; Cytochrome P450,Autophagy; Metabolic Enzyme/Protease,Galangin (Norizalpinin) is?an?agonist/antagonist?of the?arylhydrocarbon?receptor. Galangin (Norizalpinin) also shows inhibition of CYP1A1 activity.,C15H10O5,DMSO : 125 mg/mL (462.55 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C(O)=C(C2=CC=CC=C2)OC3=CC(O)=CC(O)=C13
factor c,0,0,7,0,"{21279552, 21320746, 35538031, 36078164, 36735511, 25500542, 28639199}","{36781122, 28415755, 23144621, 12192049, 33520370, 22829075, 10656693, 9742105, 29212027}", ,,#N/A,,,,,,,cyclin d1,piceatannol,HY-L025-35,H10,HY-13518,Piceatannol,Astringenin; trans-Piceatannol,10083-24-6,244.24,Apoptosis; Autophagy; Endogenous Metabolite; Syk,Apoptosis; Autophagy; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI)[1]. Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties[2]. Piceatannol induces apoptosis in DLBCL cell lines[3]. Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells[4].,C14H12O4,DMSO : ≥ 31 mg/mL (126.92 mM); H2O : 1 mg/mL (4.09 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1O
xiap,0,1,7,0,"{35604033, 26716649, 27624879, 21078544, 21304978, 35819261, 30555743}","{26485762, 31993368, 26254443, 26802028, 32249419, 30369550, 30175757, 29290992, 35249548, 26087189, 28154167, 28656888, 33006750, 27607580, 28766941, 28663582}", ,xiap downstream target of NF-KB. MCL1 inhibition might be synergistic with BRD4 inhibition (32249419),sm 164,,,,,,,cyclin d1,epa,HY-L025-69,B10,HY-B0660,Eicosapentaenoic Acid,EPA; Timnodonic acid,10417-94-4,302.45,Endogenous Metabolite; Histone Demethylase,Epigenetics; Metabolic Enzyme/Protease,Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation[1][2][3].,C20H30O2,DMSO : ≥ 53 mg/mL (175.24 mM); Ethanol : ≥ 100 mg/mL (330.63 mM),10mM,Neurological Disease; Cancer,Launched,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(O)=O
axl,0,1,7,0,"{36607777, 26438693, 32912902, 25736685, 24240689, 27087446, 30938713}","{34546978, 32416067, 36154607, 33712563, 29792310, 30524510}", ,"AXL, PI3K, CK2 inhibition synergistic with BRD4 inhibition (33712563)",r428,,,,,,,cyclin d1,vitamin k2,HY-L025-71,C05,HY-B2156,Menaquinone-4,Vitamin K2(MK-4); Menaquinone K4,863-61-6,444.65,Endogenous Metabolite,Metabolic Enzyme/Protease,"Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.",C31H40O2,DMSO : 20 mg/mL (44.98 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1C(C)=C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)\C)C(C2=C1C=CC=C2)=O
genes expression,0,0,7,0,"{30613920, 31276933, 26161927, 31920328, 29802286, 29472816, 10909469}","{30455393, 26855180, 29472532, 34539188, 31821686, 27544600, 34050937, 37072347}", ,,#N/A,,,,,,,cyclin d1,dif 3,HY-L025-45,D02,HY-145669,DIF-3,,113411-17-9,272.72,CDK; GSK-3,Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in DLD-1 cells. DIF-3 exerts a strong antiproliferative effect on the human cervical cancer cell line HeLa by inducing cyclin D1 degradation and inhibiting cyclin D1 mRNA expression[1]. ,C13H17ClO4,DMSO : 100 mg/mL (366.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C(CCCCC)C1=C(C=C(C(Cl)=C1O)OC)O
dendritic cell,0,0,7,0,"{33590726, 32060137, 26034349, 24909166, 36451859, 35920660, 32358491}","{25891802, 33161793, 32651619, 36793283, 29399399, 27060168, 29795241, 25725100, 34722316, 27846385, 30350260, 27710838, 27846392, 32234682, 36139421}", ,,#N/A,,,,,,,phosphoinositide 3 kinase,wortmannin,HY-L025-6,H04,HY-10197,Wortmannin,SL-2052; KY-12420,19545-26-7,428.43,Antibiotic; Autophagy; PI3K; Polo-like Kinase (PLK),Anti-infection; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively[1][2][3].",C23H24O8,DMSO : ≥ 50 mg/mL (116.71 mM),10mM,Cancer,No Development Reported,O=C1C([C@@](CC2)([H])[C@@]3(C)C2=O)=C([C@H](OC(C)=O)C3)[C@]4(C)C5=C1OC=C5C(O[C@@H]4COC)=O
tumor evolution,0,0,7,0,"{32582528, 28581516, 31780749, 34009137, 30430578, 28736628, 31932696}","{30467425, 30796033, 32393766, 33512458, 30844748}", ,,#N/A,,,,,,,phosphoinositide 3 kinase,gf109203x,HY-L025-41,A05,HY-13867A,Bisindolylmaleimide I (hydrochloride),GF109203X (hydrochloride); Go 6850 (hydrochloride),176504-36-2,448.94,GSK-3; PKC,Epigenetics; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad,"Bisindolylmaleimide I (GF109203X) hydrochloride is a cell-permeable and reversible PKC inhibitor (IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I hydrochloride is also a GSK-3 inhibitor[1][2][3].",C25H25ClN4O2,DMSO : 62.5 mg/mL (139.22 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Metabolic Disease,No Development Reported,[H]Cl.O=C(C(C1=CN(CCCN(C)C)C2=C1C=CC=C2)=C3C4=CNC5=C4C=CC=C5)NC3=O
yap taz,0,1,7,0,"{34395269, 32900774, 32912902, 31912905, 28381547, 31057295, 34680275}","{36781122, 31406246, 36162600, 35705032, 31281517, 30224758, 34508829}", ,,verteporfin,,,,,,,phosphoinositide 3 kinase,sb 203580,HY-L025-7,G02,HY-10256A,Adezmapimod (hydrochloride),SB 203580 (hydrochloride); RWJ 64809 (hydrochloride),869185-85-3,413.9,Autophagy; Mitophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"Adezmapimod (SB 203580) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride is an autophagy and mitophagy activator[1].",C21H17ClFN3OS,H2O : 8.43 mg/mL (20.37 mM; Need ultrasonic and warming); DMSO : 100 mg/mL (241.60 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,No Development Reported,O=S(C1=CC=C(C2=NC(C3=CC=C(F)C=C3)=C(C4=CC=NC=C4)N2)C=C1)C.[H]Cl
snai1,0,0,7,0,"{24944064, 31817229, 23761168, 32641744, 27364947, 33802809, 19860666}","{30618144, 27793799, 30745801, 31114028, 36768307, 32690869, 32923445, 35002741, 34344445, 33732255}", ,BRD4 regulates expression of SNAI1,#N/A,,,,,,,phosphoinositide 3 kinase,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
epithelial differentiation,0,0,7,0,"{22086851, 28090569, 27345450, 22232209, 19477428, 19916245, 14732924}","{23128391, 31334571, 21652721, 16435379, 17934517, 20352379, 27980063}", ,,#N/A,,,,,,,phosphoinositide 3 kinase,zstk474,HY-L025-63,H10,HY-50847,ZSTK474,,475110-96-4,417.41,Autophagy; PI3K,Autophagy; PI3K/Akt/mTOR,"ZSTK474 is an ATP-competitive pan-class I PI3K inhibitor with IC50s of 16 nM, 44 nM, 4.6 nM and 49 nM for PΙ3Κα, PI3Kβ, PI3Kδ and PI3Kγ, respectively.",C19H21F2N7O2,DMSO : 2 mg/mL (4.79 mM; Need ultrasonic),2mM,Cancer,Phase 1,FC(C1=NC2=C(N1C3=NC(N4CCOCC4)=NC(N5CCOCC5)=N3)C=CC=C2)F
demethylation,0,0,7,0,"{23912455, 32457835, 15652748, 26544625, 21472283, 26381405, 23407711}","{21447565, 25111821, 32203421, 29534238, 17687328, 35930668, 25575605, 29180474, 34070078, 34910919, 34586831, 28572115, 24360279, 29956190, 28357218, 27273316, 31363048, 36877164, 37120495, 18778484, 28169463, 30659195}", ,,#N/A,,,,,,,phosphoinositide 3 kinase,voxtalisib,HY-L025-54,H04,HY-15900,Voxtalisib,XL765; SAR245409,934493-76-2,270.29,mTOR; PI3K,PI3K/Akt/mTOR,"Voxtalisib (XL765) is a potent PI3K inhibitor, which has a similar activity toward class I PI3K (IC50s=39, 113, 9 and 43?nM for p110α, p110β, p110γ and p110δ, respectively), also inhibits DNA-PK (IC50=150?nM) and mTOR (IC50=157?nM). Voxtalisib (XL765) inhibits mTORC1 and mTORC2 with IC50s of 160 and 910 nM, respectively.",C13H14N6O,DMSO : 10 mg/mL (37.00 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1C(C2=NNC=C2)=CC3=C(C)N=C(N)N=C3N1CC
cell activity,0,0,7,0,"{35205666, 31797958, 32393543, 28980940, 29440631, 31586042, 29253566}","{32978368, 33420321, 30308518, 34876902, 33051401, 24000170, 29133261, 36823213, 30943407, 33686960, 28969075, 31018997, 32352759, 28467486}", ,,#N/A,,,,,,,phosphoinositide 3 kinase,everolimus,HY-L025-7,D10,HY-10218,Everolimus,RAD001; SDZ-RAD,159351-69-6,958.22,Apoptosis; Autophagy; Bacterial; FKBP; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; PI3K/Akt/mTOR,"Everolimus (RAD001) is a <a href=""/Rapamycin.html"" class=""link-product"" target=""_blank"">Rapamycin</a> (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].",C53H83NO14,DMSO : 50 mg/mL (52.18 mM; ultrasonic and warming and heat to 60°C); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](OCCO)CC4)OC)C)=O)=O
rtks,0,1,6,0,"{31068384, 12622410, 25736685, 35896270, 34909679, 34921013}","{36682147, 36696581, 30630822, 30537514, 31932756, 30524510, 26058079}", ,receptor tyrosine kinases,egcg,,,,,,,phosphoinositide 3 kinase,buparlisib,HY-L025-64,F10,HY-70063,Buparlisib,BKM120; NVP-BKM120,944396-07-0,410.39,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.",C18H21F3N6O2,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : ≥ 100 mg/mL (243.67 mM),10mM,Cancer,Phase 3,FC(F)(C1=C(C2=CC(N3CCOCC3)=NC(N4CCOCC4)=N2)C=NC(N)=C1)F
rb1,0,1,6,0,"{21699781, 36346366, 33483239, 29802286, 27203738, 29596894}","{30135075, 25525796, 32917124, 33876771, 33512458, 29760044, 29088303, 33838899, 27835869, 29915391}", ,RB1 is a tumor suppressor?,#N/A,,,,,,,phosphoinositide 3 kinase,taselisib,HY-L025-41,C04,HY-13898,Taselisib,GDC-0032; RG-7604,1282512-48-4,460.53,PI3K,PI3K/Akt/mTOR,"Taselisib (GDC-0032) is a potent PI3K inhibitor targets PIK3CA mutations, with Kis of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.",C24H28N8O2,DMSO : 25 mg/mL (54.29 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,CC(C)N1C(C2=CN3C(C(C(OCC3)=C4)=CC=C4C5=CN(C(C)(C(N)=O)C)N=C5)=N2)=NC(C)=N1
initiation factor,0,1,6,0,"{31740775, 34001163, 28381547, 23563181, 26483550, 32762399}","{30305285, 30232453, 36623719, 30289257, 29127434, 26358508, 35650157, 28461486, 17293877, 33125143, 30485080, 29558110, 12093919}", ,,#N/A,,,,,,,phosphoinositide 3 kinase,bkm120,HY-L025-64,F10,HY-70063,Buparlisib,BKM120; NVP-BKM120,944396-07-0,410.39,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.",C18H21F3N6O2,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : ≥ 100 mg/mL (243.67 mM),10mM,Cancer,Phase 3,FC(F)(C1=C(C2=CC(N3CCOCC3)=NC(N4CCOCC4)=N2)C=NC(N)=C1)F
cell growth and survival,0,0,6,0,"{36216931, 20858281, 26915435, 23547054, 19523441, 26575954}","{25999370, 35842703, 24293458, 29383095, 29437725}", ,,#N/A,,,,,,,phosphoinositide 3 kinase,cudc 907,HY-L025-36,A06,HY-13522,Fimepinostat,CUDC-907,1339928-25-4,508.55,Apoptosis; HDAC; PI3K,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR,"Fimepinostat (CUDC-907) potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes with an IC50 of  19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.",C23H24N8O4S,DMSO : 50 mg/mL (98.32 mM; Need ultrasonic); DMF : 5 mg/mL (9.83 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=CN=C(N(CC2=CC3=NC(C4=CC=C(OC)N=C4)=NC(N5CCOCC5)=C3S2)C)N=C1)NO
tumor suppressor protein,0,0,6,0,"{29452455, 16278378, 26972939, 11097231, 33740661, 34402431}","{25743841, 27390756, 29329830, 14759370, 26919247, 9016949, 26407966}", ,,#N/A,,,,,,,phosphoinositide 3 kinase,sp600125,HY-L025-22,G02,HY-12041,SP600125,,129-56-6,220.23,Apoptosis; Autophagy; Ferroptosis; JNK,Apoptosis; Autophagy; MAPK/ERK Pathway,"SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 inhibits autophagy and activates apoptosis[1][2][3].",C14H8N2O,DMSO : 12.5 mg/mL (56.76 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C3C(NN=C3C4=C1C=CC=C4)=CC=C2
rna binding protein,0,0,6,0,"{32814086, 29452455, 36408139, 35703534, 8893335, 28242812}","{26463137, 29563491, 27748806, 35856391, 31077320, 28481226, 29703820, 22609015, 12915580, 23241214}", ,,#N/A,,,,,,,phosphoinositide 3 kinase,duvelisib,HY-L025-57,F11,HY-17044A,Duvelisib (R enantiomer),IPI-145 R enantiomer; INK1197 R enantiomer,1261590-48-0,416.86,PI3K,PI3K/Akt/mTOR,"Duvelisib R enantiomer is a PI3K inhibitor, which is the less active enantiomer of Duvelisib. ",C22H17ClN6O,DMSO : 100 mg/mL (239.89 mM; Need ultrasonic),10mM,Cancer,No Development Reported,ClC1=C(C2=O)C(C=C([C@H](NC3=NC=NC4=C3N=CN4)C)N2C5=CC=CC=C5)=CC=C1
small interfering rnas,0,0,6,0,"{23237571, 17018633, 15682475, 28389707, 28435453, 35894141}","{33622787, 36265509, 31485609, 25146928, 32339606, 28418907, 33310044, 21149631}", ,,#N/A,,,,,,,phosphoinositide 3 kinase,genistein,HY-L025-45,H04,HY-14596,Genistein,NPI 031L,446-72-0,270.24,Apoptosis; Autophagy; EGFR; Endogenous Metabolite,Apoptosis; Autophagy; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,"Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.",C15H10O5,DMSO : ≥ 100 mg/mL (370.04 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 4,OC1=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=CC(O)=C1
sox2,0,1,6,0,"{35103981, 24026351, 24880079, 24040120, 34657147, 27175805}","{36161929, 32873880, 34285087, 24736545, 35264162, 36691621, 36775461, 33452461, 33792558, 31516082, 26663801, 37066171, 33409598, 34293822, 33958721, 25393219, 30962627, 32619460, 33574085, 33597515, 26253517, 25757017, 30467425, 33190371, 34880227, 23374840, 26115193, 26206333}", ,disrupting SOX2 and others disrupts stem cell pluripotency (36161929),metformin,,,,,,,phosphoinositide 3 kinase,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
caspase 3 7,0,0,6,0,"{29545922, 25156550, 26716649, 26228206, 25875797, 30716311}","{28468776, 30285808, 11259672, 24403256, 30018745, 31632543}", ,measurand,quercetin,,,,,,,jak stat,tofacitinib,HY-L025-63,D09,HY-40354A,Tofacitinib (citrate),Tasocitinib (citrate); CP-690550 (citrate),540737-29-9,504.49,Apoptosis; Bacterial; Fungal; Influenza Virus; JAK,Anti-infection; Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.",C22H28N6O8,DMSO : 28.57 mg/mL (56.63 mM; Need ultrasonic); H2O : 3.33 mg/mL (6.60 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O
e3 ligase,0,0,6,0,"{30423298, 30865892, 32029896, 23288781, 36741265, 29757973}","{30721025, 34520194, 31209349, 33513350, 30175757, 34494353, 33070611, 34499862, 30465816, 32080280, 32297626, 35397401, 29449372, 36516252, 34582690, 28058282, 35084845, 18082607, 32338867, 28630323, 23479607, 37126968, 29949369, 34583995, 28281917, 36202813, 31059647, 32900933, 30385614, 32820047, 22231120, 32968148, 33406420, 34675414, 36252888, 31580635, 36764765, 34215653, 34593637, 31734632, 30137962, 28288108, 18488044, 31813613, 35987950, 34652918, 36606710, 34994556, 36098557, 32355326, 31028095}", ,,#N/A,,,,,,,jak stat,wp1066,HY-L025-51,C07,HY-15312,WP1066,,857064-38-1,356.22,Apoptosis; JAK; STAT,Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"WP1066 is an inhibitor of JAK2 and STAT3, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3.",C17H14BrN3O,DMSO : ≥ 44 mg/mL (123.52 mM); Ethanol : 16.67 mg/mL (46.80 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(N[C@H](C1=CC=CC=C1)C)/C(C#N)=C/C2=NC(Br)=CC=C2
senescence associated secretory phenotype,0,0,6,0,"{25461770, 27454293, 32234521, 27454298, 32554750, 26979711}","{27099234, 31561444, 27261480, 36458010, 32392533, 34160250}", ,,#N/A,,,,,,,jak stat,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
target gene expression,0,0,6,0,"{12373606, 32571902, 35457227, 32373202, 18829525, 31150430}","{23137537, 36287107, 35011590, 24189064, 31712669, 21513889, 23686307, 30107177, 35065514, 36224430, 29467311, 29511348, 25404345, 28819026, 35390165, 33795806, 33547232, 36826464, 36216804, 29540837, 26139243, 28887413}", ,,#N/A,,,,,,,jak stat,cyt387,HY-L025-14,B06,HY-10962,Momelotinib sulfate,CYT387 (sulfate salt),1056636-06-6,610.62,Apoptosis; Autophagy; JAK,Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC50=155 nM).",C23H26N6O10S2,DMSO : 220 mg/mL (360.29 mM; Need ultrasonic); H2O : 100 mg/mL (163.77 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(NCC#N)C(C=C1)=CC=C1C2=NC(NC(C=C3)=CC=C3N4CCOCC4)=NC=C2.O=S(O)(O)=O.O=S(O)(O)=O
h2ax,0,0,6,0,"{35907592, 31174057, 30589553, 23361300, 24556918, 32554750}","{29914080, 22699752, 20224553, 32981006, 25504753, 36513631, 28881656, 26119999}", ,stain,#N/A,,,,,,,jak stat,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
smo,0,1,6,0,"{26527777, 23935937, 19136624, 27633013, 31417657, 23786654}","{24973920, 33958721, 24349540, 32380205, 25355313, 31139698, 33643826, 32913560, 26683772}", ,,lde225,,,,,,,jak stat,ruxolitinib,HY-L025-64,A05,HY-50858,Ruxolitinib (phosphate),INCB018424 phosphate,1092939-17-7,404.36,Autophagy; JAK; Mitophagy,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.",C17H21N6O4P,DMSO : ≥ 31 mg/mL (76.66 mM); H2O : 10 mg/mL (24.73 mM; Need ultrasonic),10mM,Cancer,Launched,N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2.O=P(O)(O)O
anti tumor immunity,0,0,6,0,"{33316775, 32961746, 37187730, 23422836, 26182900, 36319832}","{35517410, 34865122, 35902886, 30958600, 35755278, 30943407, 27626654}", ,,#N/A,,,,,,,jak stat,tyrphostin ag490,HY-L025-22,A04,HY-12000,AG490,Tyrphostin AG490; Tyrphostin B42,133550-30-8,294.3,Autophagy; EGFR; JAK; STAT,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.",C17H14N2O3,DMSO : ≥ 50 mg/mL (169.89 mM),10mM,Cancer,No Development Reported,O=C(NCC1=CC=CC=C1)/C(C#N)=C/C2=CC=C(O)C(O)=C2
cell identity,0,1,6,0,"{36848578, 30135074, 30014851, 31422917, 33448017, 30228219}","{23950209, 17694082, 32634370, 29263365, 28359301, 36273157, 34520583, 36161929, 35072011, 32324495, 31784732, 32710817, 34931241, 33452461, 32386862, 36823213, 28283057, 34729395, 31922235, 25263550, 30962627, 37059907, 30593613, 34848725, 36332631, 29662175, 33190371, 29930091, 26416749, 32151278, 27498864, 26546038, 30451831}", ,,#N/A,,,,,,,jak stat,ag490,HY-L025-22,A04,HY-12000,AG490,Tyrphostin AG490; Tyrphostin B42,133550-30-8,294.3,Autophagy; EGFR; JAK; STAT,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.",C17H14N2O3,DMSO : ≥ 50 mg/mL (169.89 mM),10mM,Cancer,No Development Reported,O=C(NCC1=CC=CC=C1)/C(C#N)=C/C2=CC=C(O)C(O)=C2
aldehyde dehydrogenase,0,0,6,0,"{34321315, 31430440, 21622730, 24026351, 21304978, 26609108}","{27803105, 9141699, 12906115, 16315011, 12228394, 9736747, 34458063, 8626294, 32166583, 26910138, 31534014}", ,,pargyline,,,,,,,jak stat,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
cellular growth,0,0,5,0,"{34001634, 14613582, 32967217, 27595930, 8539259}","{29393731, 25120803, 32747750, 22334664, 28630312, 25772490, 36709803, 19880750, 34385584, 20300178, 35159127, 17329240, 19111069}", ,,#N/A,,,,,,,nuclear factor kappa b,bay 11 7082,HY-L025-35,A11,HY-13453,BAY 11-7082,BAY 11-7821,19542-67-7,207.25,Apoptosis; Autophagy; Deubiquitinase; IKK; NF-κB,Apoptosis; Autophagy; Cell Cycle/DNA Damage; NF-κB,"BAY 11-7082 is an IκBα phosphorylation and NF-κB inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC50=0.19, 0.96 μM, respectively). BAY 11-7082 inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells[1][2][3][4][5].",C10H9NO2S,DMSO : ≥ 100 mg/mL (482.51 mM),10mM,Cancer; Inflammation/Immunology,No Development Reported,N#C/C=C/S(=O)(C1=CC=C(C)C=C1)=O
pp2a,0,2,5,0,"{24847881, 25250570, 10462539, 33740661, 30083262}","{26735014, 27769352, 25553514, 33603756, 33809005, 31516082, 34079065, 27965149}", ,"PP2A phosphorylates BRD4, which predicted shorter survival in TNBC (33809005)",atra,,,,,,,nuclear factor kappa b,dehydroxymethylepoxyquinomicin,HY-L025-46,B09,HY-14645,(-)-DHMEQ,Dehydroxymethylepoxyquinomicin,287194-40-5,261.23,NF-κB,NF-κB,"(-)-DHMEQ (Dehydroxymethylepoxyquinomicin) is a potent, selective and irreversible NF-κB inhibitor that covalently binds to a cysteine residue. (-)-DHMEQ inhibits nuclear translocation of NF-κB and shows anti-inflammatory and anticancer activity[1][2][3].",C13H11NO5,DMSO : 50 mg/mL (191.40 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,No Development Reported,O=C1[C@@H](O2)[C@@H]2[C@@H](O)C(NC(C3=C(O)C=CC=C3)=O)=C1
eif4e,0,0,5,0,"{31740775, 34001163, 23563181, 26609108, 31399545}","{29333921, 29127434, 28461486, 33125143, 30446586, 34565342, 25564254}", ,"BRD4 inhibition decreases eif4e, an mTOR component (34565342)",rapamycin,,,,,,,nuclear factor kappa b,apocynin,HY-L025-72,B10,HY-N0088,Apocynin,Acetovanillone,498-02-2,166.17,Apoptosis; Autophagy,Apoptosis; Autophagy,Apocynin is a selective NADPH-oxidase inhibitor with an IC50 of 10 μM.,C9H10O3,DMSO : ≥ 100 mg/mL (601.79 mM); H2O : ≥  mg/mL,10mM,Cancer,Phase 1,CC(C1=CC=C(O)C(OC)=C1)=O
n myc,0,1,5,0,"{29389953, 22462691, 28350132, 31088502, 19860666}","{35299072, 27748806, 26067464, 29581547, 26733615, 34107377, 31346162, 24952595, 24009722, 29156797}", ,,retinoic acid,,,,,,,nuclear factor kappa b,chrysin,HY-L025-45,F07,HY-14589,Chrysin,"5,7-Dihydroxyflavone",480-40-0,254.24,Estrogen Receptor/ERR,Vitamin D Related/Nuclear Receptor,Chrysin is one of the most well known estrogen blockers.,C15H10O4,DMSO : ≥ 100 mg/mL (393.33 mM),10mM,Cancer,No Development Reported,OC1=C2C(OC(C3=CC=CC=C3)=CC2=O)=CC(O)=C1
iκb kinase,0,0,5,0,"{20959520, 32004866, 23547054, 27068336, 27991926}","{22649058, 25049379, 26324948, 35002741, 30321559, 34791293}", ,ikb-kinase / nfkb regulates BRD4,imd 0354,,,,,,,nuclear factor kappa b,tacrolimus,HY-L025-39,F08,HY-13756A,Tacrolimus (monohydrate),FK506 (monohydrate); Fujimycin (monohydrate); FR900506 (monohydrate),109581-93-3,822.03,Antibiotic; Autophagy; Bacterial; FKBP; Phosphatase,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease,"Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties[1].",C44H71NO13,DMSO : 100 mg/mL (121.65 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C([C@@](CCCC1)([H])N1C(C([C@@]2(O)[C@H](C)C[C@H](OC)[C@@](O2)([H])[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H]3CC=C)=O)=O)O[C@H](/C(C)=C/[C@H]4C[C@@H](OC)[C@H](O)CC4)[C@H](C)[C@@H](O)CC3=O.O
gene expressions,0,1,5,0,"{23519249, 32949395, 16532023, 9459160, 27067801}","{24763052, 36224430, 32800944, 36768307, 28765013, 31105558, 22609015, 34075610, 29561307, 34016956, 33654205}", ,,#N/A,,,,,,,nuclear factor kappa b,bortezomib,HY-L025-7,E07,HY-10227,Bortezomib,PS-341; LDP-341; NSC 681239,179324-69-7,384.24,Apoptosis; Autophagy; NF-κB; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].",C19H25BN4O4,DMSO : 50 mg/mL (130.13 mM; Need ultrasonic); Ethanol : 66.67 mg/mL (173.51 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
jak1,0,0,5,0,"{26719042, 32046984, 28496202, 25762644, 32933947}","{34499329, 33980611, 30606790, 22904298, 27677740, 34503062, 34365463, 27622335}", ,,ruxolitinib,,,,,,,nuclear factor kappa b,piceatannol,HY-L025-35,H10,HY-13518,Piceatannol,Astringenin; trans-Piceatannol,10083-24-6,244.24,Apoptosis; Autophagy; Endogenous Metabolite; Syk,Apoptosis; Autophagy; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI)[1]. Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties[2]. Piceatannol induces apoptosis in DLBCL cell lines[3]. Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells[4].,C14H12O4,DMSO : ≥ 31 mg/mL (126.92 mM); H2O : 1 mg/mL (4.09 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1O
protein 3,0,1,5,0,"{26719042, 32626951, 24847881, 31881642, 32499447}","{34448544, 28055972, 26620551, 30628072, 26677226, 29703820, 34638508, 37043564, 28967088, 36608404, 31530390, 35642518, 31927932, 22024541, 32669118}", ,,#N/A,,,,,,,nuclear factor kappa b,atorvastatin,HY-L025-57,H04,HY-17379,Atorvastatin (hemicalcium salt),CI-981; Atorvastatin hemicalcium,134523-03-8,577.67,Autophagy; Ferroptosis; HMG-CoA Reductase (HMGCR),Apoptosis; Autophagy; Metabolic Enzyme/Protease,"Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3].",C33H34Ca0.5FN2O5,DMSO : ≥ 50 mg/mL (86.55 mM); H2O : < 0.1 mg/mL (insoluble),10mM,Metabolic Disease; Inflammation/Immunology; Cancer,Launched,FC1=CC=C(C2=C(C3=CC=CC=C3)C(C(NC4=CC=CC=C4)=O)=C(C(C)C)N2CC[C@@H](O)C[C@@H](O)CC([O-])=O)C=C1.[0.5Ca2+]
sirt1,0,0,5,0,"{25632225, 21622730, 23561972, 33135320, 25632222}","{35403781, 22802445, 32457617, 31749139, 22020252, 27106081, 30991141, 35065514, 28525743, 35052850, 35679799, 25404345, 24608443, 32165310, 34364223, 27010499, 31781323, 31265875, 28933601, 17340003, 35854052, 36942693, 26212199, 33685230, 30988278, 26663801, 30386303}", ,BRD4 inhibition upregulates SIRT1; inhibiting SIRT1 reverses effects of BRD4 inhibition (32457617),ex 527,,,,,,,nuclear factor kappa b,carvedilol,HY-L025-66,A02,HY-B0006,Carvedilol,BM 14190,72956-09-3,406.47,Adrenergic Receptor; Autophagy; Bacterial,Anti-infection; Autophagy; GPCR/G Protein; Neuronal Signaling,Carvedilol (BM 14190) is a non-selective β/α-1 blocker[1]. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome[3].,C24H26N2O4,DMSO : 100 mg/mL (246.02 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Cardiovascular Disease,Launched,OC(CNCCOC1=CC=CC=C1OC)COC2=CC=CC(N3)=C2C4=C3C=CC=C4
transcriptional factor,0,0,5,0,"{30349952, 23355395, 24954535, 17487403, 28639199}","{26878912, 34520583, 31467179, 33643826, 36077302, 36252888, 16792505}", ,,#N/A,,,,,,,nuclear factor kappa b,dexamethasone,HY-L025-46,B10,HY-14648,Dexamethasone,Hexadecadrol; Prednisolone F,50-02-2,392.46,Antibiotic; Autophagy; Bacterial; Complement System; Glucocorticoid Receptor; Mitophagy; SARS-CoV,Anti-infection; Autophagy; Immunology/Inflammation; Vitamin D Related/Nuclear Receptor,"Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.",C22H29FO5,DMSO : 250 mg/mL (637.01 mM; ultrasonic and warming and heat to 60°C); Ethanol : 8.33 mg/mL (21.23 mM; Need ultrasonic),10mM,Cancer; Infection; Endocrinology; Inflammation/Immunology,Launched,O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@@]4(C(CO)=O)O)=C1
ubiquitin proteasome,0,0,5,0,"{23049538, 33161807, 35411249, 17488476, 29749405}","{34520194, 37066758, 37217935, 34494353, 36656921, 27989401, 36940189, 34582690, 31553577, 32582706, 23479607, 28154167, 34583995, 33780296, 29725006, 33687890, 31580635, 24448221, 35065444, 32863216, 36536188}", ,,bortezomib,,,,,,,her2,lapatinib,HY-L025-64,B11,HY-50898B,Lapatinib (ditosylate monohydrate),GW572016 (ditosylate monohydrate); GW2016 (ditosylate monohydrate),388082-78-8,943.48,Autophagy; EGFR; Ferroptosis,Apoptosis; Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].",C43H44ClFN4O11S3,DMSO : 50 mg/mL (53.00 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=S(CCNCC1=CC=C(C2=CC3=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)N=CN=C3C=C2)O1)(C)=O.O=S(C6=CC=C(C)C=C6)(O)=O.O=S(C7=CC=C(C)C=C7)(O)=O.O
protein degradation,0,1,5,0,"{30423298, 33676427, 30347501, 32573499, 25632159}","{30721025, 34279939, 35303940, 37066758, 25999370, 35018781, 33567268, 31553577, 32163373, 35084845, 36563515, 33780296, 36202064, 36577875, 31200858, 28288108, 31566962, 35761277, 34520194, 36993171, 32297626, 29449372, 29551266, 33792163, 28978850, 34582690, 28058282, 37123243, 34615996, 28805821, 31059647, 30684871, 34675414, 34215653, 36606710, 28656888, 32893690, 37252349, 30369550, 29581585, 36733715, 34499862, 31470872, 36824856, 35397401, 34954522, 26620707, 35194152, 36323630, 35411247, 34816823, 36202813, 28595007, 27274052, 33687890, 36749666, 35261801, 35395439, 35882867, 34994556, 35649410, 31209349, 33513350, 36542856, 34494353, 32080280, 36516252, 36940189, 30067623, 32338867, 37084596, 29949369, 34583995, 36719036, 31653826, 35665862, 28378579, 32968148, 31580635, 31813613, 29892083, 36262390, 28339196}", ,,#N/A,,,,,,,her2,epertinib,HY-L025-11,E10,HY-107367A,Epertinib (hydrochloride),S-22611 (hydrochloride),2071195-74-7,596.48,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Epertinib (S-22611) hydrochloride is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER4 and HER2, with IC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib hydrochloride shows potent antitumor activity[1][2].",C30H28Cl2FN5O3,DMSO : 125 mg/mL (209.56 mM; Need ultrasonic); H2O : 33.33 mg/mL (55.88 mM; Need ultrasonic),10mM,Cancer,Phase 2,CC#C/C(C1=CC2=C(NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)N=CN=C2C=C1)=N\OC[C@@H]5NCCOC5.Cl
vhl,0,0,5,0,"{24196616, 37230894, 33808853, 27322423, 37201049}","{30721025, 35249548, 30175757, 34499862, 32082969, 26035625, 30540463, 31746102, 34878263, 37126968, 29949369, 36749883, 36202813, 28595007, 29507391, 35295813, 30385614, 28378579, 33406420, 34675414, 31178587, 35958877, 36764765, 28288108, 34652918}", ,vhl = von hippel landau,#N/A,,,,,,,her2,bibw 2992,HY-L025-7,G05,HY-10261,Afatinib,BIBW 2992,850140-72-6,485.94,Akt; Apoptosis; Autophagy; c-Met/HGFR; EGFR; p38 MAPK,Apoptosis; Autophagy; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK,"Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer[1][2][3][4].",C24H25ClFN5O3,DMSO : 100 mg/mL (205.79 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NC1=C(C=C2C(C(NC3=CC(Cl)=C(C=C3)F)=NC=N2)=C1)O[C@H]4CCOC4)/C=C/CN(C)C
dnmt1,0,0,5,0,"{12420225, 21573703, 30226601, 32457835, 26617245}","{28783236, 36942693, 30672294, 30977555, 16085498, 19099580, 31659326}",could be good panc cancer target (32457835),DNA methyl transferase. Inhibition affects epigenome,procainamide,,,,,,,her2,entinostat,HY-L025-23,G06,HY-12163,Entinostat,MS-275; SNDX-275,209783-80-2,376.41,Apoptosis; Autophagy; HDAC,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Entinostat is an oral and selective class I HDAC inhibitor, with IC50s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively.",C21H20N4O3,DMSO : 50 mg/mL (132.83 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,O=C(NCC1=CC=C(C=C1)C(NC2=CC=CC=C2N)=O)OCC3=CC=CN=C3
puma,0,0,5,0,"{19424582, 28160167, 23099885, 22848379, 17569628}","{29048129, 30723270, 36313707, 32445837, 36127412, 30518782}", ,PUMA upregulated in BRD4/HDAC inhibition (32445837),pifithrin α,,,,,,,her2,ont 380,HY-L025-55,D06,HY-16069A,Tucatinib (hemiethanolate),Irbinitinib (hemiethanolate); ARRY-380 (hemiethanolate); ONT-380 (hemiethanolate),1429755-56-5,503.57,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM.",C26H24N8O2.1/2C2H6O,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 125 mg/mL (248.23 mM; Need ultrasonic),10mM,Cancer,Launched,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC5=CC6=NC=NN6C=C5.CCO.[1/2]
polo,0,1,5,0,"{26091808, 34905798, 23384775, 33008426, 32355831}","{28061448, 29454094, 19152411, 33142427, 37211680, 33778212, 28766886, 31516082, 31267379, 29383095, 30125504, 31708096, 15744326, 33257688, 25891802, 34733788, 25623136, 29476067, 29716963, 33765606, 30789735}", ,plk3 = polo like kinase3,#N/A,,,,,,,her2,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
m6a,0,0,5,0,"{36403721, 33714027, 36158188, 35547245, 32355831}","{30232453, 36276071, 31801551, 34586831, 37120495, 33664855, 34375583}", ,common type of DNA methylation,#N/A,,,,,,,her2,aee788,HY-L025-2,C07,HY-10045,AEE788,NVP-AEE 788,497839-62-0,440.58,Apoptosis; EGFR,Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"AEE788 is an inhibitor of the EGFR and ErbB2 with IC50 values of 2 and 6 nM, respectively.",C27H32N6,DMSO : 50 mg/mL (113.49 mM; Need ultrasonic),10mM,Cancer,Phase 2,C[C@H](C1=CC=CC=C1)NC2=C(C=C3C(C=C4)=CC=C4CN5CCN(CC)CC5)C(N3)=NC=N2
cell cycle transition,0,0,5,0,"{18805632, 34328099, 26185420, 28947981, 16042578}","{30940648, 35461311, 24496381, 21149631}", ,,#N/A,,,,,,,her2,gw572016,HY-L025-64,B11,HY-50898B,Lapatinib (ditosylate monohydrate),GW572016 (ditosylate monohydrate); GW2016 (ditosylate monohydrate),388082-78-8,943.48,Autophagy; EGFR; Ferroptosis,Apoptosis; Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].",C43H44ClFN4O11S3,DMSO : 50 mg/mL (53.00 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=S(CCNCC1=CC=C(C2=CC3=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)N=CN=C3C=C2)O1)(C)=O.O=S(C6=CC=C(C)C=C6)(O)=O.O=S(C7=CC=C(C)C=C7)(O)=O.O
dna repair genes,0,0,5,0,"{12909734, 26034349, 25855536, 28373361, 25266736}","{32320642, 35687908, 36731467, 22623531, 25982285, 35869742, 34084283}", ,,#N/A,,,,,,,her2,abemaciclib,HY-L025-55,G10,HY-16297A,Abemaciclib,LY2835219,1231929-97-7,506.59,CDK,Cell Cycle/DNA Damage,"Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.",C27H32F2N8,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 2.94 mg/mL (5.80 mM; ultrasonic and warming and heat to 80°C),2mM,Cancer,Launched,CC1=NC2=C(F)C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=C2N1C(C)C
wd repeat,0,0,5,0,"{25753158, 26983463, 24362026, 28765935, 25632159}","{17668385, 31914881, 32917124, 30628072, 34082824, 23287019, 30387133, 31205075, 23479607, 18353305, 22024541, 12359327}", ,,#N/A,,,,,,,her2,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
gene networks,0,1,5,0,"{26880586, 34249932, 24694735, 30315093, 37201049}","{30110629, 34199719, 36692427, 33741710, 32603312, 32331282, 29748211, 31784732}", ,,#N/A,,,,,,,her2,17 aag,HY-L025-7,D07,HY-10211,Tanespimycin,17-AAG; NSC 330507; CP 127374,75747-14-7,585.69,Antibiotic; Apoptosis; Autophagy; Bacterial; HSP; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90[1][5]. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression[3].",C31H43N3O8,DMSO : 50 mg/mL (85.37 mM; Need ultrasonic),10mM,Cancer; Infection,Phase 3,O=C(C(NC(/C(C)=C/C=C\[C@H](OC)[C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](C1)C)OC)O)C)OC(N)=O)=O)=CC2=O)C1=C2NCC=C
klf5,0,0,5,0,"{35116738, 31582374, 29248441, 19671674, 24041470}","{34074211, 32619460, 34707247, 31360115, 33115806}", ,KLF5 is a core regulatory component of chromatin accessibility etc (32619460),ml264,,,,,,,her2,chloroquine,HY-L025-58,G04,HY-17589A,Chloroquine,,54-05-7,319.87,Antibiotic; Autophagy; HIV; Parasite; SARS-CoV; Toll-like Receptor (TLR),Anti-infection; Autophagy; Immunology/Inflammation,Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].,C18H26ClN3,Ethanol : 100 mg/mL (312.63 mM; Need ultrasonic); DMSO : 50 mg/mL (156.31 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,CC(NC1=CC=NC2=CC(Cl)=CC=C12)CCCN(CC)CC
mll3,0,0,5,0,"{22421440, 33099938, 34122731, 32380013, 23103869}","{28967088, 24794707, 34830196, 29263365}", ,deleting MLL3 increases PD-L1 (probably bad) (34830196),#N/A,,,,,,,her2,c75,HY-L025-25,G08,HY-12364,C75,,218137-86-1,254.32,Fatty Acid Synthase (FASN),Metabolic Enzyme/Protease,C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM[1][2][3]. C75 is a potent CPT1A activator[5].,C14H22O4,DMSO : ≥ 83.3 mg/mL (327.54 mM); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Cancer,No Development Reported,O=C(C(C1=C)C(CCCCCCCC)OC1=O)O
wd,0,0,5,0,"{25753158, 26983463, 24362026, 28765935, 25632159}","{17668385, 31914881, 32917124, 30628072, 34082824, 23287019, 30387133, 31205075, 23479607, 18353305, 22024541, 12359327}", ,,#N/A,,,,,,,her2,17 dmag,HY-L025-22,D08,HY-12024,Alvespimycin (hydrochloride),17-DMAG (hydrochloride); KOS-1022; BMS 826476,467214-21-7,653.21,Apoptosis; HSP,Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Alvespimycin hydrochloride (17-DMAG hydrochloride; KOS-1022; BMS 826476) is a potent inhibitor of Hsp90, binding to Hsp90 with EC50 of 62±29 nM.",C32H49ClN4O8,H2O : 4.76 mg/mL (7.29 mM; ultrasonic and warming and heat to 60°C); DMSO : ≥ 50 mg/mL (76.55 mM),10mM,Cancer,Phase 2,C/C1=C\C=C/[C@@H]([C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](CC(C(C(NC1=O)=CC2=O)=O)=C2NCCN(C)C)C)OC)O[H])C)OC(N)=O)OC.Cl
cytokeratins,0,0,5,0,"{16774944, 37140101, 19002021, 9639120, 26677401}","{35430756, 23128391, 26402248, 16542442, 23157742, 22777717, 34997561, 22301500}", ,,#N/A,,,,,,,her2,ndga,HY-L025-73,B04,HY-N0198,Nordihydroguaiaretic acid,NDGA,500-38-9,302.36,Autophagy; Ferroptosis; Lipoxygenase,Apoptosis; Autophagy; Metabolic Enzyme/Protease,Nordihydroguaiaretic acid is a 5-lipoxygenase (5LOX) (IC50=8 μM) and tyrosine kinase inhibitor.,C18H22O4,DMSO : 250 mg/mL (826.83 mM; Need ultrasonic),10mM,Cancer; Neurological Disease,Launched,CC(CC1=CC=C(O)C(O)=C1)C(C)CC2=CC=C(O)C(O)=C2
nuclear ribonucleoprotein,0,1,5,0,"{32814086, 35579947, 26616862, 35838046, 19609950}","{12489984, 22952229, 23154982, 25492871, 31077320, 26731470, 22084242, 24367103}", ,,#N/A,,,,,,,β catenin,atra,HY-L025-46,C02,HY-14649,Retinoic acid,Vitamin A acid; all-trans-Retinoic acid; ATRA,302-79-4,300.44,Autophagy; Endogenous Metabolite; PPAR; RAR/RXR,Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.",C20H28O2,DMSO : 50 mg/mL (166.42 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,CC1(C)C(/C=C/C(C)=C/C=C/C(C)=C/C(O)=O)=C(C)CCC1
yy1,0,0,5,0,"{31631174, 32934027, 35082383, 27793842, 36123703}","{35687908, 33849067, 30012592, 35390165, 31629407}", ,BRD4 associates with YY1 (35687908),#N/A,,,,,,,β catenin,ptx,HY-L025-69,C09,HY-B0715,Pentoxifylline,BL-191; PTX; Oxpentifylline,5/6/93,278.31,Autophagy; HIV; Phosphodiesterase (PDE),Anti-infection; Autophagy; Metabolic Enzyme/Protease,"Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].",C13H18N4O3,DMSO : ≥ 2.8 mg/mL (10.06 mM); H2O : 93.3 mg/mL (335.24 mM; Need ultrasonic and warming),10mM,Cardiovascular Disease; Cancer,Launched,O=C(N1CCCCC(C)=O)N(C)C2=C(N(C)C=N2)C1=O
nc,0,0,5,0,"{23427041, 31920328, 32626512, 33643376, 29736383}","{34672128, 36040068, 35957893, 30830987, 30696721, 34956562, 29700887, 32873880, 22095101, 30362654, 33713695, 34285087, 36387105, 24185123, 36265509, 36775461, 34297512, 35623465, 33452461, 30307375, 33562801, 35565363, 35127482, 30552129, 35444289, 37214845, 35117258, 35681742, 30139738, 34333275, 35064291, 33311588, 35836519, 35428456, 32328561, 32328562, 26586234, 29649019, 34119933}", ,,#N/A,,,,,,,β catenin,lf3,HY-L025-5,F10,HY-101486,LF3,,664969-54-4,416.56,β-catenin,Stem Cell/Wnt,LF3 is an antagonist of the β-Catenin/TCF4 interaction with antitumor activity; has an IC50 of 1.65 μM.,C20H24N4O2S2,DMSO : 250 mg/mL (600.15 mM; Need ultrasonic),10mM,Cancer,No Development Reported,S=C(N1CCN(C/C=C/C2=CC=CC=C2)CC1)NC3=CC=C(S(=O)(N)=O)C=C3
tp63,0,0,5,0,"{26909576, 36816942, 30794864, 36008214, 35701533}","{29988031, 26220994, 34172737, 32619460, 36775461, 33452461, 26829750, 32873880, 32366905, 33947836, 33115806, 27980063}", ,,#N/A,,,,,,,β catenin,fisetin,HY-L025-72,H11,HY-N0182,Fisetin,,528-48-3,286.24,PPAR; Sirtuin; TNF Receptor,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Vitamin D Related/Nuclear Receptor,"Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.",C15H10O6,DMSO : 25 mg/mL (87.34 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease,Phase 3,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC=C13
demethylase,0,0,5,0,"{35493099, 24947179, 34583087, 26544625, 26904954}","{25254151, 22493065, 21447565, 29176719, 27477906, 28439316, 37111316, 30472603, 17687328, 34572840, 31514410, 31261881, 30765888, 29393731, 33155139, 31901895, 28838216, 32522824, 20133580, 34586831, 28572115, 24360279, 31549911, 33844952, 33721694, 30880225, 28357218, 30921702, 36877164, 29432557, 30615537, 26799480, 35636729}", ,,#N/A,,,,,,,β catenin,propofol,HY-L025-69,B04,HY-B0649,Propofol,"2,6-Diisopropylphenol",2078-54-8,178.27,Endogenous Metabolite; GABA Receptor,Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling,Propofol potently and directly activates GABAA receptor and inhibits glutamate receptor mediated excitatory synaptic transmission. Propofol has antinociceptive properties and is used for sedation and hypnotic[1].,C12H18O,DMSO : 100 mg/mL (560.95 mM; Need ultrasonic); H2O : 0.5 mg/mL (2.80 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,OC1=C(C(C)C)C=CC=C1C(C)C
cell reprogramming,0,0,5,0,"{27215660, 31330317, 25698580, 32179733, 27610015}","{34520583, 33296649, 25312495, 37108181, 36332631}", ,,#N/A,,,,,,,β catenin,losartan,HY-L025-58,E05,HY-17512A,Losartan (potassium),DuP-753 (potassium),124750-99-8,461,Angiotensin Receptor,GPCR/G Protein,"Losartan potassium (DuP-753 potassium) is an angiotensin II receptor type 1 (AT1) antagonist, competing with the binding of angiotensin II to AT1 with an IC50 of 20 nM.",C22H22ClKN6O,DMSO : ≥ 110 mg/mL (238.61 mM); H2O : 50 mg/mL (108.46 mM; Need ultrasonic),10mM,Cardiovascular Disease; Endocrinology; Cancer,Launched,OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=N[N-]N=N4)C=C2.[K+]
activating protein,0,1,4,0,"{23308056, 23393225, 28720574, 22331470}","{25119042, 19828451, 33835000, 31097419, 34638508, 15456879, 18427120, 32765266, 21251160, 24804860, 28237246}", ,,#N/A,,,,,,,β catenin,cyclopamine,HY-L025-57,F03,HY-17024,Cyclopamine,11-Deoxojervine,4449-51-8,411.62,Endogenous Metabolite; Hedgehog; Smo,Metabolic Enzyme/Protease; Stem Cell/Wnt,Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay. Cyclopamine is also a selective Smo inhibitor.,C27H41NO2,DMSO : 10 mg/mL (24.29 mM; ultrasonic and warming and heat to 80°C); Ethanol : 20 mg/mL (48.59 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CC1=C2[C@@]([C@@]3([H])[C@]([C@@]4(C(C[C@@H](O)CC4)=CC3)C)([H])C2)([H])CC[C@@]15[C@@H]([C@@]6([H])[C@](C[C@H](C)CN6)([H])O5)C
gtpase activating protein,0,1,4,0,"{23639840, 22331470, 23558076, 28720574}","{25119042, 33835000, 34638508, 15456879, 18427120, 21251160, 28237246}", ,,#N/A,,,,,,,β catenin,5 fu,HY-L025-65,C06,HY-90006,5-Fluorouracil,5-FU,51-21-8,130.08,Apoptosis; Endogenous Metabolite; HIV; Nucleoside Antimetabolite/Analog,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil induces apoptosis and can be used as a chemical sensitizer[1][2]. 5-Fluorouracil also inhibits HIV[3].,C4H3FN2O2,DMSO : 50 mg/mL (384.38 mM; Need ultrasonic); H2O : 16.67 mg/mL (128.15 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(N1)NC=C(F)C1=O
mmp9,0,1,4,0,"{22884073, 31988090, 24340014, 33932087}","{24632608, 33705733, 28983590, 34421353, 33692493, 33611824, 29783800, 31621555, 31114581, 29067128, 33732255}", ,,curcumin,,,,,,,nuclear factor κb,eicosapentaenoic acid,HY-L025-69,B10,HY-B0660,Eicosapentaenoic Acid,EPA; Timnodonic acid,10417-94-4,302.45,Endogenous Metabolite; Histone Demethylase,Epigenetics; Metabolic Enzyme/Protease,Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation[1][2][3].,C20H30O2,DMSO : ≥ 53 mg/mL (175.24 mM); Ethanol : ≥ 100 mg/mL (330.63 mM),10mM,Neurological Disease; Cancer,Launched,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(O)=O
cdk1,0,1,4,0,"{36434634, 33879459, 25632222, 24791855}","{29914080, 35198433, 28062857, 25553514, 31781323, 17942543, 31516082, 33024699, 36730269, 25564254, 32575711}", ,,apigenin,,,,,,,nuclear factor κb,catalpol,HY-L025-76,E08,HY-N0820,Catalpol,Catalpinoside,2415-24-9,362.33,HBV,Anti-infection,"Catalpol (Catalpinoside), an iridoid glycoside found in Rehmannia glutinosa. Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-HBV effects[1][2][3].",C15H22O10,DMSO : ≥ 30 mg/mL (82.80 mM); H2O : 7.14 mg/mL (19.71 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Infection; Inflammation/Immunology; Neurological Disease,No Development Reported,OC[C@@]12[C@]([C@@H]3O[C@]([C@@H]([C@@H](O)[C@@H]4O)O)([H])O[C@@H]4CO)([H])[C@](C=CO3)([H])[C@H](O)[C@@H]1O2
α smooth muscle,0,0,4,0,"{34405729, 31963309, 28837246, 21856775}","{30745801, 36244457, 31731295, 31119153, 27732564, 28063381, 29366780, 32626975}", ,,#N/A,,,,,,,nuclear factor κb,dioscin,HY-L025-72,E02,HY-N0124,Dioscin,Collettiside III; CCRIS 4123,19057-60-4,869.04,Apoptosis; Autophagy,Apoptosis; Autophagy,"Dioscin(CCRIS 4123; Collettiside III) is a natural steroid saponin derived from several plants, showing potent anti-cancer effect against a variety of tumor cell lines. 
IC50 value:
Target: Anticancer agent
in vitro: dioscin (1, 2 and 4 μmol/L) could significantly inhibit the viability of LNCaP cells in a time- and concentration-dependent manner. Flow cytometry revealed that the apoptosis rate was increased after treatment of LNCaP cells with dioscin for 24 h, indicating that apoptosis was an important mechanism by which dioscin inhibited cancer [1]. dioscin abrogated AKT phosphorylation, which subsequently impaired RANKL-induced nuclear factor-kappaB (NF-κB) signaling pathway and inhibited NFATc1 transcriptional activity. Moreover, in vivo studies further verified the bone protection activity of dioscin in osteolytic animal model [2]. Dioscin reduced cell death and lactate dehydrogenase (LDH) release in cells subjected to I/R. I/R induced apoptosis and cytochrome c release from mitochondria to the cytosol and this was prevented by dioscin. In support, dioscin decreased Bax but increased Bcl-2 mRNA expression. Dioscin prevented I/R induced dissipation of ΔΨm [3].",C45H72O16,DMSO : ≥ 100 mg/mL (115.07 mM),10mM,Cancer,Launched,O[C@@H]1[C@@H](O)[C@H](C)O[C@@]([H])(O[C@H]2[C@H](O)[C@@H](O[C@]3([H])O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@](O[C@@H]4CC5=CC[C@]([C@]([H])(C[C@@]6([H])[C@]7([H])[C@H](C)[C@]8(OC[C@H](C)CC8)O6)[C@]7(C)CC9)([H])[C@@]9([H])[C@@]5(C)CC4)([H])O[C@@H]2CO)[C@@H]1O
t cell activation,0,2,4,0,"{32024640, 35166242, 37108468, 34341132}","{34215653, 25822022, 27067814, 35426377, 22802445, 26731470, 23087374, 28408401, 34696466, 34350133, 27710838, 36631514, 30475902, 31356159}", ,,#N/A,,,,,,,nuclear factor κb,quinacrine,HY-L025-39,C08,HY-13735A,Quinacrine (dihydrochloride),Mepacrine (dihydrochloride); SN-390 (dihydrochloride),69-05-6,472.88,Apoptosis; Autophagy; Mitophagy; Parasite,Anti-infection; Apoptosis; Autophagy,"Quinacrine (Mepacrine) dihydrochloride is an orally bioavailable antimalarial agent, which possess anticancer effect both in vitro and vivo. Quinacrine dihydrochloride suppresses NF-κB and activate p53 signaling, which results in the induction of the apoptosis[1].",C23H32Cl3N3O,H2O : 13.89 mg/mL (29.37 mM; Need ultrasonic); DMSO : ≥ 44 mg/mL (93.05 mM),10mM,Cancer; Infection,Phase 2,CC(NC1=C(C=C(OC)C=C2)C2=NC3=CC(Cl)=CC=C31)CCCN(CC)CC.Cl.Cl
α smooth muscle actin,0,0,4,0,"{34405729, 31963309, 28837246, 21856775}","{30745801, 36244457, 31731295, 31119153, 27732564, 28063381, 29366780, 32626975}", ,,melatonin,,,,,,,nuclear factor κb,farrerol,HY-L025-73,H08,HY-N0344,Farrerol,,24211-30-1,300.31,Others,Others,"Farrerol is a bioactive constituent of Rhododendron, with broad activities such as anti-oxidative, anti-inflammatory, anti-tumor, neuroprotective and hepatoprotective effects[1][2][3][4][5][6].",C17H16O5,DMSO : 125 mg/mL (416.24 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,No Development Reported,O=C1C[C@@H](C2=CC=C(O)C=C2)OC3=C(C)C(O)=C(C)C(O)=C13
cell function,0,0,4,0,"{23639840, 33333043, 32358491, 18204935}","{28474499, 28039300, 27799308, 22912406, 33717143, 33663517, 33850013, 33015071, 33420321, 31182641, 32482868, 30807094, 30200762, 29754817, 27428432, 28408401, 31751766, 37207130, 32060899, 34697072, 27710838, 31356159}", ,,#N/A,,,,,,,nuclear factor κb,aspirin,HY-L025-46,C07,HY-14654,Aspirin,Acetylsalicylic Acid; ASA,50-78-2,180.16,Apoptosis; Autophagy; Caspase; COX; Mitophagy; NF-κB; p38 MAPK; Virus Protease,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB,"Aspirin (Acetylsalicylic Acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis[1][2][3][4][5][6].",C9H8O4,DMSO : 400 mg/mL (2220.25 mM; Need ultrasonic); H2O : 0.1 mg/mL (0.56 mM; Need ultrasonic),10mM,Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease,Launched,OC(C1=C(OC(C)=O)C=CC=C1)=O
circular rnas,0,1,4,0,"{29781033, 33505218, 34512755, 36426933}","{33854310, 34082824, 34421353, 34579723, 35535987, 37044031, 35164758, 34730838, 31680319}", ,,#N/A,,,,,,,nuclear factor κb,docosahexaenoic acid,HY-L025-71,C06,HY-B2167,Docosahexaenoic acid,DHA; Cervonic acid,6217-54-5,328.49,Endogenous Metabolite,Metabolic Enzyme/Protease,Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk.,C22H32O2,Ethanol : 50 mg/mL (152.21 mM; Need ultrasonic); DMSO : 100 mg/mL (304.42 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(O)=O
cdk inhibitor,0,0,4,0,"{26934555, 37105116, 25931518, 19639215}","{31727874, 31900258, 26627013, 30975979, 17942543, 28281917}", ,,#N/A,,,,,,,nuclear factor κb,emodin,HY-L025-43,G03,HY-14393,Emodin,Frangula emodin,518-82-1,270.24,11β-HSD; Autophagy; Casein Kinase; SARS-CoV,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively.  Emodin ameliorates metabolic disorder in diet-induced obese mice[3].",C15H10O5,Acetone : 10.87 mg/mL (40.22 mM; Need ultrasonic); DMSO : 5.41 mg/mL (20.02 mM; Need ultrasonic); Ethanol : 10.87 mg/mL (40.22 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C(C=C(C)C=C2O)C(C3=CC(O)=CC(O)=C31)=O
histone deacetylase inhibitor,0,2,4,0,"{20419833, 23232026, 27634878, 33244070}","{25053825, 16339075, 33803654, 35787399, 36480653, 31712669, 28026145, 31215139, 28804523, 26733615, 35679799, 34533562, 25978433, 25097667, 36690761, 12840145, 32632663, 34753889, 29476067, 27494885, 26254443, 30285808, 31346162, 24435446}", ,,#N/A,,,,,,,nuclear factor κb,baicalein,HY-L025-73,B02,HY-N0196,Baicalein,"5,6,7-Trihydroxyflavone",491-67-8,270.24,Ferroptosis; Influenza Virus; Xanthine Oxidase,Anti-infection; Apoptosis; Metabolic Enzyme/Protease,"Baicalein (5,6,7-Trihydroxyflavone) is a xanthine oxidase inhibitor with an IC50 value of 3.12 μM.",C15H10O5,DMSO : 50 mg/mL (185.02 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1C=C(C2=CC=CC=C2)OC3=CC(O)=C(O)C(O)=C13
chk1,0,0,4,0,"{21289082, 34852220, 24556918, 30538111}","{35480096, 29636547, 36684069, 25553514, 36770891, 32859084, 30237520, 28881656, 31789405, 32796829, 25564254}", ,CHK1 and BRD4 synergistic (36684069),rabusertib,,,,,,,nuclear factor κb,guggulsterone,HY-L025-12,A06,HY-107738,Guggulsterone,Z/E-Guggulsterone,95975-55-6,312.45,Akt; Apoptosis; Autophagy; Caspase; FXR; JNK,Apoptosis; Autophagy; MAPK/ERK Pathway; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt[1]. Guggulsterone, a farnesoid X receptor (FXR) antagonist, decreases CDCA-induced FXR activation with IC50s of 17 and 15 μM for Z- and E-Guggulsterone, respectively[2].",C21H28O2,DMSO : 20.83 mg/mL (66.67 mM; Need ultrasonic),10mM,Cancer,No Development Reported,C[C@@]1(/C2=C/C)[C@](CC2=O)([H])[C@@]3([H])[C@]([C@@]4(C(CC3)=CC(CC4)=O)C)([H])CC1
bak,0,0,4,0,"{23232026, 19286308, 27634878, 17569628}","{32161312, 30592293, 29709701, 35787399, 25338565, 28415755, 32249419, 32445837, 35332309, 34959030, 24985178, 28418907, 28766941, 27055867}", ,"tumor suppressor, upregulated w/ BRD4 inhibition",obatoclax,,,,,,,nuclear factor κb,celastrol,HY-L025-32,A08,HY-13067,Celastrol,Tripterine; Tripterin,34157-83-0,450.61,Apoptosis; Autophagy; Endogenous Metabolite; Mitophagy; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease,Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.,C29H38O4,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 33.33 mg/mL (73.97 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C(C2=CC=C3[C@](C)([C@]4(CC[C@]3(C2=CC1=O)C)C)CC[C@@]5(C)CC[C@@](C(O)=O)(C[C@]54[H])C)C
sqstm1,0,0,4,0,"{31177911, 29153842, 32972302, 32762399}","{27864418, 31632060, 32917124, 34074211, 29475942, 28118076}", ,downregulated w/ BRD4 inhibition,rapamycin,,,,,,,nuclear factor κb,shikonin,HY-L025-76,E10,HY-N0822,Shikonin,C.I. 75535; Isoarnebin 4,517-89-5,288.3,AIM2; Chloride Channel; HIV; NF-κB; Pyruvate Kinase; TNF Receptor,Anti-infection; Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; NF-κB,Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM[1]. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor[2] and can also inhibit TNF-α and NF-κB pathway[3]. Shikonin decreases exosome secretion through the inhibition of glycolysis[4]. Shikonin inhibits AIM2 inflammasome activation[7].,C16H16O5,DMSO : 25 mg/mL (86.72 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,No Development Reported,O=C1C([C@H](O)C/C=C(C)/C)=CC(C2=C1C(O)=CC=C2O)=O
ccne1,0,1,4,0,"{24041470, 35302596, 29684357, 35664782}","{32828291, 30975979, 32044108, 33158843, 25892415}", ,,#N/A,,,,,,,nuclear factor κb,berberine,HY-L025-59,B09,HY-18258,Berberine (chloride),Natural Yellow 18 (chloride),633-65-8,371.81,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; Parasite; Reactive Oxygen Species; Topoisomerase,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,Berberine chloride is an alkaloid that acts as an antibiotic. Berberine chloride induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties[1].,C20H18ClNO4,DMSO : 12.5 mg/mL (33.62 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Cancer,Launched,COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.[Cl-]
cell proliferation inhibition,0,1,4,0,"{19016747, 23497499, 15930308, 32071301}","{25266565, 35411247, 26051217, 31267379, 27531767, 32647323, 27835869}", ,,#N/A,,,,,,,β1,propranolol,HY-L025-68,H05,HY-B0573B,Propranolol,,525-66-6,259.34,Adrenergic Receptor; Bacterial,Anti-infection; GPCR/G Protein; Neuronal Signaling,"Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively[1]. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM[2]. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3].",C16H21NO2,DMSO : 100 mg/mL (385.59 mM; Need ultrasonic),10mM,Neurological Disease; Cardiovascular Disease; Endocrinology; Cancer,Launched,OC(COC1=C2C=CC=CC2=CC=C1)CNC(C)C
foxm1,0,1,4,0,"{19860666, 26719042, 30538111, 32709695}","{30096128, 31042405, 31177574, 26618343, 28972303, 33469840, 33158995, 26877780, 29472532, 35390165, 27256375, 30206781, 30451831}", ,BRD4 inhibition inhibits oncogenic pathways such as foxm1 (33469840),dim,,,,,,,β1,bisoprolol,HY-L025-66,B10,HY-B0076,Bisoprolol (hemifumarate),,104344-23-2,383.48,Adrenergic Receptor,GPCR/G Protein; Neuronal Signaling,"Bisoprolol hemifumarate is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol hemifumarate has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research[1][2].",C18H31NO4.1/2C4H4O4,DMSO : ≥ 50 mg/mL (130.38 mM); H2O : 20 mg/mL (52.15 mM; Need ultrasonic),10mM,Cancer; Endocrinology; Inflammation/Immunology; Cardiovascular Disease,Launched,OC(CNC(C)C)COC1=CC=C(COCCOC(C)C)C=C1.OC(/C=C/C(O)=O)=O.[1/2]
twist1,0,0,4,0,"{32641744, 34150617, 31268604, 31935687}","{30876800, 27793799, 31908141, 30154425, 25568313, 32860796}", ,"BRD4 involved in epithelial-mesenchymal transition, which involves TWIST1 (31908141)",harmine,,,,,,,β1,metoprolol,HY-L025-58,D07,HY-17503A,Metoprolol (succinate),,98418-47-4,652.82,Adrenergic Receptor; Apoptosis,Apoptosis; GPCR/G Protein; Neuronal Signaling,"Metoprolol succinate is an orally active, selective β1-adrenoceptor antagonist. Metoprolol succinate shows anti-inflammation, antitumor and anti-angiogenic properties[1][2][3].",C34H56N2O10,DMSO : 16.67 mg/mL (25.54 mM; Need ultrasonic); H2O : ≥ 100 mg/mL (153.18 mM),10mM,Cardiovascular Disease; Endocrinology; Cancer,Launched,OC(CNC(C)C)COC1=CC=C(CCOC)C=C1.OC(CNC(C)C)COC2=CC=C(CCOC)C=C2.OC(CCC(O)=O)=O
cmyc,0,1,4,0,"{35261808, 31227505, 27333990, 34859959}","{26220994, 26807235, 24813887, 26752646, 27903272, 27440272, 35981367, 29914872, 33711386, 28595007}", ,,jq1,,,,,,,β1,esmolol,HY-L025-70,E10,HY-B1392,Esmolol (hydrochloride),,81161-17-3,331.83,Adrenergic Receptor; Autophagy; Mitophagy,Autophagy; GPCR/G Protein; Neuronal Signaling,Esmolol hydrochloride is a beta adrenergic receptor blocker.,C16H26ClNO4,DMSO : ≥ 100 mg/mL (301.36 mM); H2O : ≥ 50 mg/mL (150.68 mM),10mM,Cardiovascular Disease; Endocrinology; Cancer,Launched,O=C(OC)CCC1=CC=C(OCC(O)CNC(C)C)C=C1.[H]Cl
tfeb,0,0,4,0,"{32194992, 32762399, 27175909, 35838183}","{17425505, 30591082, 35646539, 28525743, 31776981}", ,,#N/A,,,,,,,β1,atenolol,HY-L025-58,D04,HY-17498,Atenolol,(RS)-Atenolol,29122-68-7,266.34,Adrenergic Receptor,GPCR/G Protein; Neuronal Signaling,"Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM atβ1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris[1][2].",C14H22N2O3,DMSO : 100 mg/mL (375.46 mM; Need ultrasonic); H2O : 8.33 mg/mL (31.28 mM; Need ultrasonic),10mM,Neurological Disease; Endocrinology; Cancer,Launched,O=C(N)CC1=CC=C(OCC(O)CNC(C)C)C=C1
histone modification,0,2,4,0,"{32531376, 36612299, 34198989, 26716510}","{33239043, 21596426, 30830987, 28723212, 22802445, 21447565, 34898574, 18513937, 27477906, 35940372, 36121114, 31784732, 26407966, 29534238, 26117538, 33907746, 31080358, 24686119, 34149798, 30220457, 35247919, 35904816, 22277300, 29025975, 26178744, 34803511, 31922235, 27911230, 27698495, 32182340, 26349765, 26458440, 31781323, 37049806, 28783698, 17049045, 29866840, 32526941, 34309725, 25946208, 22722403, 21189220, 34315876, 35746919, 36173930, 15970672, 33605616, 36737008, 34059508, 34056693, 27246590, 34174329, 21555454, 33607295}", ,,#N/A,,,,,,,chemokines,dexamethasone,HY-L025-46,B10,HY-14648,Dexamethasone,Hexadecadrol; Prednisolone F,50-02-2,392.46,Antibiotic; Autophagy; Bacterial; Complement System; Glucocorticoid Receptor; Mitophagy; SARS-CoV,Anti-infection; Autophagy; Immunology/Inflammation; Vitamin D Related/Nuclear Receptor,"Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.",C22H29FO5,DMSO : 250 mg/mL (637.01 mM; ultrasonic and warming and heat to 60°C); Ethanol : 8.33 mg/mL (21.23 mM; Need ultrasonic),10mM,Cancer; Infection; Endocrinology; Inflammation/Immunology,Launched,O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@@]4(C(CO)=O)O)=C1
notch3,0,0,4,0,"{35163206, 26880586, 31276933, 26279302}","{30302754, 33676359, 17406891, 19706770, 37213235, 30420565, 34758842, 29366875}", ,,dapt,,,,,,,ampk,staurosporine,HY-L025-49,F07,HY-15141,Staurosporine,Antibiotic AM-2282; STS; AM-2282,62996-74-1,466.53,Antibiotic; Apoptosis; Bacterial; Fungal; PKA; PKC,Anti-infection; Apoptosis; Epigenetics; Stem Cell/Wnt; TGF-beta/Smad,"Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC50s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase respectively. Staurosporine also inhibits TAOK2 with an IC50 of 3 μM. Staurosporine is an apoptosis inducer[1][2][3][4][5].",C28H26N4O3,DMSO : 62.5 mg/mL (133.97 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C(NC1)C2=C1C3=C(C4=C2C5=C(C=CC=C5)N4[C@H]6C[C@@H](NC)[C@@H](OC)[C@]7(C)O6)N7C8=CC=CC=C83
deubiquitinase,0,0,4,0,"{34599002, 34531315, 22699621, 37030295}","{33826947, 33257797, 24657799, 35194152, 34737422, 34290255, 30057199}", ,,wp1130,,,,,,,ampk,propranolol,HY-L025-68,H05,HY-B0573B,Propranolol,,525-66-6,259.34,Adrenergic Receptor; Bacterial,Anti-infection; GPCR/G Protein; Neuronal Signaling,"Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively[1]. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM[2]. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3].",C16H21NO2,DMSO : 100 mg/mL (385.59 mM; Need ultrasonic),10mM,Neurological Disease; Cardiovascular Disease; Endocrinology; Cancer,Launched,OC(COC1=C2C=CC=CC2=CC=C1)CNC(C)C
treg,0,2,4,0,"{24607504, 34279685, 33786412, 30664964}","{35517410, 34910919, 33798633, 30087114, 27799308, 28265070, 35618289, 32799413, 27710838, 30807094, 31653272, 30733722, 36139358}", ,,lenalidomide,,,,,,,ampk,n acetylcysteine,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
sonic hedgehog signaling,0,0,4,0,"{26199979, 35028532, 27003603, 29414775}","{26622824, 35852097, 31139698, 35167374}", ,,#N/A,,,,,,,ampk,salidroside,HY-L025-72,C11,HY-N0109,Salidroside,Rhodioloside,10338-51-9,300.3,Apoptosis; mTOR; Prolyl Endopeptidase  (PREP),Apoptosis; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,Salidroside is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.,C14H20O7,H2O : ≥ 100 mg/mL (333.00 mM),10mM,Cancer,No Development Reported,O[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@@H]1OCCC2=CC=C(O)C=C2
gtpase activating,0,1,3,0,"{22331470, 32559497, 28720574}","{25119042, 33835000, 34638508, 15456879, 18427120, 21251160, 28237246}", ,,#N/A,,,,,,,ampk,pioglitazone,HY-L025-45,H09,HY-14601,Pioglitazone (hydrochloride),U 72107A; AD 4833,112529-15-4,392.9,Ferroptosis; PPAR,Apoptosis; Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor,"Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.",C19H21ClN2O3S,DMSO : 100 mg/mL (254.52 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer; Metabolic Disease,Launched,CCC1=CN=C(CCOC2=CC=C(CC3C(NC(S3)=O)=O)C=C2)C=C1.Cl
cellular signaling,0,0,3,0,"{27215184, 25156550, 29670543}","{27775715, 34199719, 35149545, 25641834, 28288108, 31566962, 35740436, 34935961, 32615359}", ,,#N/A,,,,,,,ampk,e2,HY-L025-66,F04,HY-B0141,Estradiol,β-Estradiol; E2; 17β-Estradiol; 17β-Oestradiol,50-28-2,272.38,Bacterial; Endogenous Metabolite; Estrogen Receptor/ERR,Anti-infection; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Estradiol (β-Estradiol) is a steroid hormone and the major female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering[1][2].",C18H24O2,DMSO : 62.5 mg/mL (229.46 mM; ultrasonic and warming and heat to 60°C); Ethanol : 20 mg/mL (73.43 mM; Need ultrasonic),10mM,Endocrinology; Cancer,Launched,C[C@@]1([C@H]2O)[C@](CC2)([H])[C@@](CCC3=C4C=CC(O)=C3)([H])[C@]4([H])CC1
e1a,0,0,3,0,"{17911264, 21836633, 15375156}","{12941701, 11331592, 27673482, 33872011, 7583761, 34710811, 25525796, 7523245, 31253937, 9436983, 30962627, 16122695, 30723918, 34258514, 32882003, 7565781, 11244510, 35569250, 34074211, 10567538}", ,,#N/A,,,,,,,ampk,estradiol,HY-L025-70,A05,HY-B1100,Estradiol (cypionate),,313-06-4,396.56,Estrogen Receptor/ERR,Vitamin D Related/Nuclear Receptor,"Estradiol cypionate is a 17 β-cyclopentylpropinate ester of estradiol, inhibits ET-1 synthesis via estrogen receptor
IC50 value:
Target: estrogen receptor
Estradiol cypionate is a synthetic ester, is a estrogen. Compared to other commonly used estradiol esters, via the intramuscular route, Estradiol cypionate is found to have the longest duration of action with a duration of ~11 days,",C26H36O3,DMSO : ≥ 30 mg/mL (75.65 mM),10mM,Endocrinology; Cancer,Launched,C[C@@]12[C@@H](OC(CCC3CCCC3)=O)CC[C@@]1([H])[C@]4([H])CCC5=C(C=CC(O)=C5)[C@@]4([H])CC2
b cell lymphoma 2,0,0,3,0,"{29486633, 25411978, 35279012}","{28420416, 35385124, 30592293, 32246150, 28943305, 35153769, 30272279, 28074072, 26224795}", ,,curcumin,,,,,,,ampk,phenformin,HY-L025-56,A03,HY-16397A,Phenformin (hydrochloride),Phenethylbiguanide hydrochloride,834-28-6,241.72,AMPK; Autophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Phenformin hydrochloride is an anti-diabetic agent from the biguanide class, can activate AMPK activity.",C10H16ClN5,DMF : 1 mg/mL (4.14 mM; Need ultrasonic); Ethanol : 2 mg/mL (8.27 mM; Need ultrasonic); DMSO : 1 mg/mL (4.14 mM; ultrasonic and adjust pH to 2 with 1M HCl); H2O : 12.5 mg/mL (51.71 mM; Need ultrasonic),10mM,Cancer,Launched,NC(NC(NCCC1=CC=CC=C1)=N)=N.Cl
hypomethylation,0,0,3,0,"{34508795, 33060108, 33423164}","{32629664, 32826850, 31164355, 25415526, 27409175, 32762714, 30659195, 27240956}", ,,#N/A,,,,,,,hif,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
circrna,0,0,3,0,"{33505218, 34512755, 36426933}","{33833509, 33854310, 34082824, 34421353, 34579723, 33230453, 35164758, 34976188}", ,,#N/A,,,,,,,hif,doxorubicin,HY-L025-49,F08,HY-15142,Doxorubicin (hydrochloride),Hydroxydaunorubicin (hydrochloride),25316-40-9,579.98,ADC Cytotoxin; AMPK; Antibiotic; Apoptosis; Autophagy; Bacterial; HBV; HIV; Mitophagy; Topoisomerase,Antibody-drug Conjugate/ADC Related; Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR,"Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy[1][2][3].",C27H30ClNO11,DMSO : 35.71 mg/mL (61.57 mM; ultrasonic and warming and heat to 60°C); H2O : 20 mg/mL (34.48 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,COC1=C2C(C(C(C(O)=C(C[C@](C(CO)=O)(O)C[C@@H]3O[C@@]4([H])C[C@H](N)[C@H](O)[C@H](C)O4)C3=C5O)=C5C2=O)=O)=CC=C1.[H]Cl
scaffolding protein,0,0,3,0,"{25748234, 36790955, 15969750}","{34448544, 25799074, 29382722, 31110158, 35976792, 26061247}", ,,#N/A,,,,,,,hif,honokiol,HY-L025-71,F02,HY-N0003,Honokiol,NSC 293100,35354-74-6,266.33,Akt; Autophagy; ERK; HCV,Anti-infection; Autophagy; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt,"Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt. Honokiol can readily cross the blood brain barrier[1][2][3][4].",C18H18O2,DMSO : ≥ 50 mg/mL (187.74 mM),10mM,Cancer,Phase 3,OC1=C(CC=C)C=C(C2=CC(CC=C)=CC=C2O)C=C1
forkhead,0,0,3,0,"{30227407, 20157749, 20642839}","{32575577, 26812616, 31913353, 30272279, 35546353, 26877780, 30807094, 27256375, 35273398, 32353113, 31874106}", ,,#N/A,,,,,,,hif,topotecan,HY-L025-39,G10,HY-13768A,Topotecan (Hydrochloride),SKF 104864A (Hydrochloride); NSC 609669 (Hydrochloride),119413-54-6,457.91,Apoptosis; Autophagy; Topoisomerase,Apoptosis; Autophagy; Cell Cycle/DNA Damage,Topotecan Hydrochloride (SKF 104864A Hydrochloride) is a Topoisomerase I inhibitor with potent antineoplastic activities.,C23H24ClN3O5,H2O : 33.33 mg/mL (72.79 mM; Need ultrasonic); DMSO : 100 mg/mL (218.38 mM; Need ultrasonic),10mM,Cancer,Launched,[H]Cl.O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=C(CN(C)C)C(O)=CC=C5N=C4C3=C2)=O
foxo1,0,0,3,0,"{30227407, 36790955, 20642839}","{36604676, 28446439, 36232302, 30272279, 32353113, 29464061, 27980063}", ,inhibiting BRD4 promotes FOXO1 (32353113),dexamethasone,,,,,,,hif,acriflavine,HY-L025-85,H06,HY-W088075,Acriflavine (hydrochloride),Acriflavinium (chloride hydrochloride),69235-50-3,541.9,Bacterial; HIF/HIF Prolyl-Hydroxylase; SARS-CoV,Anti-infection; Metabolic Enzyme/Protease,"Acriflavine hydrochloride (Acriflavinium chloride hydrochloride) is a fluorescent acridine dye that can be used to label nucleic acid[1][2].  Acriflavine hydrochloride is an antiseptic. Acriflavine hydrochloride is a potent HIF-1 inhibitor, with antitumor activity. Acriflavine hydrochloride has antimicrobial and antiviral activities[3][4][5]. Acriflavine hydrochloride is a potent papain-like protease (PLpro) inhibitor, which inhibits SARS-CoV-2[6]",C27H27Cl3N6,DMSO : 25 mg/mL (46.13 mM; Need ultrasonic),10mM,Cancer; Infection,Phase 4,C[N+]1=C2C=C(N)C=CC2=CC3=C1C=C(N)C=C3.[H]Cl.NC4=CC=C5C(N=C6C=C(N)C=CC6=C5)=C4.[H]Cl.[Cl-]
8 cck,0,0,3,0,"{32141657, 36367161, 31047726}","{35116642, 37201092, 34082824, 36244457, 35434025, 35571403, 28545522, 35883157, 34730838, 34387610, 26456956}", ,,#N/A,,,,,,,hif,fg 4592,HY-L025-34,H05,HY-13426,Roxadustat,FG-4592,808118-40-3,352.34,Ferroptosis; HIF/HIF Prolyl-Hydroxylase,Apoptosis; Metabolic Enzyme/Protease,"Roxadustat is an orally active hypoxia-inducible factor (HIF) prolyl-hydroxylase (PHD) inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin[1].",C19H16N2O5,H2O : < 0.1 mg/mL (ultrasonic) (insoluble); DMSO : ≥ 100 mg/mL (283.82 mM),10mM,Cancer,Launched,O=C(O)CNC(C1=C(O)C2=C(C(C)=N1)C=C(OC3=CC=CC=C3)C=C2)=O
e2f1,0,1,3,0,"{27936345, 32655498, 26616862}","{34145028, 9326598, 29764999, 30036377, 23521829, 36596519, 31485609, 28653353, 25623213, 32459053, 34039605, 30223929, 31922235, 36652476, 17998543, 17507796, 20855524, 24796395, 33620209}", ,,silibinin,,,,,,,hif,yc 1,HY-L025-48,G02,HY-14927,Lificiguat,YC-1,170632-47-0,304.34,Guanylate Cyclase,GPCR/G Protein,Lificiguat binds to the β subunit of soluble guanylyl cyclase(sGC) with Kd of 0.6-1.1 μM in the presence of CO.,C19H16N2O2,DMSO : ≥ 100 mg/mL (328.58 mM),10mM,Cancer,No Development Reported,OCC1=CC=C(C2=NN(CC3=CC=CC=C3)C4=C2C=CC=C4)O1
activation of nuclear factor κb,0,1,3,0,"{37014552, 25473891, 25683115}","{33529752, 27507649, 34075610, 29694891}", ,,#N/A,,,,,,,hif,roxadustat,HY-L025-34,H05,HY-13426,Roxadustat,FG-4592,808118-40-3,352.34,Ferroptosis; HIF/HIF Prolyl-Hydroxylase,Apoptosis; Metabolic Enzyme/Protease,"Roxadustat is an orally active hypoxia-inducible factor (HIF) prolyl-hydroxylase (PHD) inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin[1].",C19H16N2O5,H2O : < 0.1 mg/mL (ultrasonic) (insoluble); DMSO : ≥ 100 mg/mL (283.82 mM),10mM,Cancer,Launched,O=C(O)CNC(C1=C(O)C2=C(C(C)=N1)C=C(OC3=CC=CC=C3)C=C2)=O
programmed death ligand 1 pd,0,1,3,0,"{32260561, 36761421, 33747719}","{30824609, 30958600, 32897000, 32630154, 32339606, 35918330, 30266108, 33158814}", ,,#N/A,,,,,,,receptor tyrosine kinases,sorafenib,HY-L025-7,A11,HY-10201A,Sorafenib (Tosylate),Bay 43-9006 (Tosylate),475207-59-1,637.03,Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR,Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator[1].",C28H24ClF3N4O6S,H2O : < 0.1 mg/mL (insoluble); DMSO : ≥ 31 mg/mL (48.66 mM),10mM,Cancer,Launched,O=S(C1=CC=C(C=C1)C)(O)=O.O=C(NC2=CC=C(C(C(F)(F)F)=C2)Cl)NC3=CC=C(OC4=CC(C(NC)=O)=NC=C4)C=C3
smarca4,0,1,3,0,"{27203738, 35302596, 35664782}","{27119626, 34473995, 36934287, 24421395, 33087508, 32877461, 28714904, 33216538, 33732255, 37021735, 31079594, 35930799, 25146928, 30877105, 26572217, 33158843, 33409598, 31406271, 26812616, 36112085, 36227159, 31178587, 35049055, 26942307, 26139243, 34083693, 28426098, 35583999}", ,,#N/A,,,,,,,receptor tyrosine kinases,sunitinib,HY-L025-7,F10,HY-10255A,Sunitinib,SU 11248,557795-19-4,398.47,Apoptosis; Autophagy; IRE1; Mitophagy; PDGFR; VEGFR,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK,"Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].",C22H27FN4O2,DMSO : 20.83 mg/mL (52.27 mM; ultrasonic and warming and heat to 80°C),10mM,Cancer,Launched,O=C(NCCN(CC)CC)C1=C(NC(/C=C2C(NC3=C\2C=C(C=C3)F)=O)=C1C)C
inhibitor of apoptosis,0,0,3,0,"{30084546, 15375156, 36581205}","{26485762, 31993368, 35426377, 26802028, 30175757, 30369550, 29290992, 37126968, 28656888, 32928920}", ,,#N/A,,,,,,,receptor tyrosine kinases,lenvatinib,HY-L025-14,C05,HY-10981A,Lenvatinib (mesylate),E7080 (mesylate),857890-39-2,522.96,c-Kit; FGFR; PDGFR; RET; VEGFR,Protein Tyrosine Kinase/RTK,"Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows  potent antitumor activities[1][2].",C22H23ClN4O7S,DMSO : 7.35 mg/mL (14.05 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=C(OC)C=C2N=CC=C(OC3=CC=C(NC(NC4CC4)=O)C(Cl)=C3)C2=C1)N.OS(=O)(C)=O
bap1,0,0,3,0,"{32641744, 35302596, 31988076}","{35194152, 34737422, 35918352, 34341073, 28426098, 32669118}", ,,#N/A,,,,,,,receptor tyrosine kinases,imatinib,HY-L025-64,D06,HY-50946,Imatinib (Mesylate),STI571 (Mesylate); CGP-57148B (Mesylate),220127-57-1,589.71,Autophagy; Bcr-Abl; c-Kit; PDGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.",C30H35N7O4S,DMSO : 125 mg/mL (211.97 mM; Need ultrasonic); H2O : ≥ 50 mg/mL (84.79 mM),10mM,Cancer,Launched,O=S(O)(C)=O.O=C(NC1=CC=C(C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)C)C4=CC=C(CN5CCN(CC5)C)C=C4
cdk inhibitors,0,0,3,0,"{35457227, 9841966, 37030295}","{23950209, 21900162, 27539364, 26627013, 36711980, 32412527, 25944566}", ,,#N/A,,,,,,,receptor tyrosine kinases,cabozantinib,HY-L025-31,D08,HY-13016,Cabozantinib,XL184; BMS-907351,849217-68-1,501.51,Apoptosis; c-Kit; c-Met/HGFR; FLT3; TAM Receptor; VEGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis[1][2].",C28H24FN3O5,DMSO : 25 mg/mL (49.85 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,O=C(C1(CC1)C(NC2=CC=C(F)C=C2)=O)NC3=CC=C(C=C3)OC4=C5C=C(OC)C(OC)=CC5=NC=C4
plk1,0,1,3,0,"{26091808, 34688654, 32355831}","{34633088, 26191363, 31620231, 35249548, 28972303, 35906200, 19152411, 30611741, 31079968, 37211680, 24584101, 32735909, 32220972, 36711980, 34729902, 32088495, 33158576, 24568369, 31516082, 31869746, 31267379, 30323893, 34710325, 29525435, 30125504, 31708096, 33705152, 27862999, 33257688, 34733788, 28586718, 30880225, 32520674, 29716963, 31042405, 36907496, 34700270, 33638254, 36330747}", ,,gsk461364a,,,,,,,receptor tyrosine kinases,crizotinib,HY-L025-64,B03,HY-50878A,Crizotinib (hydrochloride),PF-02341066 hydrochloride,1415560-69-8,486.8,Anaplastic lymphoma kinase (ALK); Autophagy; c-Met/HGFR; ROS Kinase,Autophagy; Protein Tyrosine Kinase/RTK,"Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition[1][2][3].",C21H23Cl3FN5O,DMSO : ≥ 4.9 mg/mL (10.07 mM); H2O : 50 mg/mL (102.71 mM; Need ultrasonic),10mM,Cancer,Launched,ClC1=C(F)C=CC(Cl)=C1[C@H](OC2=CC(C3=CN(N=C3)C4CCNCC4)=CN=C2N)C.[H]Cl
epigenetic mechanisms,0,1,3,0,"{19797353, 37108468, 33423164}","{19342595, 28474499, 32158467, 34661254, 33172487, 31444232, 34757001, 29703820, 33256844, 32981006, 23752591, 32324495, 35239184, 35169042, 31749139, 15322135, 27409175, 26392221, 32938017, 33395363, 28132772, 33462181, 31080358, 36297001, 31514410, 35999659, 35052850, 36648754, 35679799, 26178744, 25568313, 36077629, 34293822, 28971711, 30693439, 32208449, 21568322, 30924611, 36577469, 34549949, 26458440, 32741705, 31780938, 28935884, 31868237, 36674511, 24373973, 26972250, 34959707, 34309725, 34157407, 33945824, 30467425, 33190371, 26618343, 36971240, 28279785, 20181741, 34354157, 30615537, 22897906, 35782526, 26925174, 28504695, 27246590}", ,,#N/A,,,,,,,p16,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
wee1,0,0,3,0,"{30538111, 34688654, 24791855}","{31199520, 29048129, 23521829, 29262321, 32195191, 31523195}", ,,mk 1775,,,,,,,p16,phip,HY-L025-21,E02,HY-118716,PhIP,"2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine",105650-23-5,224.26,Others,Others,"PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) is the most abundant of generation of heterocyclic amines (HCA), resulted in the cooking of meat[1][2]. DNA damaging and mutagenic activities. PhIP also has oestrogenic activity that could contribute to its tissue specific carcinogenicity[2].",C13H12N4,DMSO : 25 mg/mL (111.48 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 1,NC1=NC2=NC=C(C=C2N1C)C3=CC=CC=C3
skp2,0,0,3,0,"{32583281, 15572689, 24902898}","{23950209, 29312470, 19828607, 28281917, 29915391}", ,,bortezomib,,,,,,,p16,atorvastatin,HY-L025-57,H04,HY-17379,Atorvastatin (hemicalcium salt),CI-981; Atorvastatin hemicalcium,134523-03-8,577.67,Autophagy; Ferroptosis; HMG-CoA Reductase (HMGCR),Apoptosis; Autophagy; Metabolic Enzyme/Protease,"Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3].",C33H34Ca0.5FN2O5,DMSO : ≥ 50 mg/mL (86.55 mM); H2O : < 0.1 mg/mL (insoluble),10mM,Metabolic Disease; Inflammation/Immunology; Cancer,Launched,FC1=CC=C(C2=C(C3=CC=CC=C3)C(C(NC4=CC=CC=C4)=O)=C(C(C)C)N2CC[C@@H](O)C[C@@H](O)CC([O-])=O)C=C1.[0.5Ca2+]
cd274,0,0,3,0,"{36705749, 35493099, 30100261}","{33987681, 35517410, 28423491, 35226658, 28249162, 36644690, 34830196, 35289334, 36814396, 27626654, 34326687}", ,,#N/A,,,,,,,p16,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
pbrm1,0,0,3,0,"{28810144, 35302596, 35392854}","{28053089, 30952871, 26812616, 27367338, 30591082, 27142060, 32630154, 35930799, 28426098, 36227159, 31178587, 32391422, 31863007}", ,,#N/A,,,,,,,notch,dapt,HY-L025-31,F03,HY-13027,DAPT,GSI-IX,208255-80-5,432.46,Amyloid-β; Apoptosis; Autophagy; Notch; γ-secretase,Apoptosis; Autophagy; Neuronal Signaling; Stem Cell/Wnt,"DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment[1][2].",C23H26F2N2O4,DMSO : 62.5 mg/mL (144.52 mM; Need ultrasonic); Ethanol : 10 mg/mL (23.12 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,No Development Reported,FC1=CC(F)=CC(CC(N[C@H](C(N[C@H](C(OC(C)(C)C)=O)C2=CC=CC=C2)=O)C)=O)=C1
inhibitor of apoptosis protein,0,0,3,0,"{30084546, 15375156, 36581205}","{35426377, 30175757, 30369550, 37126968, 28656888, 32928920}", ,,#N/A,,,,,,,notch,crenigacestat,HY-L025-26,F10,HY-12449,Crenigacestat,LY3039478,1421438-81-4,464.44,Notch; γ-secretase,Neuronal Signaling; Stem Cell/Wnt,"Crenigacestat (LY3039478) is an orally active Notch and γ-secretase inhibitor, with an IC50 of  1 nM in most of the tumor cell lines tested[1][2][3][4].",C22H23F3N4O4,DMSO : ≥ 34 mg/mL (73.21 mM),10mM,Cancer,Phase 2,O=C(N[C@@H](C)C(N[C@H]1C2=CC=CC=C2C3=CC=CN=C3N(CCO)C1=O)=O)CCC(F)(F)F
iap,0,1,3,0,"{21462088, 20720444, 8691613}","{35426377, 30175757, 30369550, 31516082, 37126968, 28154167, 32928920, 31580635}", ,,bv6,,,,,,,notch,6 shogaol,HY-L025-46,A09,HY-14616,Shogaol,[6]-Shogaol; 6-Shogaol,555-66-8,276.37,Autophagy,Autophagy,"Shogaol ([6]-Shogaol), an active compound isolated from Ginger (Zingiber officinale Rosc), exhibits a variety of biological activities including anticancer, anti-inflammation, and anti-oxidation.",C17H24O3,DMSO : ≥ 50 mg/mL (180.92 mM),10mM,Cancer,No Development Reported,OC1=C(OC)C=C(CCC(/C=C/CCCCC)=O)C=C1
krüppel,0,0,3,0,"{28581520, 29248441, 19671674}","{35694209, 17178852, 33159815, 11331592, 11230151, 10940561, 33115806, 35843263}", ,,#N/A,,,,,,,notch,cyclopamine,HY-L025-57,F03,HY-17024,Cyclopamine,11-Deoxojervine,4449-51-8,411.62,Endogenous Metabolite; Hedgehog; Smo,Metabolic Enzyme/Protease; Stem Cell/Wnt,Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay. Cyclopamine is also a selective Smo inhibitor.,C27H41NO2,DMSO : 10 mg/mL (24.29 mM; ultrasonic and warming and heat to 80°C); Ethanol : 20 mg/mL (48.59 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CC1=C2[C@@]([C@@]3([H])[C@]([C@@]4(C(C[C@@H](O)CC4)=CC3)C)([H])C2)([H])CC[C@@]15[C@@H]([C@@]6([H])[C@](C[C@H](C)CN6)([H])O5)C
epigenetic modifications,0,1,3,0,"{28188746, 34198989, 34629822}","{30096128, 36158208, 28624514, 27259267, 36839169, 35402244, 35403781, 33661583, 31272080, 18025106, 30539410, 37111316, 30459933, 29534238, 35501470, 30719265, 31521697, 32217639, 32029739, 35052850, 33144118, 35679799, 33161793, 33712705, 32619460, 31901895, 31780938, 26048844, 34341073, 31549911, 26972250, 34309725, 37120098, 32013155, 25415526, 26111464, 30212584, 36971240, 36907496, 35401196, 34354157, 35986286, 33605616, 34830196, 36938998, 28169463}", ,,#N/A,,,,,,,notch,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
pyroptosis,0,0,3,0,"{36319832, 34331036, 35633405}","{33679744, 33298848, 33162822, 34149421, 35259053, 36801999, 36539410, 35154163, 31530390, 32303673, 33535228, 36100190}", ,,#N/A,,,,,,,notch,l 685 458,HY-L025-61,D07,HY-19369,L-685458,"L-685,458",292632-98-5,672.85,Apoptosis; γ-secretase,Apoptosis; Neuronal Signaling; Stem Cell/Wnt,"L-685458 is a potent transition state analog (TSA) γ-secretase inhibitor (GSI). L-685458 inhibits amyloid β-protein precursor γ-secretase activity with IC50 of 17 nM, shows greater than 50-100-fold selectivity over other aspartyl proteases tested. L685458 inhibits γ-secretase-mediated cleavage of APP-C99 and Notch-100 with IC50s of 301.3 nM and 351.3 nM, respectively. L-685458 can be used for the research of alzheimer’s disease (AD) and cancers[1][2].",C39H52N4O6,DMSO : 83.3 mg/mL (123.80 mM; Need ultrasonic and warming),10mM,Neurological Disease; Cancer,No Development Reported,O=C(N)[C@H](CC1=CC=CC=C1)NC([C@H](CC(C)C)NC([C@H](CC2=CC=CC=C2)C[C@@H](O)[C@@H](NC(OC(C)(C)C)=O)CC3=CC=CC=C3)=O)=O
deacetylation,0,0,3,0,"{15184872, 23561972, 26166469}","{33945602, 18406149, 28114951, 12198165, 24522270, 27106081, 29804834, 29439026, 24608443, 37066171, 35467836, 24013502, 32615359, 24939842, 36416071, 21890894, 28572115, 25593309, 33190371, 34617061, 36220390, 28279785, 29523690, 29070704, 27710838, 16085498, 30386303}", ,,#N/A,,,,,,,notch,gsi xii,HY-L025-26,H02,HY-12465,Z-Ile-Leu-aldehyde,Z-IL-CHO; GSI-XII; γ-Secretase inhibitor XII,161710-10-7,362.46,Apoptosis; Notch; γ-secretase,Apoptosis; Neuronal Signaling; Stem Cell/Wnt,Z-Ile-Leu-aldehyde (Z-IL-CHO) is a potent and competitive peptide aldehyde inhibitor of γ-secretase and notch[1][2].,C20H30N2O4,DMSO : ≥ 41 mg/mL (113.12 mM),10mM,Cancer,No Development Reported,O=C(OCC1=CC=CC=C1)N[C@H](C(N[C@H](C=O)CC(C)C)=O)[C@@H](C)CC
ring finger,0,0,3,0,"{34471425, 34150617, 25416862}","{10439047, 25374327, 25961913, 10022127, 18082607, 22231120, 9699856, 10940561, 35273398, 23479607, 9742105, 18502747, 17618463}", ,,#N/A,,,,,,,notch,emodin,HY-L025-43,G03,HY-14393,Emodin,Frangula emodin,518-82-1,270.24,11β-HSD; Autophagy; Casein Kinase; SARS-CoV,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively.  Emodin ameliorates metabolic disorder in diet-induced obese mice[3].",C15H10O5,Acetone : 10.87 mg/mL (40.22 mM; Need ultrasonic); DMSO : 5.41 mg/mL (20.02 mM; Need ultrasonic); Ethanol : 10.87 mg/mL (40.22 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C(C=C(C)C=C2O)C(C3=CC(O)=CC(O)=C31)=O
s phase progression,0,0,3,0,"{15572689, 10781373, 30538111}","{15548137, 29483155, 21673141, 24319289}", ,,#N/A,,,,,,,notch,tsa,HY-L025-49,F10,HY-15144,Trichostatin A,TSA,58880-19-6,302.37,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].",C17H22N2O3,DMSO : 25 mg/mL (82.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
swi snf complex,0,2,3,0,"{29604291, 30014851, 30228219}","{32934021, 9326598, 31000582, 31913353, 24421395, 10330133, 25319830, 28714904, 18837912, 36780189, 34983841, 33232675, 26914985, 12419248, 34987057, 16648632, 7957049, 33409598, 34577604, 17023429, 26812616, 14530259, 17049045, 17030999, 34863065, 29958106, 8208605, 33602783, 24198243, 22442726, 30824168, 29523178, 26139243, 10746732, 28500727}", ,,#N/A,,,,,,,notch,pf 03084014,HY-L025-50,B05,HY-15185,Nirogacestat,PF-3084014; PF-03084014,1290543-63-3,489.64,Apoptosis; γ-secretase,Apoptosis; Neuronal Signaling; Stem Cell/Wnt,"Nirogacestat (PF-3084014) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC50 of 6.2 nM. Inhibition of Notch signaling by Nirogacestat while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers[1].",C27H41F2N5O,DMSO : 28.57 mg/mL (58.35 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 3,FC1=C2C(CC[C@H](N[C@@H](CCC)C(NC3=CN(C(C)(C)CNCC(C)(C)C)C=N3)=O)C2)=CC(F)=C1
tcf4,0,1,3,0,"{27889647, 26477318, 32972302}","{32234682, 26833129, 27846385, 30350260, 27846392, 31217338, 33654205}", ,,#N/A,,,,,,,notch,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
dnmts,0,0,3,0,"{29626481, 32457835, 22820191}","{32938017, 30672294, 31514410, 30837715, 31075731, 26799480}", ,,zebularine,,,,,,,notch,saha,HY-L025-7,E02,HY-10221,Vorinostat,SAHA; Suberoylanilide hydroxamic acid,149647-78-9,264.32,Apoptosis; Autophagy; Filovirus; HDAC; HPV; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].",C14H20N2O3,DMSO : ≥ 100 mg/mL (378.33 mM),10mM,Cancer; Infection,Launched,O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O
tripartite motif,0,0,3,0,"{32029896, 36741265, 25593307}","{21164480, 28207202, 31776034, 26061247, 29523690, 35385803, 26565999, 22231120, 27769360, 25065590, 31028095, 36631514, 36098557, 27432991}", ,,#N/A,,,,,,,notch,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
hdac2,0,0,3,0,"{33491761, 19362090, 28028031}","{33617509, 36220390, 35403781, 25606026, 35650157, 17942543, 36260688, 33968920, 29777682, 24952595, 30504275, 26044852, 36305426, 35679799, 34365463, 31989434, 37066171, 32015101}", ,,theophylline,,,,,,,notch,estradiol,HY-L025-70,A05,HY-B1100,Estradiol (cypionate),,313-06-4,396.56,Estrogen Receptor/ERR,Vitamin D Related/Nuclear Receptor,"Estradiol cypionate is a 17 β-cyclopentylpropinate ester of estradiol, inhibits ET-1 synthesis via estrogen receptor
IC50 value:
Target: estrogen receptor
Estradiol cypionate is a synthetic ester, is a estrogen. Compared to other commonly used estradiol esters, via the intramuscular route, Estradiol cypionate is found to have the longest duration of action with a duration of ~11 days,",C26H36O3,DMSO : ≥ 30 mg/mL (75.65 mM),10mM,Endocrinology; Cancer,Launched,C[C@@]12[C@@H](OC(CCC3CCCC3)=O)CC[C@@]1([H])[C@]4([H])CCC5=C(C=CC(O)=C5)[C@@]4([H])CC2
genomic stability,0,0,3,0,"{23303473, 36118868, 28894253}","{32457312, 28055972, 15467469, 32269268, 36404917, 35252219, 32796829}", ,,#N/A,,,,,,,nf κb p65,tudca,HY-L025-61,H11,HY-19696B,Tauroursodeoxycholate (dihydrate),Tauroursodeoxycholic acid (dihydrate); TUDCA (dihydrate); UR 906 (dihydrate),117609-50-4,535.73,Apoptosis; Caspase; Endogenous Metabolite; ERK,Apoptosis; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK[1][2].",C26H49NO8S,DMSO : 83.33 mg/mL (155.54 mM; Need ultrasonic),10mM,Cancer,Launched,C[C@H](CCC(NCCS(=O)(O)=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C.O.O
foxa1,0,0,3,0,"{33839689, 31919242, 32696980}","{31874106, 34493733, 32333502, 36877164, 29997232, 25568313, 30270106, 27601596, 30139998, 34850111}", ,,#N/A,,,,,,,nf κb p65,nobiletin,HY-L025-72,G02,HY-N0155,Nobiletin,,478-01-3,402.39,Apoptosis; Autophagy; Reactive Oxygen Species; ROR,Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Vitamin D Related/Nuclear Receptor,"Nobiletin is a poly-methoxylated flavone from the citrus peel that improves memory loss. Nobiletin is a retinoid acid receptor-related orphan receptors (RORs) agonist. Nobiletin can reduce reactive oxygen species (ROS) levels in differentiated C2C12 myotubes and has anti-inflammation and anti-cancer properties, including anti-angiogenesis, anti-proliferation, anti-metastasis and induced apoptosis[1][2][3][4].",C21H22O8,DMSO : 50 mg/mL (124.26 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,No Development Reported,O=C1C=C(C2=CC=C(OC)C(OC)=C2)OC3=C(OC)C(OC)=C(OC)C(OC)=C13
von hippel lindau,0,0,3,0,"{37201049, 16278378, 29693047}","{30721025, 31553577, 30175757, 30540463, 35018781, 28378579, 33070611, 34675414, 34499862, 37126968, 29949369, 35958877, 32082969}",potential PDAC target (37201049),,#N/A,,,,,,,nf κb p65,shikonin,HY-L025-76,E10,HY-N0822,Shikonin,C.I. 75535; Isoarnebin 4,517-89-5,288.3,AIM2; Chloride Channel; HIV; NF-κB; Pyruvate Kinase; TNF Receptor,Anti-infection; Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; NF-κB,Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM[1]. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor[2] and can also inhibit TNF-α and NF-κB pathway[3]. Shikonin decreases exosome secretion through the inhibition of glycolysis[4]. Shikonin inhibits AIM2 inflammasome activation[7].,C16H16O5,DMSO : 25 mg/mL (86.72 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,No Development Reported,O=C1C([C@H](O)C/C=C(C)/C)=CC(C2=C1C(O)=CC=C2O)=O
nsg,0,0,3,0,"{32446697, 30128034, 25724428}","{28042144, 35794848, 36599397, 34634662, 32380205, 35399501}", ,,#N/A,,,,,,,nf κb p65,galangin,HY-L025-74,B04,HY-N0382,Galangin,"Norizalpinin; 3,5,7-Trihydroxyflavone",548-83-4,270.24,Autophagy; Cytochrome P450,Autophagy; Metabolic Enzyme/Protease,Galangin (Norizalpinin) is?an?agonist/antagonist?of the?arylhydrocarbon?receptor. Galangin (Norizalpinin) also shows inhibition of CYP1A1 activity.,C15H10O5,DMSO : 125 mg/mL (462.55 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C(O)=C(C2=CC=CC=C2)OC3=CC(O)=CC(O)=C13
epigenetic dysregulation,0,0,3,0,"{24976721, 31300513, 25939753}","{30876800, 34865122, 27078884, 26752646, 28095495, 30844748, 34370992, 35745584, 30837715, 34791636, 35467128, 36324153, 27240956, 35279966}", ,,#N/A,,,,,,,nf κb p65,crocin,HY-L025-75,G08,HY-N0697,Crocin,Crocin I,42553-65-1,976.96,Endogenous Metabolite,Metabolic Enzyme/Protease,"Crocin (Crocin I) is a nutraceutical and the main constituent isolated from the stigmas of Crocus sativus with immense pharmacological properties as anti-inflammatory, anticancer, antidepressant and anticonvulsant[1].",C44H64O24,DMSO : 125 mg/mL (127.95 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,O[C@@H]([C@H](O)[C@H]1O)[C@H](O[C@H]1OC(/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C(O[C@@H]([C@@H]([C@@H](O)[C@@H]2O)O)O[C@@H]2CO[C@@H]([C@@H]([C@@H](O)[C@@H]3O)O)O[C@@H]3CO)=O)=O)CO[C@@H]([C@@H]([C@@H](O)[C@@H]4O)O)O[C@@H]4CO
,,,,,,,,,,,,,,,,nf κb p65,paeoniflorin,HY-L025-73,G05,HY-N0293,Paeoniflorin,Peoniflorin,23180-57-6,480.46,HSP,Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Paeoniflorin is a heat shock protein-inducing compound and commonly exists in the plants of Paeoniaceae family, with various biological activities, including anticancer activity, anti-inflammatory activity,  enhancing cognition and attenuating learning impairment, anti-oxidative stress, antiplatelet aggregation, expansion of blood vessels, and reducing blood viscosity[1][2][3].",C23H28O11,DMSO : 100 mg/mL (208.13 mM; Need ultrasonic); H2O : ≥ 100 mg/mL (208.13 mM),10mM,Cancer; Infection; Neurological Disease,Phase 3,O[C@H]1[C@H](O)[C@@H](O)[C@]([H])(O[C@]2([C@@]3(C)O[C@]4([H])O[C@@]5(C3)O)C[C@]5([H])[C@]24COC(C6=CC=CC=C6)=O)O[C@@H]1CO
,,,,,,,,,,,,,,,,nf κb p65,silibinin,HY-L025-76,C08,HY-N0779A,Silybin,Silibinin,802918-57-6,482.44,Apoptosis,Apoptosis,"Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds. Silybin induces apoptosis and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity[1][2].",C25H22O10,DMSO : 25 mg/mL (51.82 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C1[C@H](O)[C@@H](C2=CC=C(OC(CO)C(C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15
,,,,,,,,,,,,,,,,nf κb p65,dexmedetomidine,HY-L025-57,F06,HY-17034A,Dexmedetomidine (hydrochloride),(+)-Medetomidine (hydrochloride); (S)-Medetomidine (hydrochloride),145108-58-3,236.74,Adrenergic Receptor,GPCR/G Protein; Neuronal Signaling,"Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects[1][2][3].",C13H17ClN2,DMSO : 250 mg/mL (1056.01 mM; Need ultrasonic); H2O : ≥ 50 mg/mL (211.20 mM),10mM,Neurological Disease; Endocrinology; Cancer,Launched,C[C@H](C1=CN=CN1)C2=CC=CC(C)=C2C.Cl
,,,,,,,,,,,,,,,,nf κb p65,e2,HY-L025-66,F04,HY-B0141,Estradiol,β-Estradiol; E2; 17β-Estradiol; 17β-Oestradiol,50-28-2,272.38,Bacterial; Endogenous Metabolite; Estrogen Receptor/ERR,Anti-infection; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Estradiol (β-Estradiol) is a steroid hormone and the major female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering[1][2].",C18H24O2,DMSO : 62.5 mg/mL (229.46 mM; ultrasonic and warming and heat to 60°C); Ethanol : 20 mg/mL (73.43 mM; Need ultrasonic),10mM,Endocrinology; Cancer,Launched,C[C@@]1([C@H]2O)[C@](CC2)([H])[C@@](CCC3=C4C=CC(O)=C3)([H])[C@]4([H])CC1
,,,,,,,,,,,,,,,,nf κb p65,triptolide,HY-L025-63,C07,HY-32735,Triptolide,PG490,38748-32-2,360.4,Apoptosis; NF-κB,Apoptosis; NF-κB,"Triptolide is a diterpenoid triepoxide extracted from the root of Tripterygium wilfordii with immunosuppressive, anti-inflammatory, antiproliferative and antitumour effects. Triptolide is a NF-κB activation inhibitor[1][2][3][4][5][6].",C20H24O6,DMSO : 25 mg/mL (69.37 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,C[C@@]12[C@@]34[C@](O5)([C@@H]([C@](O6)(C(C)C)[C@@H]6[C@@H]3O4)O)[C@@H]5C[C@@]1([H])C7=C(C(OC7)=O)CC2
,,,,,,,,,,,,,,,,nf κb p65,rosiglitazone,HY-L025-57,H08,HY-17386,Rosiglitazone,BRL 49653,122320-73-4,357.43,Apoptosis; Autophagy; Ferroptosis; PPAR; TRP Channel,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel; Neuronal Signaling; Vitamin D Related/Nuclear Receptor,"Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer[1][2][4][7].",C18H19N3O3S,DMSO : 250 mg/mL (699.44 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic) (insoluble); Ethanol : 2 mg/mL (5.60 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease,Launched,O=C(N1)SC(CC2=CC=C(OCCN(C)C3=NC=CC=C3)C=C2)C1=O
,,,,,,,,,,,,,,,,proteasome,geldanamycin,HY-L025-50,F06,HY-15230,Geldanamycin,,30562-34-6,560.64,Antibiotic; Bacterial; HSP; Influenza Virus,Anti-infection; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,Geldanamycin is a Hsp90 inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.,C29H40N2O9,DMSO : 50 mg/mL (89.18 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,No Development Reported,COC(C(C=C1NC(/C(C)=C/C=C/[C@H](OC)[C@@H](OC(N)=O)/C(C)=C/[C@H](C)[C@H]2O)=O)=O)=C(C[C@H](C[C@@H]2OC)C)C1=O
,,,,,,,,,,,,,,,,proteasome,nelfinavir,HY-L025-51,A05,HY-15287A,Nelfinavir (Mesylate),AG 1343 Mesylate,159989-65-8,663.89,HIV; HIV Protease,Anti-infection; Metabolic Enzyme/Protease,"Nelfinavir Mesylate (AG 1343 Mesylate) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir Mesylate (AG 1343 Mesylate) is a broad-spectrum, anticancer agent[1][2][3].",C33H49N3O7S2,DMSO : 100 mg/mL (150.63 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,[H][C@]12C[C@@H](C(NC(C)(C)C)=O)N(C[C@H]([C@@H](NC(C3=C(C)C(O)=CC=C3)=O)CSC4=CC=CC=C4)O)C[C@@]1([H])CCCC2.CS(=O)(O)=O
,,,,,,,,,,,,,,,,proteasome,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,proteasome,shikonin,HY-L025-76,E10,HY-N0822,Shikonin,C.I. 75535; Isoarnebin 4,517-89-5,288.3,AIM2; Chloride Channel; HIV; NF-κB; Pyruvate Kinase; TNF Receptor,Anti-infection; Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; NF-κB,Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM[1]. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor[2] and can also inhibit TNF-α and NF-κB pathway[3]. Shikonin decreases exosome secretion through the inhibition of glycolysis[4]. Shikonin inhibits AIM2 inflammasome activation[7].,C16H16O5,DMSO : 25 mg/mL (86.72 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,No Development Reported,O=C1C([C@H](O)C/C=C(C)/C)=CC(C2=C1C(O)=CC=C2O)=O
,,,,,,,,,,,,,,,,proteasome,nac,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,proteasome,n acetylcysteine,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,proteasome,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
,,,,,,,,,,,,,,,,proteasome,lovastatin,HY-L025-74,G03,HY-N0504,Lovastatin,Mevinolin,75330-75-5,404.54,Autophagy; Ferroptosis; HMG-CoA Reductase (HMGCR),Apoptosis; Autophagy; Metabolic Enzyme/Protease,Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.,C24H36O5,DMSO : ≥ 100 mg/mL (247.19 mM),10mM,Cardiovascular Disease; Cancer,Launched,O=C([C@@H](C)CC)O[C@@H]1[C@@]([C@H]2CC[C@@H](OC3=O)C[C@H](C3)O)([H])C(C=C[C@@H]2C)=C[C@H](C)C1
,,,,,,,,,,,,,,,,tgf β1,hesperetin,HY-L025-72,G11,HY-N0168,Hesperetin,,520-33-2,302.28,Apoptosis; Autophagy; p38 MAPK,Apoptosis; Autophagy; MAPK/ERK Pathway,"Hesperetin is a natural flavanone, and acts as a potent and broad-spectrum inhibitor against human UGT activity. Hesperetin regulates apoptosis.",C16H14O6,DMSO : 100 mg/mL (330.82 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Phase 1,O=C1C[C@@H](C2=CC=C(OC)C(O)=C2)OC3=CC(O)=CC(O)=C13
,,,,,,,,,,,,,,,,tgf β1,sildenafil,HY-L025-49,B07,HY-15025A,Sildenafil (citrate),UK-92480 (citrate),171599-83-0,666.7,Apoptosis; Autophagy; Bacterial; Phosphodiesterase (PDE),Anti-infection; Apoptosis; Autophagy; Metabolic Enzyme/Protease,Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC50 of 5.22 nM.,C28H38N6O11S,DMSO : 50 mg/mL (75.00 mM; Need ultrasonic); H2O : 2 mg/mL (3.00 mM; Need ultrasonic),10mM,Cardiovascular Disease; Cancer,Launched,O=C1C(N(C)N=C2CCC)=C2N=C(C3=CC(S(=O)(N4CCN(C)CC4)=O)=CC=C3OCC)N1.O=C(CC(C(O)=O)(O)CC(O)=O)O
,,,,,,,,,,,,,,,,tgf β1,pp2,HY-L025-40,B02,HY-13805,PP2,AGL 1879,172889-27-9,301.77,Src,Protein Tyrosine Kinase/RTK,"PP2 is a reversible and ATP-competitive Src family kinases inhibitor with IC50s of 4 and 5 nM for Lck and Fyn, respectively.",C15H16ClN5,DMSO : 50 mg/mL (165.69 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,No Development Reported,NC1=C2C(N(C(C)(C)C)N=C2C3=CC=C(Cl)C=C3)=NC=N1
,,,,,,,,,,,,,,,,tgf β1,pterostilbene,HY-L025-76,F02,HY-N0828,Pterostilbene,,537-42-8,256.3,Autophagy,Autophagy,"Pterostilbene is a stilbenoid isolated from blueberries and Pterocarpus marsupium[1]. Shows anti-oxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and anti-obesity properties[1][4]. Pterostilbene blocks ROS production[3], also exhibits inhibitory activity against various free radicals such as DPPH, ABTS, hydroxyl, superoxide and hydrogen peroxide[4].",C16H16O3,DMSO : 110 mg/mL (429.18 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 3,OC1=CC=C(/C=C/C2=CC(OC)=CC(OC)=C2)C=C1
,,,,,,,,,,,,,,,,tgf β1,asiaticoside,HY-L025-74,D06,HY-N0439,Asiaticoside,,16830-15-2,959.12,Apoptosis; Endogenous Metabolite; Reactive Oxygen Species; TGF-beta/Smad,Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt; TGF-beta/Smad,"Asiaticoside, a trisaccaride triterpene from Centella asiatica, suppresses TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts; Asiaticoside shows antioxidant, anti-inflammatory, and anti-ulcer properties.",C48H78O19,DMSO : 50 mg/mL (52.13 mM; Need ultrasonic),10mM,Inflammation/Immunology; Neurological Disease; Cardiovascular Disease; Cancer,No Development Reported,C[C@@H]1CC[C@@]2(C(O[C@@H]3O[C@H](CO[C@H]4[C@H](O)[C@@H](O)[C@H](O[C@@]5([H])[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O5)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@H]3O)=O)[C@@](C6=CC[C@@]([C@](C[C@@H](O)[C@H](O)[C@]7(CO)C)(C)[C@@]7([H])CC8)([H])[C@]8(C)[C@]6(C)CC2)([H])[C@H]1C
,,,,,,,,,,,,,,,,tgf β1,α tocopherol,HY-L025-56,G04,HY-16686,α-Tocopherol (phosphate),alpha-Tocopherol phosphate; TocP; vitamin E phosphate,38976-17-9,510.69,Others,Others,"α-Tocopherol phosphate is the compound demonstrating the highest vitamin E activity, which is available both in its natural form as RRR-alpha-tocopherol isolated from plant sources.",C29H51O5P,H2O : 0.67 mg/mL (1.31 mM; Need ultrasonic); DMSO : ≥ 100 mg/mL (195.81 mM),10mM,Cancer,Phase 4,CC1=C(O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CC2)C2=C(C)C(OP(O)(O)=O)=C1C
,,,,,,,,,,,,,,,,tgf β1,tamoxifen,HY-L025-39,G02,HY-13757A,Tamoxifen,ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen,10540-29-1,371.51,Apoptosis; Autophagy; Estrogen Receptor/ERR; HSP,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells[1][2][3]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively[5]. Tamoxifen activates autophagy and induces apoptosis[4]. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse[6].",C26H29NO,DMSO : 50 mg/mL (134.59 mM; Need ultrasonic); Ethanol : 50 mg/mL (134.59 mM; Need ultrasonic),10mM,Cancer,Launched,CC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)\C3=CC=CC=C3
,,,,,,,,,,,,,,,,tgf β1,epa,HY-L025-69,B10,HY-B0660,Eicosapentaenoic Acid,EPA; Timnodonic acid,10417-94-4,302.45,Endogenous Metabolite; Histone Demethylase,Epigenetics; Metabolic Enzyme/Protease,Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation[1][2][3].,C20H30O2,DMSO : ≥ 53 mg/mL (175.24 mM); Ethanol : ≥ 100 mg/mL (330.63 mM),10mM,Neurological Disease; Cancer,Launched,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(O)=O
,,,,,,,,,,,,,,,,tgf β1,t0901317,HY-L025-11,B04,HY-10626,T0901317,,293754-55-9,481.33,Apoptosis; FXR; LXR; ROR,Apoptosis; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα[1]. T0901317 activates FXR with an EC50 of 5 μM[2]. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively[3]. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice[4][5].",C17H12F9NO3S,DMSO : 100 mg/mL (207.76 mM; Need ultrasonic); Ethanol : 100 mg/mL (207.76 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,No Development Reported,OC(C(F)(F)F)(C(F)(F)F)C1=CC=C(N(CC(F)(F)F)S(C2=CC=CC=C2)(=O)=O)C=C1
,,,,,,,,,,,,,,,,cck,diltiazem,HY-L025-46,C09,HY-14656,Diltiazem (hydrochloride),CRD-401,33286-22-5,450.98,Calcium Channel,Membrane Transporter/Ion Channel; Neuronal Signaling,Diltiazem hydrochloride is a Ca2+ influx inhibitor (slow channel blocker or calcium antagonist).,C22H27ClN2O4S,H2O : 33.33 mg/mL (73.91 mM; Need ultrasonic),10mM,Cardiovascular Disease; Cancer,Launched,CN(C)CCN1C2=CC=CC=C2S[C@@H](C3=CC=C(OC)C=C3)[C@@H](OC(C)=O)C1=O.Cl
,,,,,,,,,,,,,,,,cck,dexamethasone,HY-L025-46,B10,HY-14648,Dexamethasone,Hexadecadrol; Prednisolone F,50-02-2,392.46,Antibiotic; Autophagy; Bacterial; Complement System; Glucocorticoid Receptor; Mitophagy; SARS-CoV,Anti-infection; Autophagy; Immunology/Inflammation; Vitamin D Related/Nuclear Receptor,"Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.",C22H29FO5,DMSO : 250 mg/mL (637.01 mM; ultrasonic and warming and heat to 60°C); Ethanol : 8.33 mg/mL (21.23 mM; Need ultrasonic),10mM,Cancer; Infection; Endocrinology; Inflammation/Immunology,Launched,O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@@]4(C(CO)=O)O)=C1
,,,,,,,,,,,,,,,,cck,orlistat,HY-L025-67,B08,HY-B0218,Orlistat,Tetrahydrolipstatin; Ro-18-0647,96829-58-2,495.73,Apoptosis; Fatty Acid Synthase (FASN),Apoptosis; Metabolic Enzyme/Protease,"Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity[1].?Anti-atherosclerotic?effect[2].",C29H53NO5,DMSO : 100 mg/mL (201.72 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Metabolic Disease; Cancer,Launched,O=C1[C@@H](CCCCCC)[C@H](C[C@@H](OC([C@@H](N([H])C([H])=O)CC(C)C)=O)CCCCCCCCCCC)O1
,,,,,,,,,,,,,,,,cck,verapamil,HY-L025-65,F02,HY-A0064,Verapamil (hydrochloride),(±)-Verapamil (hydrochloride); CP-16533-1 (hydrochloride),152-11-4,491.06,Calcium Channel; Cytochrome P450; P-glycoprotein,Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling,"Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research[1][2][3].",C27H39ClN2O4,DMSO : ≥ 31 mg/mL (63.13 mM); H2O : 50 mg/mL (101.82 mM; Need ultrasonic),10mM,Cardiovascular Disease; Cancer,Launched,[H]Cl.COC1=CC=C(C(C#N)(C(C)C)CCCN(CCC2=CC=C(OC)C(OC)=C2)C)C=C1OC
,,,,,,,,,,,,,,,,jak2,sp600125,HY-L025-22,G02,HY-12041,SP600125,,129-56-6,220.23,Apoptosis; Autophagy; Ferroptosis; JNK,Apoptosis; Autophagy; MAPK/ERK Pathway,"SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 inhibits autophagy and activates apoptosis[1][2][3].",C14H8N2O,DMSO : 12.5 mg/mL (56.76 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C3C(NN=C3C4=C1C=CC=C4)=CC=C2
,,,,,,,,,,,,,,,,jak2,baicalin,HY-L025-73,B03,HY-N0197,Baicalin,Baicalein 7-O-β-D-glucuronide,21967-41-9,446.36,Autophagy; HIV; NF-κB,Anti-infection; Autophagy; NF-κB,"Baicalin, as a flavonoid glycoside, is an allosteric carnitine palmityl transferase 1 (CPT1) activator. Baicalin reduces the expression of NF-κB[1][2][3].",C21H18O11,DMSO : ≥ 100 mg/mL (224.03 mM); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Inflammation/Immunology; Cancer,Launched,O[C@H]([C@H]([C@@H]([C@@H](C(O)=O)O1)O)O)[C@@H]1OC2=C(O)C(O)=C3C(C=C(C4=CC=CC=C4)OC3=C2)=O
,,,,,,,,,,,,,,,,jak2,propofol,HY-L025-69,B04,HY-B0649,Propofol,"2,6-Diisopropylphenol",2078-54-8,178.27,Endogenous Metabolite; GABA Receptor,Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling,Propofol potently and directly activates GABAA receptor and inhibits glutamate receptor mediated excitatory synaptic transmission. Propofol has antinociceptive properties and is used for sedation and hypnotic[1].,C12H18O,DMSO : 100 mg/mL (560.95 mM; Need ultrasonic); H2O : 0.5 mg/mL (2.80 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,OC1=C(C(C)C)C=CC=C1C(C)C
,,,,,,,,,,,,,,,,jak2,fludarabine,HY-L025-66,B06,HY-B0069,Fludarabine,F-ara-A; NSC 118218,21679-14-1,285.23,Apoptosis; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog; STAT,Apoptosis; Cell Cycle/DNA Damage; JAK/STAT Signaling; Stem Cell/Wnt,Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes[1][2][3][4].,C10H12FN5O4,DMSO : 25 mg/mL (87.65 mM; Need ultrasonic),10mM,Cancer,Launched,O[C@H]1[C@H](O)[C@H](N2C(N=C(F)N=C3N)=C3N=C2)O[C@@H]1CO
,,,,,,,,,,,,,,,,jak2,bms 911543,HY-L025-50,G10,HY-15270,BMS-911543,,1271022-90-2,432.52,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"BMS-911543 is a selective JAK2 inhibitor, with IC50s of 1.1 nM, less selective at JAK1, JAK3 and TYK2 (IC50, 75, 360, 66 nM, respectively).",C23H28N8O,DMSO : 25 mg/mL (57.80 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=CC2=C(N(C)C=N3)C3=C(NC4=NN(C)C(C)=C4)N=C2N1CC)N(C5CC5)C6CC6
,,,,,,,,,,,,,,,,jak2,vorinostat,HY-L025-7,E02,HY-10221,Vorinostat,SAHA; Suberoylanilide hydroxamic acid,149647-78-9,264.32,Apoptosis; Autophagy; Filovirus; HDAC; HPV; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].",C14H20N2O3,DMSO : ≥ 100 mg/mL (378.33 mM),10mM,Cancer; Infection,Launched,O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O
,,,,,,,,,,,,,,,,jak2,baicalein,HY-L025-73,B02,HY-N0196,Baicalein,"5,6,7-Trihydroxyflavone",491-67-8,270.24,Ferroptosis; Influenza Virus; Xanthine Oxidase,Anti-infection; Apoptosis; Metabolic Enzyme/Protease,"Baicalein (5,6,7-Trihydroxyflavone) is a xanthine oxidase inhibitor with an IC50 value of 3.12 μM.",C15H10O5,DMSO : 50 mg/mL (185.02 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1C=C(C2=CC=CC=C2)OC3=CC(O)=C(O)C(O)=C13
,,,,,,,,,,,,,,,,jak2,curcumol,HY-L025-72,C09,HY-N0104,Curcumol,(-)-Curcumol,4871-97-0,236.35,Apoptosis,Apoptosis,"Curcumol ((-)-Curcumol), a bioactive sesquiterpenoid, possesses numerous pharmacological activities like anticancer, antimicrobial, antifungal, antiviral, and antiinflammatory. Curcumol is a potent inducer of apoptosis in numerous cancer cells via targeting key signaling pathways as MAPK/ERK, PI3K/Akt and NF-κB which are generally deregulated in several cancers[1].",C15H24O2,DMSO : ≥ 100 mg/mL (423.10 mM),10mM,Cancer,Phase 3,O[C@@]1(C2)[C@H](C(C)C)C[C@]3(O1)[C@@H](C)CC[C@@]3([H])C2=C
,,,,,,,,,,,,,,,,jak2,salidroside,HY-L025-72,C11,HY-N0109,Salidroside,Rhodioloside,10338-51-9,300.3,Apoptosis; mTOR; Prolyl Endopeptidase  (PREP),Apoptosis; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,Salidroside is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.,C14H20O7,H2O : ≥ 100 mg/mL (333.00 mM),10mM,Cancer,No Development Reported,O[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@@H]1OCCC2=CC=C(O)C=C2
,,,,,,,,,,,,,,,,jak2,pp2,HY-L025-40,B02,HY-13805,PP2,AGL 1879,172889-27-9,301.77,Src,Protein Tyrosine Kinase/RTK,"PP2 is a reversible and ATP-competitive Src family kinases inhibitor with IC50s of 4 and 5 nM for Lck and Fyn, respectively.",C15H16ClN5,DMSO : 50 mg/mL (165.69 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,No Development Reported,NC1=C2C(N(C(C)(C)C)N=C2C3=CC=C(Cl)C=C3)=NC=N1
,,,,,,,,,,,,,,,,jak2,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,jak2,sorafenib,HY-L025-7,A11,HY-10201A,Sorafenib (Tosylate),Bay 43-9006 (Tosylate),475207-59-1,637.03,Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR,Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator[1].",C28H24ClF3N4O6S,H2O : < 0.1 mg/mL (insoluble); DMSO : ≥ 31 mg/mL (48.66 mM),10mM,Cancer,Launched,O=S(C1=CC=C(C=C1)C)(O)=O.O=C(NC2=CC=C(C(C(F)(F)F)=C2)Cl)NC3=CC=C(OC4=CC(C(NC)=O)=NC=C4)C=C3
,,,,,,,,,,,,,,,,jak2,tyrphostin b42,HY-L025-22,A04,HY-12000,AG490,Tyrphostin AG490; Tyrphostin B42,133550-30-8,294.3,Autophagy; EGFR; JAK; STAT,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.",C17H14N2O3,DMSO : ≥ 50 mg/mL (169.89 mM),10mM,Cancer,No Development Reported,O=C(NCC1=CC=CC=C1)/C(C#N)=C/C2=CC=C(O)C(O)=C2
,,,,,,,,,,,,,,,,jak2,tg 101348,HY-L025-9,H09,HY-10409A,Fedratinib (hydrochloride hydrate),TG-101348 (hydrochloride hydrate); SAR 302503 (hydrochloride hydrate),1374744-69-0,615.62,Apoptosis; JAK,Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research[1][2].",C27H40Cl2N6O4S,DMSO : 125 mg/mL (203.05 mM; Need ultrasonic); H2O : 100 mg/mL (162.44 mM; Need ultrasonic),10mM,Cancer,Launched,[H]Cl.[H]O[H].[H]Cl.O=S(C1=CC=CC(NC2=NC(NC3=CC=C(C=C3)OCCN4CCCC4)=NC=C2C)=C1)(NC(C)(C)C)=O
,,,,,,,,,,,,,,,,jak2,berberine,HY-L025-59,B09,HY-18258,Berberine (chloride),Natural Yellow 18 (chloride),633-65-8,371.81,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; Parasite; Reactive Oxygen Species; Topoisomerase,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,Berberine chloride is an alkaloid that acts as an antibiotic. Berberine chloride induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties[1].,C20H18ClNO4,DMSO : 12.5 mg/mL (33.62 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Cancer,Launched,COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.[Cl-]
,,,,,,,,,,,,,,,,cck 8,proglumide,HY-L025-70,D08,HY-B1330,Proglumide,,6620-60-6,334.41,Cholecystokinin Receptor,GPCR/G Protein; Neuronal Signaling,Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities[1][2][3][4][5].,C18H26N2O4,DMSO : ≥ 65 mg/mL (194.37 mM),10mM,Cancer; Endocrinology; Neurological Disease,Launched,O=C(O)CCC(NC(C1=CC=CC=C1)=O)C(N(CCC)CCC)=O
,,,,,,,,,,,,,,,,annexin v,nac,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,annexin v,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
,,,,,,,,,,,,,,,,iκb,bay 11 7082,HY-L025-35,A11,HY-13453,BAY 11-7082,BAY 11-7821,19542-67-7,207.25,Apoptosis; Autophagy; Deubiquitinase; IKK; NF-κB,Apoptosis; Autophagy; Cell Cycle/DNA Damage; NF-κB,"BAY 11-7082 is an IκBα phosphorylation and NF-κB inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC50=0.19, 0.96 μM, respectively). BAY 11-7082 inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells[1][2][3][4][5].",C10H9NO2S,DMSO : ≥ 100 mg/mL (482.51 mM),10mM,Cancer; Inflammation/Immunology,No Development Reported,N#C/C=C/S(=O)(C1=CC=C(C)C=C1)=O
,,,,,,,,,,,,,,,,iκb,apigenin,HY-L025-77,B10,HY-N1201,Apigenin,"4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1",520-36-5,270.24,Autophagy; Cytochrome P450; Endogenous Metabolite,Autophagy; Metabolic Enzyme/Protease,"Apigenin (4',5,7-Trihydroxyflavone) is a competitive CYP2C9 inhibitor with a Ki of 2 μM.",C15H10O5,DMSO : 83.33 mg/mL (308.36 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=CC2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,iκb,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,iκb,bortezomib,HY-L025-7,E07,HY-10227,Bortezomib,PS-341; LDP-341; NSC 681239,179324-69-7,384.24,Apoptosis; Autophagy; NF-κB; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].",C19H25BN4O4,DMSO : 50 mg/mL (130.13 mM; Need ultrasonic); Ethanol : 66.67 mg/mL (173.51 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
,,,,,,,,,,,,,,,,iκb,dha,HY-L025-71,C06,HY-B2167,Docosahexaenoic acid,DHA; Cervonic acid,6217-54-5,328.49,Endogenous Metabolite,Metabolic Enzyme/Protease,Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk.,C22H32O2,Ethanol : 50 mg/mL (152.21 mM; Need ultrasonic); DMSO : 100 mg/mL (304.42 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(O)=O
,,,,,,,,,,,,,,,,iκb,bms 345541,HY-L025-10,E09,HY-10519,BMS-345541,,445430-58-0,255.32,IKK,NF-κB,"BMS-345541 is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC50=0.3 μM, IKK-1 IC50=4 μM). BMS-345541 binds at an allosteric site of IKK.",C14H17N5,DMSO : 10 mg/mL (39.17 mM; Need ultrasonic); H2O : 10 mg/mL (39.17 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,No Development Reported,CC1=CN=C2C(NCCN)=NC3=CC=C(C)C=C3N21
,,,,,,,,,,,,,,,,iκb,wogonin,HY-L025-74,B09,HY-N0400,Wogonin,,632-85-9,284.26,Apoptosis; Autophagy; CDK; Wnt,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Stem Cell/Wnt,"Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.",C16H12O5,DMSO : 62.5 mg/mL (219.87 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,No Development Reported,O=C1C=C(C2=CC=CC=C2)OC3=C(OC)C(O)=CC(O)=C13
,,,,,,,,,,,,,,,,iκb,parthenolide,HY-L025-72,E10,HY-N0141,Parthenolide,(-)-Parthenolide,20554-84-1,248.32,Apoptosis; Autophagy; Mitophagy; NF-κB,Apoptosis; Autophagy; NF-κB,Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting NF-κB activation; also inhibits HDAC1 protein without affecting other class I/II HDACs.,C15H20O3,H2O : < 0.1 mg/mL (insoluble); DMSO : ≥ 100 mg/mL (402.71 mM),10mM,Cancer,Phase 2,C/C1=C\CC[C@@](C)(O2)[C@H]2[C@@H](OC(C3=C)=O)[C@H]3CC1
,,,,,,,,,,,,,,,,iκb,celastrol,HY-L025-32,A08,HY-13067,Celastrol,Tripterine; Tripterin,34157-83-0,450.61,Apoptosis; Autophagy; Endogenous Metabolite; Mitophagy; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease,Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.,C29H38O4,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 33.33 mg/mL (73.97 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C(C2=CC=C3[C@](C)([C@]4(CC[C@]3(C2=CC1=O)C)C)CC[C@@]5(C)CC[C@@](C(O)=O)(C[C@]54[H])C)C
,,,,,,,,,,,,,,,,iκb,cos,HY-L025-17,A08,HY-112108,Chitosan oligosaccharide,COS,148411-57-8,N/A,AMPK; Endogenous Metabolite,Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,Chitosan oligosaccharide (COS) is an oligomer of β-(1→4)-linked D-glucosamine. Chitosan oligosaccharide (COS) activates AMPK and inhibits inflammatory signaling pathways including NF-κB and MAPK pathways.,N/A,DMSO : 50 mg/mL (Need ultrasonic); H2O : 50 mg/mL (Need ultrasonic),3mg/mL,Cancer; Metabolic Disease,No Development Reported,[Chitosan oligosaccharide]
,,,,,,,,,,,,,,,,iκb,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,iκb,deguelin,HY-L025-34,H04,HY-13425,Deguelin,(-)-Deguelin; (-)-cis-Deguelin,522-17-8,394.42,Akt; Apoptosis; Autophagy,Apoptosis; Autophagy; PI3K/Akt/mTOR,"Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.",C23H22O6,DMSO : 100 mg/mL (253.54 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1[C@]2([H])[C@](COC3=CC(OC)=C(OC)C=C32)([H])OC4=C5C=CC(C)(C)OC5=CC=C14
,,,,,,,,,,,,,,,,nfκb,wogonin,HY-L025-74,B09,HY-N0400,Wogonin,,632-85-9,284.26,Apoptosis; Autophagy; CDK; Wnt,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Stem Cell/Wnt,"Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.",C16H12O5,DMSO : 62.5 mg/mL (219.87 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,No Development Reported,O=C1C=C(C2=CC=CC=C2)OC3=C(OC)C(O)=CC(O)=C13
,,,,,,,,,,,,,,,,nfκb,thalidomide,HY-L025-46,C10,HY-14658,Thalidomide,,50-35-1,258.23,Apoptosis; Autophagy; Bacterial; Ligands for E3 Ligase; Molecular Glues,Anti-infection; Apoptosis; Autophagy; PROTAC,"Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ～250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties. Thalidomide can work as molecular glue to potentiate substrate.",C13H10N2O4,DMSO : 150 mg/mL (580.88 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Launched,O=C1N(C2CCC(NC2=O)=O)C(C3=CC=CC=C31)=O
,,,,,,,,,,,,,,,,nfκb,luteolin,HY-L025-72,G06,HY-N0162,Luteolin,Luteoline; Luteolol; Digitoflavone,491-70-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Keap1-Nrf2,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells[1][2][3].",C15H10O6,DMSO : ≥ 100 mg/mL (349.36 mM),10mM,Cancer; Inflammation/Immunology,Phase 2,O=C1C=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13
,,,,,,,,,,,,,,,,nfκb,baicalein,HY-L025-73,B02,HY-N0196,Baicalein,"5,6,7-Trihydroxyflavone",491-67-8,270.24,Ferroptosis; Influenza Virus; Xanthine Oxidase,Anti-infection; Apoptosis; Metabolic Enzyme/Protease,"Baicalein (5,6,7-Trihydroxyflavone) is a xanthine oxidase inhibitor with an IC50 value of 3.12 μM.",C15H10O5,DMSO : 50 mg/mL (185.02 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1C=C(C2=CC=CC=C2)OC3=CC(O)=C(O)C(O)=C13
,,,,,,,,,,,,,,,,nfκb,bay 11 7085,HY-L025-7,G03,HY-10257,BAY 11-7085,BAY 11-7083,196309-76-9,249.33,Apoptosis; Ferroptosis; NF-κB,Apoptosis; NF-κB,BAY 11-7085 (BAY 11-7083) is an inhibitor of NF-κB activation and phosphorylation of IκBα; it stabilizes IκBα with an IC50 of 10 μM[1].,C13H15NO2S,DMSO : ≥ 26 mg/mL (104.28 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,No Development Reported,N#C/C=C/S(C(C=C1)=CC=C1C(C)(C)C)(=O)=O
,,,,,,,,,,,,,,,,nfκb,17 dmag,HY-L025-22,D08,HY-12024,Alvespimycin (hydrochloride),17-DMAG (hydrochloride); KOS-1022; BMS 826476,467214-21-7,653.21,Apoptosis; HSP,Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Alvespimycin hydrochloride (17-DMAG hydrochloride; KOS-1022; BMS 826476) is a potent inhibitor of Hsp90, binding to Hsp90 with EC50 of 62±29 nM.",C32H49ClN4O8,H2O : 4.76 mg/mL (7.29 mM; ultrasonic and warming and heat to 60°C); DMSO : ≥ 50 mg/mL (76.55 mM),10mM,Cancer,Phase 2,C/C1=C\C=C/[C@@H]([C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](CC(C(C(NC1=O)=CC2=O)=O)=C2NCCN(C)C)C)OC)O[H])C)OC(N)=O)OC.Cl
,,,,,,,,,,,,,,,,nfκb,rutin,HY-L025-84,H04,HY-W013075,Rutin (trihydrate),Rutoside (trihydrate); Quercetin 3-O-rutinoside (trihydrate),250249-75-3,664.56,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"Rutin (Rutoside) trihydrate is a multifunctional natural flavonoid glycoside. Rutin trihydrate has been demonstrating excellent antioxidant, anti-inflammatory, anti-diabetic, and anti-carcinogenic properties. Cardioprotective and neuroprotective activities [1][2][3].",C27H36O19,DMSO : 50 mg/mL (75.24 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,O=C1C(O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO[C@H]3[C@@H]([C@@H]([C@H]([C@H](C)O3)O)O)O)O2)O)O)O)=C(C4=CC=C(O)C(O)=C4)OC5=CC(O)=CC(O)=C15.O.O.O
,,,,,,,,,,,,,,,,nfκb,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,nfκb,fty720,HY-L025-22,A09,HY-12005,Fingolimod (hydrochloride),FTY720,162359-56-0,343.93,LPL Receptor; PAK,Cell Cycle/DNA Damage; Cytoskeleton; GPCR/G Protein,"Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate (S1P) receptors modulator. Fingolimod hydrochloride is phosphorylated  by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5. Fingolimod hydrochloride induces the internalization of S1P1, and consequently, inhibits S1P activity. Fingolimod hydrochloride also is a pak1 activator[1][4].",C19H34ClNO2,DMSO : ≥ 100 mg/mL (290.76 mM); H2O : 50 mg/mL (145.38 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Launched,OCC(N)(CO)CCC1=CC=C(C=C1)CCCCCCCC.[H]Cl
,,,,,,,,,,,,,,,,nfκb,inulin,HY-L025-81,H04,HY-N7075,Inulin,,9005-80-5,N/A,Endogenous Metabolite,Metabolic Enzyme/Protease,"Inulin is a storage polysaccharide and belongs to a group of non-digestible carbohydrates, fructan. Inulin is from  plants of the Compositae and Lilialiaceaes families, often used as a prebiotic, fat replacer, sugar replacer, texture modifier, plays beneficial role in gastric [1].",N/A,DMSO : 100 mg/mL (Need ultrasonic); H2O : ≥ 50 mg/mL,3mg/mL,Metabolic Disease; Cancer,Launched,[Inulin]
,,,,,,,,,,,,,,,,nfκb,salubrinal,HY-L025-52,D06,HY-15486,Salubrinal,,405060-95-9,479.8,Apoptosis; Autophagy; HSV; Phosphatase,Anti-infection; Apoptosis; Autophagy; Metabolic Enzyme/Protease,Salubrinal is a cell-permeable and selective inhibitor of eIF2α dephosphorylation[1]. Salubrinal acts as a dual-specificity phosphatase 2 (Dusp2) inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis[2]. Salubrinal has antiviral activity against HSV-1 and inhibits dephosphorylation of eIF2α mediated by the HSV-1 protein ICP34.5[3].,C21H17Cl3N4OS,DMSO : 50 mg/mL (104.21 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,No Development Reported,O=C(NC(NC(NC1=CC=CC2=C1N=CC=C2)=S)C(Cl)(Cl)Cl)/C=C/C3=CC=CC=C3
,,,,,,,,,,,,,,,,nfκb,nac,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,nfκb,n acetylcysteine,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,nfκb,pevonedistat,HY-L025-64,F09,HY-70062,Pevonedistat,MLN4924,905579-51-3,443.52,NEDD8-activating Enzyme,Metabolic Enzyme/Protease,Pevonedistat (MLN4924) is a potent and selective NEDD8-activating enzyme (NAE) inhibitor with an IC50 of 4.7 nM[1].,C21H25N5O4S,DMSO : 62.5 mg/mL (140.92 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=S(OC[C@@H]1C[C@@H](N2C3=NC=NC(N[C@H]4CCC5=C4C=CC=C5)=C3C=C2)C[C@@H]1O)(N)=O
,,,,,,,,,,,,,,,,nfκb,aspirin,HY-L025-46,C07,HY-14654,Aspirin,Acetylsalicylic Acid; ASA,50-78-2,180.16,Apoptosis; Autophagy; Caspase; COX; Mitophagy; NF-κB; p38 MAPK; Virus Protease,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB,"Aspirin (Acetylsalicylic Acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis[1][2][3][4][5][6].",C9H8O4,DMSO : 400 mg/mL (2220.25 mM; Need ultrasonic); H2O : 0.1 mg/mL (0.56 mM; Need ultrasonic),10mM,Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease,Launched,OC(C1=C(OC(C)=O)C=CC=C1)=O
,,,,,,,,,,,,,,,,nfκb,mln4924,HY-L025-64,F09,HY-70062,Pevonedistat,MLN4924,905579-51-3,443.52,NEDD8-activating Enzyme,Metabolic Enzyme/Protease,Pevonedistat (MLN4924) is a potent and selective NEDD8-activating enzyme (NAE) inhibitor with an IC50 of 4.7 nM[1].,C21H25N5O4S,DMSO : 62.5 mg/mL (140.92 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=S(OC[C@@H]1C[C@@H](N2C3=NC=NC(N[C@H]4CCC5=C4C=CC=C5)=C3C=C2)C[C@@H]1O)(N)=O
,,,,,,,,,,,,,,,,wnt β catenin,wogonin,HY-L025-74,B09,HY-N0400,Wogonin,,632-85-9,284.26,Apoptosis; Autophagy; CDK; Wnt,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Stem Cell/Wnt,"Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.",C16H12O5,DMSO : 62.5 mg/mL (219.87 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,No Development Reported,O=C1C=C(C2=CC=CC=C2)OC3=C(OC)C(O)=CC(O)=C13
,,,,,,,,,,,,,,,,wnt β catenin,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,wnt β catenin,sulindac,HY-L025-66,A03,HY-B0008,Sulindac,MK-231,38194-50-2,356.41,NF-κB; PD-1/PD-L1,Immunology/Inflammation; NF-κB,"Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer[1][2].",C20H17FO3S,DMSO : 50 mg/mL (140.29 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,Launched,O=C(CC(C1=C2C=CC(F)=C1)=C(/C2=C/C3=CC=C(C=C3)S(C)=O)C)O
,,,,,,,,,,,,,,,,wnt β catenin,pnu 74654,HY-L025-4,H05,HY-101130,PNU-74654,,113906-27-7,320.34,Apoptosis; Wnt; β-catenin,Apoptosis; Stem Cell/Wnt,PNU-74654 is an inhibitor of Wnt/β-catenin pathway with an IC50 of 129.8 μM in NCI-H295 cell. ,C19H16N2O3,DMSO : ≥ 30 mg/mL (93.65 mM),10mM,Cancer,No Development Reported,O=C(N/N=C/C1=CC=C(C)O1)C2=CC=CC=C2OC3=CC=CC=C3
,,,,,,,,,,,,,,,,wnt β catenin,cardamonin,HY-L025-73,F05,HY-N0279,Cardamonin,Cardamomin; Alpinetin chalcone,18956-16-6,270.28,Apoptosis; Bcl-2 Family; NF-κB; STAT; Wnt; β-catenin,Apoptosis; JAK/STAT Signaling; NF-κB; Stem Cell/Wnt,"Cardamonin can be found from cardamom, and target various signaling molecules, transcriptional factors, cytokines and enzymes. Cardamonin can inhibit mTOR, NF-κB, Akt, STAT3, Wnt/β-catenin and COX-2. Cardamonin shows anticancer, anti-inflammatory, antimicrobial and antidiabetic activities[1][2].",C16H14O4,DMSO : 125 mg/mL (462.48 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease,No Development Reported,O=C(C1=C(OC)C=C(O)C=C1O)/C=C/C2=CC=CC=C2
,,,,,,,,,,,,,,,,wnt β catenin,g007 lk,HY-L025-26,F03,HY-12438,G007-LK,,1380672-07-0,529.96,PARP,Cell Cycle/DNA Damage; Epigenetics,"G007-LK is a potent and selective inhibitor of TNKS1 and TNKS2, with IC50s of 46 nM and 25 nM, respectively.",C25H16ClN7O3S,DMSO : ≥ 30 mg/mL (56.61 mM),10mM,Cancer,No Development Reported,ClC1=C(C=CC=C1)N2C(/C=C/C3=NN=C(C4=CC=C(C#N)C=C4)O3)=NN=C2C5=CC=C(S(C)(=O)=O)C=N5
,,,,,,,,,,,,,,,,wnt β catenin,regorafenib,HY-L025-34,C03,HY-13308,Regorafenib (Hydrochloride),BAY 73-4506 (hydrochloride),835621-07-3,519.28,Autophagy; PDGFR; Raf; RET; VEGFR,Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[1].",C21H16Cl2F4N4O3,DMSO : ≥ 5.6 mg/mL (10.78 mM); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,ClC1=C(C(F)(F)F)C=C(NC(NC2=C(F)C=C(OC3=CC=NC(C(NC)=O)=C3)C=C2)=O)C=C1.Cl
,,,,,,,,,,,,,,,,wnt β catenin,emodin,HY-L025-43,G03,HY-14393,Emodin,Frangula emodin,518-82-1,270.24,11β-HSD; Autophagy; Casein Kinase; SARS-CoV,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively.  Emodin ameliorates metabolic disorder in diet-induced obese mice[3].",C15H10O5,Acetone : 10.87 mg/mL (40.22 mM; Need ultrasonic); DMSO : 5.41 mg/mL (20.02 mM; Need ultrasonic); Ethanol : 10.87 mg/mL (40.22 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C(C=C(C)C=C2O)C(C3=CC(O)=CC(O)=C31)=O
,,,,,,,,,,,,,,,,wnt β catenin,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,wnt β catenin,niclosamide,HY-L025-68,E03,HY-B0497,Niclosamide,BAY2353,50-65-7,327.12,Antibiotic; Parasite; STAT,Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt,"Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells[2][3][5].",C13H8Cl2N2O4,DMSO : 4.55 mg/mL (13.91 mM; Need ultrasonic); DMF : 5 mg/mL (15.28 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Infection; Cancer,Launched,O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2O
,,,,,,,,,,,,,,,,wnt β catenin,propofol,HY-L025-69,B04,HY-B0649,Propofol,"2,6-Diisopropylphenol",2078-54-8,178.27,Endogenous Metabolite; GABA Receptor,Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling,Propofol potently and directly activates GABAA receptor and inhibits glutamate receptor mediated excitatory synaptic transmission. Propofol has antinociceptive properties and is used for sedation and hypnotic[1].,C12H18O,DMSO : 100 mg/mL (560.95 mM; Need ultrasonic); H2O : 0.5 mg/mL (2.80 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,OC1=C(C(C)C)C=CC=C1C(C)C
,,,,,,,,,,,,,,,,akt1,kaempferol,HY-L025-45,F09,HY-14590,Kaempferol,Kempferol; Robigenin,520-18-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Estrogen Receptor/ERR; HIV; Mitophagy; Parasite,Anti-infection; Apoptosis; Autophagy; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer[1][2][3][4].",C15H10O6,DMSO : ≥ 32 mg/mL (111.79 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=C(O)C2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,akt1,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,akt1,mk 2206,HY-L025-9,B02,HY-10358,MK-2206 (dihydrochloride),MK-2206 (2HCl),1032350-13-2,480.39,Akt; Apoptosis; Autophagy,Apoptosis; Autophagy; PI3K/Akt/mTOR,"MK-2206 dihydrochloride (MK-2206 (2HCl)) is an orally active allosteric AKT inhibitor with IC50s of 5 nM, 12 nM, and 65 nM for AKT1, AKT2, and AKT3, respectively. MK-2206 dihydrochloride induces autophagy[1][3].",C25H23Cl2N5O,DMSO : 50 mg/mL (104.08 mM; ultrasonic and warming and heat to 60°C); H2O : 3.57 mg/mL (7.43 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=C1N2C(C3=CC(C4=CC=CC=C4)=C(N=C3C=C2)C5=CC=C(C6(N)CCC6)C=C5)=NN1.Cl.Cl
,,,,,,,,,,,,,,,,akt1,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,akt1,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,akt1,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
,,,,,,,,,,,,,,,,akt1,a 674563,HY-L025-33,E04,HY-13254A,A-674563 (hydrochloride),,2070009-66-2,394.9,Akt,PI3K/Akt/mTOR,A-674563 hydrochloride is a potent and selective Akt1 inhibitor with Ki of 11 nM.,C22H23ClN4O,DMSO : 62.5 mg/mL (158.27 mM; Need ultrasonic); H2O : 100 mg/mL (253.23 mM; Need ultrasonic),10mM,Cancer,No Development Reported,N[C@@H](CC1=CC=CC=C1)COC2=CC(C3=CC4=C(C=C3)NN=C4C)=CN=C2.[H]Cl
,,,,,,,,,,,,,,,,akt1,wortmannin,HY-L025-6,H04,HY-10197,Wortmannin,SL-2052; KY-12420,19545-26-7,428.43,Antibiotic; Autophagy; PI3K; Polo-like Kinase (PLK),Anti-infection; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively[1][2][3].",C23H24O8,DMSO : ≥ 50 mg/mL (116.71 mM),10mM,Cancer,No Development Reported,O=C1C([C@@](CC2)([H])[C@@]3(C)C2=O)=C([C@H](OC(C)=O)C3)[C@]4(C)C5=C1OC=C5C(O[C@@H]4COC)=O
,,,,,,,,,,,,,,,,akt1,dioscin,HY-L025-72,E02,HY-N0124,Dioscin,Collettiside III; CCRIS 4123,19057-60-4,869.04,Apoptosis; Autophagy,Apoptosis; Autophagy,"Dioscin(CCRIS 4123; Collettiside III) is a natural steroid saponin derived from several plants, showing potent anti-cancer effect against a variety of tumor cell lines. 
IC50 value:
Target: Anticancer agent
in vitro: dioscin (1, 2 and 4 μmol/L) could significantly inhibit the viability of LNCaP cells in a time- and concentration-dependent manner. Flow cytometry revealed that the apoptosis rate was increased after treatment of LNCaP cells with dioscin for 24 h, indicating that apoptosis was an important mechanism by which dioscin inhibited cancer [1]. dioscin abrogated AKT phosphorylation, which subsequently impaired RANKL-induced nuclear factor-kappaB (NF-κB) signaling pathway and inhibited NFATc1 transcriptional activity. Moreover, in vivo studies further verified the bone protection activity of dioscin in osteolytic animal model [2]. Dioscin reduced cell death and lactate dehydrogenase (LDH) release in cells subjected to I/R. I/R induced apoptosis and cytochrome c release from mitochondria to the cytosol and this was prevented by dioscin. In support, dioscin decreased Bax but increased Bcl-2 mRNA expression. Dioscin prevented I/R induced dissipation of ΔΨm [3].",C45H72O16,DMSO : ≥ 100 mg/mL (115.07 mM),10mM,Cancer,Launched,O[C@@H]1[C@@H](O)[C@H](C)O[C@@]([H])(O[C@H]2[C@H](O)[C@@H](O[C@]3([H])O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@](O[C@@H]4CC5=CC[C@]([C@]([H])(C[C@@]6([H])[C@]7([H])[C@H](C)[C@]8(OC[C@H](C)CC8)O6)[C@]7(C)CC9)([H])[C@@]9([H])[C@@]5(C)CC4)([H])O[C@@H]2CO)[C@@H]1O
,,,,,,,,,,,,,,,,akt1,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,p akt,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,p akt,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
,,,,,,,,,,,,,,,,p akt,y 27632,HY-L025-10,H04,HY-10583,Y-27632 (dihydrochloride),,129830-38-2,320.26,ROCK,Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad,Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor (ROCK-I Ki=220 nM; ROCK-II Ki=300 nM). Y-27632 dihydrochloride shows antiepileptic effects[1][2][3][4].,C14H23Cl2N3O,DMSO : 33.33 mg/mL (104.07 mM; Need ultrasonic); H2O : 100 mg/mL (312.25 mM; Need ultrasonic),10mM,Cancer; Neurological Disease,No Development Reported,O=C([C@@H]1CC[C@]([C@H](N)C)([H])CC1)NC2=CC=NC=C2.[H]Cl.[H]Cl
,,,,,,,,,,,,,,,,p akt,shikonin,HY-L025-76,E10,HY-N0822,Shikonin,C.I. 75535; Isoarnebin 4,517-89-5,288.3,AIM2; Chloride Channel; HIV; NF-κB; Pyruvate Kinase; TNF Receptor,Anti-infection; Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; NF-κB,Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM[1]. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor[2] and can also inhibit TNF-α and NF-κB pathway[3]. Shikonin decreases exosome secretion through the inhibition of glycolysis[4]. Shikonin inhibits AIM2 inflammasome activation[7].,C16H16O5,DMSO : 25 mg/mL (86.72 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,No Development Reported,O=C1C([C@H](O)C/C=C(C)/C)=CC(C2=C1C(O)=CC=C2O)=O
,,,,,,,,,,,,,,,,p akt,5 fu,HY-L025-65,C06,HY-90006,5-Fluorouracil,5-FU,51-21-8,130.08,Apoptosis; Endogenous Metabolite; HIV; Nucleoside Antimetabolite/Analog,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil induces apoptosis and can be used as a chemical sensitizer[1][2]. 5-Fluorouracil also inhibits HIV[3].,C4H3FN2O2,DMSO : 50 mg/mL (384.38 mM; Need ultrasonic); H2O : 16.67 mg/mL (128.15 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(N1)NC=C(F)C1=O
,,,,,,,,,,,,,,,,p akt,celecoxib,HY-L025-43,G07,HY-14398,Celecoxib,SC 58635,169590-42-5,381.37,COX,Immunology/Inflammation,"Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.",C17H14F3N3O2S,DMSO : ≥ 50 mg/mL (131.11 mM),10mM,Inflammation/Immunology; Cancer,Launched,CC1=CC=C(C=C1)C2=CC(C(F)(F)F)=NN2C3=CC=C(C=C3)S(=O)(N)=O
,,,,,,,,,,,,,,,,p akt,luteolin,HY-L025-72,G06,HY-N0162,Luteolin,Luteoline; Luteolol; Digitoflavone,491-70-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Keap1-Nrf2,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells[1][2][3].",C15H10O6,DMSO : ≥ 100 mg/mL (349.36 mM),10mM,Cancer; Inflammation/Immunology,Phase 2,O=C1C=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13
,,,,,,,,,,,,,,,,p akt,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,p akt,dasatinib,HY-L025-6,D08,HY-10181B,Dasatinib (monohydrate),BMS-354825 (monohydrate),863127-77-9,506.02,Apoptosis; Autophagy; Bcr-Abl; Src,Apoptosis; Autophagy; Protein Tyrosine Kinase/RTK,"Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively.  Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively[1]. Dasatinib monohydrate also induces apoptosis and autophagy.",C22H28ClN7O3S,10 mM in DMSO,10mM,Cancer,Launched,O=C(C1=CN=C(NC2=NC(C)=NC(N3CCN(CCO)CC3)=C2)S1)NC4=C(C)C=CC=C4Cl.[H]O[H]
,,,,,,,,,,,,,,,,p akt,paclitaxel,HY-L025-66,A07,HY-B0015,Paclitaxel,,33069-62-4,853.91,ADC Cytotoxin; Apoptosis; Autophagy; Microtubule/Tubulin,Antibody-drug Conjugate/ADC Related; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton,Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy[1][2].,C47H51NO14,H2O : < 0.1 mg/mL (insoluble); DMSO : 100 mg/mL (117.11 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=CC=CC=C1)N[C@@H](C2=CC=CC=C2)[C@H](C(O[C@@H]3C(C)=C([C@@H](OC(C)=O)C([C@@]4(C)[C@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]4O)([H])[C@@H]6OC(C7=CC=CC=C7)=O)=O)C(C)(C)[C@@]6(O)C3)=O)O
,,,,,,,,,,,,,,,,p akt,gemcitabine,HY-L025-65,H10,HY-B0003,Gemcitabine (hydrochloride),LY 188011 (hydrochloride),122111-03-9,299.66,Apoptosis; Autophagy; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog,Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[1][2].",C9H12ClF2N3O4,H2O : 33.33 mg/mL (111.23 mM; Need ultrasonic); DMSO : 25 mg/mL (83.43 mM; ultrasonic and warming and heat to 60°C); DMF : 2.5 mg/mL (8.34 mM; Need ultrasonic),10mM,Cancer,Launched,O[C@H]1C(F)(F)[C@H](N2C(N=C(N)C=C2)=O)O[C@@H]1CO.Cl
,,,,,,,,,,,,,,,,p akt,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,p akt,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,p akt,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,p akt,wortmannin,HY-L025-6,H04,HY-10197,Wortmannin,SL-2052; KY-12420,19545-26-7,428.43,Antibiotic; Autophagy; PI3K; Polo-like Kinase (PLK),Anti-infection; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively[1][2][3].",C23H24O8,DMSO : ≥ 50 mg/mL (116.71 mM),10mM,Cancer,No Development Reported,O=C1C([C@@](CC2)([H])[C@@]3(C)C2=O)=C([C@H](OC(C)=O)C3)[C@]4(C)C5=C1OC=C5C(O[C@@H]4COC)=O
,,,,,,,,,,,,,,,,p akt,sorafenib,HY-L025-7,A11,HY-10201A,Sorafenib (Tosylate),Bay 43-9006 (Tosylate),475207-59-1,637.03,Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR,Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator[1].",C28H24ClF3N4O6S,H2O : < 0.1 mg/mL (insoluble); DMSO : ≥ 31 mg/mL (48.66 mM),10mM,Cancer,Launched,O=S(C1=CC=C(C=C1)C)(O)=O.O=C(NC2=CC=C(C(C(F)(F)F)=C2)Cl)NC3=CC=C(OC4=CC(C(NC)=O)=NC=C4)C=C3
,,,,,,,,,,,,,,,,p akt,gefitinib,HY-L025-64,B07,HY-50895A,Gefitinib (hydrochloride),ZD-1839 hydrochloride,184475-55-6,483.36,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Gefitinib hydrochloride (ZD1839 hydrochloride) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib hydrochloride selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib hydrochloride also induces autophagy. Gefitinib hydrochloride has antitumour activity[1][2].",C22H25Cl2FN4O3,DMSO : 0.227 mg/mL (0.47 mM; Need ultrasonic and warming); H2O : 6.25 mg/mL (12.93 mM; Need ultrasonic),10mM,Cancer,Launched,ClC1=C(C=CC(NC2=NC=NC3=C2C=C(C(OC)=C3)OCCCN4CCOCC4)=C1)F.[H]Cl
,,,,,,,,,,,,,,,,p akt,matrine,HY-L025-72,G08,HY-N0164,Matrine,Matridin-15-one; Vegard; α-Matrine,519-02-8,248.36,Apoptosis; Autophagy; Ferroptosis; Mitophagy; Opioid Receptor,Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling,"Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI)[1][2][3][4][5].",C15H24N2O,H2O : 20 mg/mL (80.53 mM; Need ultrasonic); DMSO : ≥ 50 mg/mL (201.32 mM),10mM,Cancer; Inflammation/Immunology,Launched,O=C1CCC[C@]2([H])[C@@]3([H])CCCN4[C@@]3([H])[C@](CCC4)([H])CN21
,,,,,,,,,,,,,,,,p27,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,p27,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,p27,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,p27,silibinin,HY-L025-76,C08,HY-N0779A,Silybin,Silibinin,802918-57-6,482.44,Apoptosis,Apoptosis,"Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds. Silybin induces apoptosis and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity[1][2].",C25H22O10,DMSO : 25 mg/mL (51.82 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C1[C@H](O)[C@@H](C2=CC=C(OC(CO)C(C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15
,,,,,,,,,,,,,,,,p27,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,p27,berberine,HY-L025-59,B09,HY-18258,Berberine (chloride),Natural Yellow 18 (chloride),633-65-8,371.81,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; Parasite; Reactive Oxygen Species; Topoisomerase,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,Berberine chloride is an alkaloid that acts as an antibiotic. Berberine chloride induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties[1].,C20H18ClNO4,DMSO : 12.5 mg/mL (33.62 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Cancer,Launched,COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.[Cl-]
,,,,,,,,,,,,,,,,p27,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,ets,yk 4 279,HY-L025-44,F08,HY-14507,YK-4-279,,1037184-44-3,366.2,Apoptosis; DNA/RNA Synthesis,Apoptosis; Cell Cycle/DNA Damage,YK-4-279 blocks RNA Helicase A (RHA) binding with EWS-FLI1 (oncogenic protein). YK-4-279 induces apoptosis and shows anti-proliferation activities towards various cancer cells. YK-4-279 has a chiral center and it can be separated into two enantiomers. YK-4-279 can be used for the research of cancer[1][2].,C17H13Cl2NO4,DMSO : 25 mg/mL (68.27 mM; Need ultrasonic),10mM,Cancer,No Development Reported,ClC1=C2C(C(O)(CC(C3=CC=C(OC)C=C3)=O)C(N2)=O)=C(Cl)C=C1
,,,,,,,,,,,,,,,,cdk4,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,cdk4,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
,,,,,,,,,,,,,,,,cdk4,kaempferol,HY-L025-45,F09,HY-14590,Kaempferol,Kempferol; Robigenin,520-18-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Estrogen Receptor/ERR; HIV; Mitophagy; Parasite,Anti-infection; Apoptosis; Autophagy; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer[1][2][3][4].",C15H10O6,DMSO : ≥ 32 mg/mL (111.79 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=C(O)C2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,cdk4,honokiol,HY-L025-71,F02,HY-N0003,Honokiol,NSC 293100,35354-74-6,266.33,Akt; Autophagy; ERK; HCV,Anti-infection; Autophagy; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt,"Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt. Honokiol can readily cross the blood brain barrier[1][2][3][4].",C18H18O2,DMSO : ≥ 50 mg/mL (187.74 mM),10mM,Cancer,Phase 3,OC1=C(CC=C)C=C(C2=CC(CC=C)=CC=C2O)C=C1
,,,,,,,,,,,,,,,,cdk4,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,cdk4,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,cdk4,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,cdk4,magnolol,HY-L025-72,G07,HY-N0163,Magnolol,,528-43-8,266.33,Autophagy; Bacterial; PPAR; RAR/RXR,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both RXRα and PPARγ, with EC50 values of 10.4 μM and 17.7 μM, respectively.",C18H18O2,DMSO : 100 mg/mL (375.47 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease,Launched,OC1=CC=C(CC=C)C=C1C2=CC(CC=C)=CC=C2O
,,,,,,,,,,,,,,,,cdk4,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,cdk4,lee011,HY-L025-54,B09,HY-15777B,Ribociclib succinate,LEE011 (succinate),1374639-75-4,552.63,CDK,Cell Cycle/DNA Damage,"Ribociclib succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.",C27H36N8O5,DMSO : 9.38 mg/mL (16.97 mM; ultrasonic and warming and heat to 60°C); H2O : 4.17 mg/mL (7.55 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(N(C)C)C(N1C2CCCC2)=CC(C1=N3)=CN=C3NC(N=C4)=CC=C4N5CCNCC5.OC(CCC(O)=O)=O
,,,,,,,,,,,,,,,,cdk4,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,cdk4,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
,,,,,,,,,,,,,,,,cdk4,pristimerin,HY-L025-78,A07,HY-N1937,Pristimerin,Celastrol methyl ester,1258-84-0,464.64,Bacterial,Anti-infection,Pristimerin is a potent and reversible monoacylglycerol lipase (MGL) inhibitor with an IC50 of 93 nM.,C30H40O4,DMSO : 20 mg/mL (43.04 mM; Need ultrasonic); DMF : 25 mg/mL (53.81 mM; Need ultrasonic),10mM,Cancer,No Development Reported,C[C@](C1=CC=C(C(C)=C2O)C3=CC2=O)(CC[C@]4(C)[C@@]5([H])C[C@@](C(OC)=O)(C)CC4)[C@]5(CC[C@]13C)C
,,,,,,,,,,,,,,,,cdk4,silibinin,HY-L025-76,C08,HY-N0779A,Silybin,Silibinin,802918-57-6,482.44,Apoptosis,Apoptosis,"Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds. Silybin induces apoptosis and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity[1][2].",C25H22O10,DMSO : 25 mg/mL (51.82 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C1[C@H](O)[C@@H](C2=CC=C(OC(CO)C(C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15
,,,,,,,,,,,,,,,,cdk4,berberine,HY-L025-59,B09,HY-18258,Berberine (chloride),Natural Yellow 18 (chloride),633-65-8,371.81,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; Parasite; Reactive Oxygen Species; Topoisomerase,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,Berberine chloride is an alkaloid that acts as an antibiotic. Berberine chloride induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties[1].,C20H18ClNO4,DMSO : 12.5 mg/mL (33.62 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Cancer,Launched,COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.[Cl-]
,,,,,,,,,,,,,,,,nf kb,paeonol,HY-L025-72,G05,HY-N0159,Paeonol,,552-41-0,166.17,Autophagy; Monoamine Oxidase,Autophagy; Neuronal Signaling,"Paeonol is an active extraction from the root of Paeonia suffruticosa, Paeonol inhibits MAO-A and MAO-B with IC50 of 54.6 μM and 42.5 μM, respectively.",C9H10O3,DMSO : ≥ 38 mg/mL (228.68 mM); Ethanol : 50 mg/mL (300.90 mM; Need ultrasonic); H2O : 1 mg/mL (6.02 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,CC(C1=CC=C(OC)C=C1O)=O
,,,,,,,,,,,,,,,,nf kb,n acetylcysteine,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,nf kb,propranolol,HY-L025-68,H05,HY-B0573B,Propranolol,,525-66-6,259.34,Adrenergic Receptor; Bacterial,Anti-infection; GPCR/G Protein; Neuronal Signaling,"Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively[1]. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM[2]. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3].",C16H21NO2,DMSO : 100 mg/mL (385.59 mM; Need ultrasonic),10mM,Neurological Disease; Cardiovascular Disease; Endocrinology; Cancer,Launched,OC(COC1=C2C=CC=CC2=CC=C1)CNC(C)C
,,,,,,,,,,,,,,,,nf kb,dexamethasone,HY-L025-46,B10,HY-14648,Dexamethasone,Hexadecadrol; Prednisolone F,50-02-2,392.46,Antibiotic; Autophagy; Bacterial; Complement System; Glucocorticoid Receptor; Mitophagy; SARS-CoV,Anti-infection; Autophagy; Immunology/Inflammation; Vitamin D Related/Nuclear Receptor,"Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.",C22H29FO5,DMSO : 250 mg/mL (637.01 mM; ultrasonic and warming and heat to 60°C); Ethanol : 8.33 mg/mL (21.23 mM; Need ultrasonic),10mM,Cancer; Infection; Endocrinology; Inflammation/Immunology,Launched,O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@@]4(C(CO)=O)O)=C1
,,,,,,,,,,,,,,,,nf kb,progesterone,HY-L025-74,D04,HY-N0437,Progesterone,"Pregn-4-ene-3,20-dione",57-83-0,314.46,Endogenous Metabolite; Progesterone Receptor,Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,Progesterone is a steroid hormone that regulates the menstrual cycle and is crucial for pregnancy.,C21H30O2,H2O : 0.1 mg/mL (0.32 mM; Need ultrasonic); DMSO : 25 mg/mL (79.50 mM; Need ultrasonic),10mM,Cardiovascular Disease; Cancer,Launched,CC([C@H]1CC[C@@]2([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O)=O
,,,,,,,,,,,,,,,,nf kb,silibinin,HY-L025-76,C08,HY-N0779A,Silybin,Silibinin,802918-57-6,482.44,Apoptosis,Apoptosis,"Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds. Silybin induces apoptosis and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity[1][2].",C25H22O10,DMSO : 25 mg/mL (51.82 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C1[C@H](O)[C@@H](C2=CC=C(OC(CO)C(C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15
,,,,,,,,,,,,,,,,nf kb,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
,,,,,,,,,,,,,,,,nf kb,apocynin,HY-L025-72,B10,HY-N0088,Apocynin,Acetovanillone,498-02-2,166.17,Apoptosis; Autophagy,Apoptosis; Autophagy,Apocynin is a selective NADPH-oxidase inhibitor with an IC50 of 10 μM.,C9H10O3,DMSO : ≥ 100 mg/mL (601.79 mM); H2O : ≥  mg/mL,10mM,Cancer,Phase 1,CC(C1=CC=C(O)C(OC)=C1)=O
,,,,,,,,,,,,,,,,nf kb,caffeic acid phenethyl ester,HY-L025-73,E11,HY-N0274,Caffeic acid phenethyl ester,,104594-70-9,284.31,Apoptosis; NF-κB,Apoptosis; NF-κB,Caffeic acid phenethyl ester is a NF-κB inhibitor.,C17H16O4,DMSO : 100 mg/mL (351.73 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble),10mM,Cancer; Inflammation/Immunology,No Development Reported,O=C(OCCC1=CC=CC=C1)/C=C/C2=CC=C(O)C(O)=C2
,,,,,,,,,,,,,,,,nf kb,nac,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,nf kb,fk506,HY-L025-39,F08,HY-13756A,Tacrolimus (monohydrate),FK506 (monohydrate); Fujimycin (monohydrate); FR900506 (monohydrate),109581-93-3,822.03,Antibiotic; Autophagy; Bacterial; FKBP; Phosphatase,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease,"Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties[1].",C44H71NO13,DMSO : 100 mg/mL (121.65 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C([C@@](CCCC1)([H])N1C(C([C@@]2(O)[C@H](C)C[C@H](OC)[C@@](O2)([H])[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H]3CC=C)=O)=O)O[C@H](/C(C)=C/[C@H]4C[C@@H](OC)[C@H](O)CC4)[C@H](C)[C@@H](O)CC3=O.O
,,,,,,,,,,,,,,,,nf kb,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,nf kb,parthenolide,HY-L025-72,E10,HY-N0141,Parthenolide,(-)-Parthenolide,20554-84-1,248.32,Apoptosis; Autophagy; Mitophagy; NF-κB,Apoptosis; Autophagy; NF-κB,Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting NF-κB activation; also inhibits HDAC1 protein without affecting other class I/II HDACs.,C15H20O3,H2O : < 0.1 mg/mL (insoluble); DMSO : ≥ 100 mg/mL (402.71 mM),10mM,Cancer,Phase 2,C/C1=C\CC[C@@](C)(O2)[C@H]2[C@@H](OC(C3=C)=O)[C@H]3CC1
,,,,,,,,,,,,,,,,bcl2,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,bcl2,e2,HY-L025-66,F04,HY-B0141,Estradiol,β-Estradiol; E2; 17β-Estradiol; 17β-Oestradiol,50-28-2,272.38,Bacterial; Endogenous Metabolite; Estrogen Receptor/ERR,Anti-infection; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Estradiol (β-Estradiol) is a steroid hormone and the major female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering[1][2].",C18H24O2,DMSO : 62.5 mg/mL (229.46 mM; ultrasonic and warming and heat to 60°C); Ethanol : 20 mg/mL (73.43 mM; Need ultrasonic),10mM,Endocrinology; Cancer,Launched,C[C@@]1([C@H]2O)[C@](CC2)([H])[C@@](CCC3=C4C=CC(O)=C3)([H])[C@]4([H])CC1
,,,,,,,,,,,,,,,,bcl2,eugenol,HY-L025-73,H07,HY-N0337,Eugenol,,97-53-0,164.2,Apoptosis; Bacterial; Ferroptosis; Parasite; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Eugenol is an essential oil found in cloves with antibacterial, anthelmintic and antioxidant activity. Eugenol is shown to inhibit lipid peroxidation.",C10H12O2,DMSO : ≥ 100 mg/mL (609.01 mM),10mM,Infection; Inflammation/Immunology; Cancer,Launched,OC1=CC=C(CC=C)C=C1OC
,,,,,,,,,,,,,,,,bcl2,cyclopamine,HY-L025-57,F03,HY-17024,Cyclopamine,11-Deoxojervine,4449-51-8,411.62,Endogenous Metabolite; Hedgehog; Smo,Metabolic Enzyme/Protease; Stem Cell/Wnt,Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay. Cyclopamine is also a selective Smo inhibitor.,C27H41NO2,DMSO : 10 mg/mL (24.29 mM; ultrasonic and warming and heat to 80°C); Ethanol : 20 mg/mL (48.59 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CC1=C2[C@@]([C@@]3([H])[C@]([C@@]4(C(C[C@@H](O)CC4)=CC3)C)([H])C2)([H])CC[C@@]15[C@@H]([C@@]6([H])[C@](C[C@H](C)CN6)([H])O5)C
,,,,,,,,,,,,,,,,bcl2,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
,,,,,,,,,,,,,,,,bcl2,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
,,,,,,,,,,,,,,,,bcl2,propofol,HY-L025-69,B04,HY-B0649,Propofol,"2,6-Diisopropylphenol",2078-54-8,178.27,Endogenous Metabolite; GABA Receptor,Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling,Propofol potently and directly activates GABAA receptor and inhibits glutamate receptor mediated excitatory synaptic transmission. Propofol has antinociceptive properties and is used for sedation and hypnotic[1].,C12H18O,DMSO : 100 mg/mL (560.95 mM; Need ultrasonic); H2O : 0.5 mg/mL (2.80 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,OC1=C(C(C)C)C=CC=C1C(C)C
,,,,,,,,,,,,,,,,bcl2,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,bcl2,rutin,HY-L025-84,H04,HY-W013075,Rutin (trihydrate),Rutoside (trihydrate); Quercetin 3-O-rutinoside (trihydrate),250249-75-3,664.56,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"Rutin (Rutoside) trihydrate is a multifunctional natural flavonoid glycoside. Rutin trihydrate has been demonstrating excellent antioxidant, anti-inflammatory, anti-diabetic, and anti-carcinogenic properties. Cardioprotective and neuroprotective activities [1][2][3].",C27H36O19,DMSO : 50 mg/mL (75.24 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,O=C1C(O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO[C@H]3[C@@H]([C@@H]([C@H]([C@H](C)O3)O)O)O)O2)O)O)O)=C(C4=CC=C(O)C(O)=C4)OC5=CC(O)=CC(O)=C15.O.O.O
,,,,,,,,,,,,,,,,bcl2,paclitaxel,HY-L025-66,A07,HY-B0015,Paclitaxel,,33069-62-4,853.91,ADC Cytotoxin; Apoptosis; Autophagy; Microtubule/Tubulin,Antibody-drug Conjugate/ADC Related; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton,Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy[1][2].,C47H51NO14,H2O : < 0.1 mg/mL (insoluble); DMSO : 100 mg/mL (117.11 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=CC=CC=C1)N[C@@H](C2=CC=CC=C2)[C@H](C(O[C@@H]3C(C)=C([C@@H](OC(C)=O)C([C@@]4(C)[C@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]4O)([H])[C@@H]6OC(C7=CC=CC=C7)=O)=O)C(C)(C)[C@@]6(O)C3)=O)O
,,,,,,,,,,,,,,,,bcl2,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,bcl2,abt 263,HY-L025-4,A02,HY-10087,Navitoclax,ABT-263,923564-51-6,974.61,Bcl-2 Family,Apoptosis,"Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM[1].",C47H55ClF3N5O6S3,DMSO : 75 mg/mL (76.95 mM; Need ultrasonic); DMF : ≥ 100 mg/mL (102.61 mM),10mM,Cancer,Phase 3,O=S(C1=CC(S(NC(C2=CC=C(N3CCN(CC4=C(CCC(C)(C4)C)C5=CC=C(Cl)C=C5)CC3)C=C2)=O)(=O)=O)=CC=C1N[C@H](CCN6CCOCC6)CSC7=CC=CC=C7)(C(F)(F)F)=O
,,,,,,,,,,,,,,,,bcl2,navitoclax,HY-L025-4,A02,HY-10087,Navitoclax,ABT-263,923564-51-6,974.61,Bcl-2 Family,Apoptosis,"Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM[1].",C47H55ClF3N5O6S3,DMSO : 75 mg/mL (76.95 mM; Need ultrasonic); DMF : ≥ 100 mg/mL (102.61 mM),10mM,Cancer,Phase 3,O=S(C1=CC(S(NC(C2=CC=C(N3CCN(CC4=C(CCC(C)(C4)C)C5=CC=C(Cl)C=C5)CC3)C=C2)=O)(=O)=O)=CC=C1N[C@H](CCN6CCOCC6)CSC7=CC=CC=C7)(C(F)(F)F)=O
,,,,,,,,,,,,,,,,bcl2,jq1,HY-L025-31,F06,HY-13030,(+)-JQ-1,JQ1,1268524-70-4,456.99,Autophagy; Epigenetic Reader Domain; Ligands for Target Protein for PROTAC,Autophagy; Epigenetics; PROTAC,"(+)-JQ-1 (JQ1) is a potent, specific, and reversible BET bromodomain inhibitor, with IC50s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2))[1]. (+)-JQ-1 also activates autophagy[2].",C23H25ClN4O2S,DMSO : ≥ 45 mg/mL (98.47 mM),10mM,Cancer,No Development Reported,O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C
,,,,,,,,,,,,,,,,bcl2,apigenin,HY-L025-77,B10,HY-N1201,Apigenin,"4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1",520-36-5,270.24,Autophagy; Cytochrome P450; Endogenous Metabolite,Autophagy; Metabolic Enzyme/Protease,"Apigenin (4',5,7-Trihydroxyflavone) is a competitive CYP2C9 inhibitor with a Ki of 2 μM.",C15H10O5,DMSO : 83.33 mg/mL (308.36 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=CC2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,adp ribose polymerase,niraparib,HY-L025-11,B03,HY-10619E,Niraparib (tosylate hydrate),MK-4827 (tosylate hydrate),1613220-15-7,510.61,Apoptosis; PARP,Apoptosis; Cell Cycle/DNA Damage; Epigenetics,"Niraparib (MK-4827) tosylate hydrate is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib tosylate hydrate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity[1][2][3].",C26H30N4O5S,10 mM in DMSO,10mM,Cancer,Launched,NC(C1=CC=CC2=CN(C3=CC=C([C@H]4CNCCC4)C=C3)N=C21)=O.O=S(C5=CC=C(C)C=C5)(O)=O.O
,,,,,,,,,,,,,,,,adp ribose polymerase,veliparib,HY-L025-5,D08,HY-10130,Veliparib (dihydrochloride),ABT-888 dihydrochloride,912445-05-7,317.21,Autophagy; PARP,Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Veliparib (dihydrochloride) is a potent inhibitor of?PARP1?and?PARP2?with?Kis?of 5.2 nM and 2.9 nM in cell-free assays, respectively.",C13H18Cl2N4O,DMSO : ≥ 3.2 mg/mL (10.09 mM); H2O : 250 mg/mL (788.12 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(C1=C2NC([C@@]3(NCCC3)C)=NC2=CC=C1)N.Cl.Cl
,,,,,,,,,,,,,,,,adp ribose polymerase,rucaparib,HY-L025-11,A08,HY-10617A,Rucaparib,AG014699; PF-01367338,283173-50-2,323.36,PARP,Cell Cycle/DNA Damage; Epigenetics,"Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research[1][2][3][4].",C19H18FN3O,DMSO : 25 mg/mL (77.31 mM; ultrasonic and adjust pH to 4 with HCl); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,FC1=CC2=C3C(CCNC2=O)=C(C4=CC=C(CNC)C=C4)NC3=C1
,,,,,,,,,,,,,,,,adp ribose polymerase,nicotinamide,HY-L025-66,F09,HY-B0150,Nicotinamide,Niacinamide; Nicotinic acid amide,98-92-0,122.12,Endogenous Metabolite; HBV; Sirtuin,Anti-infection; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease,"Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity[1][2][3][4].",C6H6N2O,DMSO : 50 mg/mL (409.43 mM; Need ultrasonic); H2O : ≥ 50 mg/mL (409.43 mM),10mM,Cancer,Launched,O=C(C1=CC=CN=C1)N
,,,,,,,,,,,,,,,,adp ribose polymerase,3 aminobenzamide,HY-L025-22,D06,HY-12022,3-Aminobenzamide,PARP-IN-1,3544-24-9,136.15,PARP,Cell Cycle/DNA Damage; Epigenetics,"3-Aminobenzamide (PARP-IN-1) is a potent inhibitor of?PARP?with?IC50?of appr 50 nM in CHO cells, and acts as a mediator of oxidant-induced myocyte dysfunction during reperfusion.",C7H8N2O,H2O : ≥ 11.11 mg/mL (81.60 mM),10mM,Cancer,No Development Reported,O=C(C1=CC=CC(N)=C1)N
,,,,,,,,,,,,,,,,adp ribose polymerase,olaparib,HY-L025-6,B03,HY-10162,Olaparib,AZD2281; KU0059436,763113-22-0,434.46,Autophagy; Mitophagy; PARP,Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].",C24H23FN4O3,DMSO : 100 mg/mL (230.17 mM; Need ultrasonic); DMF : 50 mg/mL (115.09 mM; Need ultrasonic); Ethanol : 3.12 mg/mL (7.18 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CC(CC(C2=C3C=CC=C2)=NNC3=O)=CC=C1F)N4CCN(C(C5CC5)=O)CC4
,,,,,,,,,,,,,,,,poly adp ribose polymerase,olaparib,HY-L025-6,B03,HY-10162,Olaparib,AZD2281; KU0059436,763113-22-0,434.46,Autophagy; Mitophagy; PARP,Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].",C24H23FN4O3,DMSO : 100 mg/mL (230.17 mM; Need ultrasonic); DMF : 50 mg/mL (115.09 mM; Need ultrasonic); Ethanol : 3.12 mg/mL (7.18 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CC(CC(C2=C3C=CC=C2)=NNC3=O)=CC=C1F)N4CCN(C(C5CC5)=O)CC4
,,,,,,,,,,,,,,,,poly adp ribose polymerase,nicotinic acid amide,HY-L025-66,F09,HY-B0150,Nicotinamide,Niacinamide; Nicotinic acid amide,98-92-0,122.12,Endogenous Metabolite; HBV; Sirtuin,Anti-infection; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease,"Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity[1][2][3][4].",C6H6N2O,DMSO : 50 mg/mL (409.43 mM; Need ultrasonic); H2O : ≥ 50 mg/mL (409.43 mM),10mM,Cancer,Launched,O=C(C1=CC=CN=C1)N
,,,,,,,,,,,,,,,,poly adp ribose polymerase,nac,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,poly adp ribose polymerase,ag14361,HY-L025-22,E06,HY-12032,AG14361,,328543-09-5,320.39,PARP,Cell Cycle/DNA Damage; Epigenetics,"AG14361 is a potent PARP-1 inhibitor, with a Ki of < 5 nM, and in permeabilized SW620 and intact SW620 cells, the IC50s are 29 nM and 14 nM, respectively.",C19H20N4O,DMSO : 10 mg/mL (31.21 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,No Development Reported,O=C1NCCN2C3=C1C=CC=C3N=C2C4=CC=C(C=C4)CN(C)C
,,,,,,,,,,,,,,,,poly adp ribose polymerase,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,poly adp ribose polymerase,n acetylcysteine,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,poly adp ribose polymerase,ino 1001,HY-L025-49,C09,HY-15045,INO-1001,,501364-82-5,439.53,PARP,Cell Cycle/DNA Damage; Epigenetics,"INO-1001 is a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor. INO-1001 is a potent enhancer of radiation sensitivity and enhances radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death[1]. INO-1001 has anti-tumor effects[2].",C23H25N3O4S,DMSO : 31.25 mg/mL (71.10 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1NC2=C(C3=CC=CC=C31)CC4=C2C=CC(S(NCCCN5CCOCC5)(=O)=O)=C4
,,,,,,,,,,,,,,,,poly adp ribose polymerase,abt 888,HY-L025-5,D03,HY-10129,Veliparib,ABT-888,912444-00-9,244.29,Autophagy; PARP,Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively[1].",C13H16N4O,DMSO : ≥ 29 mg/mL (118.71 mM),10mM,Cancer,Phase 3,O=C(C1=C2NC([C@@]3(NCCC3)C)=NC2=CC=C1)N
,,,,,,,,,,,,,,,,poly adp ribose polymerase,nu1025,HY-L025-49,C08,HY-15044,NU1025,,90417-38-2,176.17,PARP,Cell Cycle/DNA Damage; Epigenetics,NU1025 is a potent PARP inhibitor with an IC50 of 400 nM and a Ki of 48 nM. NU1025 potentiates the cytotoxicity of ionizing radiation and anticancer agents. NU1025 has anti-cancer and neuroprotective activity[1][2][3].,C9H8N2O2,DMSO : 125 mg/mL (709.54 mM; Need ultrasonic),10mM,Cancer; Neurological Disease,No Development Reported,OC1=C(N=C(C)NC2=O)C2=CC=C1
,,,,,,,,,,,,,,,,poly adp ribose polymerase,theophylline,HY-L025-69,F08,HY-B0809,Theophylline,"1,3-Dimethylxanthine; Theo-24",58-55-9,180.16,Adenosine Receptor; Apoptosis; Endogenous Metabolite; HDAC; Interleukin Related; Phosphodiesterase (PDE); TNF Receptor,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease,"Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research[1][2][3][4][5].",C7H8N4O2,H2O : 5 mg/mL (27.75 mM; Need ultrasonic); DMSO : 11.11 mg/mL (61.67 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(N1C)N(C)C2=C(N=CN2)C1=O
,,,,,,,,,,,,,,,,poly adp ribose polymerase,thymidine,HY-L025-77,B08,HY-N1150,Thymidine,DThyd; NSC 21548,50-89-5,242.23,DNA/RNA Synthesis; Endogenous Metabolite; Orthopoxvirus,Anti-infection; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Thymidine, a specific precursor of deoxyribonucleic acid, is used as a cell synchronizing agent. Thymidine is a DNA synthesis inhibitor that can arrest cell at G1/S boundary, prior to DNA replication[1][2][3].",C10H14N2O5,DMSO : 50 mg/mL (206.42 mM; Need ultrasonic); H2O : 33.33 mg/mL (137.60 mM; Need ultrasonic),10mM,Cancer,Phase 2,O[C@H]1C[C@H](N2C(NC(C(C)=C2)=O)=O)O[C@@H]1CO
,,,,,,,,,,,,,,,,poly adp ribose polymerase,talazoparib,HY-L025-55,D10,HY-16106,Talazoparib,BMN-673; LT-673,1207456-01-6,380.35,PARP,Cell Cycle/DNA Damage; Epigenetics,"Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity[1].",C19H14F2N6O,DMSO : 25 mg/mL (65.73 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1NN=C2C3=C1C=C(F)C=C3N[C@H](C4=CC=C(F)C=C4)[C@H]2C5=NC=NN5C
,,,,,,,,,,,,,,,,poly adp ribose polymerase,rucaparib,HY-L025-11,A08,HY-10617A,Rucaparib,AG014699; PF-01367338,283173-50-2,323.36,PARP,Cell Cycle/DNA Damage; Epigenetics,"Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research[1][2][3][4].",C19H18FN3O,DMSO : 25 mg/mL (77.31 mM; ultrasonic and adjust pH to 4 with HCl); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,FC1=CC2=C3C(CCNC2=O)=C(C4=CC=C(CNC)C=C4)NC3=C1
,,,,,,,,,,,,,,,,poly adp ribose polymerase,nicotinamide,HY-L025-66,F09,HY-B0150,Nicotinamide,Niacinamide; Nicotinic acid amide,98-92-0,122.12,Endogenous Metabolite; HBV; Sirtuin,Anti-infection; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease,"Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity[1][2][3][4].",C6H6N2O,DMSO : 50 mg/mL (409.43 mM; Need ultrasonic); H2O : ≥ 50 mg/mL (409.43 mM),10mM,Cancer,Launched,O=C(C1=CC=CN=C1)N
,,,,,,,,,,,,,,,,poly adp ribose polymerase,veliparib,HY-L025-5,D08,HY-10130,Veliparib (dihydrochloride),ABT-888 dihydrochloride,912445-05-7,317.21,Autophagy; PARP,Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Veliparib (dihydrochloride) is a potent inhibitor of?PARP1?and?PARP2?with?Kis?of 5.2 nM and 2.9 nM in cell-free assays, respectively.",C13H18Cl2N4O,DMSO : ≥ 3.2 mg/mL (10.09 mM); H2O : 250 mg/mL (788.12 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(C1=C2NC([C@@]3(NCCC3)C)=NC2=CC=C1)N.Cl.Cl
,,,,,,,,,,,,,,,,poly adp ribose polymerase,niraparib,HY-L025-11,B03,HY-10619E,Niraparib (tosylate hydrate),MK-4827 (tosylate hydrate),1613220-15-7,510.61,Apoptosis; PARP,Apoptosis; Cell Cycle/DNA Damage; Epigenetics,"Niraparib (MK-4827) tosylate hydrate is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib tosylate hydrate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity[1][2][3].",C26H30N4O5S,10 mM in DMSO,10mM,Cancer,Launched,NC(C1=CC=CC2=CN(C3=CC=C([C@H]4CNCCC4)C=C3)N=C21)=O.O=S(C5=CC=C(C)C=C5)(O)=O.O
,,,,,,,,,,,,,,,,stat1,myricetin,HY-L025-49,D10,HY-15097,Myricetin,Cannabiscetin,529-44-2,318.24,Apoptosis; Autophagy; Endogenous Metabolite,Apoptosis; Autophagy; Metabolic Enzyme/Protease,"Myricetin is a common plant-derived flavonoid with a wide range of activities including strong anti-oxidant, anticancer, antidiabetic and anti-inflammatory activities.",C15H10O8,DMSO : ≥ 31 mg/mL (97.41 mM); Ethanol : 28.57 mg/mL (89.78 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC1=CC(O)=C(C(C(O)=C(C2=CC(O)=C(O)C(O)=C2)O3)=O)C3=C1
,,,,,,,,,,,,,,,,stat1,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
,,,,,,,,,,,,,,,,stat1,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,stat1,dha,HY-L025-71,C06,HY-B2167,Docosahexaenoic acid,DHA; Cervonic acid,6217-54-5,328.49,Endogenous Metabolite,Metabolic Enzyme/Protease,Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk.,C22H32O2,Ethanol : 50 mg/mL (152.21 mM; Need ultrasonic); DMSO : 100 mg/mL (304.42 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(O)=O
,,,,,,,,,,,,,,,,stat1,luteolin,HY-L025-72,G06,HY-N0162,Luteolin,Luteoline; Luteolol; Digitoflavone,491-70-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Keap1-Nrf2,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells[1][2][3].",C15H10O6,DMSO : ≥ 100 mg/mL (349.36 mM),10mM,Cancer; Inflammation/Immunology,Phase 2,O=C1C=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13
,,,,,,,,,,,,,,,,stat1,dexamethasone,HY-L025-46,B10,HY-14648,Dexamethasone,Hexadecadrol; Prednisolone F,50-02-2,392.46,Antibiotic; Autophagy; Bacterial; Complement System; Glucocorticoid Receptor; Mitophagy; SARS-CoV,Anti-infection; Autophagy; Immunology/Inflammation; Vitamin D Related/Nuclear Receptor,"Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.",C22H29FO5,DMSO : 250 mg/mL (637.01 mM; ultrasonic and warming and heat to 60°C); Ethanol : 8.33 mg/mL (21.23 mM; Need ultrasonic),10mM,Cancer; Infection; Endocrinology; Inflammation/Immunology,Launched,O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@@]4(C(CO)=O)O)=C1
,,,,,,,,,,,,,,,,stat1,tofacitinib,HY-L025-63,D09,HY-40354A,Tofacitinib (citrate),Tasocitinib (citrate); CP-690550 (citrate),540737-29-9,504.49,Apoptosis; Bacterial; Fungal; Influenza Virus; JAK,Anti-infection; Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.",C22H28N6O8,DMSO : 28.57 mg/mL (56.63 mM; Need ultrasonic); H2O : 3.33 mg/mL (6.60 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O
,,,,,,,,,,,,,,,,stat1,ruxolitinib,HY-L025-64,A05,HY-50858,Ruxolitinib (phosphate),INCB018424 phosphate,1092939-17-7,404.36,Autophagy; JAK; Mitophagy,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.",C17H21N6O4P,DMSO : ≥ 31 mg/mL (76.66 mM); H2O : 10 mg/mL (24.73 mM; Need ultrasonic),10mM,Cancer,Launched,N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2.O=P(O)(O)O
,,,,,,,,,,,,,,,,stat1,ag490,HY-L025-22,A04,HY-12000,AG490,Tyrphostin AG490; Tyrphostin B42,133550-30-8,294.3,Autophagy; EGFR; JAK; STAT,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.",C17H14N2O3,DMSO : ≥ 50 mg/mL (169.89 mM),10mM,Cancer,No Development Reported,O=C(NCC1=CC=CC=C1)/C(C#N)=C/C2=CC=C(O)C(O)=C2
,,,,,,,,,,,,,,,,stat1,berberine,HY-L025-59,B09,HY-18258,Berberine (chloride),Natural Yellow 18 (chloride),633-65-8,371.81,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; Parasite; Reactive Oxygen Species; Topoisomerase,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,Berberine chloride is an alkaloid that acts as an antibiotic. Berberine chloride induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties[1].,C20H18ClNO4,DMSO : 12.5 mg/mL (33.62 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Cancer,Launched,COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.[Cl-]
,,,,,,,,,,,,,,,,stat1,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,stat1,baicalein,HY-L025-73,B02,HY-N0196,Baicalein,"5,6,7-Trihydroxyflavone",491-67-8,270.24,Ferroptosis; Influenza Virus; Xanthine Oxidase,Anti-infection; Apoptosis; Metabolic Enzyme/Protease,"Baicalein (5,6,7-Trihydroxyflavone) is a xanthine oxidase inhibitor with an IC50 value of 3.12 μM.",C15H10O5,DMSO : 50 mg/mL (185.02 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1C=C(C2=CC=CC=C2)OC3=CC(O)=C(O)C(O)=C13
,,,,,,,,,,,,,,,,stat1,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
,,,,,,,,,,,,,,,,stat1,fludarabine,HY-L025-66,B06,HY-B0069,Fludarabine,F-ara-A; NSC 118218,21679-14-1,285.23,Apoptosis; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog; STAT,Apoptosis; Cell Cycle/DNA Damage; JAK/STAT Signaling; Stem Cell/Wnt,Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes[1][2][3][4].,C10H12FN5O4,DMSO : 25 mg/mL (87.65 mM; Need ultrasonic),10mM,Cancer,Launched,O[C@H]1[C@H](O)[C@H](N2C(N=C(F)N=C3N)=C3N=C2)O[C@@H]1CO
,,,,,,,,,,,,,,,,stat1,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,xl,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
,,,,,,,,,,,,,,,,xl,abt 199,HY-L025-52,G02,HY-15531,Venetoclax,ABT-199; GDC-0199; RG7601,1257044-40-8,868.44,Autophagy; Bcl-2 Family,Apoptosis; Autophagy,"Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy[1][2][3].",C45H50ClN7O7S,DMSO : 77.5 mg/mL (89.24 mM; Need ultrasonic); Ethanol : < 1 mg/mL (insoluble),10mM,Cancer,Launched,O=C(NS(=O)(C1=CC=C(NCC2CCOCC2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCN(CC5=C(C6=CC=C(Cl)C=C6)CC(C)(C)CC5)CC4)C=C3OC7=CN=C(NC=C8)C8=C7
,,,,,,,,,,,,,,,,xl,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,xl,nac,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,xl,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,xl,saha,HY-L025-7,E02,HY-10221,Vorinostat,SAHA; Suberoylanilide hydroxamic acid,149647-78-9,264.32,Apoptosis; Autophagy; Filovirus; HDAC; HPV; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].",C14H20N2O3,DMSO : ≥ 100 mg/mL (378.33 mM),10mM,Cancer; Infection,Launched,O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O
,,,,,,,,,,,,,,,,xl,gossypol,HY-L025-58,E03,HY-17510,Gossypol (acetic acid),(±)-Gossypol-acetic acid; BL-193 (acetic acid),12542-36-8,578.61,Bcl-2 Family,Apoptosis,"Gossypol acetic acid ((±)-Gossypol-acetic acid) binds to Bcl-xL protein and Bcl-2 protein with Kis of 0.5-0.6 μM and 0.2-0.3 mM, respectively.",C32H34O10,DMSO : 25 mg/mL (43.21 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,OC1=C(C2=C(O)C(C(C=O)=C(O)C(O)=C3C(C)C)=C3C=C2C)C(C)=CC4=C(C(C)C)C(O)=C(O)C(C=O)=C41.O=C(O)C
,,,,,,,,,,,,,,,,xl,ag490,HY-L025-22,A04,HY-12000,AG490,Tyrphostin AG490; Tyrphostin B42,133550-30-8,294.3,Autophagy; EGFR; JAK; STAT,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.",C17H14N2O3,DMSO : ≥ 50 mg/mL (169.89 mM),10mM,Cancer,No Development Reported,O=C(NCC1=CC=CC=C1)/C(C#N)=C/C2=CC=C(O)C(O)=C2
,,,,,,,,,,,,,,,,xl,abt 737,HY-L025-64,C06,HY-50907,ABT-737,,852808-04-9,813.43,Apoptosis; Autophagy; Bcl-2 Family; Mitophagy,Apoptosis; Autophagy,"ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research[1][2][3].",C42H45ClN6O5S2,DMSO : 50 mg/mL (61.47 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(CC[C@@H](NC1=CC=C(C=C1[N+]([O-])=O)S(NC(C2=CC=C(C=C2)N3CCN(CC3)CC4=CC=CC=C4C5=CC=C(C=C5)Cl)=O)(=O)=O)CSC6=CC=CC=C6)C
,,,,,,,,,,,,,,,,xl,abt 263,HY-L025-4,A02,HY-10087,Navitoclax,ABT-263,923564-51-6,974.61,Bcl-2 Family,Apoptosis,"Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM[1].",C47H55ClF3N5O6S3,DMSO : 75 mg/mL (76.95 mM; Need ultrasonic); DMF : ≥ 100 mg/mL (102.61 mM),10mM,Cancer,Phase 3,O=S(C1=CC(S(NC(C2=CC=C(N3CCN(CC4=C(CCC(C)(C4)C)C5=CC=C(Cl)C=C5)CC3)C=C2)=O)(=O)=O)=CC=C1N[C@H](CCN6CCOCC6)CSC7=CC=CC=C7)(C(F)(F)F)=O
,,,,,,,,,,,,,,,,xl,obatoclax,HY-L025-14,B09,HY-10969,Obatoclax (Mesylate),GX15-070 (Mesylate),803712-79-0,413.49,Autophagy; Bcl-2 Family; Parasite,Anti-infection; Apoptosis; Autophagy,"Obatoclax Mesylate (GX15-070 Mesylate), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a Ki of 220 nM for BCL-2[1][2]. Obatoclax Mesylate induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax Mesylate has anti-cancer and broad-spectrum antiparasitic activity[3][4].",C21H23N3O4S,DMSO : 12.5 mg/mL (30.23 mM; Need ultrasonic),10mM,Cancer; Infection,Phase 3,COC1=CC(C2=CC3=C(C=CC=C3)N2)=N/C1=C\C4=C(C=C(N4)C)C.CS(=O)(O)=O
,,,,,,,,,,,,,,,,xl,a 1331852,HY-L025-62,B06,HY-19741,A-1331852,,1430844-80-6,658.81,Bcl-2 Family,Apoptosis,A-1331852 is an orally available BCL-XL selective inhibitor with a Ki of less than 10 pM.,C38H38N6O3S,DMSO : ≥ 50 mg/mL (75.89 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble); Ethanol : 4 mg/mL (6.07 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,No Development Reported,O=C(C1=NC(N2CC3=C(C=CC=C3C(NC4=NC5=CC=CC=C5S4)=O)CC2)=CC=C1C6=C(C)N(CC7(C8)CC9CC8CC(C9)C7)N=C6)O
,,,,,,,,,,,,,,,,xl,navitoclax,HY-L025-4,A02,HY-10087,Navitoclax,ABT-263,923564-51-6,974.61,Bcl-2 Family,Apoptosis,"Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM[1].",C47H55ClF3N5O6S3,DMSO : 75 mg/mL (76.95 mM; Need ultrasonic); DMF : ≥ 100 mg/mL (102.61 mM),10mM,Cancer,Phase 3,O=S(C1=CC(S(NC(C2=CC=C(N3CCN(CC4=C(CCC(C)(C4)C)C5=CC=C(Cl)C=C5)CC3)C=C2)=O)(=O)=O)=CC=C1N[C@H](CCN6CCOCC6)CSC7=CC=CC=C7)(C(F)(F)F)=O
,,,,,,,,,,,,,,,,mtorc1,cc214 2,HY-L025-45,G05,HY-145931,CC214-2,,1228012-18-7,383.44,Autophagy; mTOR,Autophagy; PI3K/Akt/mTOR,"CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo[1][2].",C20H25N5O3,DMSO : 12.5 mg/mL (32.60 mM; ultrasonic and warming and heat to 80°C),10mM,Cancer,No Development Reported,O=C1N=C2NC=C(C3=CC=C(C(C)(C)O)N=C3)N=C2N(CC4CCOCC4)C1
,,,,,,,,,,,,,,,,mtorc1,chloroquine,HY-L025-58,G04,HY-17589A,Chloroquine,,54-05-7,319.87,Antibiotic; Autophagy; HIV; Parasite; SARS-CoV; Toll-like Receptor (TLR),Anti-infection; Autophagy; Immunology/Inflammation,Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].,C18H26ClN3,Ethanol : 100 mg/mL (312.63 mM; Need ultrasonic); DMSO : 50 mg/mL (156.31 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,CC(NC1=CC=NC2=CC(Cl)=CC=C12)CCCN(CC)CC
,,,,,,,,,,,,,,,,mtorc1,bez235,HY-L025-50,A09,HY-15174,Dactolisib (Tosylate),BEZ235 (Tosylate); NVP-BEZ 235 (Tosylate),1028385-32-1,641.74,Autophagy; mTOR; PI3K,Autophagy; PI3K/Akt/mTOR,"Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.",C37H31N5O4S,H2O : < 0.1 mg/mL (insoluble); DMSO : 34 mg/mL (52.98 mM; Need ultrasonic and warming),10mM,Cancer,Phase 3,CN(C1=C2C3=CC(C4=CC5=CC=CC=C5N=C4)=CC=C3N=C1)C(N2C6=CC=C(C=C6)C(C)(C#N)C)=O.CC7=CC=C(S(=O)(O)=O)C=C7
,,,,,,,,,,,,,,,,mtorc1,ruxolitinib,HY-L025-64,A05,HY-50858,Ruxolitinib (phosphate),INCB018424 phosphate,1092939-17-7,404.36,Autophagy; JAK; Mitophagy,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.",C17H21N6O4P,DMSO : ≥ 31 mg/mL (76.66 mM); H2O : 10 mg/mL (24.73 mM; Need ultrasonic),10mM,Cancer,Launched,N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2.O=P(O)(O)O
,,,,,,,,,,,,,,,,mtorc1,torin 2,HY-L025-31,C09,HY-13002,Torin 2,,1223001-51-1,432.4,Apoptosis; Autophagy; DNA-PK; mTOR,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Torin 2 is an mTOR inhibitor with EC50 of 0.25 nM for inhibiting cellular mTOR activity, and exhibits 800-fold selectivity over PI3K (EC50: 200 nM). Torin 2 also inhibits DNA-PK with an IC50 of 0.5 nM in the cell free assay. Torin 2 can suppress both mTORC1 and mTORC2.",C24H15F3N4O,DMSO : 15.62 mg/mL (36.12 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1N(C2=C(C=C1)C=NC3=CC=C(C=C32)C4=CC=C(N=C4)N)C5=CC=CC(C(F)(F)F)=C5
,,,,,,,,,,,,,,,,mtorc1,exemestane,HY-L025-37,G06,HY-13632,Exemestane,FCE 24304; EXE,107868-30-4,296.4,Cytochrome P450,Metabolic Enzyme/Protease,"Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].",C20H24O2,DMSO : ≥ 54 mg/mL (182.19 mM),10mM,Cancer; Endocrinology,Launched,C[C@]1([C@](CC2)([H])[C@]3([H])CC(C4=CC(C=C[C@]4(C)[C@@]3([H])CC1)=O)=C)C2=O
,,,,,,,,,,,,,,,,mtorc1,sunitinib,HY-L025-7,F10,HY-10255A,Sunitinib,SU 11248,557795-19-4,398.47,Apoptosis; Autophagy; IRE1; Mitophagy; PDGFR; VEGFR,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK,"Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].",C22H27FN4O2,DMSO : 20.83 mg/mL (52.27 mM; ultrasonic and warming and heat to 80°C),10mM,Cancer,Launched,O=C(NCCN(CC)CC)C1=C(NC(/C=C2C(NC3=C\2C=C(C=C3)F)=O)=C1C)C
,,,,,,,,,,,,,,,,mtorc1,trametinib,HY-L025-14,D08,HY-10999A,Trametinib (DMSO solvate),GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate),1187431-43-1,693.53,Apoptosis; MEK,Apoptosis; MAPK/ERK Pathway,Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis[1][2].,C28H29FIN5O5S,DMSO : 69 mg/mL (99.49 mM; Need ultrasonic),10mM,Cancer,Launched,CN1C(C(C)=C(N(C(N(C2=O)C3CC3)=O)C4=CC=CC(NC(C)=O)=C4)C2=C1NC5=CC=C(C=C5F)I)=O.CS(C)=O
,,,,,,,,,,,,,,,,mtorc1,aicar,HY-L025-34,G08,HY-13417A,AICAR (phosphate),Acadesine phosphate; AICA Riboside phosphate,681006-28-0,356.23,AMPK; Autophagy; Endogenous Metabolite; Mitophagy; YAP,Autophagy; Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Stem Cell/Wnt,"AICAR phosphate (Acadesine phosphate) is an adenosine analog and a AMPK activator. AICAR phosphate regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR phosphate is also an autophagy, YAP and mitophagy inhibitor[1][2].",C9H17N4O9P,H2O : 100 mg/mL (280.72 mM; Need ultrasonic),10mM,Cancer,Phase 3,OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C=NC(C(N)=O)=C2N)O1.O=P(O)(O)O
,,,,,,,,,,,,,,,,mtorc1,cc 223,HY-L025-57,C07,HY-16956,Onatasertib,CC-223; ATG-008,1228013-30-6,397.47,Apoptosis; mTOR,Apoptosis; PI3K/Akt/mTOR,"Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC50 value for mTOR kinase of 16 nM. Onatasertib inhibits both mTORC1 and mTORC2.",C21H27N5O3,DMSO : ≥ 27 mg/mL (67.93 mM),10mM,Cancer,Phase 2,O=C1CNC2=NC=C(C3=CC=C(C(C)(O)C)N=C3)N=C2N1[C@H]4CC[C@H](OC)CC4
,,,,,,,,,,,,,,,,mtorc1,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,mtorc1,sapanisertib,HY-L025-34,D11,HY-13328,Sapanisertib,INK-128; MLN0128; TAK-228,1224844-38-5,309.33,Autophagy; mTOR,Autophagy; PI3K/Akt/mTOR,"Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.",C15H15N7O,DMSO : 55 mg/mL (177.80 mM; Need ultrasonic),10mM,Cancer,Phase 2,NC1=NC=NC2=C1C(C3=CC4=C(C=C3)OC(N)=N4)=NN2C(C)C
,,,,,,,,,,,,,,,,mtorc1,pi 103,HY-L025-4,H11,HY-10115A,PI-103 (Hydrochloride),,371935-79-4,384.82,Apoptosis; Autophagy; DNA-PK; mTOR; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"PI-103 Hydrochloride is a dual PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy[1][2][3][4].",C19H17ClN4O3,DMSO : 4.1 mg/mL (10.65 mM; Need ultrasonic and warming); H2O : 1 mg/mL (2.60 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,No Development Reported,OC1=CC(C2=NC3=C(OC4=C3C=CC=N4)C(N5CCOCC5)=N2)=CC=C1.[H]Cl
,,,,,,,,,,,,,,,,mtorc1,pf 4708671,HY-L025-54,B05,HY-15773,PF-4708671,,1255517-76-0,390.41,Autophagy; Ribosomal S6 Kinase (RSK),Autophagy; MAPK/ERK Pathway,PF-4708671 is a potent cell-permeable S6K1 inhibitor with a Ki of 20 nM and IC50 of 160 nM.,C19H21F3N6,DMSO : 33.33 mg/mL (85.37 mM; Need ultrasonic),10mM,Cancer,No Development Reported,FC(C1=CC=C2N=C(CN3CCN(C4=NC=NC=C4CC)CC3)NC2=C1)(F)F
,,,,,,,,,,,,,,,,mtorc1,mk 2206,HY-L025-9,B02,HY-10358,MK-2206 (dihydrochloride),MK-2206 (2HCl),1032350-13-2,480.39,Akt; Apoptosis; Autophagy,Apoptosis; Autophagy; PI3K/Akt/mTOR,"MK-2206 dihydrochloride (MK-2206 (2HCl)) is an orally active allosteric AKT inhibitor with IC50s of 5 nM, 12 nM, and 65 nM for AKT1, AKT2, and AKT3, respectively. MK-2206 dihydrochloride induces autophagy[1][3].",C25H23Cl2N5O,DMSO : 50 mg/mL (104.08 mM; ultrasonic and warming and heat to 60°C); H2O : 3.57 mg/mL (7.43 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=C1N2C(C3=CC(C4=CC=CC=C4)=C(N=C3C=C2)C5=CC=C(C6(N)CCC6)C=C5)=NN1.Cl.Cl
,,,,,,,,,,,,,,,,mtorc1,xl388,HY-L025-40,B04,HY-13806,XL388,,1251156-08-7,455.5,Autophagy; mTOR,Autophagy; PI3K/Akt/mTOR,XL388 is a highly potent and ATP-competitive mTOR inhibitor with an IC50 of 9.9 nM. XL388 simultaneously inhibits both mTORC1 and mTORC2.,C23H22FN3O4S,DMSO : 50 mg/mL (109.77 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C(N1CCOC2=CC=C(C3=CC=C(N)N=C3)C=C2C1)C4=CC=C(S(=O)(C)=O)C(F)=C4C
,,,,,,,,,,,,,,,,bcl xl,betulinic acid,HY-L025-10,F05,HY-10529,Betulinic acid,Lupatic acid; Betulic acid,472-15-1,456.7,Apoptosis; Autophagy; Endogenous Metabolite; HIV; Mitophagy; NF-κB; Parasite; Topoisomerase,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; NF-κB,"Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic topoisomerase I inhibitor, with an IC50 of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties[1][2][3][4].",C30H48O3,DMSO : 35.71 mg/mL (78.19 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Phase 2,[H][C@@]12CC[C@@]3(C)[C@]4(C)CC[C@]5(C(O)=O)[C@@]([C@H](C(C)=C)CC5)([H])[C@@](CC[C@@]([H])3[C@@]1(C)CC[C@H](O)C2(C)C)4[H]
,,,,,,,,,,,,,,,,bcl xl,s63845,HY-L025-3,E11,HY-100741,S63845,,1799633-27-4,829.26,Bcl-2 Family,Apoptosis,S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor with a Kd of 0.19 nM for human MCL1[1].,C39H37ClF4N6O6S,DMSO : 33.33 mg/mL (40.19 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CC(C(Cl)=C(OCCN1CCN(C)CC1)C=C2)=[C@@]2[C@]3=C(C4=CC=C(F)O4)SC5=NC=NC(O[C@H](CC6=C(OCC7=CC=NN7CC(F)(F)F)C=CC=C6)C(O)=O)=C53
,,,,,,,,,,,,,,,,bcl xl,cudc 907,HY-L025-36,A06,HY-13522,Fimepinostat,CUDC-907,1339928-25-4,508.55,Apoptosis; HDAC; PI3K,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR,"Fimepinostat (CUDC-907) potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes with an IC50 of  19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.",C23H24N8O4S,DMSO : 50 mg/mL (98.32 mM; Need ultrasonic); DMF : 5 mg/mL (9.83 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=CN=C(N(CC2=CC3=NC(C4=CC=C(OC)N=C4)=NC(N5CCOCC5)=C3S2)C)N=C1)NO
,,,,,,,,,,,,,,,,bcl xl,butein,HY-L025-56,C08,HY-16558,Butein,"2’,3,4,4’-tetrahydroxy Chalcone",487-52-5,272.25,Apoptosis; Autophagy; EGFR; Phosphodiesterase (PDE),Apoptosis; Autophagy; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4[1]. Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells[2]. Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a[3]. Butein is a SIRT1 activator (STAC).,C15H12O5,DMSO : 50 mg/mL (183.65 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC1=CC=C(C(/C=C/C2=CC(O)=C(O)C=C2)=O)C(O)=C1
,,,,,,,,,,,,,,,,bcl xl,celecoxib,HY-L025-43,G07,HY-14398,Celecoxib,SC 58635,169590-42-5,381.37,COX,Immunology/Inflammation,"Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.",C17H14F3N3O2S,DMSO : ≥ 50 mg/mL (131.11 mM),10mM,Inflammation/Immunology; Cancer,Launched,CC1=CC=C(C=C1)C2=CC(C(F)(F)F)=NN2C3=CC=C(C=C3)S(=O)(N)=O
,,,,,,,,,,,,,,,,bcl xl,ptx,HY-L025-69,C09,HY-B0715,Pentoxifylline,BL-191; PTX; Oxpentifylline,5/6/93,278.31,Autophagy; HIV; Phosphodiesterase (PDE),Anti-infection; Autophagy; Metabolic Enzyme/Protease,"Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].",C13H18N4O3,DMSO : ≥ 2.8 mg/mL (10.06 mM); H2O : 93.3 mg/mL (335.24 mM; Need ultrasonic and warming),10mM,Cardiovascular Disease; Cancer,Launched,O=C(N1CCCCC(C)=O)N(C)C2=C(N(C)C=N2)C1=O
,,,,,,,,,,,,,,,,bcl xl,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,bcl xl,csa,HY-L025-68,H08,HY-B0579,Cyclosporin A,Cyclosporine A; Ciclosporin A; CsA,59865-13-3,1202.61,Antibiotic; Complement System; Molecular Glues; Phosphatase,Anti-infection; Immunology/Inflammation; Metabolic Enzyme/Protease; PROTAC,Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of calcineurin with an IC50 of 5 nM[3]. Cyclosporin A also inhibits CD11a/CD18 adhesion[8].,C62H111N11O12,Ethanol : 50 mg/mL (41.58 mM; Need ultrasonic); DMSO : 62.5 mg/mL (51.97 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Launched,C/C=C/C[C@H]([C@@H](O)[C@@]1(N(C)C([C@]([H])(C(C)C)N(C)C([C@H](CC(C)C)N(C)C([C@]([H])(CC(C)C)N(C)C([C@@H](C)NC([C@H](C)NC([C@@H](N(C([C@@]([H])(NC([C@@H](N(C(CN(C([C@@H](NC1=O)CC)=O)C)=O)C)CC(C)C)=O)C(C)C)=O)C)CC(C)C)=O)=O)=O)=O)=O)=O)[H])C
,,,,,,,,,,,,,,,,bcl xl,a 1210477,HY-L025-26,H10,HY-12468,A-1210477,,1668553-26-1,850.04,Apoptosis; Bcl-2 Family,Apoptosis,A-1210477 is a potent and selective inhibitor of MCL-1 with a Ki of 0.45 nM[1]. A-1210477 specifically binds MCL-1 and promotes apoptosis of cancer cells in an MCL-1-dependent manner[2].,C46H55N7O7S,DMSO : 10 mg/mL (11.76 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C(C(N1CCN2CCOCC2)=C(CCCOC3=C4C=CC=CC4=CC=C3)C5=C1C(C6=C(COC7=CC=C(N8CCN(S(=O)(N(C)C)=O)CC8)C=C7)N(C)N=C6C)=CC=C5)O
,,,,,,,,,,,,,,,,bcl xl,ps 341,HY-L025-7,E07,HY-10227,Bortezomib,PS-341; LDP-341; NSC 681239,179324-69-7,384.24,Apoptosis; Autophagy; NF-κB; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].",C19H25BN4O4,DMSO : 50 mg/mL (130.13 mM; Need ultrasonic); Ethanol : 66.67 mg/mL (173.51 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
,,,,,,,,,,,,,,,,bcl xl,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,bcl xl,naringin,HY-L025-72,F11,HY-N0153,Naringin,Naringoside,10236-47-2,580.53,Autophagy; Cytochrome P450; Endogenous Metabolite; Mitophagy,Autophagy; Metabolic Enzyme/Protease,"Naringin is a major flavanone glycoside obtained from tomatoes, grapefruits, and many other citrus fruits. Naringin exhibits biological properties such as antioxidant, anti-inflammatory, and antiapoptotic activities.",C27H32O14,DMSO : 125 mg/mL (215.32 mM; Need ultrasonic); H2O : 1 mg/mL (1.72 mM; ultrasonic and warming and heat to 80°C); Ethanol : < 1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble),10mM,Inflammation/Immunology; Cancer,No Development Reported,O=C1C[C@@H](C2=CC=C(O)C=C2)OC3=CC(O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O[C@@]5([H])[C@@H]([C@@H]([C@H]([C@H](C)O5)O)O)O)=CC(O)=C13
,,,,,,,,,,,,,,,,bcl xl,baicalein,HY-L025-73,B02,HY-N0196,Baicalein,"5,6,7-Trihydroxyflavone",491-67-8,270.24,Ferroptosis; Influenza Virus; Xanthine Oxidase,Anti-infection; Apoptosis; Metabolic Enzyme/Protease,"Baicalein (5,6,7-Trihydroxyflavone) is a xanthine oxidase inhibitor with an IC50 value of 3.12 μM.",C15H10O5,DMSO : 50 mg/mL (185.02 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1C=C(C2=CC=CC=C2)OC3=CC(O)=C(O)C(O)=C13
,,,,,,,,,,,,,,,,bcl xl,ro 31 8220,HY-L025-41,A03,HY-13866,Ro 31-8220 (mesylate),Ro 31-8220 methanesulfonate; Bisindolylmaleimide IX mesylate,138489-18-6,553.65,PKC,Epigenetics; TGF-beta/Smad,"Ro 31-8220 mesylate is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7.",C26H27N5O5S2,DMSO : 35.71 mg/mL (64.50 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Neurological Disease; Cardiovascular Disease; Cancer,No Development Reported,NC(SCCCN1C=C(C2=C(C3=CN(C)C4=C3C=CC=C4)C(NC2=O)=O)C5=C1C=CC=C5)=N.CS(=O)(O)=O
,,,,,,,,,,,,,,,,cdk,ly2835219,HY-L025-55,G10,HY-16297A,Abemaciclib,LY2835219,1231929-97-7,506.59,CDK,Cell Cycle/DNA Damage,"Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.",C27H32F2N8,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 2.94 mg/mL (5.80 mM; ultrasonic and warming and heat to 80°C),2mM,Cancer,Launched,CC1=NC2=C(F)C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=C2N1C(C)C
,,,,,,,,,,,,,,,,cdk,pd98059,HY-L025-22,E02,HY-12028,PD98059,,167869-21-8,267.28,Aryl Hydrocarbon Receptor; Autophagy; ERK; MEK,Autophagy; Immunology/Inflammation; MAPK/ERK Pathway; Stem Cell/Wnt,"PD98059 is a potent and selective MEK inhibitor with an IC50 of 5 μM. PD98059 binds to the inactive form of MEK, thereby preventing the activation of MEK1 (IC50 of 2-7 μM) and MEK2 (IC50 of 50 μM) by upstream kinases. PD98059 is a ERK1/2 signaling inhibitor. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC50 of 4 μM) and AHR transformation (IC50 of 1 μM). PD98059 also inhibits Mycobacterium bovis Bacillus CalmetteGuerin (BCG)-induced autophagy[1][2][3].",C16H13NO3,DMSO : 33.33 mg/mL (124.70 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,No Development Reported,O=C1C=C(OC2=CC=CC=C21)C3=CC=CC(OC)=C3N
,,,,,,,,,,,,,,,,cdk,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,cdk,fulvestrant,HY-L025-37,H04,HY-13636,Fulvestrant,ICI 182780; ZD 9238; ZM 182780,129453-61-8,606.77,Apoptosis; Autophagy; Estrogen Receptor/ERR,Apoptosis; Autophagy; Vitamin D Related/Nuclear Receptor,Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy[1].,C32H47F5O3S,DMSO : 250 mg/mL (412.02 mM; Need ultrasonic),10mM,Cancer,Launched,C[C@@]12[C@@H](O)CC[C@@]1([H])[C@]3([H])[C@H](CCCCCCCCCS(CCCC(F)(F)C(F)(F)F)=O)CC4=C(C=CC(O)=C4)[C@@]3([H])CC2
,,,,,,,,,,,,,,,,cdk,esculetin,HY-L025-73,F09,HY-N0284,Esculetin,,305-01-1,178.14,Akt; PI3K,PI3K/Akt/mTOR,"Esculetin is an active ingredient extracted mainly from the bark of Fraxinus rhynchophylla. Esculetin inhibits platelet-derived growth factor (PDGF)-induced airway smooth muscle cells (ASMCs) phenotype switching through inhibition of PI3K/Akt pathway. Esculetin has antioxidant, antiinflammatory, and antitumor activities[1].",C9H6O4,DMSO : 125 mg/mL (701.70 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,No Development Reported,O=C1C=CC2=CC(O)=C(O)C=C2O1
,,,,,,,,,,,,,,,,cdk,tsa,HY-L025-49,F10,HY-15144,Trichostatin A,TSA,58880-19-6,302.37,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].",C17H22N2O3,DMSO : 25 mg/mL (82.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
,,,,,,,,,,,,,,,,cdk,apigenin,HY-L025-77,B10,HY-N1201,Apigenin,"4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1",520-36-5,270.24,Autophagy; Cytochrome P450; Endogenous Metabolite,Autophagy; Metabolic Enzyme/Protease,"Apigenin (4',5,7-Trihydroxyflavone) is a competitive CYP2C9 inhibitor with a Ki of 2 μM.",C15H10O5,DMSO : 83.33 mg/mL (308.36 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=CC2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,cdk,drb,HY-L025-43,G02,HY-14392,"5,6-Dichlorobenzimidazole riboside",DRB,53-85-0,319.14,CDK,Cell Cycle/DNA Damage,"5,6-Dichlorobenzimidazole riboside is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II and CDKs[1][2][3][4]. 5,6-Dichlorobenzimidazole riboside trigger p53-dependent apoptosis of human colon adenocarcinoma cells without inducing genotoxic stress to healthy cells[5].",C12H12Cl2N2O4,Ethanol : 7.69 mg/mL (24.10 mM; Need ultrasonic); DMF : 100 mg/mL (313.34 mM; Need ultrasonic); DMSO : 100 mg/mL (313.34 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=CC(Cl)=C(Cl)C=C3N=C2)O1
,,,,,,,,,,,,,,,,cdk,kenpaullone,HY-L025-25,B09,HY-12302,Kenpaullone,9-Bromopaullone; NSC-664704,142273-20-9,327.18,CDK; GSK-3,Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"Kenpaullone is a potent inhibitor of CDK1/cyclin B and GSK-3β, with IC50s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC50s of 0.68 μM, 7.5 μM, 0.85 μM, respectively. Kenpaullone, a small molecule inhibitor of KLF4, reduces self-renewal of breast cancer stem cells and cell motility in vitro.",C16H11BrN2O,DMSO : ≥ 35 mg/mL (106.97 mM),10mM,Cancer,No Development Reported,O=C1NC2=CC=CC=C2C(NC3=C4C=C(Br)C=C3)=C4C1
,,,,,,,,,,,,,,,,cdk,everolimus,HY-L025-7,D10,HY-10218,Everolimus,RAD001; SDZ-RAD,159351-69-6,958.22,Apoptosis; Autophagy; Bacterial; FKBP; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; PI3K/Akt/mTOR,"Everolimus (RAD001) is a <a href=""/Rapamycin.html"" class=""link-product"" target=""_blank"">Rapamycin</a> (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].",C53H83NO14,DMSO : 50 mg/mL (52.18 mM; ultrasonic and warming and heat to 60°C); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](OCCO)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,cdk,indirubin,HY-L025-72,D08,HY-N0117,Indirubin,Couroupitine B; Indigo red; Indigopurpurin,479-41-4,262.26,Apoptosis,Apoptosis,Indirubin (Couroupitine B) is a bis-indole alkaloid and has emarkable anticancer activity against chronic myelocytic leukemia[1][2].,C16H10N2O2,DMSO : 5 mg/mL (19.07 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C1NC2=C(C=CC=C2)/C1=C3NC4=C(C=CC=C4)C\3=O
,,,,,,,,,,,,,,,,cdk,bohemine,HY-L025-29,G05,HY-12843,Bohemine,,189232-42-6,340.42,CDK; ERK,Cell Cycle/DNA Damage; MAPK/ERK Pathway; Stem Cell/Wnt,"Bohemine is a purine analogue and is a synthetic and selective CDK inhibitor with IC50s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC50 of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities[1][2].",C18H24N6O,DMSO : 100 mg/mL (293.75 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OCCCNC1=NC(NCC2=CC=CC=C2)=C3N=CN(C(C)C)C3=N1
,,,,,,,,,,,,,,,,cdk,dexamethasone,HY-L025-46,B10,HY-14648,Dexamethasone,Hexadecadrol; Prednisolone F,50-02-2,392.46,Antibiotic; Autophagy; Bacterial; Complement System; Glucocorticoid Receptor; Mitophagy; SARS-CoV,Anti-infection; Autophagy; Immunology/Inflammation; Vitamin D Related/Nuclear Receptor,"Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.",C22H29FO5,DMSO : 250 mg/mL (637.01 mM; ultrasonic and warming and heat to 60°C); Ethanol : 8.33 mg/mL (21.23 mM; Need ultrasonic),10mM,Cancer; Infection; Endocrinology; Inflammation/Immunology,Launched,O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@@]4(C(CO)=O)O)=C1
,,,,,,,,,,,,,,,,cdk,sch 727965,HY-L025-10,C09,HY-10492,Dinaciclib,SCH 727965,779353-01-4,396.49,Apoptosis; CDK,Apoptosis; Cell Cycle/DNA Damage,"Dinaciclib (SCH 727965) is a potent inhibitor of CDK, with IC50s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively[1].",C21H28N6O2,DMSO : 50 mg/mL (126.11 mM; Need ultrasonic),10mM,Cancer,Launched,OCC[C@H]1N(CCCC1)C2=NC3=C(C=NN3C(NCC4=C[N+]([O-])=CC=C4)=C2)CC
,,,,,,,,,,,,,,,,cdk,abt 737,HY-L025-64,C06,HY-50907,ABT-737,,852808-04-9,813.43,Apoptosis; Autophagy; Bcl-2 Family; Mitophagy,Apoptosis; Autophagy,"ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research[1][2][3].",C42H45ClN6O5S2,DMSO : 50 mg/mL (61.47 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(CC[C@@H](NC1=CC=C(C=C1[N+]([O-])=O)S(NC(C2=CC=C(C=C2)N3CCN(CC3)CC4=CC=CC=C4C5=CC=C(C=C5)Cl)=O)(=O)=O)CSC6=CC=CC=C6)C
,,,,,,,,,,,,,,,,cdk,cr8,HY-L025-59,D04,HY-18340A,(R)-CR8 (trihydrochloride),"CR8, (R)-Isomer (trihydrochloride)",1786438-30-9,540.92,Apoptosis; CDK; Molecular Glues,Apoptosis; Cell Cycle/DNA Damage; PROTAC,"(R)-CR8 (CR8) trihydrochloride, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 trihydrochloride inhibits CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 trihydrochloride induces apoptosis and has neuroprotective effect[1][2]. (R)-CR8 trihydrochloride acts as a molecular glue degrader that depletes cyclin K[3].",C24H32Cl3N7O,DMSO : 50 mg/mL (92.44 mM; Need ultrasonic),10mM,Cancer; Neurological Disease,No Development Reported,CC[C@@H](NC1=NC(NCC2=CC=C(C3=NC=CC=C3)C=C2)=C4N=CN(C(C)C)C4=N1)CO.[H]Cl.[H]Cl.[H]Cl
,,,,,,,,,,,,,,,,cdk,sns 032,HY-L025-1,C10,HY-10008,SNS-032,BMS-387032,345627-80-7,380.53,Apoptosis; CDK,Apoptosis; Cell Cycle/DNA Damage,"SNS-032 (BMS-387032) is a potent and selective inhibitor of?CDK2, CDK7, and CDK9 with?IC50s?of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect[1].",C17H24N4O2S2,DMSO : 62.5 mg/mL (164.24 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 1,CC(C)(C1=CN=C(CSC2=CN=C(NC(C3CCNCC3)=O)S2)O1)C
,,,,,,,,,,,,,,,,janus kinase,tofacitinib,HY-L025-63,D09,HY-40354A,Tofacitinib (citrate),Tasocitinib (citrate); CP-690550 (citrate),540737-29-9,504.49,Apoptosis; Bacterial; Fungal; Influenza Virus; JAK,Anti-infection; Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.",C22H28N6O8,DMSO : 28.57 mg/mL (56.63 mM; Need ultrasonic); H2O : 3.33 mg/mL (6.60 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O
,,,,,,,,,,,,,,,,janus kinase,jsi 124,HY-L025-77,D08,HY-N1405,Cucurbitacin I,Elatericin B; JSI-124; NSC-521777,7/3/22,514.65,JAK; STAT,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Cucurbitacin I is a natural selective inhibitor of JAK2/STAT3, with potent anti-cancer activity.",C30H42O7,DMSO : ≥ 100 mg/mL (194.31 mM),10mM,Cancer,No Development Reported,CC(C)(C1=CC[C@@]2([H])[C@@]3(C[C@@H](O)[C@@H]([C@]3(C4)C)[C@@](C)(O)C(/C=C/C(C)(O)C)=O)C)C(C(O)=C[C@@]1([H])[C@]2(C)C4=O)=O
,,,,,,,,,,,,,,,,janus kinase,tasocitinib,HY-L025-63,D09,HY-40354A,Tofacitinib (citrate),Tasocitinib (citrate); CP-690550 (citrate),540737-29-9,504.49,Apoptosis; Bacterial; Fungal; Influenza Virus; JAK,Anti-infection; Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.",C22H28N6O8,DMSO : 28.57 mg/mL (56.63 mM; Need ultrasonic); H2O : 3.33 mg/mL (6.60 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O
,,,,,,,,,,,,,,,,janus kinase,filgotinib,HY-L025-59,C07,HY-18300,Filgotinib,GLPG0634,1206161-97-8,425.5,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Filgotinib (GLPG0634) is a selective and orally active JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.",C21H23N5O3S,DMSO : 25 mg/mL (58.75 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,O=C(C1CC1)NC2=NN3C(C4=CC=C(CN5CCS(CC5)(=O)=O)C=C4)=CC=CC3=N2
,,,,,,,,,,,,,,,,janus kinase,pyridone 6,HY-L025-44,A04,HY-14435,Pyridone 6,,457081-03-7,309.34,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Pyridone 6 is a pan-JAK inhibitor, which potently inhibits the JAK kinase family, with IC50s of 1 nM for JAK2 and TYK2, 5 nM for JAK3, and 15 nM for JAK1, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.",C18H16FN3O,DMSO : ≥ 100 mg/mL (323.27 mM),10mM,Cancer,No Development Reported,FC1=CC2=C(C(NC=C3)=O)C3=C(N=C(C(C)(C)C)N4)C4=C2C=C1
,,,,,,,,,,,,,,,,janus kinase,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,janus kinase,fedratinib,HY-L025-9,H09,HY-10409A,Fedratinib (hydrochloride hydrate),TG-101348 (hydrochloride hydrate); SAR 302503 (hydrochloride hydrate),1374744-69-0,615.62,Apoptosis; JAK,Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research[1][2].",C27H40Cl2N6O4S,DMSO : 125 mg/mL (203.05 mM; Need ultrasonic); H2O : 100 mg/mL (162.44 mM; Need ultrasonic),10mM,Cancer,Launched,[H]Cl.[H]O[H].[H]Cl.O=S(C1=CC=CC(NC2=NC(NC3=CC=C(C=C3)OCCN4CCCC4)=NC=C2C)=C1)(NC(C)(C)C)=O
,,,,,,,,,,,,,,,,janus kinase,ag490,HY-L025-22,A04,HY-12000,AG490,Tyrphostin AG490; Tyrphostin B42,133550-30-8,294.3,Autophagy; EGFR; JAK; STAT,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.",C17H14N2O3,DMSO : ≥ 50 mg/mL (169.89 mM),10mM,Cancer,No Development Reported,O=C(NCC1=CC=CC=C1)/C(C#N)=C/C2=CC=C(O)C(O)=C2
,,,,,,,,,,,,,,,,janus kinase,ruxolitinib,HY-L025-64,A05,HY-50858,Ruxolitinib (phosphate),INCB018424 phosphate,1092939-17-7,404.36,Autophagy; JAK; Mitophagy,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.",C17H21N6O4P,DMSO : ≥ 31 mg/mL (76.66 mM); H2O : 10 mg/mL (24.73 mM; Need ultrasonic),10mM,Cancer,Launched,N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2.O=P(O)(O)O
,,,,,,,,,,,,,,,,janus kinase,cp 690550,HY-L025-63,D09,HY-40354A,Tofacitinib (citrate),Tasocitinib (citrate); CP-690550 (citrate),540737-29-9,504.49,Apoptosis; Bacterial; Fungal; Influenza Virus; JAK,Anti-infection; Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.",C22H28N6O8,DMSO : 28.57 mg/mL (56.63 mM; Need ultrasonic); H2O : 3.33 mg/mL (6.60 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O
,,,,,,,,,,,,,,,,janus kinase,methotrexate,HY-L025-44,G05,HY-14519A,Methotrexate (disodium),Amethopterin (disodium); CL14377 (disodium); WR19039 (disodium),7413-34-5,498.4,ADC Cytotoxin; Antifolate; Apoptosis; Bacterial; DNA/RNA Synthesis,Antibody-drug Conjugate/ADC Related; Anti-infection; Apoptosis; Cell Cycle/DNA Damage,"Methotrexate (Amethopterin) disodium, an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate disodium, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia)[1][2][3].",C20H20N8Na2O5,DMSO : 5 mg/mL (10.03 mM; ultrasonic and warming and adjust pH to 5 with HCl and heat to 60°C); H2O : 50 mg/mL (100.32 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Launched,NC1=NC(N)=C2C(N=CC(CN(C)C3=CC=C(C(N[C@@H](CCC(O[Na])=O)C(O[Na])=O)=O)C=C3)=N2)=N1
,,,,,,,,,,,,,,,,ikk,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,ikk,kaempferol,HY-L025-45,F09,HY-14590,Kaempferol,Kempferol; Robigenin,520-18-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Estrogen Receptor/ERR; HIV; Mitophagy; Parasite,Anti-infection; Apoptosis; Autophagy; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer[1][2][3][4].",C15H10O6,DMSO : ≥ 32 mg/mL (111.79 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=C(O)C2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,ikk,pristimerin,HY-L025-78,A07,HY-N1937,Pristimerin,Celastrol methyl ester,1258-84-0,464.64,Bacterial,Anti-infection,Pristimerin is a potent and reversible monoacylglycerol lipase (MGL) inhibitor with an IC50 of 93 nM.,C30H40O4,DMSO : 20 mg/mL (43.04 mM; Need ultrasonic); DMF : 25 mg/mL (53.81 mM; Need ultrasonic),10mM,Cancer,No Development Reported,C[C@](C1=CC=C(C(C)=C2O)C3=CC2=O)(CC[C@]4(C)[C@@]5([H])C[C@@](C(OC)=O)(C)CC4)[C@]5(CC[C@]13C)C
,,,,,,,,,,,,,,,,ikk,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,ikk,sc 514,HY-L025-40,A09,HY-13802,SC-514,GK 01140,354812-17-2,224.3,IKK,NF-κB,"SC-514 is a selective IKK-2 inhibitor (IC50=11.2 μM), which does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.",C9H8N2OS2,DMSO : 50 mg/mL (222.92 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C(C1=C(N)C=C(C2=CSC=C2)S1)N
,,,,,,,,,,,,,,,,ikk,apigenin,HY-L025-77,B10,HY-N1201,Apigenin,"4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1",520-36-5,270.24,Autophagy; Cytochrome P450; Endogenous Metabolite,Autophagy; Metabolic Enzyme/Protease,"Apigenin (4',5,7-Trihydroxyflavone) is a competitive CYP2C9 inhibitor with a Ki of 2 μM.",C15H10O5,DMSO : 83.33 mg/mL (308.36 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=CC2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,ikk,nac,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,ikk,wedelolactone,HY-L025-75,A03,HY-N0551,Wedelolactone,,524-12-9,314.25,Apoptosis; Caspase; Lipoxygenase,Apoptosis; Metabolic Enzyme/Protease,"Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibits the IKK Complex. Wedelolactone also inhibits 5-lipoxygenase (5-Lox) with an IC50 of 2.5 μM. Wedelolactone induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt. Wedelolactone can extract from Eclipta alba, and it can be used for the research of cancer[1][2][3].",C16H10O7,DMSO : 125 mg/mL (397.77 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,No Development Reported,O=C1C2=C(OC3=CC(O)=C(O)C=C32)C4=C(O)C=C(OC)C=C4O1
,,,,,,,,,,,,,,,,ikk,fisetin,HY-L025-72,H11,HY-N0182,Fisetin,,528-48-3,286.24,PPAR; Sirtuin; TNF Receptor,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Vitamin D Related/Nuclear Receptor,"Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.",C15H10O6,DMSO : 25 mg/mL (87.34 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease,Phase 3,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC=C13
,,,,,,,,,,,,,,,,ikk,imd 0354,HY-L025-6,B09,HY-10172,IMD-0354,IKK2 Inhibitor V,978-62-1,383.67,IKK,NF-κB,IMD-0354 (IKK2 Inhibitor V) is a selective IKKβ inhibitor which inhibits NF-κB activity[1]. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC50 of 1.2 uM[2].,C15H8ClF6NO2,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : ≥ 100 mg/mL (260.64 mM),10mM,Cancer,No Development Reported,O=C(NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C2=CC(Cl)=CC=C2O
,,,,,,,,,,,,,,,,ikk,celastrol,HY-L025-32,A08,HY-13067,Celastrol,Tripterine; Tripterin,34157-83-0,450.61,Apoptosis; Autophagy; Endogenous Metabolite; Mitophagy; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease,Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.,C29H38O4,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 33.33 mg/mL (73.97 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C(C2=CC=C3[C@](C)([C@]4(CC[C@]3(C2=CC1=O)C)C)CC[C@@]5(C)CC[C@@](C(O)=O)(C[C@]54[H])C)C
,,,,,,,,,,,,,,,,cdk2,purvalanol a,HY-L025-59,C06,HY-18299A,Purvalanol A,NG-60,212844-53-6,388.89,Apoptosis; Autophagy; CDK,Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, resepctively.",C19H25ClN6O,DMSO : ≥ 50 mg/mL (128.57 mM),10mM,Cancer,No Development Reported,CC([C@@H](NC1=NC(NC2=CC=CC(Cl)=C2)=C3N=CN(C(C)C)C3=N1)CO)C
,,,,,,,,,,,,,,,,cdk2,embelin,HY-L025-58,C09,HY-17473,Embelin,Embelic acid; Emberine; NSC 91874,550-24-3,294.39,Apoptosis; Autophagy; IAP; NF-κB,Apoptosis; Autophagy; NF-κB,"Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC50=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells[1][2][3].",C17H26O4,DMSO : ≥ 50 mg/mL (169.84 mM),10mM,Cancer,No Development Reported,O=C1C(O)=C(CCCCCCCCCCC)C(C(O)=C1)=O
,,,,,,,,,,,,,,,,cdk2,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
,,,,,,,,,,,,,,,,cdk2,honokiol,HY-L025-71,F02,HY-N0003,Honokiol,NSC 293100,35354-74-6,266.33,Akt; Autophagy; ERK; HCV,Anti-infection; Autophagy; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt,"Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt. Honokiol can readily cross the blood brain barrier[1][2][3][4].",C18H18O2,DMSO : ≥ 50 mg/mL (187.74 mM),10mM,Cancer,Phase 3,OC1=C(CC=C)C=C(C2=CC(CC=C)=CC=C2O)C=C1
,,,,,,,,,,,,,,,,cdk2,chidamide,HY-L025-13,E06,HY-109015,Tucidinostat,Chidamide; HBI-8000; CS 055,1616493-44-7,390.41,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Tucidinostat (Chidamide) is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC50s, 733 nM, 432 nM, respectively), and shows no effect on HDAC4/5/6/7/9[1].",C22H19FN4O2,DMSO : ≥ 50 mg/mL (128.07 mM),10mM,Cancer,Launched,O=C(C1=CC=C(CNC(/C=C/C2=CN=CC=C2)=O)C=C1)NC(C=CC(F)=C3)=C3N
,,,,,,,,,,,,,,,,cdk2,apigenin,HY-L025-77,B10,HY-N1201,Apigenin,"4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1",520-36-5,270.24,Autophagy; Cytochrome P450; Endogenous Metabolite,Autophagy; Metabolic Enzyme/Protease,"Apigenin (4',5,7-Trihydroxyflavone) is a competitive CYP2C9 inhibitor with a Ki of 2 μM.",C15H10O5,DMSO : 83.33 mg/mL (308.36 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=CC2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,cdk2,luteolin,HY-L025-72,G06,HY-N0162,Luteolin,Luteoline; Luteolol; Digitoflavone,491-70-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Keap1-Nrf2,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells[1][2][3].",C15H10O6,DMSO : ≥ 100 mg/mL (349.36 mM),10mM,Cancer; Inflammation/Immunology,Phase 2,O=C1C=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13
,,,,,,,,,,,,,,,,cdk2,dha,HY-L025-71,C06,HY-B2167,Docosahexaenoic acid,DHA; Cervonic acid,6217-54-5,328.49,Endogenous Metabolite,Metabolic Enzyme/Protease,Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk.,C22H32O2,Ethanol : 50 mg/mL (152.21 mM; Need ultrasonic); DMSO : 100 mg/mL (304.42 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(O)=O
,,,,,,,,,,,,,,,,cdk2,magnolol,HY-L025-72,G07,HY-N0163,Magnolol,,528-43-8,266.33,Autophagy; Bacterial; PPAR; RAR/RXR,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both RXRα and PPARγ, with EC50 values of 10.4 μM and 17.7 μM, respectively.",C18H18O2,DMSO : 100 mg/mL (375.47 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease,Launched,OC1=CC=C(CC=C)C=C1C2=CC(CC=C)=CC=C2O
,,,,,,,,,,,,,,,,cdk2,dexamethasone,HY-L025-46,B10,HY-14648,Dexamethasone,Hexadecadrol; Prednisolone F,50-02-2,392.46,Antibiotic; Autophagy; Bacterial; Complement System; Glucocorticoid Receptor; Mitophagy; SARS-CoV,Anti-infection; Autophagy; Immunology/Inflammation; Vitamin D Related/Nuclear Receptor,"Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.",C22H29FO5,DMSO : 250 mg/mL (637.01 mM; ultrasonic and warming and heat to 60°C); Ethanol : 8.33 mg/mL (21.23 mM; Need ultrasonic),10mM,Cancer; Infection; Endocrinology; Inflammation/Immunology,Launched,O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@@]4(C(CO)=O)O)=C1
,,,,,,,,,,,,,,,,cdk2,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,mmp9,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,mmp9,atorvastatin,HY-L025-57,H04,HY-17379,Atorvastatin (hemicalcium salt),CI-981; Atorvastatin hemicalcium,134523-03-8,577.67,Autophagy; Ferroptosis; HMG-CoA Reductase (HMGCR),Apoptosis; Autophagy; Metabolic Enzyme/Protease,"Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3].",C33H34Ca0.5FN2O5,DMSO : ≥ 50 mg/mL (86.55 mM); H2O : < 0.1 mg/mL (insoluble),10mM,Metabolic Disease; Inflammation/Immunology; Cancer,Launched,FC1=CC=C(C2=C(C3=CC=CC=C3)C(C(NC4=CC=CC=C4)=O)=C(C(C)C)N2CC[C@@H](O)C[C@@H](O)CC([O-])=O)C=C1.[0.5Ca2+]
,,,,,,,,,,,,,,,,mmp9,zoledronic acid,HY-L025-39,H05,HY-13777,Zoledronic Acid,Zoledronate; CGP 42446; CGP42446A; ZOL 446,118072-93-8,272.09,Apoptosis; Autophagy; Bacterial,Anti-infection; Apoptosis; Autophagy,"Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects[1].",C5H10N2O7P2,H2O : 4.81 mg/mL (17.68 mM; ultrasonic and warming and adjust pH to 6 with NaOH and heat to 60°C),10mM,Cancer; Metabolic Disease,Launched,OC(P(O)(O)=O)(P(O)(O)=O)CN1C=CN=C1
,,,,,,,,,,,,,,,,mmp9,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,mmp9,bortezomib,HY-L025-7,E07,HY-10227,Bortezomib,PS-341; LDP-341; NSC 681239,179324-69-7,384.24,Apoptosis; Autophagy; NF-κB; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].",C19H25BN4O4,DMSO : 50 mg/mL (130.13 mM; Need ultrasonic); Ethanol : 66.67 mg/mL (173.51 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
,,,,,,,,,,,,,,,,mmp9,nac,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,mmp9,luteolin,HY-L025-72,G06,HY-N0162,Luteolin,Luteoline; Luteolol; Digitoflavone,491-70-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Keap1-Nrf2,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells[1][2][3].",C15H10O6,DMSO : ≥ 100 mg/mL (349.36 mM),10mM,Cancer; Inflammation/Immunology,Phase 2,O=C1C=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13
,,,,,,,,,,,,,,,,mmp9,baicalein,HY-L025-73,B02,HY-N0196,Baicalein,"5,6,7-Trihydroxyflavone",491-67-8,270.24,Ferroptosis; Influenza Virus; Xanthine Oxidase,Anti-infection; Apoptosis; Metabolic Enzyme/Protease,"Baicalein (5,6,7-Trihydroxyflavone) is a xanthine oxidase inhibitor with an IC50 value of 3.12 μM.",C15H10O5,DMSO : 50 mg/mL (185.02 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1C=C(C2=CC=CC=C2)OC3=CC(O)=C(O)C(O)=C13
,,,,,,,,,,,,,,,,mmp9,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,mmp9,silibinin,HY-L025-76,C08,HY-N0779A,Silybin,Silibinin,802918-57-6,482.44,Apoptosis,Apoptosis,"Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds. Silybin induces apoptosis and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity[1][2].",C25H22O10,DMSO : 25 mg/mL (51.82 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C1[C@H](O)[C@@H](C2=CC=C(OC(CO)C(C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15
,,,,,,,,,,,,,,,,mmp9,minocycline,HY-L025-58,A05,HY-17412,Minocycline (hydrochloride),,13614-98-7,493.94,Antibiotic; Apoptosis; Bacterial; Calcium Channel; HIF/HIF Prolyl-Hydroxylase; MDM-2/p53; Potassium Channel,Anti-infection; Apoptosis; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling,"Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect[1][2][3][4][5][6][7].",C23H28ClN3O7,DMSO : 19.23 mg/mL (38.93 mM; Need ultrasonic); H2O : 10 mg/mL (20.25 mM; Need ultrasonic),10mM,Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease,Launched,OC1=C(C(N)=O)C([C@@]2(O)C(O)=C3C(C4=C(O)C=CC(N(C)C)=C4C[C@@]3([H])C[C@@]2([H])[C@@H]1N(C)C)=O)=O.Cl
,,,,,,,,,,,,,,,,mmp9,celecoxib,HY-L025-43,G07,HY-14398,Celecoxib,SC 58635,169590-42-5,381.37,COX,Immunology/Inflammation,"Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.",C17H14F3N3O2S,DMSO : ≥ 50 mg/mL (131.11 mM),10mM,Inflammation/Immunology; Cancer,Launched,CC1=CC=C(C=C1)C2=CC(C(F)(F)F)=NN2C3=CC=C(C=C3)S(=O)(N)=O
,,,,,,,,,,,,,,,,mmp9,propofol,HY-L025-69,B04,HY-B0649,Propofol,"2,6-Diisopropylphenol",2078-54-8,178.27,Endogenous Metabolite; GABA Receptor,Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling,Propofol potently and directly activates GABAA receptor and inhibits glutamate receptor mediated excitatory synaptic transmission. Propofol has antinociceptive properties and is used for sedation and hypnotic[1].,C12H18O,DMSO : 100 mg/mL (560.95 mM; Need ultrasonic); H2O : 0.5 mg/mL (2.80 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,OC1=C(C(C)C)C=CC=C1C(C)C
,,,,,,,,,,,,,,,,mmp9,saha,HY-L025-7,E02,HY-10221,Vorinostat,SAHA; Suberoylanilide hydroxamic acid,149647-78-9,264.32,Apoptosis; Autophagy; Filovirus; HDAC; HPV; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].",C14H20N2O3,DMSO : ≥ 100 mg/mL (378.33 mM),10mM,Cancer; Infection,Launched,O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O
,,,,,,,,,,,,,,,,mmp9,pd98059,HY-L025-22,E02,HY-12028,PD98059,,167869-21-8,267.28,Aryl Hydrocarbon Receptor; Autophagy; ERK; MEK,Autophagy; Immunology/Inflammation; MAPK/ERK Pathway; Stem Cell/Wnt,"PD98059 is a potent and selective MEK inhibitor with an IC50 of 5 μM. PD98059 binds to the inactive form of MEK, thereby preventing the activation of MEK1 (IC50 of 2-7 μM) and MEK2 (IC50 of 50 μM) by upstream kinases. PD98059 is a ERK1/2 signaling inhibitor. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC50 of 4 μM) and AHR transformation (IC50 of 1 μM). PD98059 also inhibits Mycobacterium bovis Bacillus CalmetteGuerin (BCG)-induced autophagy[1][2][3].",C16H13NO3,DMSO : 33.33 mg/mL (124.70 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,No Development Reported,O=C1C=C(OC2=CC=CC=C21)C3=CC=CC(OC)=C3N
,,,,,,,,,,,,,,,,mmp9,progesterone,HY-L025-74,D04,HY-N0437,Progesterone,"Pregn-4-ene-3,20-dione",57-83-0,314.46,Endogenous Metabolite; Progesterone Receptor,Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,Progesterone is a steroid hormone that regulates the menstrual cycle and is crucial for pregnancy.,C21H30O2,H2O : 0.1 mg/mL (0.32 mM; Need ultrasonic); DMSO : 25 mg/mL (79.50 mM; Need ultrasonic),10mM,Cardiovascular Disease; Cancer,Launched,CC([C@H]1CC[C@@]2([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O)=O
,,,,,,,,,,,,,,,,mmp9,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,mmp9,sb 3ct,HY-L025-25,F08,HY-12354,SB-3CT,,292605-14-2,306.4,MMP,Metabolic Enzyme/Protease,"SB-3CT is a potent and competitive matrix metalloproteinase MMP-2 and MMP-9 inhibitor with Ki values of 13.9 and 600 nM, respectively. SB-3CT has high selectivity for gelatinases. SB-3CT shows blood-brain barrier permeability and has neuroprotective effects and anticancer activity[1][2][3].",C15H14O3S2,DMSO : ≥ 50 mg/mL (163.19 mM),10mM,Cancer,No Development Reported,O=S(CC1SC1)(C2=CC=C(OC3=CC=CC=C3)C=C2)=O
,,,,,,,,,,,,,,,,rtks,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,rtks,sorafenib,HY-L025-7,A11,HY-10201A,Sorafenib (Tosylate),Bay 43-9006 (Tosylate),475207-59-1,637.03,Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR,Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator[1].",C28H24ClF3N4O6S,H2O : < 0.1 mg/mL (insoluble); DMSO : ≥ 31 mg/mL (48.66 mM),10mM,Cancer,Launched,O=S(C1=CC=C(C=C1)C)(O)=O.O=C(NC2=CC=C(C(C(F)(F)F)=C2)Cl)NC3=CC=C(OC4=CC(C(NC)=O)=NC=C4)C=C3
,,,,,,,,,,,,,,,,rtks,sunitinib,HY-L025-7,F10,HY-10255A,Sunitinib,SU 11248,557795-19-4,398.47,Apoptosis; Autophagy; IRE1; Mitophagy; PDGFR; VEGFR,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK,"Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].",C22H27FN4O2,DMSO : 20.83 mg/mL (52.27 mM; ultrasonic and warming and heat to 80°C),10mM,Cancer,Launched,O=C(NCCN(CC)CC)C1=C(NC(/C=C2C(NC3=C\2C=C(C=C3)F)=O)=C1C)C
,,,,,,,,,,,,,,,,rtks,cabozantinib,HY-L025-31,D08,HY-13016,Cabozantinib,XL184; BMS-907351,849217-68-1,501.51,Apoptosis; c-Kit; c-Met/HGFR; FLT3; TAM Receptor; VEGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis[1][2].",C28H24FN3O5,DMSO : 25 mg/mL (49.85 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,O=C(C1(CC1)C(NC2=CC=C(F)C=C2)=O)NC3=CC=C(C=C3)OC4=C5C=C(OC)C(OC)=CC5=NC=C4
,,,,,,,,,,,,,,,,rtks,imatinib,HY-L025-64,D06,HY-50946,Imatinib (Mesylate),STI571 (Mesylate); CGP-57148B (Mesylate),220127-57-1,589.71,Autophagy; Bcr-Abl; c-Kit; PDGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.",C30H35N7O4S,DMSO : 125 mg/mL (211.97 mM; Need ultrasonic); H2O : ≥ 50 mg/mL (84.79 mM),10mM,Cancer,Launched,O=S(O)(C)=O.O=C(NC1=CC=C(C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)C)C4=CC=C(CN5CCN(CC5)C)C=C4
,,,,,,,,,,,,,,,,pi3k mtor,bez235,HY-L025-50,A09,HY-15174,Dactolisib (Tosylate),BEZ235 (Tosylate); NVP-BEZ 235 (Tosylate),1028385-32-1,641.74,Autophagy; mTOR; PI3K,Autophagy; PI3K/Akt/mTOR,"Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.",C37H31N5O4S,H2O : < 0.1 mg/mL (insoluble); DMSO : 34 mg/mL (52.98 mM; Need ultrasonic and warming),10mM,Cancer,Phase 3,CN(C1=C2C3=CC(C4=CC5=CC=CC=C5N=C4)=CC=C3N=C1)C(N2C6=CC=C(C=C6)C(C)(C#N)C)=O.CC7=CC=C(S(=O)(O)=O)C=C7
,,,,,,,,,,,,,,,,arid1a,mk 2206,HY-L025-9,B02,HY-10358,MK-2206 (dihydrochloride),MK-2206 (2HCl),1032350-13-2,480.39,Akt; Apoptosis; Autophagy,Apoptosis; Autophagy; PI3K/Akt/mTOR,"MK-2206 dihydrochloride (MK-2206 (2HCl)) is an orally active allosteric AKT inhibitor with IC50s of 5 nM, 12 nM, and 65 nM for AKT1, AKT2, and AKT3, respectively. MK-2206 dihydrochloride induces autophagy[1][3].",C25H23Cl2N5O,DMSO : 50 mg/mL (104.08 mM; ultrasonic and warming and heat to 60°C); H2O : 3.57 mg/mL (7.43 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=C1N2C(C3=CC(C4=CC=CC=C4)=C(N=C3C=C2)C5=CC=C(C6(N)CCC6)C=C5)=NN1.Cl.Cl
,,,,,,,,,,,,,,,,hif 1α,fg 4592,HY-L025-34,H05,HY-13426,Roxadustat,FG-4592,808118-40-3,352.34,Ferroptosis; HIF/HIF Prolyl-Hydroxylase,Apoptosis; Metabolic Enzyme/Protease,"Roxadustat is an orally active hypoxia-inducible factor (HIF) prolyl-hydroxylase (PHD) inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin[1].",C19H16N2O5,H2O : < 0.1 mg/mL (ultrasonic) (insoluble); DMSO : ≥ 100 mg/mL (283.82 mM),10mM,Cancer,Launched,O=C(O)CNC(C1=C(O)C2=C(C(C)=N1)C=C(OC3=CC=CC=C3)C=C2)=O
,,,,,,,,,,,,,,,,hif 1α,sn 38,HY-L025-39,A03,HY-13704,SN-38,7-Ethyl-10-hydroxycamptothecin,86639-52-3,392.4,ADC Cytotoxin; Autophagy; Topoisomerase,Antibody-drug Conjugate/ADC Related; Autophagy; Cell Cycle/DNA Damage,"SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively[1][2][3][4].",C22H20N2O5,DMSO : 25 mg/mL (63.71 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C(CC)C5=CC(O)=CC=C5N=C4C3=C2)=O
,,,,,,,,,,,,,,,,hif 1α,temsirolimus,HY-L025-64,C08,HY-50910,Temsirolimus,CCI-779,162635-04-3,1030.29,Apoptosis; Autophagy; Bacterial; mTOR,Anti-infection; Apoptosis; Autophagy; PI3K/Akt/mTOR,Temsirolimus is an inhibitor of mTOR with an IC50 of 1.76 μM. Temsirolimus activates autophagy and prevents deterioration of cardiac function in animal model[8].,C56H87NO16,H2O : < 0.1 mg/mL (insoluble); DMSO : 250 mg/mL (242.65 mM; Need ultrasonic); Ethanol : 200 mg/mL (194.12 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](OC(C(C)(CO)CO)=O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,hif 1α,bufalin,HY-L025-76,G08,HY-N0877,Bufalin,,465-21-4,386.52,Na+/K+ ATPase,Membrane Transporter/Ion Channel,"Bufalin is an active component isolated from Chan Su, acts as a potent Na+/K+-ATPase inhibitor, binds to the subunit α1, α2 and α3, with Kd of 42.5, 45 and 40 nM, respectively[1][2]. Anti-cancer activity[2].",C24H34O4,DMSO : 100 mg/mL (258.72 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O[C@]([C@@](CC[C@@]1([H])[C@@]2(CC[C@H](O)C1)C)([H])[C@]2([H])CC3)(CC[C@@H]4C(C=C5)=COC5=O)[C@]34C
,,,,,,,,,,,,,,,,hif 1α,celecoxib,HY-L025-43,G07,HY-14398,Celecoxib,SC 58635,169590-42-5,381.37,COX,Immunology/Inflammation,"Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.",C17H14F3N3O2S,DMSO : ≥ 50 mg/mL (131.11 mM),10mM,Inflammation/Immunology; Cancer,Launched,CC1=CC=C(C=C1)C2=CC(C(F)(F)F)=NN2C3=CC=C(C=C3)S(=O)(N)=O
,,,,,,,,,,,,,,,,hif 1α,oroxylin a,HY-L025-75,A06,HY-N0560,Oroxylin A,Baicalein 6-methyl ether; 6-Methoxybaicalein,480-11-5,284.26,Autophagy; HIF/HIF Prolyl-Hydroxylase; Virus Protease,Anti-infection; Autophagy; Metabolic Enzyme/Protease,"Oroxylin A is a natural active flavonoid with strong anticancer effects.
IC50 value:
Target:
In vitro: Oroxylin A suppressed the MDM2-mediated degradation of p53 via downregulating MDM2 transcription in wt-p53 cancer cells [1]. Oroxylin A remarkably reduced the generation of lactate and glucose uptake under hypoxia in HepG2 cells, inhibited HIF-1α expression and its stability [2]. Oroxylin A promotes superoxide dismutase (SOD2) gene expression through SIRT3-regulated DNA-binding activity of FOXO3a and increases the activity of SOD2 by promoting SIRT3-mediated deacetylation [3]. 
In vivo: Oroxylin A inhibited the tumor growth of nude mice-inoculated MCF-7 or HCT116 cells. The expression of MDM2 protein in tumor tissue was downregulated by oroxylin A as well [1].",C16H12O5,DMSO : ≥ 32 mg/mL (112.57 mM),10mM,Cancer,No Development Reported,O=C1C=C(C2=CC=CC=C2)OC3=CC(O)=C(OC)C(O)=C13
,,,,,,,,,,,,,,,,hif 1α,17 aag,HY-L025-7,D07,HY-10211,Tanespimycin,17-AAG; NSC 330507; CP 127374,75747-14-7,585.69,Antibiotic; Apoptosis; Autophagy; Bacterial; HSP; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90[1][5]. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression[3].",C31H43N3O8,DMSO : 50 mg/mL (85.37 mM; Need ultrasonic),10mM,Cancer; Infection,Phase 3,O=C(C(NC(/C(C)=C/C=C\[C@H](OC)[C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](C1)C)OC)O)C)OC(N)=O)=O)=CC2=O)C1=C2NCC=C
,,,,,,,,,,,,,,,,hif 1α,tempol,HY-L025-2,H07,HY-100561,Tempol,4-Hydroxy-TEMPO,2226-96-2,172.24,Autophagy; Reactive Oxygen Species,Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,Tempol is a general superoxide dismutase (SOD)-mimetic agent that efficiently neutralizes reactive oxygen species (ROS).,C9H18NO2*,H2O : 5.56 mg/mL (32.28 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,[O]N1C(C)(C)CC(O)CC1(C)C
,,,,,,,,,,,,,,,,hif 1α,bso,HY-L025-11,B07,HY-106376,"DL-Buthionine-(S,R)-sulfoximine",Buthionine sulfoximine; BSO,5072-26-4,222.31,Ferroptosis,Apoptosis,"DL-Buthionine-(S,R)-sulfoximine is a potent inhibitor of glutamylcysteine synthetase biosynthesis.",C8H18N2O3S,H2O : 25 mg/mL (112.46 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 1,OC(C(N)CCS(CCCC)(=N)=O)=O
,,,,,,,,,,,,,,,,hif 1α,gw9662,HY-L025-56,D09,HY-16578,GW9662,,22978-25-2,276.68,PPAR,Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor,"GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively.",C13H9ClN2O3,DMSO : ≥ 100 mg/mL (361.43 mM),10mM,Cancer,No Development Reported,O=C(NC1=CC=CC=C1)C2=CC([N+]([O-])=O)=CC=C2Cl
,,,,,,,,,,,,,,,,hif 1α,rotenone,HY-L025-70,H11,HY-B1756,Rotenone,,83-79-4,394.42,Apoptosis; Autophagy; Mitochondrial Metabolism,Apoptosis; Autophagy; Metabolic Enzyme/Protease,Rotenone is a mitochondrial electron transport chain complex I inhibitor.  Rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production.,C23H22O6,H2O : < 0.1 mg/mL (ultrasonic) (insoluble); DMSO : 50 mg/mL (126.77 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,No Development Reported,O=C1[C@]2([H])[C@](COC3=CC(OC)=C(OC)C=C32)([H])OC4=C5C(O[C@@H](C(C)=C)C5)=CC=C14
,,,,,,,,,,,,,,,,hif 1α,lificiguat,HY-L025-48,G02,HY-14927,Lificiguat,YC-1,170632-47-0,304.34,Guanylate Cyclase,GPCR/G Protein,Lificiguat binds to the β subunit of soluble guanylyl cyclase(sGC) with Kd of 0.6-1.1 μM in the presence of CO.,C19H16N2O2,DMSO : ≥ 100 mg/mL (328.58 mM),10mM,Cancer,No Development Reported,OCC1=CC=C(C2=NN(CC3=CC=CC=C3)C4=C2C=CC=C4)O1
,,,,,,,,,,,,,,,,smad3,kaempferol,HY-L025-45,F09,HY-14590,Kaempferol,Kempferol; Robigenin,520-18-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Estrogen Receptor/ERR; HIV; Mitophagy; Parasite,Anti-infection; Apoptosis; Autophagy; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer[1][2][3][4].",C15H10O6,DMSO : ≥ 32 mg/mL (111.79 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=C(O)C2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,smad3,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
,,,,,,,,,,,,,,,,smad3,pirfenidone,HY-L025-69,C05,HY-B0673,Pirfenidone,AMR69,53179-13-8,185.22,CCR; TGF-beta/Smad,GPCR/G Protein; Immunology/Inflammation; Stem Cell/Wnt; TGF-beta/Smad,Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities[1][2][3].,C12H11NO,DMSO : ≥ 100 mg/mL (539.90 mM); H2O : 16.67 mg/mL (90.00 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Launched,O=C1C=CC(C)=CN1C2=CC=CC=C2
,,,,,,,,,,,,,,,,smad3,fenofibrate,HY-L025-57,G03,HY-17356,Fenofibrate,,49562-28-9,360.83,Autophagy; Cytochrome P450; PPAR,Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.",C20H21ClO4,DMSO : 250 mg/mL (692.85 mM; Need ultrasonic),10mM,Cardiovascular Disease; Cancer,Launched,CC(C)(OC1=CC=C(C(C2=CC=C(Cl)C=C2)=O)C=C1)C(OC(C)C)=O
,,,,,,,,,,,,,,,,smad3,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
,,,,,,,,,,,,,,,,smad3,artesunate,HY-L025-73,A10,HY-N0193,Artesunate,,88495-63-0,384.42,Ferroptosis; Parasite; STAT; Virus Protease,Anti-infection; Apoptosis; JAK/STAT Signaling; Stem Cell/Wnt,Artesunate is an inhibitor of both STAT-3 and exported protein 1 (EXP1).,C19H28O8,H2O : 0.67 mg/mL (1.74 mM; Need ultrasonic); 7.5% sodium bicarbonate : 20 mg/mL (52.03 mM; Need ultrasonic); DMSO : 83.33 mg/mL (216.77 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(O[C@H]1[C@H](C)[C@]2([H])CC[C@@H](C)[C@]3([H])CC[C@@](O4)(C)OO[C@]32[C@]4([H])O1)CCC(O)=O
,,,,,,,,,,,,,,,,smad3,emodin,HY-L025-43,G03,HY-14393,Emodin,Frangula emodin,518-82-1,270.24,11β-HSD; Autophagy; Casein Kinase; SARS-CoV,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively.  Emodin ameliorates metabolic disorder in diet-induced obese mice[3].",C15H10O5,Acetone : 10.87 mg/mL (40.22 mM; Need ultrasonic); DMSO : 5.41 mg/mL (20.02 mM; Need ultrasonic); Ethanol : 10.87 mg/mL (40.22 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C(C=C(C)C=C2O)C(C3=CC(O)=CC(O)=C31)=O
,,,,,,,,,,,,,,,,smad3,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,smad3,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,smad3,paeonol,HY-L025-72,G05,HY-N0159,Paeonol,,552-41-0,166.17,Autophagy; Monoamine Oxidase,Autophagy; Neuronal Signaling,"Paeonol is an active extraction from the root of Paeonia suffruticosa, Paeonol inhibits MAO-A and MAO-B with IC50 of 54.6 μM and 42.5 μM, respectively.",C9H10O3,DMSO : ≥ 38 mg/mL (228.68 mM); Ethanol : 50 mg/mL (300.90 mM; Need ultrasonic); H2O : 1 mg/mL (6.02 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,CC(C1=CC=C(OC)C=C1O)=O
,,,,,,,,,,,,,,,,smad3,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,mdm2,nutlin 3,HY-L025-63,G05,HY-50696,Nutlin-3,,548472-68-0,581.49,E1/E2/E3 Enzyme; MDM-2/p53,Apoptosis; Metabolic Enzyme/Protease,"Nutlin-3 is a commercial available p53-MDM2 inhibitor, with Ki of 90 nM.",C30H30Cl2N4O4,Ethanol : 100 mg/mL (171.97 mM; Need ultrasonic); DMSO : ≥ 50 mg/mL (85.99 mM),10mM,Cancer,No Development Reported,O=C1NCCN(C(N2[C@@H](C3=CC=C(Cl)C=C3)[C@@H](C4=CC=C(Cl)C=C4)N=C2C5=CC=C(OC)C=C5OC(C)C)=O)C1
,,,,,,,,,,,,,,,,mdm2,ds 3032b,HY-L025-5,B11,HY-101266B,Milademetan (tosylate hydrate),DS-3032b; DS-3032 (tosylate hydrate),2095625-97-9,808.74,Apoptosis; E1/E2/E3 Enzyme; MDM-2/p53,Apoptosis; Metabolic Enzyme/Protease,"Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest, senescence and apoptosis[1][2].",C37H44Cl2FN5O8S,DMSO : 50 mg/mL (61.82 mM; Need ultrasonic),10mM,Cancer,Phase 2,CC1=CC=C(S(=O)(O)=O)C=C1.O=C2NC3=CC(Cl)=CC=C3[C@]24C5(N[C@H]([C@@H]4C6=CC=NC(Cl)=C6F)C(N[C@@H]7CC[C@H](OC7)C(N)=O)=O)CCC(C)(CC5)C.[H]O[H]
,,,,,,,,,,,,,,,,mdm2,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
,,,,,,,,,,,,,,,,mdm2,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,mdm2,oroxylin a,HY-L025-75,A06,HY-N0560,Oroxylin A,Baicalein 6-methyl ether; 6-Methoxybaicalein,480-11-5,284.26,Autophagy; HIF/HIF Prolyl-Hydroxylase; Virus Protease,Anti-infection; Autophagy; Metabolic Enzyme/Protease,"Oroxylin A is a natural active flavonoid with strong anticancer effects.
IC50 value:
Target:
In vitro: Oroxylin A suppressed the MDM2-mediated degradation of p53 via downregulating MDM2 transcription in wt-p53 cancer cells [1]. Oroxylin A remarkably reduced the generation of lactate and glucose uptake under hypoxia in HepG2 cells, inhibited HIF-1α expression and its stability [2]. Oroxylin A promotes superoxide dismutase (SOD2) gene expression through SIRT3-regulated DNA-binding activity of FOXO3a and increases the activity of SOD2 by promoting SIRT3-mediated deacetylation [3]. 
In vivo: Oroxylin A inhibited the tumor growth of nude mice-inoculated MCF-7 or HCT116 cells. The expression of MDM2 protein in tumor tissue was downregulated by oroxylin A as well [1].",C16H12O5,DMSO : ≥ 32 mg/mL (112.57 mM),10mM,Cancer,No Development Reported,O=C1C=C(C2=CC=CC=C2)OC3=CC(O)=C(OC)C(O)=C13
,,,,,,,,,,,,,,,,mdm2,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,mdm2,triptolide,HY-L025-63,C07,HY-32735,Triptolide,PG490,38748-32-2,360.4,Apoptosis; NF-κB,Apoptosis; NF-κB,"Triptolide is a diterpenoid triepoxide extracted from the root of Tripterygium wilfordii with immunosuppressive, anti-inflammatory, antiproliferative and antitumour effects. Triptolide is a NF-κB activation inhibitor[1][2][3][4][5][6].",C20H24O6,DMSO : 25 mg/mL (69.37 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,C[C@@]12[C@@]34[C@](O5)([C@@H]([C@](O6)(C(C)C)[C@@H]6[C@@H]3O4)O)[C@@H]5C[C@@]1([H])C7=C(C(OC7)=O)CC2
,,,,,,,,,,,,,,,,mdm2,mi 773,HY-L025-58,D03,HY-17493,MI-773,,1303607-07-9,562.5,E1/E2/E3 Enzyme; MDM-2/p53,Apoptosis; Metabolic Enzyme/Protease,MI-773 is a potent MDM2-p53 protein‐protein interaction (PPI) inhibitor with high binding affinity against MDM2 (Kd=8.2 nM). MI-773 has antitumor activity[1][2].,C29H34Cl2FN3O3,DMSO : ≥ 53 mg/mL (94.22 mM),10mM,Cancer,No Development Reported,O=C([C@H](N[C@@H]1CC(C)(C)C)[C@H](C2=CC=CC(Cl)=C2F)[C@]31C(NC4=C3C=CC(Cl)=C4)=O)N[C@H]5CC[C@H](O)CC5
,,,,,,,,,,,,,,,,mdm2,pd98059,HY-L025-22,E02,HY-12028,PD98059,,167869-21-8,267.28,Aryl Hydrocarbon Receptor; Autophagy; ERK; MEK,Autophagy; Immunology/Inflammation; MAPK/ERK Pathway; Stem Cell/Wnt,"PD98059 is a potent and selective MEK inhibitor with an IC50 of 5 μM. PD98059 binds to the inactive form of MEK, thereby preventing the activation of MEK1 (IC50 of 2-7 μM) and MEK2 (IC50 of 50 μM) by upstream kinases. PD98059 is a ERK1/2 signaling inhibitor. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC50 of 4 μM) and AHR transformation (IC50 of 1 μM). PD98059 also inhibits Mycobacterium bovis Bacillus CalmetteGuerin (BCG)-induced autophagy[1][2][3].",C16H13NO3,DMSO : 33.33 mg/mL (124.70 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,No Development Reported,O=C1C=C(OC2=CC=CC=C21)C3=CC=CC(OC)=C3N
,,,,,,,,,,,,,,,,mdm2,trametinib,HY-L025-14,D08,HY-10999A,Trametinib (DMSO solvate),GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate),1187431-43-1,693.53,Apoptosis; MEK,Apoptosis; MAPK/ERK Pathway,Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis[1][2].,C28H29FIN5O5S,DMSO : 69 mg/mL (99.49 mM; Need ultrasonic),10mM,Cancer,Launched,CN1C(C(C)=C(N(C(N(C2=O)C3CC3)=O)C4=CC=CC(NC(C)=O)=C4)C2=C1NC5=CC=C(C=C5F)I)=O.CS(C)=O
,,,,,,,,,,,,,,,,mdm2,rg7388,HY-L025-53,D09,HY-15676,Idasanutlin,RG7388,1229705-06-9,616.48,E1/E2/E3 Enzyme; MDM-2/p53,Apoptosis; Metabolic Enzyme/Protease,"Idasanutlin (RG7388) is a potent and selective MDM2 antagonist, inhibiting p53-MDM2 binding, with an IC50 of 6 nM.",C31H29Cl2F2N3O4,DMSO : ≥ 45 mg/mL (73.00 mM),10mM,Cancer,Phase 3,O=C(O)C1=CC(OC)=C(NC([C@H]2[C@H](C3=C(F)C(Cl)=CC=C3)[C@](C4=CC=C(Cl)C=C4F)(C#N)[C@H](CC(C)(C)C)N2)=O)C=C1
,,,,,,,,,,,,,,,,mdm2,rita,HY-L025-34,H03,HY-13424,RITA,NSC 652287,213261-59-7,292.37,Autophagy; DNA Alkylator/Crosslinker; MDM-2/p53,Apoptosis; Autophagy; Cell Cycle/DNA Damage,"RITA is an inhibitor of p53-HDM-2 interaction, binds to p53dN, with a Kd of 1.5 nM, and also induces DNA-DNA cross-links.",C14H12O3S2,DMSO : ≥ 100 mg/mL (342.03 mM),10mM,Cancer,Phase 2,OCC1=CC=C(C2=CC=C(C3=CC=C(CO)S3)O2)S1
,,,,,,,,,,,,,,,,mdm2,sp 141,HY-L025-14,G10,HY-110182,SP-141,,1253491-42-7,324.38,MDM-2/p53,Apoptosis,SP-141 is a specific inhibitor of MDM2. SP-141 promotes MDM2 auto-ubiquitination and degradation. SP-141 might be used for the research of pancreatic cancer and breast cancer cells[1].,C22H16N2O,DMSO : 125 mg/mL (385.35 mM; Need ultrasonic),10mM,Cancer,No Development Reported,COC1=CC2=C(NC3=C2C=CN=C3C4=C5C=CC=CC5=CC=C4)C=C1
,,,,,,,,,,,,,,,,mdm2,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,mdm2,sar405838,HY-L025-61,A02,HY-18986,SAR405838,MI-77301,1303607-60-4,562.5,Apoptosis; E1/E2/E3 Enzyme; MDM-2/p53,Apoptosis; Metabolic Enzyme/Protease,"SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective MDM2-p53 interaction inhibitor. SAR405838 binds to MDM2 with a Ki of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity[1][2].",C29H34Cl2FN3O3,DMSO : 100 mg/mL (177.78 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C([C@H](N[C@H]1CC(C)(C)C)[C@H](C2=CC=CC(Cl)=C2F)[C@@]31C(NC4=C3C=CC(Cl)=C4)=O)N[C@@H]5CC[C@@H](O)CC5
,,,,,,,,,,,,,,,,meki,pd98059,HY-L025-22,E02,HY-12028,PD98059,,167869-21-8,267.28,Aryl Hydrocarbon Receptor; Autophagy; ERK; MEK,Autophagy; Immunology/Inflammation; MAPK/ERK Pathway; Stem Cell/Wnt,"PD98059 is a potent and selective MEK inhibitor with an IC50 of 5 μM. PD98059 binds to the inactive form of MEK, thereby preventing the activation of MEK1 (IC50 of 2-7 μM) and MEK2 (IC50 of 50 μM) by upstream kinases. PD98059 is a ERK1/2 signaling inhibitor. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC50 of 4 μM) and AHR transformation (IC50 of 1 μM). PD98059 also inhibits Mycobacterium bovis Bacillus CalmetteGuerin (BCG)-induced autophagy[1][2][3].",C16H13NO3,DMSO : 33.33 mg/mL (124.70 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,No Development Reported,O=C1C=C(OC2=CC=CC=C21)C3=CC=CC(OC)=C3N
,,,,,,,,,,,,,,,,pp2a,atra,HY-L025-46,C02,HY-14649,Retinoic acid,Vitamin A acid; all-trans-Retinoic acid; ATRA,302-79-4,300.44,Autophagy; Endogenous Metabolite; PPAR; RAR/RXR,Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.",C20H28O2,DMSO : 50 mg/mL (166.42 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,CC1(C)C(/C=C/C(C)=C/C=C/C(C)=C/C(O)=O)=C(C)CCC1
,,,,,,,,,,,,,,,,pp2a,forskolin,HY-L025-51,G04,HY-15371,Forskolin,Coleonol; Colforsin; HL 362,66575-29-9,410.5,Adenylate Cyclase; Autophagy; FXR,Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease,"Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC50 of 41 nM and an EC50 of 0.5 μM for type I adenylyl cyclase[1]. Forskolin is also an inducer of intracellular cAMP formation[2]. Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR[3]. Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy[4][5].",C22H34O7,DMSO : 100 mg/mL (243.61 mM; Need ultrasonic),10mM,Cancer; Endocrinology; Metabolic Disease; Inflammation/Immunology,No Development Reported,O=C1[C@@]2(O)[C@]([C@@H](OC(C)=O)[C@@H](O)[C@@]3([H])C(C)(C)CC[C@H](O)[C@@]32C)(C)O[C@@](C)(C=C)C1
,,,,,,,,,,,,,,,,pp2a,pentoxifylline,HY-L025-69,C09,HY-B0715,Pentoxifylline,BL-191; PTX; Oxpentifylline,5/6/93,278.31,Autophagy; HIV; Phosphodiesterase (PDE),Anti-infection; Autophagy; Metabolic Enzyme/Protease,"Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].",C13H18N4O3,DMSO : ≥ 2.8 mg/mL (10.06 mM); H2O : 93.3 mg/mL (335.24 mM; Need ultrasonic and warming),10mM,Cardiovascular Disease; Cancer,Launched,O=C(N1CCCCC(C)=O)N(C)C2=C(N(C)C=N2)C1=O
,,,,,,,,,,,,,,,,pp2a,fty720,HY-L025-22,A09,HY-12005,Fingolimod (hydrochloride),FTY720,162359-56-0,343.93,LPL Receptor; PAK,Cell Cycle/DNA Damage; Cytoskeleton; GPCR/G Protein,"Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate (S1P) receptors modulator. Fingolimod hydrochloride is phosphorylated  by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5. Fingolimod hydrochloride induces the internalization of S1P1, and consequently, inhibits S1P activity. Fingolimod hydrochloride also is a pak1 activator[1][4].",C19H34ClNO2,DMSO : ≥ 100 mg/mL (290.76 mM); H2O : 50 mg/mL (145.38 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Launched,OCC(N)(CO)CCC1=CC=C(C=C1)CCCCCCCC.[H]Cl
,,,,,,,,,,,,,,,,pp2a,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,pp2a,propofol,HY-L025-69,B04,HY-B0649,Propofol,"2,6-Diisopropylphenol",2078-54-8,178.27,Endogenous Metabolite; GABA Receptor,Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling,Propofol potently and directly activates GABAA receptor and inhibits glutamate receptor mediated excitatory synaptic transmission. Propofol has antinociceptive properties and is used for sedation and hypnotic[1].,C12H18O,DMSO : 100 mg/mL (560.95 mM; Need ultrasonic); H2O : 0.5 mg/mL (2.80 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,OC1=C(C(C)C)C=CC=C1C(C)C
,,,,,,,,,,,,,,,,pp2a,estradiol,HY-L025-70,A05,HY-B1100,Estradiol (cypionate),,313-06-4,396.56,Estrogen Receptor/ERR,Vitamin D Related/Nuclear Receptor,"Estradiol cypionate is a 17 β-cyclopentylpropinate ester of estradiol, inhibits ET-1 synthesis via estrogen receptor
IC50 value:
Target: estrogen receptor
Estradiol cypionate is a synthetic ester, is a estrogen. Compared to other commonly used estradiol esters, via the intramuscular route, Estradiol cypionate is found to have the longest duration of action with a duration of ~11 days,",C26H36O3,DMSO : ≥ 30 mg/mL (75.65 mM),10mM,Endocrinology; Cancer,Launched,C[C@@]12[C@@H](OC(CCC3CCCC3)=O)CC[C@@]1([H])[C@]4([H])CCC5=C(C=CC(O)=C5)[C@@]4([H])CC2
,,,,,,,,,,,,,,,,vimentin,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,vimentin,salidroside,HY-L025-72,C11,HY-N0109,Salidroside,Rhodioloside,10338-51-9,300.3,Apoptosis; mTOR; Prolyl Endopeptidase  (PREP),Apoptosis; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,Salidroside is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.,C14H20O7,H2O : ≥ 100 mg/mL (333.00 mM),10mM,Cancer,No Development Reported,O[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@@H]1OCCC2=CC=C(O)C=C2
,,,,,,,,,,,,,,,,vimentin,berberine,HY-L025-59,B09,HY-18258,Berberine (chloride),Natural Yellow 18 (chloride),633-65-8,371.81,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; Parasite; Reactive Oxygen Species; Topoisomerase,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,Berberine chloride is an alkaloid that acts as an antibiotic. Berberine chloride induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties[1].,C20H18ClNO4,DMSO : 12.5 mg/mL (33.62 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Cancer,Launched,COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.[Cl-]
,,,,,,,,,,,,,,,,vimentin,triptolide,HY-L025-63,C07,HY-32735,Triptolide,PG490,38748-32-2,360.4,Apoptosis; NF-κB,Apoptosis; NF-κB,"Triptolide is a diterpenoid triepoxide extracted from the root of Tripterygium wilfordii with immunosuppressive, anti-inflammatory, antiproliferative and antitumour effects. Triptolide is a NF-κB activation inhibitor[1][2][3][4][5][6].",C20H24O6,DMSO : 25 mg/mL (69.37 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,C[C@@]12[C@@]34[C@](O5)([C@@H]([C@](O6)(C(C)C)[C@@H]6[C@@H]3O4)O)[C@@H]5C[C@@]1([H])C7=C(C(OC7)=O)CC2
,,,,,,,,,,,,,,,,vimentin,silibinin,HY-L025-76,C08,HY-N0779A,Silybin,Silibinin,802918-57-6,482.44,Apoptosis,Apoptosis,"Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds. Silybin induces apoptosis and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity[1][2].",C25H22O10,DMSO : 25 mg/mL (51.82 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C1[C@H](O)[C@@H](C2=CC=C(OC(CO)C(C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15
,,,,,,,,,,,,,,,,vimentin,oridonin,HY-L025-71,F03,HY-N0004,Oridonin,NSC-250682; Isodonol,28957-04-2,364.43,Akt; Bacterial,Anti-infection; PI3K/Akt/mTOR,"Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of AKT, with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.",C20H28O6,DMSO : 62.5 mg/mL (171.50 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Phase 4,O[C@@H]1[C@]2(CO3)[C@@]([C@H](O)[C@]3(O)[C@]45[C@@]2([H])CC[C@](C(C5=O)=C)([H])[C@@]4([H])O)([H])C(C)(C)CC1
,,,,,,,,,,,,,,,,vimentin,puerarin,HY-L025-72,F03,HY-N0145,Puerarin,,3681-99-0,416.38,5-HT Receptor,GPCR/G Protein; Neuronal Signaling,"Puerarin, an isoflavone extracted from Radix puerariae, is a 5-HT2C receptor antagonist.",C21H20O9,DMSO : 50 mg/mL (120.08 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Launched,O=C1C(C2=CC=C(O)C=C2)=COC3=C([C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)C(O)=CC=C13
,,,,,,,,,,,,,,,,vimentin,colchicine,HY-L025-56,D07,HY-16569,Colchicine,,64-86-8,399.44,Apoptosis; Autophagy; Microtubule/Tubulin,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton,Colchicine is a tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM[1][2][3]. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs)[4].,C22H25NO6,DMSO : ≥ 48 mg/mL (120.17 mM); H2O : ≥ 33.33 mg/mL (83.44 mM),10mM,Cancer,Launched,CC(N[C@H](C1=C2)CCC3=CC(OC)=C(OC)C(OC)=C3C1=CC=C(OC)C2=O)=O
,,,,,,,,,,,,,,,,vimentin,celecoxib,HY-L025-43,G07,HY-14398,Celecoxib,SC 58635,169590-42-5,381.37,COX,Immunology/Inflammation,"Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.",C17H14F3N3O2S,DMSO : ≥ 50 mg/mL (131.11 mM),10mM,Inflammation/Immunology; Cancer,Launched,CC1=CC=C(C=C1)C2=CC(C(F)(F)F)=NN2C3=CC=C(C=C3)S(=O)(N)=O
,,,,,,,,,,,,,,,,vimentin,luteolin,HY-L025-72,G06,HY-N0162,Luteolin,Luteoline; Luteolol; Digitoflavone,491-70-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Keap1-Nrf2,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells[1][2][3].",C15H10O6,DMSO : ≥ 100 mg/mL (349.36 mM),10mM,Cancer; Inflammation/Immunology,Phase 2,O=C1C=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13
,,,,,,,,,,,,,,,,vimentin,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,vimentin,propofol,HY-L025-69,B04,HY-B0649,Propofol,"2,6-Diisopropylphenol",2078-54-8,178.27,Endogenous Metabolite; GABA Receptor,Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling,Propofol potently and directly activates GABAA receptor and inhibits glutamate receptor mediated excitatory synaptic transmission. Propofol has antinociceptive properties and is used for sedation and hypnotic[1].,C12H18O,DMSO : 100 mg/mL (560.95 mM; Need ultrasonic); H2O : 0.5 mg/mL (2.80 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,OC1=C(C(C)C)C=CC=C1C(C)C
,,,,,,,,,,,,,,,,vimentin,salinomycin,HY-L025-58,B06,HY-17439,Salinomycin (sodium salt),Salinomycin sodium; Sodium salinomycin,55721-31-8,772.98,Antibiotic; Apoptosis; Autophagy; Bacterial; Parasite; Wnt; β-catenin,Anti-infection; Apoptosis; Autophagy; Stem Cell/Wnt,"Salinomycin sodium salt (Salinomycin sodium), an antibiotic potassium ionophore, is a potent inhibitor of Wnt/β-catenin signaling. Salinomycin sodium salt (Salinomycin sodium) acts on the Wnt/Fzd/LRP complex, blocks Wnt-induced LRP6 phosphorylation, and causes degradation of the LRP6 protein. Salinomycin sodium salt (Salinomycin sodium) shows selective activity against human cancer stem cells[1][2][3].",C42H69NaO11,DMSO : 100 mg/mL (129.37 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble),10mM,Cancer,No Development Reported,[H][C@]1([C@](C)(CC2)O[C@]32[C@H](O)C=C[C@]4(O[C@]([H])([C@@H](CC)C([C@@H](C)[C@@H](O)[C@H](C)[C@]5([H])O[C@]([C@@H](CC)C(O[Na])=O)([H])CC[C@@H]5C)=O)[C@@H](C)C[C@H]4C)O3)CC[C@@](CC)(O)[C@H](C)O1
,,,,,,,,,,,,,,,,vimentin,dapt,HY-L025-31,F03,HY-13027,DAPT,GSI-IX,208255-80-5,432.46,Amyloid-β; Apoptosis; Autophagy; Notch; γ-secretase,Apoptosis; Autophagy; Neuronal Signaling; Stem Cell/Wnt,"DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment[1][2].",C23H26F2N2O4,DMSO : 62.5 mg/mL (144.52 mM; Need ultrasonic); Ethanol : 10 mg/mL (23.12 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,No Development Reported,FC1=CC(F)=CC(CC(N[C@H](C(N[C@H](C(OC(C)(C)C)=O)C2=CC=CC=C2)=O)C)=O)=C1
,,,,,,,,,,,,,,,,mcl 1,at 101,HY-L025-52,B08,HY-15464A,(R)-(-)-Gossypol acetic acid,AT-101 (acetic acid); (-)-Gossypol acetic acid; (R)-Gossypol acetic acid,866541-93-7,578.61,Autophagy; Bcl-2 Family,Apoptosis; Autophagy,"(R)-(-)-Gossypol acetic acid (AT-101 (acetic acid)) is the levorotatory isomer of a natural product Gossypol. AT-101 is determined to bind to Bcl-2, Mcl-1 and Bcl-xL proteins with Kis of 260±30 nM, 170±10 nM, and 480±40 nM, respectively.",C32H34O10,DMSO : 25 mg/mL (43.21 mM; Need ultrasonic),10mM,Cancer,Phase 2,OC1=C2C(C=O)=C(O)C(O)=C(C(C)C)C2=CC(C)=[C@]1[C@]3=C(C)C=C4C(C(C)C)=C(O)C(O)=C(C=O)C4=C3O.CC(O)=O.[R]
,,,,,,,,,,,,,,,,mcl 1,berberine,HY-L025-59,B09,HY-18258,Berberine (chloride),Natural Yellow 18 (chloride),633-65-8,371.81,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; Parasite; Reactive Oxygen Species; Topoisomerase,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,Berberine chloride is an alkaloid that acts as an antibiotic. Berberine chloride induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties[1].,C20H18ClNO4,DMSO : 12.5 mg/mL (33.62 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Cancer,Launched,COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.[Cl-]
,,,,,,,,,,,,,,,,mcl 1,ruxolitinib,HY-L025-64,A05,HY-50858,Ruxolitinib (phosphate),INCB018424 phosphate,1092939-17-7,404.36,Autophagy; JAK; Mitophagy,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.",C17H21N6O4P,DMSO : ≥ 31 mg/mL (76.66 mM); H2O : 10 mg/mL (24.73 mM; Need ultrasonic),10mM,Cancer,Launched,N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2.O=P(O)(O)O
,,,,,,,,,,,,,,,,mcl 1,pha 767491,HY-L025-35,B11,HY-13461A,PHA-767491 (hydrochloride),CAY-10572 hydrochloride,942425-68-5,249.7,Apoptosis; CDK,Apoptosis; Cell Cycle/DNA Damage,"PHA-767491 hydrochloride is a dual Cdc7/Cdk9 inhibitor, with IC50s of 10 nM and 34 nM, respectively.",C12H12ClN3O,DMSO : 17.33 mg/mL (69.40 mM; Need ultrasonic and warming); H2O : 50 mg/mL (200.24 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C(NC(C3=CC=NC=C3)=C2)CCN1.[H]Cl
,,,,,,,,,,,,,,,,mcl 1,gossypol,HY-L025-58,E03,HY-17510,Gossypol (acetic acid),(±)-Gossypol-acetic acid; BL-193 (acetic acid),12542-36-8,578.61,Bcl-2 Family,Apoptosis,"Gossypol acetic acid ((±)-Gossypol-acetic acid) binds to Bcl-xL protein and Bcl-2 protein with Kis of 0.5-0.6 μM and 0.2-0.3 mM, respectively.",C32H34O10,DMSO : 25 mg/mL (43.21 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,OC1=C(C2=C(O)C(C(C=O)=C(O)C(O)=C3C(C)C)=C3C=C2C)C(C)=CC4=C(C(C)C)C(O)=C(O)C(C=O)=C41.O=C(O)C
,,,,,,,,,,,,,,,,mcl 1,apigenin,HY-L025-77,B10,HY-N1201,Apigenin,"4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1",520-36-5,270.24,Autophagy; Cytochrome P450; Endogenous Metabolite,Autophagy; Metabolic Enzyme/Protease,"Apigenin (4',5,7-Trihydroxyflavone) is a competitive CYP2C9 inhibitor with a Ki of 2 μM.",C15H10O5,DMSO : 83.33 mg/mL (308.36 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=CC2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,mcl 1,chrysin,HY-L025-45,F07,HY-14589,Chrysin,"5,7-Dihydroxyflavone",480-40-0,254.24,Estrogen Receptor/ERR,Vitamin D Related/Nuclear Receptor,Chrysin is one of the most well known estrogen blockers.,C15H10O4,DMSO : ≥ 100 mg/mL (393.33 mM),10mM,Cancer,No Development Reported,OC1=C2C(OC(C3=CC=CC=C3)=CC2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,mcl 1,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,mcl 1,atra,HY-L025-46,C02,HY-14649,Retinoic acid,Vitamin A acid; all-trans-Retinoic acid; ATRA,302-79-4,300.44,Autophagy; Endogenous Metabolite; PPAR; RAR/RXR,Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.",C20H28O2,DMSO : 50 mg/mL (166.42 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,CC1(C)C(/C=C/C(C)=C/C=C/C(C)=C/C(O)=O)=C(C)CCC1
,,,,,,,,,,,,,,,,mcl 1,thz1,HY-L025-65,C04,HY-80013A,THZ1 (Hydrochloride),,,602.51,CDK,Cell Cycle/DNA Damage,THZ1 Hydrochloride is a selective and potent covalent CDK7 inhibitor with an IC50 of 3.2 nM. THZ1 Hydrochloride also inhibits the closely related kinases CDK12 and CDK13 and downregulates MYC expression[1][2].,C31H29Cl2N7O2,DMSO : 22.5 mg/mL (37.34 mM; Need ultrasonic and warming); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,No Development Reported,ClC1=CN=C(NC2=CC(NC(C3=CC=C(NC(/C=C/CN(C)C)=O)C=C3)=O)=CC=C2)N=C1C4=CNC5=CC=CC=C54.Cl
,,,,,,,,,,,,,,,,mcl 1,wp1066,HY-L025-51,C07,HY-15312,WP1066,,857064-38-1,356.22,Apoptosis; JAK; STAT,Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"WP1066 is an inhibitor of JAK2 and STAT3, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3.",C17H14BrN3O,DMSO : ≥ 44 mg/mL (123.52 mM); Ethanol : 16.67 mg/mL (46.80 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(N[C@H](C1=CC=CC=C1)C)/C(C#N)=C/C2=NC(Br)=CC=C2
,,,,,,,,,,,,,,,,mcl 1,oridonin,HY-L025-71,F03,HY-N0004,Oridonin,NSC-250682; Isodonol,28957-04-2,364.43,Akt; Bacterial,Anti-infection; PI3K/Akt/mTOR,"Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of AKT, with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.",C20H28O6,DMSO : 62.5 mg/mL (171.50 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Phase 4,O[C@@H]1[C@]2(CO3)[C@@]([C@H](O)[C@]3(O)[C@]45[C@@]2([H])CC[C@](C(C5=O)=C)([H])[C@@]4([H])O)([H])C(C)(C)CC1
,,,,,,,,,,,,,,,,mcl 1,jq1,HY-L025-31,F06,HY-13030,(+)-JQ-1,JQ1,1268524-70-4,456.99,Autophagy; Epigenetic Reader Domain; Ligands for Target Protein for PROTAC,Autophagy; Epigenetics; PROTAC,"(+)-JQ-1 (JQ1) is a potent, specific, and reversible BET bromodomain inhibitor, with IC50s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2))[1]. (+)-JQ-1 also activates autophagy[2].",C23H25ClN4O2S,DMSO : ≥ 45 mg/mL (98.47 mM),10mM,Cancer,No Development Reported,O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C
,,,,,,,,,,,,,,,,mcl 1,regorafenib,HY-L025-34,C03,HY-13308,Regorafenib (Hydrochloride),BAY 73-4506 (hydrochloride),835621-07-3,519.28,Autophagy; PDGFR; Raf; RET; VEGFR,Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[1].",C21H16Cl2F4N4O3,DMSO : ≥ 5.6 mg/mL (10.78 mM); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,ClC1=C(C(F)(F)F)C=C(NC(NC2=C(F)C=C(OC3=CC=NC(C(NC)=O)=C3)C=C2)=O)C=C1.Cl
,,,,,,,,,,,,,,,,mcl 1,everolimus,HY-L025-7,D10,HY-10218,Everolimus,RAD001; SDZ-RAD,159351-69-6,958.22,Apoptosis; Autophagy; Bacterial; FKBP; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; PI3K/Akt/mTOR,"Everolimus (RAD001) is a <a href=""/Rapamycin.html"" class=""link-product"" target=""_blank"">Rapamycin</a> (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].",C53H83NO14,DMSO : 50 mg/mL (52.18 mM; ultrasonic and warming and heat to 60°C); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](OCCO)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,mcl 1,alvocidib,HY-L025-1,C08,HY-10006,Flavopiridol (Hydrochloride),Alvocidib (Hydrochloride); L86-8275 (Hydrochloride); HMR-1275 (Hydrochloride),131740-09-5,438.3,Autophagy; CDK; HIV,Anti-infection; Autophagy; Cell Cycle/DNA Damage,"Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.",C21H21Cl2NO5,DMF : 7.69 mg/mL (17.55 mM; Need ultrasonic); DMSO : ≥ 20 mg/mL (45.63 mM); H2O : ≥ 20 mg/mL (45.63 mM),10mM,Cancer,Phase 2,O=C1C2=C(C=C(C([C@]3([H])[C@H](O)CN(C)CC3)=C2OC(C4=CC=CC=C4Cl)=C1)O)O.[H]Cl
,,,,,,,,,,,,,,,,mcl 1,ptc596,HY-L025-16,H02,HY-112041,Unesbulin,PTC596,1610964-64-1,420.34,Apoptosis,Apoptosis,Unesbulin (PTC596) is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. Unesbulin downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia (AML) cells. Unesbulin has anti-leukemic activity[1][2].,C19H13F5N6,DMSO : 16.67 mg/mL (39.66 mM; Need ultrasonic),10mM,Cancer,Phase 3,NC1=C(F)C(NC2=CC=C(C(F)(F)F)C=C2)=NC(N3C4=CC(F)=CC=C4N=C3C)=N1
,,,,,,,,,,,,,,,,mcl 1,sbha,HY-L025-84,D09,HY-W009776,Suberoyl bis-hydroxamic acid,Suberohydroxamic acid; SBHA,38937-66-5,204.22,Apoptosis; HDAC,Apoptosis; Cell Cycle/DNA Damage; Epigenetics,"Suberoyl bis-hydroxamic acid (Suberohydroxamic acid; SBHA) is a competitive and cell-permeable HDAC1 and HDAC3 inhibitor with ID50 values of 0.25 μM and 0.30 μM, respectively[1].Suberoyl bis-hydroxamic acid renders MM cells susceptible to apoptosis and facilitates the mitochondrial apoptotic pathways[2].Suberoyl bis-hydroxamic acid can be used for the study of medullary thyroid carcinoma (MTC)[3].",C8H16N2O4,H2O : 8.33 mg/mL (40.79 mM; Need ultrasonic); DMSO : 50 mg/mL (244.83 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C(NO)CCCCCCC(NO)=O
,,,,,,,,,,,,,,,,mcl 1,paclitaxel,HY-L025-66,A07,HY-B0015,Paclitaxel,,33069-62-4,853.91,ADC Cytotoxin; Apoptosis; Autophagy; Microtubule/Tubulin,Antibody-drug Conjugate/ADC Related; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton,Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy[1][2].,C47H51NO14,H2O : < 0.1 mg/mL (insoluble); DMSO : 100 mg/mL (117.11 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=CC=CC=C1)N[C@@H](C2=CC=CC=C2)[C@H](C(O[C@@H]3C(C)=C([C@@H](OC(C)=O)C([C@@]4(C)[C@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]4O)([H])[C@@H]6OC(C7=CC=CC=C7)=O)=O)C(C)(C)[C@@]6(O)C3)=O)O
,,,,,,,,,,,,,,,,sp1,sp600125,HY-L025-22,G02,HY-12041,SP600125,,129-56-6,220.23,Apoptosis; Autophagy; Ferroptosis; JNK,Apoptosis; Autophagy; MAPK/ERK Pathway,"SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 inhibits autophagy and activates apoptosis[1][2][3].",C14H8N2O,DMSO : 12.5 mg/mL (56.76 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C3C(NN=C3C4=C1C=CC=C4)=CC=C2
,,,,,,,,,,,,,,,,sp1,esculetin,HY-L025-73,F09,HY-N0284,Esculetin,,305-01-1,178.14,Akt; PI3K,PI3K/Akt/mTOR,"Esculetin is an active ingredient extracted mainly from the bark of Fraxinus rhynchophylla. Esculetin inhibits platelet-derived growth factor (PDGF)-induced airway smooth muscle cells (ASMCs) phenotype switching through inhibition of PI3K/Akt pathway. Esculetin has antioxidant, antiinflammatory, and antitumor activities[1].",C9H6O4,DMSO : 125 mg/mL (701.70 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,No Development Reported,O=C1C=CC2=CC(O)=C(O)C=C2O1
,,,,,,,,,,,,,,,,sp1,emodin,HY-L025-43,G03,HY-14393,Emodin,Frangula emodin,518-82-1,270.24,11β-HSD; Autophagy; Casein Kinase; SARS-CoV,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively.  Emodin ameliorates metabolic disorder in diet-induced obese mice[3].",C15H10O5,Acetone : 10.87 mg/mL (40.22 mM; Need ultrasonic); DMSO : 5.41 mg/mL (20.02 mM; Need ultrasonic); Ethanol : 10.87 mg/mL (40.22 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C(C=C(C)C=C2O)C(C3=CC(O)=CC(O)=C31)=O
,,,,,,,,,,,,,,,,sp1,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,sp1,terameprocol,HY-L025-10,A11,HY-10447,Terameprocol,EM-1421,24150-24-1,358.47,Lipoxygenase,Metabolic Enzyme/Protease,Terameprocol is a synthetic derivative of Nordihydroguaiaretic acid and a non-selective lipoxygenase inhibitor. Terameprocol has antiviral and antitumor effects[1][2][3].,C22H30O4,DMSO : 100 mg/mL (278.96 mM; Need ultrasonic),10mM,Cancer; Infection,Phase 2,COC1=CC(C[C@H](C)[C@H](C)CC2=CC=C(OC)C(OC)=C2)=CC=C1OC
,,,,,,,,,,,,,,,,sp1,triptolide,HY-L025-63,C07,HY-32735,Triptolide,PG490,38748-32-2,360.4,Apoptosis; NF-κB,Apoptosis; NF-κB,"Triptolide is a diterpenoid triepoxide extracted from the root of Tripterygium wilfordii with immunosuppressive, anti-inflammatory, antiproliferative and antitumour effects. Triptolide is a NF-κB activation inhibitor[1][2][3][4][5][6].",C20H24O6,DMSO : 25 mg/mL (69.37 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,C[C@@]12[C@@]34[C@](O5)([C@@H]([C@](O6)(C(C)C)[C@@H]6[C@@H]3O4)O)[C@@H]5C[C@@]1([H])C7=C(C(OC7)=O)CC2
,,,,,,,,,,,,,,,,sp1,tsa,HY-L025-49,F10,HY-15144,Trichostatin A,TSA,58880-19-6,302.37,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].",C17H22N2O3,DMSO : 25 mg/mL (82.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
,,,,,,,,,,,,,,,,sp1,wortmannin,HY-L025-6,H04,HY-10197,Wortmannin,SL-2052; KY-12420,19545-26-7,428.43,Antibiotic; Autophagy; PI3K; Polo-like Kinase (PLK),Anti-infection; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively[1][2][3].",C23H24O8,DMSO : ≥ 50 mg/mL (116.71 mM),10mM,Cancer,No Development Reported,O=C1C([C@@](CC2)([H])[C@@]3(C)C2=O)=C([C@H](OC(C)=O)C3)[C@]4(C)C5=C1OC=C5C(O[C@@H]4COC)=O
,,,,,,,,,,,,,,,,sp1,betulinic acid,HY-L025-10,F05,HY-10529,Betulinic acid,Lupatic acid; Betulic acid,472-15-1,456.7,Apoptosis; Autophagy; Endogenous Metabolite; HIV; Mitophagy; NF-κB; Parasite; Topoisomerase,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; NF-κB,"Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic topoisomerase I inhibitor, with an IC50 of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties[1][2][3][4].",C30H48O3,DMSO : 35.71 mg/mL (78.19 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Phase 2,[H][C@@]12CC[C@@]3(C)[C@]4(C)CC[C@]5(C(O)=O)[C@@]([C@H](C(C)=C)CC5)([H])[C@@](CC[C@@]([H])3[C@@]1(C)CC[C@H](O)C2(C)C)4[H]
,,,,,,,,,,,,,,,,sp1,n acetylcysteine,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,sp1,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,sp1,tolfenamic acid,HY-L025-67,H02,HY-B0335,Tolfenamic Acid,GEA 6414,13710-19-5,261.7,COX,Immunology/Inflammation,"Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1.",C14H12ClNO2,H2O : ≥ 0.1 mg/mL (0.38 mM); DMSO : ≥ 100 mg/mL (382.12 mM),10mM,Inflammation/Immunology; Cancer,Launched,O=C(O)C1=CC=CC=C1NC2=C(C)C(Cl)=CC=C2
,,,,,,,,,,,,,,,,sp1,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,sp1,trichostatin a,HY-L025-49,F10,HY-15144,Trichostatin A,TSA,58880-19-6,302.37,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].",C17H22N2O3,DMSO : 25 mg/mL (82.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
,,,,,,,,,,,,,,,,sp1,bortezomib,HY-L025-7,E07,HY-10227,Bortezomib,PS-341; LDP-341; NSC 681239,179324-69-7,384.24,Apoptosis; Autophagy; NF-κB; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].",C19H25BN4O4,DMSO : 50 mg/mL (130.13 mM; Need ultrasonic); Ethanol : 66.67 mg/mL (173.51 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
,,,,,,,,,,,,,,,,keap1,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,keap1,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,keap1,nac,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,keap1,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,keap1,andrographolide,HY-L025-73,A08,HY-N0191,Andrographolide,Andrographis,5508-58-7,350.45,Autophagy; Influenza Virus; NF-κB; Parasite; SARS-CoV,Anti-infection; Autophagy; NF-κB,"Andrographolide is a NF-κB inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.",C20H30O5,DMSO : 100 mg/mL (285.35 mM; Need ultrasonic); H2O : 0.1 mg/mL (0.29 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C1OC[C@@H](O)/C1=C\C[C@@H]2C(CC[C@]3([H])[C@](C)(CO)[C@H](O)CC[C@@]23C)=C
,,,,,,,,,,,,,,,,keap1,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
,,,,,,,,,,,,,,,,eif4e,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,eif4e,sorafenib,HY-L025-7,A11,HY-10201A,Sorafenib (Tosylate),Bay 43-9006 (Tosylate),475207-59-1,637.03,Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR,Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator[1].",C28H24ClF3N4O6S,H2O : < 0.1 mg/mL (insoluble); DMSO : ≥ 31 mg/mL (48.66 mM),10mM,Cancer,Launched,O=S(C1=CC=C(C=C1)C)(O)=O.O=C(NC2=CC=C(C(C(F)(F)F)=C2)Cl)NC3=CC=C(OC4=CC(C(NC)=O)=NC=C4)C=C3
,,,,,,,,,,,,,,,,eif4e,4egi 1,HY-L025-62,E08,HY-19831,4EGI-1,,315706-13-9,451.28,Apoptosis; Autophagy; Eukaryotic Initiation Factor (eIF),Apoptosis; Autophagy; Cell Cycle/DNA Damage,"4EGI-1 is an inhibitor of eIF4E/eIF4G interaction, with a Kd of 25 μM against eIF4E binding.",C18H12Cl2N4O4S,DMSO : ≥ 35 mg/mL (77.56 mM),10mM,Cancer,No Development Reported,O=C(O)/C(CC1=CC=CC=C1[N+]([O-])=O)=N/NC2=NC(C3=CC=C(Cl)C(Cl)=C3)=CS2
,,,,,,,,,,,,,,,,eif4e,ribavirin,HY-L025-68,C03,HY-B0434,Ribavirin,Ribasphere,36791-04-5,244.2,Antibiotic; HCV; Orthopoxvirus; RSV,Anti-infection,"Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.",C8H12N4O5,H2O : 100 mg/mL (409.50 mM; Need ultrasonic); DMSO : 100 mg/mL (409.50 mM; Need ultrasonic),10mM,Infection; Cancer,Launched,O[C@H]1[C@@H](O)[C@H](N2N=C(C(N)=O)N=C2)O[C@@H]1CO
,,,,,,,,,,,,,,,,ccnd1,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,ccnd1,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
,,,,,,,,,,,,,,,,ccnd1,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,notch1,pf 03084014,HY-L025-50,B05,HY-15185,Nirogacestat,PF-3084014; PF-03084014,1290543-63-3,489.64,Apoptosis; γ-secretase,Apoptosis; Neuronal Signaling; Stem Cell/Wnt,"Nirogacestat (PF-3084014) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC50 of 6.2 nM. Inhibition of Notch signaling by Nirogacestat while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers[1].",C27H41F2N5O,DMSO : 28.57 mg/mL (58.35 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 3,FC1=C2C(CC[C@H](N[C@@H](CCC)C(NC3=CN(C(C)(C)CNCC(C)(C)C)C=N3)=O)C2)=CC(F)=C1
,,,,,,,,,,,,,,,,notch1,emodin,HY-L025-43,G03,HY-14393,Emodin,Frangula emodin,518-82-1,270.24,11β-HSD; Autophagy; Casein Kinase; SARS-CoV,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively.  Emodin ameliorates metabolic disorder in diet-induced obese mice[3].",C15H10O5,Acetone : 10.87 mg/mL (40.22 mM; Need ultrasonic); DMSO : 5.41 mg/mL (20.02 mM; Need ultrasonic); Ethanol : 10.87 mg/mL (40.22 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C(C=C(C)C=C2O)C(C3=CC(O)=CC(O)=C31)=O
,,,,,,,,,,,,,,,,notch1,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,notch1,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,notch1,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
,,,,,,,,,,,,,,,,notch1,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,notch1,ro4929097,HY-L025-15,C03,HY-11102,RO4929097,RG-4733,847925-91-1,469.4,Notch; γ-secretase,Neuronal Signaling; Stem Cell/Wnt,"RO4929097 (RG-4733) is a γ secretase inhibitor with IC50 of 4 nM, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively[1].",C22H20F5N3O3,DMSO : ≥ 49 mg/mL (104.39 mM),10mM,Neurological Disease; Cancer,Phase 2,O=C(C(C)(C(NCC(F)(C(F)(F)F)F)=O)C)N[C@H]1C2=CC=CC=C2C3=CC=CC=C3NC1=O
,,,,,,,,,,,,,,,,notch1,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,notch1,bortezomib,HY-L025-7,E07,HY-10227,Bortezomib,PS-341; LDP-341; NSC 681239,179324-69-7,384.24,Apoptosis; Autophagy; NF-κB; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].",C19H25BN4O4,DMSO : 50 mg/mL (130.13 mM; Need ultrasonic); Ethanol : 66.67 mg/mL (173.51 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
,,,,,,,,,,,,,,,,notch1,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,notch1,dapt,HY-L025-31,F03,HY-13027,DAPT,GSI-IX,208255-80-5,432.46,Amyloid-β; Apoptosis; Autophagy; Notch; γ-secretase,Apoptosis; Autophagy; Neuronal Signaling; Stem Cell/Wnt,"DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment[1][2].",C23H26F2N2O4,DMSO : 62.5 mg/mL (144.52 mM; Need ultrasonic); Ethanol : 10 mg/mL (23.12 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,No Development Reported,FC1=CC(F)=CC(CC(N[C@H](C(N[C@H](C(OC(C)(C)C)=O)C2=CC=CC=C2)=O)C)=O)=C1
,,,,,,,,,,,,,,,,n myc,retinoic acid,HY-L025-46,C02,HY-14649,Retinoic acid,Vitamin A acid; all-trans-Retinoic acid; ATRA,302-79-4,300.44,Autophagy; Endogenous Metabolite; PPAR; RAR/RXR,Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.",C20H28O2,DMSO : 50 mg/mL (166.42 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,CC1(C)C(/C=C/C(C)=C/C=C/C(C)=C/C(O)=O)=C(C)CCC1
,,,,,,,,,,,,,,,,n myc,jq1,HY-L025-31,F06,HY-13030,(+)-JQ-1,JQ1,1268524-70-4,456.99,Autophagy; Epigenetic Reader Domain; Ligands for Target Protein for PROTAC,Autophagy; Epigenetics; PROTAC,"(+)-JQ-1 (JQ1) is a potent, specific, and reversible BET bromodomain inhibitor, with IC50s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2))[1]. (+)-JQ-1 also activates autophagy[2].",C23H25ClN4O2S,DMSO : ≥ 45 mg/mL (98.47 mM),10mM,Cancer,No Development Reported,O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C
,,,,,,,,,,,,,,,,telomerase,braco 19,HY-L025-52,F09,HY-15523A,Braco-19 (trihydrochloride),,1177798-88-7,703.14,CMV; DNA/RNA Synthesis,Anti-infection; Cell Cycle/DNA Damage,"Braco-19 trihydrochloride is a potent?telomerase/telomere?inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus?replication inhibitor[1][2].",C35H46Cl3N7O2,H2O : 22 mg/mL (31.29 mM; Need ultrasonic and warming),10mM,Cancer; Infection,No Development Reported,CN(C1=CC=C(NC2=C(C=CC(NC(CCN3CCCC3)=O)=C4)C4=NC5=CC(NC(CCN6CCCC6)=O)=CC=C52)C=C1)C.Cl.Cl.Cl
,,,,,,,,,,,,,,,,telomerase,suramin,HY-L025-69,F10,HY-B0879A,Suramin (sodium salt),Suramin (hexasodium salt),129-46-4,1429.17,Apoptosis; Parasite; Phosphatase; Reverse Transcriptase; SARS-CoV; Sirtuin; Topoisomerase,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease,"Suramin sodium salt	(Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor[1]. Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM)[2]. Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM)[3][4]. Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor[5]. Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent[6][7][8].",C51H34N6Na6O23S6,DMSO : 83.33 mg/mL (58.31 mM; Need ultrasonic); H2O : 50 mg/mL (34.99 mM; Need ultrasonic),10mM,Cancer; Infection; Cardiovascular Disease,Launched,O=C(NC1=CC(C(NC2=CC(C(NC3=CC=C(S(=O)(O[Na])=O)C4=CC(S(=O)(O[Na])=O)=CC(S(=O)(O[Na])=O)=C34)=O)=CC=C2C)=O)=CC=C1)NC5=CC(C(NC6=CC(C(NC7=CC=C(S(=O)(O[Na])=O)C8=CC(S(=O)(O[Na])=O)=CC(S(=O)(O[Na])=O)=C78)=O)=CC=C6C)=O)=CC=C5
,,,,,,,,,,,,,,,,telomerase,daunorubicin,HY-L025-32,A03,HY-13062,Daunorubicin (hydrochloride),Daunomycin (hydrochloride); RP 13057 (hydrochloride); Rubidomycin (hydrochloride),23541-50-6,563.98,ADC Cytotoxin; Antibiotic; Apoptosis; Autophagy; Bacterial; DNA/RNA Synthesis; Topoisomerase,Antibody-drug Conjugate/ADC Related; Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor[1][2][4][5].",C27H30ClNO10,H2O : ≥ 34 mg/mL (60.29 mM); DMSO : 50 mg/mL (88.66 mM; Need ultrasonic),10mM,Cancer; Infection; Neurological Disease,Launched,O=C(C(C(OC)=CC=C1)=C1C2=O)C3=C2C(O)=C(C[C@@](O)(C(C)=O)C[C@@H]4O[C@@]5([H])C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O.[H]Cl
,,,,,,,,,,,,,,,,telomerase,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
,,,,,,,,,,,,,,,,telomerase,oridonin,HY-L025-71,F03,HY-N0004,Oridonin,NSC-250682; Isodonol,28957-04-2,364.43,Akt; Bacterial,Anti-infection; PI3K/Akt/mTOR,"Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of AKT, with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.",C20H28O6,DMSO : 62.5 mg/mL (171.50 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Phase 4,O[C@@H]1[C@]2(CO3)[C@@]([C@H](O)[C@]3(O)[C@]45[C@@]2([H])CC[C@](C(C5=O)=C)([H])[C@@]4([H])O)([H])C(C)(C)CC1
,,,,,,,,,,,,,,,,telomerase,pterostilbene,HY-L025-76,F02,HY-N0828,Pterostilbene,,537-42-8,256.3,Autophagy,Autophagy,"Pterostilbene is a stilbenoid isolated from blueberries and Pterocarpus marsupium[1]. Shows anti-oxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and anti-obesity properties[1][4]. Pterostilbene blocks ROS production[3], also exhibits inhibitory activity against various free radicals such as DPPH, ABTS, hydroxyl, superoxide and hydrogen peroxide[4].",C16H16O3,DMSO : 110 mg/mL (429.18 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 3,OC1=CC=C(/C=C/C2=CC(OC)=CC(OC)=C2)C=C1
,,,,,,,,,,,,,,,,telomerase,wogonin,HY-L025-74,B09,HY-N0400,Wogonin,,632-85-9,284.26,Apoptosis; Autophagy; CDK; Wnt,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Stem Cell/Wnt,"Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.",C16H12O5,DMSO : 62.5 mg/mL (219.87 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,No Development Reported,O=C1C=C(C2=CC=CC=C2)OC3=C(OC)C(O)=CC(O)=C13
,,,,,,,,,,,,,,,,telomerase,novobiocin,HY-L025-68,B11,HY-B0425A,Novobiocin (sodium),Albamycin (sodium); Cathomycin (sodium),1476-53-5,634.61,Antibiotic; Apoptosis; Bacterial; DNA/RNA Synthesis; HSP; Orthopoxvirus,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,Novobiocin (Albamycin) sodium is a potent and orally active antibiotic. Novobiocin sodium also is a DNA gyrase inhibitor and a heat shock protein 90 (Hsp90) antagonist. Novobiocin sodium has the potential for the research of highly beta-lactam-resistant pneumococcal infections. Novobiocin sodium shows anti-orthopoxvirus activity[1][2][3][4].,C31H35N2NaO11,DMSO : ≥ 30 mg/mL (47.27 mM); H2O : 50 mg/mL (78.79 mM; Need ultrasonic),10mM,Infection; Cancer,Launched,CC1=C(OC2=O)C(C(O)=C2NC(C3=CC(C/C=C(C)/C)=C(O[Na])C=C3)=O)=CC=C1O[C@H](OC(C)(C)[C@H](OC)[C@H]4OC(N)=O)[C@@H]4O
,,,,,,,,,,,,,,,,telomerase,silibinin,HY-L025-76,C08,HY-N0779A,Silybin,Silibinin,802918-57-6,482.44,Apoptosis,Apoptosis,"Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds. Silybin induces apoptosis and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity[1][2].",C25H22O10,DMSO : 25 mg/mL (51.82 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C1[C@H](O)[C@@H](C2=CC=C(OC(CO)C(C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15
,,,,,,,,,,,,,,,,telomerase,catechin,HY-L025-76,H09,HY-N0898,Catechin,(+)-Catechin; Cianidanol; Catechuic acid,154-23-4,290.27,Apoptosis; COX; Endogenous Metabolite; Influenza Virus,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease,Catechin ((+)-Catechin) inhibits cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM.,C15H14O6,H2O : 12.5 mg/mL (43.06 mM; Need ultrasonic); DMSO : ≥ 100 mg/mL (344.51 mM),10mM,Cancer,Launched,O[C@@H]1[C@@H](C2=CC(O)=C(O)C=C2)OC3=CC(O)=CC(O)=C3C1
,,,,,,,,,,,,,,,,b cell lymphoma 2,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,b cell lymphoma 2,navitoclax,HY-L025-4,A02,HY-10087,Navitoclax,ABT-263,923564-51-6,974.61,Bcl-2 Family,Apoptosis,"Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM[1].",C47H55ClF3N5O6S3,DMSO : 75 mg/mL (76.95 mM; Need ultrasonic); DMF : ≥ 100 mg/mL (102.61 mM),10mM,Cancer,Phase 3,O=S(C1=CC(S(NC(C2=CC=C(N3CCN(CC4=C(CCC(C)(C4)C)C5=CC=C(Cl)C=C5)CC3)C=C2)=O)(=O)=O)=CC=C1N[C@H](CCN6CCOCC6)CSC7=CC=CC=C7)(C(F)(F)F)=O
,,,,,,,,,,,,,,,,b cell lymphoma 2,fisetin,HY-L025-72,H11,HY-N0182,Fisetin,,528-48-3,286.24,PPAR; Sirtuin; TNF Receptor,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Vitamin D Related/Nuclear Receptor,"Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.",C15H10O6,DMSO : 25 mg/mL (87.34 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease,Phase 3,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC=C13
,,,,,,,,,,,,,,,,b cell lymphoma 2,abt 199,HY-L025-52,G02,HY-15531,Venetoclax,ABT-199; GDC-0199; RG7601,1257044-40-8,868.44,Autophagy; Bcl-2 Family,Apoptosis; Autophagy,"Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy[1][2][3].",C45H50ClN7O7S,DMSO : 77.5 mg/mL (89.24 mM; Need ultrasonic); Ethanol : < 1 mg/mL (insoluble),10mM,Cancer,Launched,O=C(NS(=O)(C1=CC=C(NCC2CCOCC2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCN(CC5=C(C6=CC=C(Cl)C=C6)CC(C)(C)CC5)CC4)C=C3OC7=CN=C(NC=C8)C8=C7
,,,,,,,,,,,,,,,,b cell lymphoma 2,abt 263,HY-L025-4,A02,HY-10087,Navitoclax,ABT-263,923564-51-6,974.61,Bcl-2 Family,Apoptosis,"Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM[1].",C47H55ClF3N5O6S3,DMSO : 75 mg/mL (76.95 mM; Need ultrasonic); DMF : ≥ 100 mg/mL (102.61 mM),10mM,Cancer,Phase 3,O=S(C1=CC(S(NC(C2=CC=C(N3CCN(CC4=C(CCC(C)(C4)C)C5=CC=C(Cl)C=C5)CC3)C=C2)=O)(=O)=O)=CC=C1N[C@H](CCN6CCOCC6)CSC7=CC=CC=C7)(C(F)(F)F)=O
,,,,,,,,,,,,,,,,b cell lymphoma 2,genistein,HY-L025-45,H04,HY-14596,Genistein,NPI 031L,446-72-0,270.24,Apoptosis; Autophagy; EGFR; Endogenous Metabolite,Apoptosis; Autophagy; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,"Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.",C15H10O5,DMSO : ≥ 100 mg/mL (370.04 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 4,OC1=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,b cell lymphoma 2,shikonin,HY-L025-76,E10,HY-N0822,Shikonin,C.I. 75535; Isoarnebin 4,517-89-5,288.3,AIM2; Chloride Channel; HIV; NF-κB; Pyruvate Kinase; TNF Receptor,Anti-infection; Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; NF-κB,Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM[1]. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor[2] and can also inhibit TNF-α and NF-κB pathway[3]. Shikonin decreases exosome secretion through the inhibition of glycolysis[4]. Shikonin inhibits AIM2 inflammasome activation[7].,C16H16O5,DMSO : 25 mg/mL (86.72 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,No Development Reported,O=C1C([C@H](O)C/C=C(C)/C)=CC(C2=C1C(O)=CC=C2O)=O
,,,,,,,,,,,,,,,,b cell lymphoma 2,venetoclax,HY-L025-52,G02,HY-15531,Venetoclax,ABT-199; GDC-0199; RG7601,1257044-40-8,868.44,Autophagy; Bcl-2 Family,Apoptosis; Autophagy,"Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy[1][2][3].",C45H50ClN7O7S,DMSO : 77.5 mg/mL (89.24 mM; Need ultrasonic); Ethanol : < 1 mg/mL (insoluble),10mM,Cancer,Launched,O=C(NS(=O)(C1=CC=C(NCC2CCOCC2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCN(CC5=C(C6=CC=C(Cl)C=C6)CC(C)(C)CC5)CC4)C=C3OC7=CN=C(NC=C8)C8=C7
,,,,,,,,,,,,,,,,b cell lymphoma 2,ibrutinib,HY-L025-14,D06,HY-10997A,Ibrutinib (Racemate),PCI-32765 (Racemate),936563-87-0,440.5,Btk,Protein Tyrosine Kinase/RTK,"Ibrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM.",C25H24N6O2,DMSO : 25 mg/mL (56.75 mM; Need ultrasonic),10mM,Cancer,Launched,C=CC(N1CC(N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C5=C(N)N=CN=C52)CCC1)=O
,,,,,,,,,,,,,,,,b cell lymphoma 2,abt 737,HY-L025-64,C06,HY-50907,ABT-737,,852808-04-9,813.43,Apoptosis; Autophagy; Bcl-2 Family; Mitophagy,Apoptosis; Autophagy,"ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research[1][2][3].",C42H45ClN6O5S2,DMSO : 50 mg/mL (61.47 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(CC[C@@H](NC1=CC=C(C=C1[N+]([O-])=O)S(NC(C2=CC=C(C=C2)N3CCN(CC3)CC4=CC=CC=C4C5=CC=C(C=C5)Cl)=O)(=O)=O)CSC6=CC=CC=C6)C
,,,,,,,,,,,,,,,,iκb kinase,imd 0354,HY-L025-6,B09,HY-10172,IMD-0354,IKK2 Inhibitor V,978-62-1,383.67,IKK,NF-κB,IMD-0354 (IKK2 Inhibitor V) is a selective IKKβ inhibitor which inhibits NF-κB activity[1]. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC50 of 1.2 uM[2].,C15H8ClF6NO2,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : ≥ 100 mg/mL (260.64 mM),10mM,Cancer,No Development Reported,O=C(NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C2=CC(Cl)=CC=C2O
,,,,,,,,,,,,,,,,iκb kinase,wedelolactone,HY-L025-75,A03,HY-N0551,Wedelolactone,,524-12-9,314.25,Apoptosis; Caspase; Lipoxygenase,Apoptosis; Metabolic Enzyme/Protease,"Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibits the IKK Complex. Wedelolactone also inhibits 5-lipoxygenase (5-Lox) with an IC50 of 2.5 μM. Wedelolactone induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt. Wedelolactone can extract from Eclipta alba, and it can be used for the research of cancer[1][2][3].",C16H10O7,DMSO : 125 mg/mL (397.77 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,No Development Reported,O=C1C2=C(OC3=CC(O)=C(O)C=C32)C4=C(O)C=C(OC)C=C4O1
,,,,,,,,,,,,,,,,iκb kinase,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,iκb kinase,ps 1145,HY-L025-58,H05,HY-18008,PS-1145,,431898-65-6,322.75,Apoptosis; IKK,Apoptosis; NF-κB,PS-1145 is an IκB kinase (IKK) inhibitor with an IC50 of 88 nM.,C17H11ClN4O,DMSO : 20.83 mg/mL (64.54 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C(C1=CC=CN=C1)NC2=CC(Cl)=CC3=C2NC4=C3C=CN=C4
,,,,,,,,,,,,,,,,iκb kinase,bms 345541,HY-L025-10,E09,HY-10519,BMS-345541,,445430-58-0,255.32,IKK,NF-κB,"BMS-345541 is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC50=0.3 μM, IKK-1 IC50=4 μM). BMS-345541 binds at an allosteric site of IKK.",C14H17N5,DMSO : 10 mg/mL (39.17 mM; Need ultrasonic); H2O : 10 mg/mL (39.17 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,No Development Reported,CC1=CN=C2C(NCCN)=NC3=CC=C(C)C=C3N21
,,,,,,,,,,,,,,,,iκb kinase,bay 11 7082,HY-L025-35,A11,HY-13453,BAY 11-7082,BAY 11-7821,19542-67-7,207.25,Apoptosis; Autophagy; Deubiquitinase; IKK; NF-κB,Apoptosis; Autophagy; Cell Cycle/DNA Damage; NF-κB,"BAY 11-7082 is an IκBα phosphorylation and NF-κB inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC50=0.19, 0.96 μM, respectively). BAY 11-7082 inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells[1][2][3][4][5].",C10H9NO2S,DMSO : ≥ 100 mg/mL (482.51 mM),10mM,Cancer; Inflammation/Immunology,No Development Reported,N#C/C=C/S(=O)(C1=CC=C(C)C=C1)=O
,,,,,,,,,,,,,,,,cyclin dependent kinases,honokiol,HY-L025-71,F02,HY-N0003,Honokiol,NSC 293100,35354-74-6,266.33,Akt; Autophagy; ERK; HCV,Anti-infection; Autophagy; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt,"Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt. Honokiol can readily cross the blood brain barrier[1][2][3][4].",C18H18O2,DMSO : ≥ 50 mg/mL (187.74 mM),10mM,Cancer,Phase 3,OC1=C(CC=C)C=C(C2=CC(CC=C)=CC=C2O)C=C1
,,,,,,,,,,,,,,,,cyclin dependent kinases,abemaciclib,HY-L025-55,G10,HY-16297A,Abemaciclib,LY2835219,1231929-97-7,506.59,CDK,Cell Cycle/DNA Damage,"Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.",C27H32F2N8,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 2.94 mg/mL (5.80 mM; ultrasonic and warming and heat to 80°C),2mM,Cancer,Launched,CC1=NC2=C(F)C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=C2N1C(C)C
,,,,,,,,,,,,,,,,cyclin dependent kinases,ribociclib,HY-L025-54,B07,HY-15777,Ribociclib,LEE011,1211441-98-3,434.54,CDK,Cell Cycle/DNA Damage,"Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[1].",C23H30N8O,DMSO : 20 mg/mL (46.03 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(N(C)C)C(N1C2CCCC2)=CC(C1=N3)=CN=C3NC(N=C4)=CC=C4N5CCNCC5
,,,,,,,,,,,,,,,,cyclin dependent kinases,kenpaullone,HY-L025-25,B09,HY-12302,Kenpaullone,9-Bromopaullone; NSC-664704,142273-20-9,327.18,CDK; GSK-3,Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"Kenpaullone is a potent inhibitor of CDK1/cyclin B and GSK-3β, with IC50s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC50s of 0.68 μM, 7.5 μM, 0.85 μM, respectively. Kenpaullone, a small molecule inhibitor of KLF4, reduces self-renewal of breast cancer stem cells and cell motility in vitro.",C16H11BrN2O,DMSO : ≥ 35 mg/mL (106.97 mM),10mM,Cancer,No Development Reported,O=C1NC2=CC=CC=C2C(NC3=C4C=C(Br)C=C3)=C4C1
,,,,,,,,,,,,,,,,cyclin dependent kinases,at7519,HY-L025-64,D05,HY-50943,AT7519 (Hydrochloride),,902135-91-5,418.71,Apoptosis; CDK,Apoptosis; Cell Cycle/DNA Damage,"AT7519 Hydrochloride is a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.",C16H18Cl3N5O2,DMSO : ≥ 300 mg/mL (716.49 mM); H2O : 8.33 mg/mL (19.89 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C(C(Cl)=CC=C1)=C1Cl)NC2=CNN=C2C(NC3CCNCC3)=O.[H]Cl
,,,,,,,,,,,,,,,,cyclin dependent kinases,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,cyclin dependent kinases,sns 032,HY-L025-1,C10,HY-10008,SNS-032,BMS-387032,345627-80-7,380.53,Apoptosis; CDK,Apoptosis; Cell Cycle/DNA Damage,"SNS-032 (BMS-387032) is a potent and selective inhibitor of?CDK2, CDK7, and CDK9 with?IC50s?of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect[1].",C17H24N4O2S2,DMSO : 62.5 mg/mL (164.24 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 1,CC(C)(C1=CN=C(CSC2=CN=C(NC(C3CCNCC3)=O)S2)O1)C
,,,,,,,,,,,,,,,,cyclin dependent kinases,silibinin,HY-L025-76,C08,HY-N0779A,Silybin,Silibinin,802918-57-6,482.44,Apoptosis,Apoptosis,"Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds. Silybin induces apoptosis and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity[1][2].",C25H22O10,DMSO : 25 mg/mL (51.82 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C1[C@H](O)[C@@H](C2=CC=C(OC(CO)C(C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15
,,,,,,,,,,,,,,,,cyclin dependent kinases,dinaciclib,HY-L025-10,C09,HY-10492,Dinaciclib,SCH 727965,779353-01-4,396.49,Apoptosis; CDK,Apoptosis; Cell Cycle/DNA Damage,"Dinaciclib (SCH 727965) is a potent inhibitor of CDK, with IC50s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively[1].",C21H28N6O2,DMSO : 50 mg/mL (126.11 mM; Need ultrasonic),10mM,Cancer,Launched,OCC[C@H]1N(CCCC1)C2=NC3=C(C=NN3C(NCC4=C[N+]([O-])=CC=C4)=C2)CC
,,,,,,,,,,,,,,,,cyclin dependent kinases,butyrolactone i,HY-L025-15,E06,HY-111237,Butyrolactone I,Olomoucin,87414-49-1,424.44,CDK,Cell Cycle/DNA Damage,"Butyrolactone I is an ATP-competitive inhibitor of CDK1 as a secondary metabolite from A. terreus[1]. Butyrolactone I has antitumor effects in non-small cell lung, small cell lung, and prostate cancer cell lines[2].",C24H24O7,DMSO : 100 mg/mL (235.60 mM; Need ultrasonic),10mM,Cancer,No Development Reported,COC([C@]1(C(C2=CC=C(C=C2)O)=C(C(O1)=O)O)CC3=CC(C/C=C(C)\C)=C(C=C3)O)=O
,,,,,,,,,,,,,,,,cyclin dependent kinases,indirubin,HY-L025-72,D08,HY-N0117,Indirubin,Couroupitine B; Indigo red; Indigopurpurin,479-41-4,262.26,Apoptosis,Apoptosis,Indirubin (Couroupitine B) is a bis-indole alkaloid and has emarkable anticancer activity against chronic myelocytic leukemia[1][2].,C16H10N2O2,DMSO : 5 mg/mL (19.07 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C1NC2=C(C=CC=C2)/C1=C3NC4=C(C=CC=C4)C\3=O
,,,,,,,,,,,,,,,,cyclin dependent kinases,palbociclib,HY-L025-65,F03,HY-A0065,Palbociclib (isethionate),PD 0332991 isethionate,827022-33-3,573.66,CDK,Cell Cycle/DNA Damage,"Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma[1][3][4].",C26H35N7O6S,H2O : 50 mg/mL (87.16 mM; Need ultrasonic); DMSO : 10 mg/mL (17.43 mM; Need ultrasonic),10mM,Cancer,Launched,CC(C1=C(N2C3CCCC3)N=C(NC4=NC=C(N5CCNCC5)C=C4)N=C1)=C(C(C)=O)C2=O.OCCS(O)(=O)=O
,,,,,,,,,,,,,,,,cyclin dependent kinases,flavopiridol,HY-L025-1,C08,HY-10006,Flavopiridol (Hydrochloride),Alvocidib (Hydrochloride); L86-8275 (Hydrochloride); HMR-1275 (Hydrochloride),131740-09-5,438.3,Autophagy; CDK; HIV,Anti-infection; Autophagy; Cell Cycle/DNA Damage,"Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.",C21H21Cl2NO5,DMF : 7.69 mg/mL (17.55 mM; Need ultrasonic); DMSO : ≥ 20 mg/mL (45.63 mM); H2O : ≥ 20 mg/mL (45.63 mM),10mM,Cancer,Phase 2,O=C1C2=C(C=C(C([C@]3([H])[C@H](O)CN(C)CC3)=C2OC(C4=CC=CC=C4Cl)=C1)O)O.[H]Cl
,,,,,,,,,,,,,,,,cyclin dependent kinases,seliciclib,HY-L025-63,C02,HY-30237,(R)-Roscovitine,Seliciclib; CYC202,186692-46-6,354.45,CDK,Cell Cycle/DNA Damage,"(R)-Roscovitine (Seliciclib) is an orally bioavailable and selective CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.",C19H26N6O,DMSO : ≥ 100 mg/mL (282.13 mM),10mM,Cancer,Phase 2,OC[C@H](NC1=NC(NCC2=CC=CC=C2)=C3C(N(C=N3)C(C)C)=N1)CC
,,,,,,,,,,,,,,,,cyclin a,apigenin,HY-L025-77,B10,HY-N1201,Apigenin,"4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1",520-36-5,270.24,Autophagy; Cytochrome P450; Endogenous Metabolite,Autophagy; Metabolic Enzyme/Protease,"Apigenin (4',5,7-Trihydroxyflavone) is a competitive CYP2C9 inhibitor with a Ki of 2 μM.",C15H10O5,DMSO : 83.33 mg/mL (308.36 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=CC2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,cyclin a,cpt,HY-L025-56,C10,HY-16560,Camptothecin,Campathecin; (S)-(+)-Camptothecin; CPT,3/4/89,348.35,ADC Cytotoxin; Antibiotic; Apoptosis; Fungal; Influenza Virus; MicroRNA; Topoisomerase,Antibody-drug Conjugate/ADC Related; Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics,"Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM[1]. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells[2][3].",C20H16N2O4,DMSO : 6.25 mg/mL (17.94 mM; Need ultrasonic); 1M NaOH : 10 mg/mL (28.71 mM; ultrasonic and adjust pH to 11 with NaOH),10mM,Cancer; Infection,Launched,O=C1C2=C([C@@](O)(CC)C(OC2)=O)C=C(N1C3)C(C3=C4)=NC5=C4C=CC=C5
,,,,,,,,,,,,,,,,cyclin a,celecoxib,HY-L025-43,G07,HY-14398,Celecoxib,SC 58635,169590-42-5,381.37,COX,Immunology/Inflammation,"Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.",C17H14F3N3O2S,DMSO : ≥ 50 mg/mL (131.11 mM),10mM,Inflammation/Immunology; Cancer,Launched,CC1=CC=C(C=C1)C2=CC(C(F)(F)F)=NN2C3=CC=C(C=C3)S(=O)(N)=O
,,,,,,,,,,,,,,,,cyclin a,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,cyclin a,dha,HY-L025-71,C06,HY-B2167,Docosahexaenoic acid,DHA; Cervonic acid,6217-54-5,328.49,Endogenous Metabolite,Metabolic Enzyme/Protease,Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk.,C22H32O2,Ethanol : 50 mg/mL (152.21 mM; Need ultrasonic); DMSO : 100 mg/mL (304.42 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(O)=O
,,,,,,,,,,,,,,,,cyclin a,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,cyclin a,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,cyclin a,tsa,HY-L025-49,F10,HY-15144,Trichostatin A,TSA,58880-19-6,302.37,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].",C17H22N2O3,DMSO : 25 mg/mL (82.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
,,,,,,,,,,,,,,,,cyclin a,sp600125,HY-L025-22,G02,HY-12041,SP600125,,129-56-6,220.23,Apoptosis; Autophagy; Ferroptosis; JNK,Apoptosis; Autophagy; MAPK/ERK Pathway,"SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 inhibits autophagy and activates apoptosis[1][2][3].",C14H8N2O,DMSO : 12.5 mg/mL (56.76 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C3C(NN=C3C4=C1C=CC=C4)=CC=C2
,,,,,,,,,,,,,,,,cyclin a,pd98059,HY-L025-22,E02,HY-12028,PD98059,,167869-21-8,267.28,Aryl Hydrocarbon Receptor; Autophagy; ERK; MEK,Autophagy; Immunology/Inflammation; MAPK/ERK Pathway; Stem Cell/Wnt,"PD98059 is a potent and selective MEK inhibitor with an IC50 of 5 μM. PD98059 binds to the inactive form of MEK, thereby preventing the activation of MEK1 (IC50 of 2-7 μM) and MEK2 (IC50 of 50 μM) by upstream kinases. PD98059 is a ERK1/2 signaling inhibitor. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC50 of 4 μM) and AHR transformation (IC50 of 1 μM). PD98059 also inhibits Mycobacterium bovis Bacillus CalmetteGuerin (BCG)-induced autophagy[1][2][3].",C16H13NO3,DMSO : 33.33 mg/mL (124.70 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,No Development Reported,O=C1C=C(OC2=CC=CC=C21)C3=CC=CC(OC)=C3N
,,,,,,,,,,,,,,,,rela,bortezomib,HY-L025-7,E07,HY-10227,Bortezomib,PS-341; LDP-341; NSC 681239,179324-69-7,384.24,Apoptosis; Autophagy; NF-κB; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].",C19H25BN4O4,DMSO : 50 mg/mL (130.13 mM; Need ultrasonic); Ethanol : 66.67 mg/mL (173.51 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
,,,,,,,,,,,,,,,,rela,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,rela,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,rela,celastrol,HY-L025-32,A08,HY-13067,Celastrol,Tripterine; Tripterin,34157-83-0,450.61,Apoptosis; Autophagy; Endogenous Metabolite; Mitophagy; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease,Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.,C29H38O4,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 33.33 mg/mL (73.97 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C(C2=CC=C3[C@](C)([C@]4(CC[C@]3(C2=CC1=O)C)C)CC[C@@]5(C)CC[C@@](C(O)=O)(C[C@]54[H])C)C
,,,,,,,,,,,,,,,,jak1,ruxolitinib,HY-L025-64,A05,HY-50858,Ruxolitinib (phosphate),INCB018424 phosphate,1092939-17-7,404.36,Autophagy; JAK; Mitophagy,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.",C17H21N6O4P,DMSO : ≥ 31 mg/mL (76.66 mM); H2O : 10 mg/mL (24.73 mM; Need ultrasonic),10mM,Cancer,Launched,N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2.O=P(O)(O)O
,,,,,,,,,,,,,,,,jak1,piceatannol,HY-L025-35,H10,HY-13518,Piceatannol,Astringenin; trans-Piceatannol,10083-24-6,244.24,Apoptosis; Autophagy; Endogenous Metabolite; Syk,Apoptosis; Autophagy; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI)[1]. Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties[2]. Piceatannol induces apoptosis in DLBCL cell lines[3]. Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells[4].,C14H12O4,DMSO : ≥ 31 mg/mL (126.92 mM); H2O : 1 mg/mL (4.09 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1O
,,,,,,,,,,,,,,,,jak1,myricetin,HY-L025-49,D10,HY-15097,Myricetin,Cannabiscetin,529-44-2,318.24,Apoptosis; Autophagy; Endogenous Metabolite,Apoptosis; Autophagy; Metabolic Enzyme/Protease,"Myricetin is a common plant-derived flavonoid with a wide range of activities including strong anti-oxidant, anticancer, antidiabetic and anti-inflammatory activities.",C15H10O8,DMSO : ≥ 31 mg/mL (97.41 mM); Ethanol : 28.57 mg/mL (89.78 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC1=CC(O)=C(C(C(O)=C(C2=CC(O)=C(O)C(O)=C2)O3)=O)C3=C1
,,,,,,,,,,,,,,,,jak1,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,jak1,itacitinib,HY-L025-57,E05,HY-16997,Itacitinib,INCB039110,1334298-90-6,553.51,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Itacitinib (INCB039110) is an orally active and selective inhibitor of JAK1 with an IC50 of 2 nM for human JAK1. Itacitinib shows >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis[1][2].,C26H23F4N9O,DMSO : ≥ 30 mg/mL (54.20 mM),10mM,Cancer,Phase 3,N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(C5CCN(C(C6=C(F)C(C(F)(F)F)=NC=C6)=O)CC5)C1
,,,,,,,,,,,,,,,,jak1,ag490,HY-L025-22,A04,HY-12000,AG490,Tyrphostin AG490; Tyrphostin B42,133550-30-8,294.3,Autophagy; EGFR; JAK; STAT,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.",C17H14N2O3,DMSO : ≥ 50 mg/mL (169.89 mM),10mM,Cancer,No Development Reported,O=C(NCC1=CC=CC=C1)/C(C#N)=C/C2=CC=C(O)C(O)=C2
,,,,,,,,,,,,,,,,jak1,filgotinib,HY-L025-59,C07,HY-18300,Filgotinib,GLPG0634,1206161-97-8,425.5,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Filgotinib (GLPG0634) is a selective and orally active JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.",C21H23N5O3S,DMSO : 25 mg/mL (58.75 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,O=C(C1CC1)NC2=NN3C(C4=CC=C(CN5CCS(CC5)(=O)=O)C=C4)=CC=CC3=N2
,,,,,,,,,,,,,,,,jak1,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,jak1,tofacitinib,HY-L025-63,D09,HY-40354A,Tofacitinib (citrate),Tasocitinib (citrate); CP-690550 (citrate),540737-29-9,504.49,Apoptosis; Bacterial; Fungal; Influenza Virus; JAK,Anti-infection; Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.",C22H28N6O8,DMSO : 28.57 mg/mL (56.63 mM; Need ultrasonic); H2O : 3.33 mg/mL (6.60 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O
,,,,,,,,,,,,,,,,jak1,glpg0634,HY-L025-59,C07,HY-18300,Filgotinib,GLPG0634,1206161-97-8,425.5,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Filgotinib (GLPG0634) is a selective and orally active JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.",C21H23N5O3S,DMSO : 25 mg/mL (58.75 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,O=C(C1CC1)NC2=NN3C(C4=CC=C(CN5CCS(CC5)(=O)=O)C=C4)=CC=CC3=N2
,,,,,,,,,,,,,,,,jak1,incb039110,HY-L025-57,E05,HY-16997,Itacitinib,INCB039110,1334298-90-6,553.51,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Itacitinib (INCB039110) is an orally active and selective inhibitor of JAK1 with an IC50 of 2 nM for human JAK1. Itacitinib shows >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis[1][2].,C26H23F4N9O,DMSO : ≥ 30 mg/mL (54.20 mM),10mM,Cancer,Phase 3,N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(C5CCN(C(C6=C(F)C(C(F)(F)F)=NC=C6)=O)CC5)C1
,,,,,,,,,,,,,,,,jak1,momelotinib,HY-L025-14,B04,HY-10961,Momelotinib,CYT387,1056634-68-4,414.46,Apoptosis; Autophagy; JAK,Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50a of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3.",C23H22N6O2,DMSO : 20.83 mg/mL (50.26 mM; ultrasonic and warming and heat to 80°C),10mM,Cancer,Phase 3,O=C(C1=CC=C(C2=NC(NC3=CC=C(N4CCOCC4)C=C3)=NC=C2)C=C1)NCC#N
,,,,,,,,,,,,,,,,jak1,pacritinib,HY-L025-55,H09,HY-16379,Pacritinib,SB1518,937272-79-2,472.58,FLT3; JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM).,C28H32N4O3,DMSO : 5 mg/mL (10.58 mM; Need ultrasonic),10mM,Cancer,Launched,C1(COC/C=C/COCC2=C(OCCN3CCCC3)C=CC4=C2)=CC=CC(C5=N/C(NC=C5)=N\4)=C1
,,,,,,,,,,,,,,,,jak1,cyt387,HY-L025-14,B06,HY-10962,Momelotinib sulfate,CYT387 (sulfate salt),1056636-06-6,610.62,Apoptosis; Autophagy; JAK,Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC50=155 nM).",C23H26N6O10S2,DMSO : 220 mg/mL (360.29 mM; Need ultrasonic); H2O : 100 mg/mL (163.77 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(NCC#N)C(C=C1)=CC=C1C2=NC(NC(C=C3)=CC=C3N4CCOCC4)=NC=C2.O=S(O)(O)=O.O=S(O)(O)=O
,,,,,,,,,,,,,,,,cdk1,apigenin,HY-L025-77,B10,HY-N1201,Apigenin,"4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1",520-36-5,270.24,Autophagy; Cytochrome P450; Endogenous Metabolite,Autophagy; Metabolic Enzyme/Protease,"Apigenin (4',5,7-Trihydroxyflavone) is a competitive CYP2C9 inhibitor with a Ki of 2 μM.",C15H10O5,DMSO : 83.33 mg/mL (308.36 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=CC2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,cdk1,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
,,,,,,,,,,,,,,,,cdk1,purvalanol a,HY-L025-59,C06,HY-18299A,Purvalanol A,NG-60,212844-53-6,388.89,Apoptosis; Autophagy; CDK,Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, resepctively.",C19H25ClN6O,DMSO : ≥ 50 mg/mL (128.57 mM),10mM,Cancer,No Development Reported,CC([C@@H](NC1=NC(NC2=CC=CC(Cl)=C2)=C3N=CN(C(C)C)C3=N1)CO)C
,,,,,,,,,,,,,,,,cdk1,azd1775,HY-L025-14,D02,HY-10993,Adavosertib,AZD1775; MK-1775,955365-80-7,500.6,Wee1,Cell Cycle/DNA Damage,Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC50 of 5.2 nM.,C27H32N8O2,DMSO : 125 mg/mL (249.70 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1N(N(C2=NC(NC3=CC=C(C=C3)N4CCN(CC4)C)=NC=C21)C5=NC(C(O)(C)C)=CC=C5)CC=C
,,,,,,,,,,,,,,,,cdk1,at7519,HY-L025-64,D05,HY-50943,AT7519 (Hydrochloride),,902135-91-5,418.71,Apoptosis; CDK,Apoptosis; Cell Cycle/DNA Damage,"AT7519 Hydrochloride is a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.",C16H18Cl3N5O2,DMSO : ≥ 300 mg/mL (716.49 mM); H2O : 8.33 mg/mL (19.89 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C(C(Cl)=CC=C1)=C1Cl)NC2=CNN=C2C(NC3CCNCC3)=O.[H]Cl
,,,,,,,,,,,,,,,,cdk1,dinaciclib,HY-L025-10,C09,HY-10492,Dinaciclib,SCH 727965,779353-01-4,396.49,Apoptosis; CDK,Apoptosis; Cell Cycle/DNA Damage,"Dinaciclib (SCH 727965) is a potent inhibitor of CDK, with IC50s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively[1].",C21H28N6O2,DMSO : 50 mg/mL (126.11 mM; Need ultrasonic),10mM,Cancer,Launched,OCC[C@H]1N(CCCC1)C2=NC3=C(C=NN3C(NCC4=C[N+]([O-])=CC=C4)=C2)CC
,,,,,,,,,,,,,,,,cdk1,alsterpaullone,HY-L025-12,F02,HY-108359,Alsterpaullone,9-Nitropaullone; NSC 705701,237430-03-4,293.28,Apoptosis; CDK; GSK-3,Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"Alsterpaullone (9-Nitropaullone) is a potent CDK inhibitor, with IC50s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to GSK-3alpha/GSK-3beta with IC50s of both 4 nM. Alsterpaullone has antitumor activity, and possesses potential for the study in neurodegenerative and proliferative disorders[1]. Alsterpaullone induces apoptosis in leukemia cell line[2].",C16H11N3O3,10 mM in DMSO,10mM,Cancer,No Development Reported,O=C1NC2=CC=CC=C2C(NC3=C4C=C([N+]([O-])=O)C=C3)=C4C1
,,,,,,,,,,,,,,,,cdk1,kaempferol,HY-L025-45,F09,HY-14590,Kaempferol,Kempferol; Robigenin,520-18-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Estrogen Receptor/ERR; HIV; Mitophagy; Parasite,Anti-infection; Apoptosis; Autophagy; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer[1][2][3][4].",C15H10O6,DMSO : ≥ 32 mg/mL (111.79 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=C(O)C2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,cdk1,sp600125,HY-L025-22,G02,HY-12041,SP600125,,129-56-6,220.23,Apoptosis; Autophagy; Ferroptosis; JNK,Apoptosis; Autophagy; MAPK/ERK Pathway,"SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 inhibits autophagy and activates apoptosis[1][2][3].",C14H8N2O,DMSO : 12.5 mg/mL (56.76 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C3C(NN=C3C4=C1C=CC=C4)=CC=C2
,,,,,,,,,,,,,,,,cdk1,butyrolactone i,HY-L025-15,E06,HY-111237,Butyrolactone I,Olomoucin,87414-49-1,424.44,CDK,Cell Cycle/DNA Damage,"Butyrolactone I is an ATP-competitive inhibitor of CDK1 as a secondary metabolite from A. terreus[1]. Butyrolactone I has antitumor effects in non-small cell lung, small cell lung, and prostate cancer cell lines[2].",C24H24O7,DMSO : 100 mg/mL (235.60 mM; Need ultrasonic),10mM,Cancer,No Development Reported,COC([C@]1(C(C2=CC=C(C=C2)O)=C(C(O1)=O)O)CC3=CC(C/C=C(C)\C)=C(C=C3)O)=O
,,,,,,,,,,,,,,,,cdk1,bortezomib,HY-L025-7,E07,HY-10227,Bortezomib,PS-341; LDP-341; NSC 681239,179324-69-7,384.24,Apoptosis; Autophagy; NF-κB; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].",C19H25BN4O4,DMSO : 50 mg/mL (130.13 mM; Need ultrasonic); Ethanol : 66.67 mg/mL (173.51 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
,,,,,,,,,,,,,,,,cdk1,silibinin,HY-L025-76,C08,HY-N0779A,Silybin,Silibinin,802918-57-6,482.44,Apoptosis,Apoptosis,"Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds. Silybin induces apoptosis and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity[1][2].",C25H22O10,DMSO : 25 mg/mL (51.82 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C1[C@H](O)[C@@H](C2=CC=C(OC(CO)C(C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15
,,,,,,,,,,,,,,,,cdk1,baicalein,HY-L025-73,B02,HY-N0196,Baicalein,"5,6,7-Trihydroxyflavone",491-67-8,270.24,Ferroptosis; Influenza Virus; Xanthine Oxidase,Anti-infection; Apoptosis; Metabolic Enzyme/Protease,"Baicalein (5,6,7-Trihydroxyflavone) is a xanthine oxidase inhibitor with an IC50 value of 3.12 μM.",C15H10O5,DMSO : 50 mg/mL (185.02 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1C=C(C2=CC=CC=C2)OC3=CC(O)=C(O)C(O)=C13
,,,,,,,,,,,,,,,,cdk1,genistein,HY-L025-45,H04,HY-14596,Genistein,NPI 031L,446-72-0,270.24,Apoptosis; Autophagy; EGFR; Endogenous Metabolite,Apoptosis; Autophagy; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,"Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.",C15H10O5,DMSO : ≥ 100 mg/mL (370.04 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 4,OC1=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,cdk1,flavopiridol,HY-L025-1,C08,HY-10006,Flavopiridol (Hydrochloride),Alvocidib (Hydrochloride); L86-8275 (Hydrochloride); HMR-1275 (Hydrochloride),131740-09-5,438.3,Autophagy; CDK; HIV,Anti-infection; Autophagy; Cell Cycle/DNA Damage,"Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.",C21H21Cl2NO5,DMF : 7.69 mg/mL (17.55 mM; Need ultrasonic); DMSO : ≥ 20 mg/mL (45.63 mM); H2O : ≥ 20 mg/mL (45.63 mM),10mM,Cancer,Phase 2,O=C1C2=C(C=C(C([C@]3([H])[C@H](O)CN(C)CC3)=C2OC(C4=CC=CC=C4Cl)=C1)O)O.[H]Cl
,,,,,,,,,,,,,,,,akt2,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,akt2,mk 2206,HY-L025-9,B02,HY-10358,MK-2206 (dihydrochloride),MK-2206 (2HCl),1032350-13-2,480.39,Akt; Apoptosis; Autophagy,Apoptosis; Autophagy; PI3K/Akt/mTOR,"MK-2206 dihydrochloride (MK-2206 (2HCl)) is an orally active allosteric AKT inhibitor with IC50s of 5 nM, 12 nM, and 65 nM for AKT1, AKT2, and AKT3, respectively. MK-2206 dihydrochloride induces autophagy[1][3].",C25H23Cl2N5O,DMSO : 50 mg/mL (104.08 mM; ultrasonic and warming and heat to 60°C); H2O : 3.57 mg/mL (7.43 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=C1N2C(C3=CC(C4=CC=CC=C4)=C(N=C3C=C2)C5=CC=C(C6(N)CCC6)C=C5)=NN1.Cl.Cl
,,,,,,,,,,,,,,,,α smooth muscle actin,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
,,,,,,,,,,,,,,,,α smooth muscle actin,apigenin,HY-L025-77,B10,HY-N1201,Apigenin,"4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1",520-36-5,270.24,Autophagy; Cytochrome P450; Endogenous Metabolite,Autophagy; Metabolic Enzyme/Protease,"Apigenin (4',5,7-Trihydroxyflavone) is a competitive CYP2C9 inhibitor with a Ki of 2 μM.",C15H10O5,DMSO : 83.33 mg/mL (308.36 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=CC2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,α smooth muscle actin,pioglitazone,HY-L025-45,H09,HY-14601,Pioglitazone (hydrochloride),U 72107A; AD 4833,112529-15-4,392.9,Ferroptosis; PPAR,Apoptosis; Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor,"Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.",C19H21ClN2O3S,DMSO : 100 mg/mL (254.52 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer; Metabolic Disease,Launched,CCC1=CN=C(CCOC2=CC=C(CC3C(NC(S3)=O)=O)C=C2)C=C1.Cl
,,,,,,,,,,,,,,,,α smooth muscle actin,berberine,HY-L025-59,B09,HY-18258,Berberine (chloride),Natural Yellow 18 (chloride),633-65-8,371.81,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; Parasite; Reactive Oxygen Species; Topoisomerase,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,Berberine chloride is an alkaloid that acts as an antibiotic. Berberine chloride induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties[1].,C20H18ClNO4,DMSO : 12.5 mg/mL (33.62 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Cancer,Launched,COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.[Cl-]
,,,,,,,,,,,,,,,,α smooth muscle actin,atra,HY-L025-46,C02,HY-14649,Retinoic acid,Vitamin A acid; all-trans-Retinoic acid; ATRA,302-79-4,300.44,Autophagy; Endogenous Metabolite; PPAR; RAR/RXR,Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.",C20H28O2,DMSO : 50 mg/mL (166.42 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,CC1(C)C(/C=C/C(C)=C/C=C/C(C)=C/C(O)=O)=C(C)CCC1
,,,,,,,,,,,,,,,,α smooth muscle actin,rosiglitazone,HY-L025-57,H08,HY-17386,Rosiglitazone,BRL 49653,122320-73-4,357.43,Apoptosis; Autophagy; Ferroptosis; PPAR; TRP Channel,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel; Neuronal Signaling; Vitamin D Related/Nuclear Receptor,"Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer[1][2][4][7].",C18H19N3O3S,DMSO : 250 mg/mL (699.44 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic) (insoluble); Ethanol : 2 mg/mL (5.60 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease,Launched,O=C(N1)SC(CC2=CC=C(OCCN(C)C3=NC=CC=C3)C=C2)C1=O
,,,,,,,,,,,,,,,,α smooth muscle actin,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,α smooth muscle actin,y 27632,HY-L025-10,H04,HY-10583,Y-27632 (dihydrochloride),,129830-38-2,320.26,ROCK,Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad,Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor (ROCK-I Ki=220 nM; ROCK-II Ki=300 nM). Y-27632 dihydrochloride shows antiepileptic effects[1][2][3][4].,C14H23Cl2N3O,DMSO : 33.33 mg/mL (104.07 mM; Need ultrasonic); H2O : 100 mg/mL (312.25 mM; Need ultrasonic),10mM,Cancer; Neurological Disease,No Development Reported,O=C([C@@H]1CC[C@]([C@H](N)C)([H])CC1)NC2=CC=NC=C2.[H]Cl.[H]Cl
,,,,,,,,,,,,,,,,α smooth muscle actin,icg 001,HY-L025-43,H10,HY-14428,ICG-001,,780757-88-2,548.63,Apoptosis; β-catenin,Apoptosis; Stem Cell/Wnt,ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.,C33H32N4O4,DMSO : ≥ 50 mg/mL (91.14 mM),10mM,Cancer,No Development Reported,O=C(NCC1=CC=CC=C1)N2CCC(N([C@@]2(CN(C3=O)CC4=C5C=CC=CC5=CC=C4)[H])[C@H]3CC6=CC=C(C=C6)O)=O
,,,,,,,,,,,,,,,,α smooth muscle actin,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,α smooth muscle actin,fty720,HY-L025-22,A09,HY-12005,Fingolimod (hydrochloride),FTY720,162359-56-0,343.93,LPL Receptor; PAK,Cell Cycle/DNA Damage; Cytoskeleton; GPCR/G Protein,"Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate (S1P) receptors modulator. Fingolimod hydrochloride is phosphorylated  by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5. Fingolimod hydrochloride induces the internalization of S1P1, and consequently, inhibits S1P activity. Fingolimod hydrochloride also is a pak1 activator[1][4].",C19H34ClNO2,DMSO : ≥ 100 mg/mL (290.76 mM); H2O : 50 mg/mL (145.38 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Launched,OCC(N)(CO)CCC1=CC=C(C=C1)CCCCCCCC.[H]Cl
,,,,,,,,,,,,,,,,α smooth muscle actin,genistein,HY-L025-45,H04,HY-14596,Genistein,NPI 031L,446-72-0,270.24,Apoptosis; Autophagy; EGFR; Endogenous Metabolite,Apoptosis; Autophagy; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,"Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.",C15H10O5,DMSO : ≥ 100 mg/mL (370.04 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 4,OC1=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,α smooth muscle actin,chrysin,HY-L025-45,F07,HY-14589,Chrysin,"5,7-Dihydroxyflavone",480-40-0,254.24,Estrogen Receptor/ERR,Vitamin D Related/Nuclear Receptor,Chrysin is one of the most well known estrogen blockers.,C15H10O4,DMSO : ≥ 100 mg/mL (393.33 mM),10mM,Cancer,No Development Reported,OC1=C2C(OC(C3=CC=CC=C3)=CC2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,α smooth muscle actin,losartan,HY-L025-58,E05,HY-17512A,Losartan (potassium),DuP-753 (potassium),124750-99-8,461,Angiotensin Receptor,GPCR/G Protein,"Losartan potassium (DuP-753 potassium) is an angiotensin II receptor type 1 (AT1) antagonist, competing with the binding of angiotensin II to AT1 with an IC50 of 20 nM.",C22H22ClKN6O,DMSO : ≥ 110 mg/mL (238.61 mM); H2O : 50 mg/mL (108.46 mM; Need ultrasonic),10mM,Cardiovascular Disease; Endocrinology; Cancer,Launched,OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=N[N-]N=N4)C=C2.[K+]
,,,,,,,,,,,,,,,,α smooth muscle actin,pirfenidone,HY-L025-69,C05,HY-B0673,Pirfenidone,AMR69,53179-13-8,185.22,CCR; TGF-beta/Smad,GPCR/G Protein; Immunology/Inflammation; Stem Cell/Wnt; TGF-beta/Smad,Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities[1][2][3].,C12H11NO,DMSO : ≥ 100 mg/mL (539.90 mM); H2O : 16.67 mg/mL (90.00 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Launched,O=C1C=CC(C)=CN1C2=CC=CC=C2
,,,,,,,,,,,,,,,,α smooth muscle actin,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,cdk6,apigenin,HY-L025-77,B10,HY-N1201,Apigenin,"4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1",520-36-5,270.24,Autophagy; Cytochrome P450; Endogenous Metabolite,Autophagy; Metabolic Enzyme/Protease,"Apigenin (4',5,7-Trihydroxyflavone) is a competitive CYP2C9 inhibitor with a Ki of 2 μM.",C15H10O5,DMSO : 83.33 mg/mL (308.36 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=CC2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,cdk6,ly2835219,HY-L025-55,G10,HY-16297A,Abemaciclib,LY2835219,1231929-97-7,506.59,CDK,Cell Cycle/DNA Damage,"Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.",C27H32F2N8,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 2.94 mg/mL (5.80 mM; ultrasonic and warming and heat to 80°C),2mM,Cancer,Launched,CC1=NC2=C(F)C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=C2N1C(C)C
,,,,,,,,,,,,,,,,cdk6,flavopiridol,HY-L025-1,C08,HY-10006,Flavopiridol (Hydrochloride),Alvocidib (Hydrochloride); L86-8275 (Hydrochloride); HMR-1275 (Hydrochloride),131740-09-5,438.3,Autophagy; CDK; HIV,Anti-infection; Autophagy; Cell Cycle/DNA Damage,"Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.",C21H21Cl2NO5,DMF : 7.69 mg/mL (17.55 mM; Need ultrasonic); DMSO : ≥ 20 mg/mL (45.63 mM); H2O : ≥ 20 mg/mL (45.63 mM),10mM,Cancer,Phase 2,O=C1C2=C(C=C(C([C@]3([H])[C@H](O)CN(C)CC3)=C2OC(C4=CC=CC=C4Cl)=C1)O)O.[H]Cl
,,,,,,,,,,,,,,,,cdk6,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
,,,,,,,,,,,,,,,,cdk6,fisetin,HY-L025-72,H11,HY-N0182,Fisetin,,528-48-3,286.24,PPAR; Sirtuin; TNF Receptor,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Vitamin D Related/Nuclear Receptor,"Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.",C15H10O6,DMSO : 25 mg/mL (87.34 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease,Phase 3,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC=C13
,,,,,,,,,,,,,,,,cdk6,honokiol,HY-L025-71,F02,HY-N0003,Honokiol,NSC 293100,35354-74-6,266.33,Akt; Autophagy; ERK; HCV,Anti-infection; Autophagy; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt,"Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt. Honokiol can readily cross the blood brain barrier[1][2][3][4].",C18H18O2,DMSO : ≥ 50 mg/mL (187.74 mM),10mM,Cancer,Phase 3,OC1=C(CC=C)C=C(C2=CC(CC=C)=CC=C2O)C=C1
,,,,,,,,,,,,,,,,cdk6,lee011,HY-L025-54,B09,HY-15777B,Ribociclib succinate,LEE011 (succinate),1374639-75-4,552.63,CDK,Cell Cycle/DNA Damage,"Ribociclib succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.",C27H36N8O5,DMSO : 9.38 mg/mL (16.97 mM; ultrasonic and warming and heat to 60°C); H2O : 4.17 mg/mL (7.55 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(N(C)C)C(N1C2CCCC2)=CC(C1=N3)=CN=C3NC(N=C4)=CC=C4N5CCNCC5.OC(CCC(O)=O)=O
,,,,,,,,,,,,,,,,cdk6,gsk525762a,HY-L025-31,F08,HY-13032,Molibresib,I-BET762; GSK525762; GSK525762A,1260907-17-2,423.9,Epigenetic Reader Domain,Epigenetics,Molibresib (I-BET762; GSK525762) is a BET bromodomain inhibitor with IC50 of 32.5-42.5 nM.,C22H22ClN5O2,1M HCl : 100 mg/mL (235.90 mM; ultrasonic and adjust pH to 1 with HCl); DMSO : 200 mg/mL (471.81 mM; Need ultrasonic),10mM,Cancer,Phase 2,ClC1=CC=C(C2=N[C@@H](CC(NCC)=O)C3=NN=C(C)N3C4=CC=C(OC)C=C24)C=C1
,,,,,,,,,,,,,,,,cdk6,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,cdk6,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,cdk6,pd 0332991,HY-L025-63,H07,HY-50767A,Palbociclib (monohydrochloride),PD 0332991 (monohydrochloride),827022-32-2,483.99,CDK,Cell Cycle/DNA Damage,"Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma[1][3][4].",C24H30ClN7O2,DMSO : 4.63 mg/mL (9.57 mM; ultrasonic and warming and heat to 80°C); H2O : 7.14 mg/mL (14.75 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C1C(C(C)=O)=C(C)C2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C5CCCC5.Cl
,,,,,,,,,,,,,,,,cdk6,tsa,HY-L025-49,F10,HY-15144,Trichostatin A,TSA,58880-19-6,302.37,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].",C17H22N2O3,DMSO : 25 mg/mL (82.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
,,,,,,,,,,,,,,,,cdk6,ribociclib,HY-L025-54,B07,HY-15777,Ribociclib,LEE011,1211441-98-3,434.54,CDK,Cell Cycle/DNA Damage,"Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[1].",C23H30N8O,DMSO : 20 mg/mL (46.03 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(N(C)C)C(N1C2CCCC2)=CC(C1=N3)=CN=C3NC(N=C4)=CC=C4N5CCNCC5
,,,,,,,,,,,,,,,,cdk6,dim,HY-L025-54,A02,HY-15758,"3,3'-Diindolylmethane",DIM; Arundine; HB 236,5/4/68,246.31,Androgen Receptor; Autophagy,Autophagy; Vitamin D Related/Nuclear Receptor,"3,3'-Diindolylmethane is a strong, pure androgen receptor (AR) antagonist.",C17H14N2,DMSO : ≥ 100 mg/mL (405.99 mM),10mM,Cancer,Phase 4,C1(CC2=CNC3=C2C=CC=C3)=CNC4=C1C=CC=C4
,,,,,,,,,,,,,,,,cdk6,abemaciclib,HY-L025-55,G10,HY-16297A,Abemaciclib,LY2835219,1231929-97-7,506.59,CDK,Cell Cycle/DNA Damage,"Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.",C27H32F2N8,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 2.94 mg/mL (5.80 mM; ultrasonic and warming and heat to 80°C),2mM,Cancer,Launched,CC1=NC2=C(F)C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=C2N1C(C)C
,,,,,,,,,,,,,,,,cdk6,atra,HY-L025-46,C02,HY-14649,Retinoic acid,Vitamin A acid; all-trans-Retinoic acid; ATRA,302-79-4,300.44,Autophagy; Endogenous Metabolite; PPAR; RAR/RXR,Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.",C20H28O2,DMSO : 50 mg/mL (166.42 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,CC1(C)C(/C=C/C(C)=C/C=C/C(C)=C/C(O)=O)=C(C)CCC1
,,,,,,,,,,,,,,,,dna methyltransferase,vorinostat,HY-L025-7,E02,HY-10221,Vorinostat,SAHA; Suberoylanilide hydroxamic acid,149647-78-9,264.32,Apoptosis; Autophagy; Filovirus; HDAC; HPV; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].",C14H20N2O3,DMSO : ≥ 100 mg/mL (378.33 mM),10mM,Cancer; Infection,Launched,O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O
,,,,,,,,,,,,,,,,dna methyltransferase,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,dna methyltransferase,sgi 1027,HY-L025-42,C08,HY-13962,SGI-1027,,1020149-73-8,461.52,Apoptosis; DNA Methyltransferase,Apoptosis; Epigenetics,"SGI-1027 is a DNA methyltransferase (DNMT) inhibitor, with IC50s of 7.5 μM, 8 μM, and 12.5 μM for DNMT3B, DNMT3A, and DNMT1 with poly(dI-dC) as substrate.",C27H23N7O,DMSO : 27 mg/mL (58.50 mM; Need ultrasonic and warming),10mM,Cancer,No Development Reported,O=C(NC1=CC=C(NC2=NC(N)=NC(C)=C2)C=C1)C3=CC=C(NC4=CC=NC5=CC=CC=C45)C=C3
,,,,,,,,,,,,,,,,dna methyltransferase,genistein,HY-L025-45,H04,HY-14596,Genistein,NPI 031L,446-72-0,270.24,Apoptosis; Autophagy; EGFR; Endogenous Metabolite,Apoptosis; Autophagy; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,"Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.",C15H10O5,DMSO : ≥ 100 mg/mL (370.04 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 4,OC1=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,dna methyltransferase,panobinostat,HY-L025-7,E05,HY-10224,Panobinostat,LBH589; NVP-LBH589,404950-80-7,349.43,Apoptosis; Autophagy; HDAC; HIV,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].",C21H23N3O2,DMSO : ≥ 100 mg/mL (286.18 mM),10mM,Cancer,Launched,O=C(/C=C/C1=CC=C(CNCCC2=C(NC3=C2C=CC=C3)C)C=C1)NO
,,,,,,,,,,,,,,,,dna methyltransferase,5 azac,HY-L025-10,H06,HY-10586,5-Azacytidine,Azacitidine; 5-AzaC; Ladakamycin,320-67-2,244.2,Antibiotic; Autophagy; Bacterial; DNA Methyltransferase; Nucleoside Antimetabolite/Analog,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Epigenetics,5-Azacytidine (Azacitidine; 5-AzaC; Ladakamycin) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation. 5-Azacytidine is incorporated into DNA to covalently trap DNA methyltransferases and contributes to reverse epigenetic changes[1][2]. 5-Azacytidine induces cell autophagy[4].,C8H12N4O5,DMSO : ≥ 31 mg/mL (126.95 mM); H2O : 33.33 mg/mL (136.49 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)N=C2)=O)O1
,,,,,,,,,,,,,,,,dna methyltransferase,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,dna methyltransferase,suberoylanilide hydroxamic acid,HY-L025-7,E02,HY-10221,Vorinostat,SAHA; Suberoylanilide hydroxamic acid,149647-78-9,264.32,Apoptosis; Autophagy; Filovirus; HDAC; HPV; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].",C14H20N2O3,DMSO : ≥ 100 mg/mL (378.33 mM),10mM,Cancer; Infection,Launched,O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O
,,,,,,,,,,,,,,,,dna methyltransferase,5 aza cdr,HY-L025-65,D02,HY-A0004,Decitabine,5-Aza-2'-deoxycytidine; 5-AZA-CdR; NSC 127716,2353-33-5,228.21,Apoptosis; DNA Methyltransferase; Nucleoside Antimetabolite/Analog,Apoptosis; Cell Cycle/DNA Damage; Epigenetics,Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and a DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell apoptosis. Decitabine has potent anticancer activity[1][2].,C8H12N4O4,H2O : 20 mg/mL (87.64 mM; Need ultrasonic); DMSO : ≥ 50 mg/mL (219.10 mM),10mM,Cancer,Launched,O[C@H]1C[C@H](N2C(N=C(N)N=C2)=O)O[C@@H]1CO
,,,,,,,,,,,,,,,,dna methyltransferase,decitabine,HY-L025-65,D02,HY-A0004,Decitabine,5-Aza-2'-deoxycytidine; 5-AZA-CdR; NSC 127716,2353-33-5,228.21,Apoptosis; DNA Methyltransferase; Nucleoside Antimetabolite/Analog,Apoptosis; Cell Cycle/DNA Damage; Epigenetics,Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and a DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell apoptosis. Decitabine has potent anticancer activity[1][2].,C8H12N4O4,H2O : 20 mg/mL (87.64 mM; Need ultrasonic); DMSO : ≥ 50 mg/mL (219.10 mM),10mM,Cancer,Launched,O[C@H]1C[C@H](N2C(N=C(N)N=C2)=O)O[C@@H]1CO
,,,,,,,,,,,,,,,,dna methyltransferase,azacitidine,HY-L025-10,H06,HY-10586,5-Azacytidine,Azacitidine; 5-AzaC; Ladakamycin,320-67-2,244.2,Antibiotic; Autophagy; Bacterial; DNA Methyltransferase; Nucleoside Antimetabolite/Analog,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Epigenetics,5-Azacytidine (Azacitidine; 5-AzaC; Ladakamycin) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation. 5-Azacytidine is incorporated into DNA to covalently trap DNA methyltransferases and contributes to reverse epigenetic changes[1][2]. 5-Azacytidine induces cell autophagy[4].,C8H12N4O5,DMSO : ≥ 31 mg/mL (126.95 mM); H2O : 33.33 mg/mL (136.49 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)N=C2)=O)O1
,,,,,,,,,,,,,,,,dna methyltransferase,5 azacytidine,HY-L025-10,H06,HY-10586,5-Azacytidine,Azacitidine; 5-AzaC; Ladakamycin,320-67-2,244.2,Antibiotic; Autophagy; Bacterial; DNA Methyltransferase; Nucleoside Antimetabolite/Analog,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Epigenetics,5-Azacytidine (Azacitidine; 5-AzaC; Ladakamycin) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation. 5-Azacytidine is incorporated into DNA to covalently trap DNA methyltransferases and contributes to reverse epigenetic changes[1][2]. 5-Azacytidine induces cell autophagy[4].,C8H12N4O5,DMSO : ≥ 31 mg/mL (126.95 mM); H2O : 33.33 mg/mL (136.49 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)N=C2)=O)O1
,,,,,,,,,,,,,,,,dna methyltransferase,5 aza 2 deoxycytidine,HY-L025-65,D02,HY-A0004,Decitabine,5-Aza-2'-deoxycytidine; 5-AZA-CdR; NSC 127716,2353-33-5,228.21,Apoptosis; DNA Methyltransferase; Nucleoside Antimetabolite/Analog,Apoptosis; Cell Cycle/DNA Damage; Epigenetics,Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and a DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell apoptosis. Decitabine has potent anticancer activity[1][2].,C8H12N4O4,H2O : 20 mg/mL (87.64 mM; Need ultrasonic); DMSO : ≥ 50 mg/mL (219.10 mM),10mM,Cancer,Launched,O[C@H]1C[C@H](N2C(N=C(N)N=C2)=O)O[C@@H]1CO
,,,,,,,,,,,,,,,,dna methyltransferase,trichostatin a,HY-L025-49,F10,HY-15144,Trichostatin A,TSA,58880-19-6,302.37,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].",C17H22N2O3,DMSO : 25 mg/mL (82.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
,,,,,,,,,,,,,,,,dna methyltransferase,zebularine,HY-L025-34,G10,HY-13420,Zebularine,NSC309132; 4-Deoxyuridine,10/6/90,228.2,Autophagy; DNA Methyltransferase,Autophagy; Epigenetics,Zebularine (NSC309132; 4-Deoxyuridine) is a DNA methyltransferase inhibitor. Zebularine also inhibits cytidine deaminase with a Ki of 0.95 μM.,C9H12N2O5,DMSO : ≥ 100 mg/mL (438.21 mM); H2O : 50 mg/mL (219.11 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=CC=C2)=O)O1
,,,,,,,,,,,,,,,,snail,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,snail,celecoxib,HY-L025-43,G07,HY-14398,Celecoxib,SC 58635,169590-42-5,381.37,COX,Immunology/Inflammation,"Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.",C17H14F3N3O2S,DMSO : ≥ 50 mg/mL (131.11 mM),10mM,Inflammation/Immunology; Cancer,Launched,CC1=CC=C(C=C1)C2=CC(C(F)(F)F)=NN2C3=CC=C(C=C3)S(=O)(N)=O
,,,,,,,,,,,,,,,,snail,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,snail,honokiol,HY-L025-71,F02,HY-N0003,Honokiol,NSC 293100,35354-74-6,266.33,Akt; Autophagy; ERK; HCV,Anti-infection; Autophagy; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt,"Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt. Honokiol can readily cross the blood brain barrier[1][2][3][4].",C18H18O2,DMSO : ≥ 50 mg/mL (187.74 mM),10mM,Cancer,Phase 3,OC1=C(CC=C)C=C(C2=CC(CC=C)=CC=C2O)C=C1
,,,,,,,,,,,,,,,,snail,oridonin,HY-L025-71,F03,HY-N0004,Oridonin,NSC-250682; Isodonol,28957-04-2,364.43,Akt; Bacterial,Anti-infection; PI3K/Akt/mTOR,"Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of AKT, with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.",C20H28O6,DMSO : 62.5 mg/mL (171.50 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Phase 4,O[C@@H]1[C@]2(CO3)[C@@]([C@H](O)[C@]3(O)[C@]45[C@@]2([H])CC[C@](C(C5=O)=C)([H])[C@@]4([H])O)([H])C(C)(C)CC1
,,,,,,,,,,,,,,,,snail,apigenin,HY-L025-77,B10,HY-N1201,Apigenin,"4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1",520-36-5,270.24,Autophagy; Cytochrome P450; Endogenous Metabolite,Autophagy; Metabolic Enzyme/Protease,"Apigenin (4',5,7-Trihydroxyflavone) is a competitive CYP2C9 inhibitor with a Ki of 2 μM.",C15H10O5,DMSO : 83.33 mg/mL (308.36 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=CC2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,snail,shikonin,HY-L025-76,E10,HY-N0822,Shikonin,C.I. 75535; Isoarnebin 4,517-89-5,288.3,AIM2; Chloride Channel; HIV; NF-κB; Pyruvate Kinase; TNF Receptor,Anti-infection; Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; NF-κB,Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM[1]. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor[2] and can also inhibit TNF-α and NF-κB pathway[3]. Shikonin decreases exosome secretion through the inhibition of glycolysis[4]. Shikonin inhibits AIM2 inflammasome activation[7].,C16H16O5,DMSO : 25 mg/mL (86.72 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,No Development Reported,O=C1C([C@H](O)C/C=C(C)/C)=CC(C2=C1C(O)=CC=C2O)=O
,,,,,,,,,,,,,,,,snail,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,snail,dapt,HY-L025-31,F03,HY-13027,DAPT,GSI-IX,208255-80-5,432.46,Amyloid-β; Apoptosis; Autophagy; Notch; γ-secretase,Apoptosis; Autophagy; Neuronal Signaling; Stem Cell/Wnt,"DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment[1][2].",C23H26F2N2O4,DMSO : 62.5 mg/mL (144.52 mM; Need ultrasonic); Ethanol : 10 mg/mL (23.12 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,No Development Reported,FC1=CC(F)=CC(CC(N[C@H](C(N[C@H](C(OC(C)(C)C)=O)C2=CC=CC=C2)=O)C)=O)=C1
,,,,,,,,,,,,,,,,snail,tsa,HY-L025-49,F10,HY-15144,Trichostatin A,TSA,58880-19-6,302.37,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].",C17H22N2O3,DMSO : 25 mg/mL (82.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
,,,,,,,,,,,,,,,,snail,dha,HY-L025-71,C06,HY-B2167,Docosahexaenoic acid,DHA; Cervonic acid,6217-54-5,328.49,Endogenous Metabolite,Metabolic Enzyme/Protease,Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk.,C22H32O2,Ethanol : 50 mg/mL (152.21 mM; Need ultrasonic); DMSO : 100 mg/mL (304.42 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(O)=O
,,,,,,,,,,,,,,,,snail,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,snail,genistein,HY-L025-45,H04,HY-14596,Genistein,NPI 031L,446-72-0,270.24,Apoptosis; Autophagy; EGFR; Endogenous Metabolite,Apoptosis; Autophagy; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,"Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.",C15H10O5,DMSO : ≥ 100 mg/mL (370.04 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 4,OC1=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,snail,ag490,HY-L025-22,A04,HY-12000,AG490,Tyrphostin AG490; Tyrphostin B42,133550-30-8,294.3,Autophagy; EGFR; JAK; STAT,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.",C17H14N2O3,DMSO : ≥ 50 mg/mL (169.89 mM),10mM,Cancer,No Development Reported,O=C(NCC1=CC=CC=C1)/C(C#N)=C/C2=CC=C(O)C(O)=C2
,,,,,,,,,,,,,,,,snail,emodin,HY-L025-43,G03,HY-14393,Emodin,Frangula emodin,518-82-1,270.24,11β-HSD; Autophagy; Casein Kinase; SARS-CoV,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively.  Emodin ameliorates metabolic disorder in diet-induced obese mice[3].",C15H10O5,Acetone : 10.87 mg/mL (40.22 mM; Need ultrasonic); DMSO : 5.41 mg/mL (20.02 mM; Need ultrasonic); Ethanol : 10.87 mg/mL (40.22 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C(C=C(C)C=C2O)C(C3=CC(O)=CC(O)=C31)=O
,,,,,,,,,,,,,,,,snail,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
,,,,,,,,,,,,,,,,snail,silibinin,HY-L025-76,C08,HY-N0779A,Silybin,Silibinin,802918-57-6,482.44,Apoptosis,Apoptosis,"Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds. Silybin induces apoptosis and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity[1][2].",C25H22O10,DMSO : 25 mg/mL (51.82 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C1[C@H](O)[C@@H](C2=CC=C(OC(CO)C(C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15
,,,,,,,,,,,,,,,,snail,cyclopamine,HY-L025-57,F03,HY-17024,Cyclopamine,11-Deoxojervine,4449-51-8,411.62,Endogenous Metabolite; Hedgehog; Smo,Metabolic Enzyme/Protease; Stem Cell/Wnt,Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay. Cyclopamine is also a selective Smo inhibitor.,C27H41NO2,DMSO : 10 mg/mL (24.29 mM; ultrasonic and warming and heat to 80°C); Ethanol : 20 mg/mL (48.59 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CC1=C2[C@@]([C@@]3([H])[C@]([C@@]4(C(C[C@@H](O)CC4)=CC3)C)([H])C2)([H])CC[C@@]15[C@@H]([C@@]6([H])[C@](C[C@H](C)CN6)([H])O5)C
,,,,,,,,,,,,,,,,snail,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,foxo1,dexamethasone,HY-L025-46,B10,HY-14648,Dexamethasone,Hexadecadrol; Prednisolone F,50-02-2,392.46,Antibiotic; Autophagy; Bacterial; Complement System; Glucocorticoid Receptor; Mitophagy; SARS-CoV,Anti-infection; Autophagy; Immunology/Inflammation; Vitamin D Related/Nuclear Receptor,"Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.",C22H29FO5,DMSO : 250 mg/mL (637.01 mM; ultrasonic and warming and heat to 60°C); Ethanol : 8.33 mg/mL (21.23 mM; Need ultrasonic),10mM,Cancer; Infection; Endocrinology; Inflammation/Immunology,Launched,O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@@]4(C(CO)=O)O)=C1
,,,,,,,,,,,,,,,,foxo1,entinostat,HY-L025-23,G06,HY-12163,Entinostat,MS-275; SNDX-275,209783-80-2,376.41,Apoptosis; Autophagy; HDAC,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Entinostat is an oral and selective class I HDAC inhibitor, with IC50s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively.",C21H20N4O3,DMSO : 50 mg/mL (132.83 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,O=C(NCC1=CC=C(C=C1)C(NC2=CC=CC=C2N)=O)OCC3=CC=CN=C3
,,,,,,,,,,,,,,,,foxo1,e2,HY-L025-66,F04,HY-B0141,Estradiol,β-Estradiol; E2; 17β-Estradiol; 17β-Oestradiol,50-28-2,272.38,Bacterial; Endogenous Metabolite; Estrogen Receptor/ERR,Anti-infection; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Estradiol (β-Estradiol) is a steroid hormone and the major female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering[1][2].",C18H24O2,DMSO : 62.5 mg/mL (229.46 mM; ultrasonic and warming and heat to 60°C); Ethanol : 20 mg/mL (73.43 mM; Need ultrasonic),10mM,Endocrinology; Cancer,Launched,C[C@@]1([C@H]2O)[C@](CC2)([H])[C@@](CCC3=C4C=CC(O)=C3)([H])[C@]4([H])CC1
,,,,,,,,,,,,,,,,foxo1,wortmannin,HY-L025-6,H04,HY-10197,Wortmannin,SL-2052; KY-12420,19545-26-7,428.43,Antibiotic; Autophagy; PI3K; Polo-like Kinase (PLK),Anti-infection; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively[1][2][3].",C23H24O8,DMSO : ≥ 50 mg/mL (116.71 mM),10mM,Cancer,No Development Reported,O=C1C([C@@](CC2)([H])[C@@]3(C)C2=O)=C([C@H](OC(C)=O)C3)[C@]4(C)C5=C1OC=C5C(O[C@@H]4COC)=O
,,,,,,,,,,,,,,,,foxo1,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,foxo1,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,foxo1,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
,,,,,,,,,,,,,,,,foxo1,nac,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,foxo1,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,foxo1,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,foxo1,saha,HY-L025-7,E02,HY-10221,Vorinostat,SAHA; Suberoylanilide hydroxamic acid,149647-78-9,264.32,Apoptosis; Autophagy; Filovirus; HDAC; HPV; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].",C14H20N2O3,DMSO : ≥ 100 mg/mL (378.33 mM),10mM,Cancer; Infection,Launched,O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O
,,,,,,,,,,,,,,,,foxo1,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,foxo1,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,zeb1,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,zeb1,silibinin,HY-L025-76,C08,HY-N0779A,Silybin,Silibinin,802918-57-6,482.44,Apoptosis,Apoptosis,"Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds. Silybin induces apoptosis and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity[1][2].",C25H22O10,DMSO : 25 mg/mL (51.82 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C1[C@H](O)[C@@H](C2=CC=C(OC(CO)C(C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15
,,,,,,,,,,,,,,,,zeb1,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,cdk4 6,ly2835219,HY-L025-55,G10,HY-16297A,Abemaciclib,LY2835219,1231929-97-7,506.59,CDK,Cell Cycle/DNA Damage,"Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.",C27H32F2N8,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 2.94 mg/mL (5.80 mM; ultrasonic and warming and heat to 80°C),2mM,Cancer,Launched,CC1=NC2=C(F)C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=C2N1C(C)C
,,,,,,,,,,,,,,,,cdk4 6,fulvestrant,HY-L025-37,H04,HY-13636,Fulvestrant,ICI 182780; ZD 9238; ZM 182780,129453-61-8,606.77,Apoptosis; Autophagy; Estrogen Receptor/ERR,Apoptosis; Autophagy; Vitamin D Related/Nuclear Receptor,Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy[1].,C32H47F5O3S,DMSO : 250 mg/mL (412.02 mM; Need ultrasonic),10mM,Cancer,Launched,C[C@@]12[C@@H](O)CC[C@@]1([H])[C@]3([H])[C@H](CCCCCCCCCS(CCCC(F)(F)C(F)(F)F)=O)CC4=C(C=CC(O)=C4)[C@@]3([H])CC2
,,,,,,,,,,,,,,,,cdk4 6,everolimus,HY-L025-7,D10,HY-10218,Everolimus,RAD001; SDZ-RAD,159351-69-6,958.22,Apoptosis; Autophagy; Bacterial; FKBP; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; PI3K/Akt/mTOR,"Everolimus (RAD001) is a <a href=""/Rapamycin.html"" class=""link-product"" target=""_blank"">Rapamycin</a> (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].",C53H83NO14,DMSO : 50 mg/mL (52.18 mM; ultrasonic and warming and heat to 60°C); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](OCCO)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,cdk4 6,palbociclib,HY-L025-65,F03,HY-A0065,Palbociclib (isethionate),PD 0332991 isethionate,827022-33-3,573.66,CDK,Cell Cycle/DNA Damage,"Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma[1][3][4].",C26H35N7O6S,H2O : 50 mg/mL (87.16 mM; Need ultrasonic); DMSO : 10 mg/mL (17.43 mM; Need ultrasonic),10mM,Cancer,Launched,CC(C1=C(N2C3CCCC3)N=C(NC4=NC=C(N5CCNCC5)C=C4)N=C1)=C(C(C)=O)C2=O.OCCS(O)(=O)=O
,,,,,,,,,,,,,,,,cdk4 6,dinaciclib,HY-L025-10,C09,HY-10492,Dinaciclib,SCH 727965,779353-01-4,396.49,Apoptosis; CDK,Apoptosis; Cell Cycle/DNA Damage,"Dinaciclib (SCH 727965) is a potent inhibitor of CDK, with IC50s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively[1].",C21H28N6O2,DMSO : 50 mg/mL (126.11 mM; Need ultrasonic),10mM,Cancer,Launched,OCC[C@H]1N(CCCC1)C2=NC3=C(C=NN3C(NCC4=C[N+]([O-])=CC=C4)=C2)CC
,,,,,,,,,,,,,,,,cdk4 6,ribociclib,HY-L025-54,B07,HY-15777,Ribociclib,LEE011,1211441-98-3,434.54,CDK,Cell Cycle/DNA Damage,"Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[1].",C23H30N8O,DMSO : 20 mg/mL (46.03 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(N(C)C)C(N1C2CCCC2)=CC(C1=N3)=CN=C3NC(N=C4)=CC=C4N5CCNCC5
,,,,,,,,,,,,,,,,cdk4 6,talazoparib,HY-L025-55,D10,HY-16106,Talazoparib,BMN-673; LT-673,1207456-01-6,380.35,PARP,Cell Cycle/DNA Damage; Epigenetics,"Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity[1].",C19H14F2N6O,DMSO : 25 mg/mL (65.73 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1NN=C2C3=C1C=C(F)C=C3N[C@H](C4=CC=C(F)C=C4)[C@H]2C5=NC=NN5C
,,,,,,,,,,,,,,,,cdk4 6,abemaciclib,HY-L025-55,G10,HY-16297A,Abemaciclib,LY2835219,1231929-97-7,506.59,CDK,Cell Cycle/DNA Damage,"Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.",C27H32F2N8,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 2.94 mg/mL (5.80 mM; ultrasonic and warming and heat to 80°C),2mM,Cancer,Launched,CC1=NC2=C(F)C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=C2N1C(C)C
,,,,,,,,,,,,,,,,cdk4 6,pd 0332991,HY-L025-63,H07,HY-50767A,Palbociclib (monohydrochloride),PD 0332991 (monohydrochloride),827022-32-2,483.99,CDK,Cell Cycle/DNA Damage,"Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma[1][3][4].",C24H30ClN7O2,DMSO : 4.63 mg/mL (9.57 mM; ultrasonic and warming and heat to 80°C); H2O : 7.14 mg/mL (14.75 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C1C(C(C)=O)=C(C)C2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C5CCCC5.Cl
,,,,,,,,,,,,,,,,cdk4 6,lee011,HY-L025-54,B09,HY-15777B,Ribociclib succinate,LEE011 (succinate),1374639-75-4,552.63,CDK,Cell Cycle/DNA Damage,"Ribociclib succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.",C27H36N8O5,DMSO : 9.38 mg/mL (16.97 mM; ultrasonic and warming and heat to 60°C); H2O : 4.17 mg/mL (7.55 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(N(C)C)C(N1C2CCCC2)=CC(C1=N3)=CN=C3NC(N=C4)=CC=C4N5CCNCC5.OC(CCC(O)=O)=O
,,,,,,,,,,,,,,,,cdk4 6,trametinib,HY-L025-14,D08,HY-10999A,Trametinib (DMSO solvate),GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate),1187431-43-1,693.53,Apoptosis; MEK,Apoptosis; MAPK/ERK Pathway,Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis[1][2].,C28H29FIN5O5S,DMSO : 69 mg/mL (99.49 mM; Need ultrasonic),10mM,Cancer,Launched,CN1C(C(C)=C(N(C(N(C2=O)C3CC3)=O)C4=CC=CC(NC(C)=O)=C4)C2=C1NC5=CC=C(C=C5F)I)=O.CS(C)=O
,,,,,,,,,,,,,,,,cdk4 6,alpelisib,HY-L025-50,F10,HY-15244,Alpelisib,BYL-719,1217486-61-7,441.47,PI3K,PI3K/Akt/mTOR,"Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC50s of 5/250/290/1200 nM, respectively. Antineoplastic activity[1][2][3].",C19H22F3N5O2S,DMSO : 83.33 mg/mL (188.76 mM; Need ultrasonic),10mM,Cancer,Launched,CC(N=C(S1)NC(N2CCC[C@H]2C(N)=O)=O)=C1C3=CC(C(C)(C(F)(F)F)C)=NC=C3
,,,,,,,,,,,,,,,,sirt1,ex 527,HY-L025-52,A07,HY-15452,Selisistat,EX-527,49843-98-3,248.71,Sirtuin,Cell Cycle/DNA Damage; Epigenetics,Selisistat (EX-527) is a potent and selective SirT1 (Sir2 in Drosophila melanogaster) inhibitor with an IC50 of 123 nM for SirT1. Selisistat alleviates pathology in multiple animal and cell models of Huntington's disease[1][2].,C13H13ClN2O,DMSO : ≥ 100 mg/mL (402.07 mM),10mM,Cancer; Inflammation/Immunology,Phase 2,O=C(C1C(NC2=C3C=C(Cl)C=C2)=C3CCC1)N
,,,,,,,,,,,,,,,,sirt1,capsaicin,HY-L025-10,B02,HY-10448,Capsaicin,(E)-Capsaicin,404-86-4,305.41,Apoptosis; Autophagy; Endogenous Metabolite; TRP Channel,Apoptosis; Autophagy; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling,"Capsaicin ((E)-Capsaicin), an active component of chili peppers, is a TRPV1 agonist. Capsaicin has pain relief, antioxidant, anti-inflammatory, neuroprotection and anti-cancer effects[1][2].",C18H27NO3,DMSO : 100 mg/mL (327.43 mM; Need ultrasonic); Ethanol : 100 mg/mL (327.43 mM; Need ultrasonic),10mM,Cancer,Launched,CC(C)/C=C/CCCCC(NCC1=CC=C(O)C(OC)=C1)=O
,,,,,,,,,,,,,,,,sirt1,nac,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,sirt1,troxerutin,HY-L025-72,E08,HY-N0139,Troxerutin,Trihydroxyethylrutin,7085-55-4,742.68,NOD-like Receptor (NLR),Immunology/Inflammation,"Troxerutin, also known as vitamin P4, is a tri-hydroxyethylated derivative of natural bioflavonoid rutins which can inhibit the production of reactive oxygen species (ROS) and depress ER stress-mediated NOD activation.",C33H42O19,DMSO : 100 mg/mL (134.65 mM; Need ultrasonic and warming); H2O : ≥ 50 mg/mL (67.32 mM),10mM,Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease,Launched,O=C1C(O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO[C@H]3[C@@H]([C@@H]([C@H]([C@H](C)O3)O)O)O)O2)O)O)O)=C(C4=CC=C(OCCO)C(OCCO)=C4)OC5=CC(OCCO)=CC(O)=C15
,,,,,,,,,,,,,,,,sirt1,fenofibrate,HY-L025-57,G03,HY-17356,Fenofibrate,,49562-28-9,360.83,Autophagy; Cytochrome P450; PPAR,Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.",C20H21ClO4,DMSO : 250 mg/mL (692.85 mM; Need ultrasonic),10mM,Cardiovascular Disease; Cancer,Launched,CC(C)(OC1=CC=C(C(C2=CC=C(Cl)C=C2)=O)C=C1)C(OC(C)C)=O
,,,,,,,,,,,,,,,,sirt1,puerarin,HY-L025-72,F03,HY-N0145,Puerarin,,3681-99-0,416.38,5-HT Receptor,GPCR/G Protein; Neuronal Signaling,"Puerarin, an isoflavone extracted from Radix puerariae, is a 5-HT2C receptor antagonist.",C21H20O9,DMSO : 50 mg/mL (120.08 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Launched,O=C1C(C2=CC=C(O)C=C2)=COC3=C([C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)C(O)=CC=C13
,,,,,,,,,,,,,,,,sirt1,pterostilbene,HY-L025-76,F02,HY-N0828,Pterostilbene,,537-42-8,256.3,Autophagy,Autophagy,"Pterostilbene is a stilbenoid isolated from blueberries and Pterocarpus marsupium[1]. Shows anti-oxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and anti-obesity properties[1][4]. Pterostilbene blocks ROS production[3], also exhibits inhibitory activity against various free radicals such as DPPH, ABTS, hydroxyl, superoxide and hydrogen peroxide[4].",C16H16O3,DMSO : 110 mg/mL (429.18 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 3,OC1=CC=C(/C=C/C2=CC(OC)=CC(OC)=C2)C=C1
,,,,,,,,,,,,,,,,sirt1,rotenone,HY-L025-70,H11,HY-B1756,Rotenone,,83-79-4,394.42,Apoptosis; Autophagy; Mitochondrial Metabolism,Apoptosis; Autophagy; Metabolic Enzyme/Protease,Rotenone is a mitochondrial electron transport chain complex I inhibitor.  Rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production.,C23H22O6,H2O : < 0.1 mg/mL (ultrasonic) (insoluble); DMSO : 50 mg/mL (126.77 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,No Development Reported,O=C1[C@]2([H])[C@](COC3=CC(OC)=C(OC)C=C32)([H])OC4=C5C(O[C@@H](C(C)=C)C5)=CC=C14
,,,,,,,,,,,,,,,,sirt1,propofol,HY-L025-69,B04,HY-B0649,Propofol,"2,6-Diisopropylphenol",2078-54-8,178.27,Endogenous Metabolite; GABA Receptor,Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling,Propofol potently and directly activates GABAA receptor and inhibits glutamate receptor mediated excitatory synaptic transmission. Propofol has antinociceptive properties and is used for sedation and hypnotic[1].,C12H18O,DMSO : 100 mg/mL (560.95 mM; Need ultrasonic); H2O : 0.5 mg/mL (2.80 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,OC1=C(C(C)C)C=CC=C1C(C)C
,,,,,,,,,,,,,,,,sirt1,luteolin,HY-L025-72,G06,HY-N0162,Luteolin,Luteoline; Luteolol; Digitoflavone,491-70-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Keap1-Nrf2,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells[1][2][3].",C15H10O6,DMSO : ≥ 100 mg/mL (349.36 mM),10mM,Cancer; Inflammation/Immunology,Phase 2,O=C1C=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13
,,,,,,,,,,,,,,,,sirt1,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,sirt1,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,sirt1,splitomicin,HY-L025-3,A08,HY-100585,Splitomicin,Splitomycin,3/9/90,198.22,HDAC,Cell Cycle/DNA Damage; Epigenetics,Splitomicin (Splitomycin) is a selective Sir2p inhibitor. Splitomicin inhibits NAD+-dependent HDAC activity  of Sir2 protein. Splitomicin induces dose-dependent inhibition of HDAC in the yeast extract with an IC50 of 60 μM[1].,C13H10O2,DMSO : 100 mg/mL (504.49 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1CCC2=C3C=CC=CC3=CC=C2O1
,,,,,,,,,,,,,,,,cxcl1,sp600125,HY-L025-22,G02,HY-12041,SP600125,,129-56-6,220.23,Apoptosis; Autophagy; Ferroptosis; JNK,Apoptosis; Autophagy; MAPK/ERK Pathway,"SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 inhibits autophagy and activates apoptosis[1][2][3].",C14H8N2O,DMSO : 12.5 mg/mL (56.76 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C3C(NN=C3C4=C1C=CC=C4)=CC=C2
,,,,,,,,,,,,,,,,cxcl1,azithromycin,HY-L025-58,D09,HY-17506,Azithromycin,CP 62993,83905-01-5,748.98,Antibiotic; Autophagy; Bacterial; Parasite,Anti-infection; Autophagy,Azithromycin is a macrolide antibiotic useful for the treatment of a number of bacterial infections.,C38H72N2O12,DMSO : ≥ 100 mg/mL (133.51 mM),10mM,Infection; Cancer,Launched,C[C@@H]([C@@H]([C@@](C(O[C@@H]([C@@](C)(O)[C@@H]1O)CC)=O)([H])C)O[C@@](O[C@@H](C)[C@@H]2O)([H])C[C@@]2(C)OC)[C@H]([C@](O)(C[C@H](CN([C@@H]1C)C)C)C)O[C@@](O[C@H](C)C[C@@H]3N(C)C)([H])[C@@H]3O
,,,,,,,,,,,,,,,,cxcl1,sb225002,HY-L025-56,H06,HY-16711,SB225002,,182498-32-4,352.14,CXCR,GPCR/G Protein; Immunology/Inflammation,"SB225002, a potent, selective and non-peptide CXCR2 antagonist, inhibits 125I-IL-8 binding to CXCR2  with an IC50 of 22 nM.",C13H10BrN3O4,DMSO : ≥ 100 mg/mL (283.98 mM),10mM,Inflammation/Immunology; Endocrinology; Cancer,No Development Reported,O=C(NC1=CC=C([N+]([O-])=O)C=C1O)NC2=CC=CC=C2Br
,,,,,,,,,,,,,,,,cxcl1,triptolide,HY-L025-63,C07,HY-32735,Triptolide,PG490,38748-32-2,360.4,Apoptosis; NF-κB,Apoptosis; NF-κB,"Triptolide is a diterpenoid triepoxide extracted from the root of Tripterygium wilfordii with immunosuppressive, anti-inflammatory, antiproliferative and antitumour effects. Triptolide is a NF-κB activation inhibitor[1][2][3][4][5][6].",C20H24O6,DMSO : 25 mg/mL (69.37 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,C[C@@]12[C@@]34[C@](O5)([C@@H]([C@](O6)(C(C)C)[C@@H]6[C@@H]3O4)O)[C@@H]5C[C@@]1([H])C7=C(C(OC7)=O)CC2
,,,,,,,,,,,,,,,,cxcl1,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,cxcl1,progesterone,HY-L025-74,D04,HY-N0437,Progesterone,"Pregn-4-ene-3,20-dione",57-83-0,314.46,Endogenous Metabolite; Progesterone Receptor,Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,Progesterone is a steroid hormone that regulates the menstrual cycle and is crucial for pregnancy.,C21H30O2,H2O : 0.1 mg/mL (0.32 mM; Need ultrasonic); DMSO : 25 mg/mL (79.50 mM; Need ultrasonic),10mM,Cardiovascular Disease; Cancer,Launched,CC([C@H]1CC[C@@]2([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O)=O
,,,,,,,,,,,,,,,,cxcl1,dexamethasone,HY-L025-46,B10,HY-14648,Dexamethasone,Hexadecadrol; Prednisolone F,50-02-2,392.46,Antibiotic; Autophagy; Bacterial; Complement System; Glucocorticoid Receptor; Mitophagy; SARS-CoV,Anti-infection; Autophagy; Immunology/Inflammation; Vitamin D Related/Nuclear Receptor,"Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.",C22H29FO5,DMSO : 250 mg/mL (637.01 mM; ultrasonic and warming and heat to 60°C); Ethanol : 8.33 mg/mL (21.23 mM; Need ultrasonic),10mM,Cancer; Infection; Endocrinology; Inflammation/Immunology,Launched,O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@@]4(C(CO)=O)O)=C1
,,,,,,,,,,,,,,,,xiap,sm 164,HY-L025-55,B05,HY-15989,SM-164,,957135-43-2,1121.42,Apoptosis; IAP,Apoptosis,SM-164 is a cell-permeable Smac mimetic compound. SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains with an IC50 value of 1.39 nM and functions as an extremely potent antagonist of XIAP.,C62H84N14O6,DMSO : 25 mg/mL (22.29 mM; Need ultrasonic),2mM,Cancer,No Development Reported,C[C@H](NC)C(N[C@H]1CCCC[C@](CC[C@H]2C(N[C@@H](C3=CC=CC=C3)C4=CN(CCCCC5=CC=C(CCCCN6N=NC([C@@H](NC([C@@H]7CC[C@@](CCCC[C@@H]8NC([C@@H](NC)C)=O)([H])N7C8=O)=O)C9=CC=CC=C9)=C6)C=C5)N=N4)=O)([H])N2C1=O)=O
,,,,,,,,,,,,,,,,xiap,nac,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,xiap,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
,,,,,,,,,,,,,,,,xiap,saha,HY-L025-7,E02,HY-10221,Vorinostat,SAHA; Suberoylanilide hydroxamic acid,149647-78-9,264.32,Apoptosis; Autophagy; Filovirus; HDAC; HPV; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].",C14H20N2O3,DMSO : ≥ 100 mg/mL (378.33 mM),10mM,Cancer; Infection,Launched,O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O
,,,,,,,,,,,,,,,,xiap,triptolide,HY-L025-63,C07,HY-32735,Triptolide,PG490,38748-32-2,360.4,Apoptosis; NF-κB,Apoptosis; NF-κB,"Triptolide is a diterpenoid triepoxide extracted from the root of Tripterygium wilfordii with immunosuppressive, anti-inflammatory, antiproliferative and antitumour effects. Triptolide is a NF-κB activation inhibitor[1][2][3][4][5][6].",C20H24O6,DMSO : 25 mg/mL (69.37 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,C[C@@]12[C@@]34[C@](O5)([C@@H]([C@](O6)(C(C)C)[C@@H]6[C@@H]3O4)O)[C@@H]5C[C@@]1([H])C7=C(C(OC7)=O)CC2
,,,,,,,,,,,,,,,,xiap,emodin,HY-L025-43,G03,HY-14393,Emodin,Frangula emodin,518-82-1,270.24,11β-HSD; Autophagy; Casein Kinase; SARS-CoV,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively.  Emodin ameliorates metabolic disorder in diet-induced obese mice[3].",C15H10O5,Acetone : 10.87 mg/mL (40.22 mM; Need ultrasonic); DMSO : 5.41 mg/mL (20.02 mM; Need ultrasonic); Ethanol : 10.87 mg/mL (40.22 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C(C=C(C)C=C2O)C(C3=CC(O)=CC(O)=C31)=O
,,,,,,,,,,,,,,,,xiap,lcl161,HY-L025-52,F05,HY-15518,LCL161,,1005342-46-0,500.63,IAP,Apoptosis,"LCL161 is a IAP inhibitor which inhibits XIAP in HEK293 cell and cIAP1 in MDA-MB-231 cell with IC50s of 35 and 0.4 nM, respectively.",C26H33FN4O3S,DMSO : 100 mg/mL (199.75 mM; Need ultrasonic),10mM,Cancer,Phase 2,C[C@H](NC)C(N[C@@H](C1CCCCC1)C(N2[C@H](C3=NC(C(C4=CC=C(F)C=C4)=O)=CS3)CCC2)=O)=O
,,,,,,,,,,,,,,,,xiap,apigenin,HY-L025-77,B10,HY-N1201,Apigenin,"4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1",520-36-5,270.24,Autophagy; Cytochrome P450; Endogenous Metabolite,Autophagy; Metabolic Enzyme/Protease,"Apigenin (4',5,7-Trihydroxyflavone) is a competitive CYP2C9 inhibitor with a Ki of 2 μM.",C15H10O5,DMSO : 83.33 mg/mL (308.36 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,No Development Reported,OC1=C2C(OC(C3=CC=C(O)C=C3)=CC2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,xiap,tetrac,HY-L025-84,C10,HY-W008859,Tetrac,"Tetraiodothyroacetic acid; 3,3',5,5'-Tetraiodothyroacetic acid",67-30-1,747.83,Endogenous Metabolite; Integrin,Cytoskeleton; Metabolic Enzyme/Protease,"Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities[1][2].",C14H8I4O4,DMSO : 100 mg/mL (133.72 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C(O)CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1
,,,,,,,,,,,,,,,,xiap,astx660,HY-L025-14,A07,HY-109565,ASTX660,,1799328-86-1,539.68,Apoptosis; IAP,Apoptosis,ASTX660 is an orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibitor of apoptosis protein (XIAP).,C30H42FN5O3,DMSO : 100 mg/mL (185.29 mM; Need ultrasonic),10mM,Cancer,Phase 2,C[C@H]1N(C[C@@H]2N(CC(N3CC(C)(C)C4=NC(CO)=C(CC5=CC=C(F)C=C5)C=C43)=O)C[C@@H](C)NC2)CCOC1
,,,,,,,,,,,,,,,,xiap,sp600125,HY-L025-22,G02,HY-12041,SP600125,,129-56-6,220.23,Apoptosis; Autophagy; Ferroptosis; JNK,Apoptosis; Autophagy; MAPK/ERK Pathway,"SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 inhibits autophagy and activates apoptosis[1][2][3].",C14H8N2O,DMSO : 12.5 mg/mL (56.76 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C3C(NN=C3C4=C1C=CC=C4)=CC=C2
,,,,,,,,,,,,,,,,xiap,at 406,HY-L025-52,A11,HY-15454,Xevinapant,AT-406; Debio 1143; SM-406,1071992-99-8,561.71,Apoptosis; IAP,Apoptosis,"Xevinapant (AT-406) is a potent and orally bioavailable Smac mimetic and an antagonist of IAPs, and it binds to XIAP, cIAP1, and cIAP2 proteins with Ki of 66.4, 1.9, and 5.1 nM, respectively.",C32H43N5O4,DMSO : 100 mg/mL (178.03 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C([C@@H]1CC[C@@](CCN(C(CC(C)C)=O)C[C@@H]2NC([C@@H](NC)C)=O)([H])N1C2=O)NC(C3=CC=CC=C3)C4=CC=CC=C4
,,,,,,,,,,,,,,,,ubiquitin proteasome,bortezomib,HY-L025-7,E07,HY-10227,Bortezomib,PS-341; LDP-341; NSC 681239,179324-69-7,384.24,Apoptosis; Autophagy; NF-κB; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].",C19H25BN4O4,DMSO : 50 mg/mL (130.13 mM; Need ultrasonic); Ethanol : 66.67 mg/mL (173.51 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
,,,,,,,,,,,,,,,,e2f1,silibinin,HY-L025-76,C08,HY-N0779A,Silybin,Silibinin,802918-57-6,482.44,Apoptosis,Apoptosis,"Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds. Silybin induces apoptosis and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity[1][2].",C25H22O10,DMSO : 25 mg/mL (51.82 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C1[C@H](O)[C@@H](C2=CC=C(OC(CO)C(C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15
,,,,,,,,,,,,,,,,e2f1,dha,HY-L025-71,C06,HY-B2167,Docosahexaenoic acid,DHA; Cervonic acid,6217-54-5,328.49,Endogenous Metabolite,Metabolic Enzyme/Protease,Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk.,C22H32O2,Ethanol : 50 mg/mL (152.21 mM; Need ultrasonic); DMSO : 100 mg/mL (304.42 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Launched,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(O)=O
,,,,,,,,,,,,,,,,e2f1,honokiol,HY-L025-71,F02,HY-N0003,Honokiol,NSC 293100,35354-74-6,266.33,Akt; Autophagy; ERK; HCV,Anti-infection; Autophagy; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt,"Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt. Honokiol can readily cross the blood brain barrier[1][2][3][4].",C18H18O2,DMSO : ≥ 50 mg/mL (187.74 mM),10mM,Cancer,Phase 3,OC1=C(CC=C)C=C(C2=CC(CC=C)=CC=C2O)C=C1
,,,,,,,,,,,,,,,,e2f1,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,e2f1,flavopiridol,HY-L025-1,C08,HY-10006,Flavopiridol (Hydrochloride),Alvocidib (Hydrochloride); L86-8275 (Hydrochloride); HMR-1275 (Hydrochloride),131740-09-5,438.3,Autophagy; CDK; HIV,Anti-infection; Autophagy; Cell Cycle/DNA Damage,"Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.",C21H21Cl2NO5,DMF : 7.69 mg/mL (17.55 mM; Need ultrasonic); DMSO : ≥ 20 mg/mL (45.63 mM); H2O : ≥ 20 mg/mL (45.63 mM),10mM,Cancer,Phase 2,O=C1C2=C(C=C(C([C@]3([H])[C@H](O)CN(C)CC3)=C2OC(C4=CC=CC=C4Cl)=C1)O)O.[H]Cl
,,,,,,,,,,,,,,,,e2f1,eugenol,HY-L025-73,H07,HY-N0337,Eugenol,,97-53-0,164.2,Apoptosis; Bacterial; Ferroptosis; Parasite; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Eugenol is an essential oil found in cloves with antibacterial, anthelmintic and antioxidant activity. Eugenol is shown to inhibit lipid peroxidation.",C10H12O2,DMSO : ≥ 100 mg/mL (609.01 mM),10mM,Infection; Inflammation/Immunology; Cancer,Launched,OC1=CC=C(CC=C)C=C1OC
,,,,,,,,,,,,,,,,e2f1,celecoxib,HY-L025-43,G07,HY-14398,Celecoxib,SC 58635,169590-42-5,381.37,COX,Immunology/Inflammation,"Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.",C17H14F3N3O2S,DMSO : ≥ 50 mg/mL (131.11 mM),10mM,Inflammation/Immunology; Cancer,Launched,CC1=CC=C(C=C1)C2=CC(C(F)(F)F)=NN2C3=CC=C(C=C3)S(=O)(N)=O
,,,,,,,,,,,,,,,,yap1,verteporfin,HY-L025-66,F07,HY-B0146,Verteporfin,CL 318952,129497-78-5,718.79,Apoptosis; Autophagy; YAP,Apoptosis; Autophagy; Stem Cell/Wnt,Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis[1]. Verteporfinis an autophagy inhibitor that blocks?autophagy?at an early stage by inhibiting autophagosome formation[3].,C41H42N4O8,DMF : 10 mg/mL (13.91 mM; ultrasonic and warming and heat to 60°C); DMSO : 100 mg/mL (139.12 mM; Need ultrasonic),10mM,Cancer,Launched,C[C@]1(/C2=C/C(N3)=C4C)C(C(/C=C(C(C)=C/5C=C)\NC5=C/C6=N/C(C(CCC(OC)=O)=C6C)=C\C3=C4CCC(O)=O)=N2)=CC=C(C(OC)=O)[C@H]1C(OC)=O.C[C@]7(/C8=C/C(N9)=C%10C)C(C(/C=C(C(C)=C/%11C=C)\NC%11=C/C%12=N/C(C(CCC(O)=O)=C%12C)=C\C9=C%10CCC(OC)=O)=N8)=CC=C(C(OC)=O)[C@H]7C(OC)=O
,,,,,,,,,,,,,,,,yap1,jq1,HY-L025-31,F06,HY-13030,(+)-JQ-1,JQ1,1268524-70-4,456.99,Autophagy; Epigenetic Reader Domain; Ligands for Target Protein for PROTAC,Autophagy; Epigenetics; PROTAC,"(+)-JQ-1 (JQ1) is a potent, specific, and reversible BET bromodomain inhibitor, with IC50s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2))[1]. (+)-JQ-1 also activates autophagy[2].",C23H25ClN4O2S,DMSO : ≥ 45 mg/mL (98.47 mM),10mM,Cancer,No Development Reported,O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C
,,,,,,,,,,,,,,,,sox2,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,sox2,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,sox2,salinomycin,HY-L025-58,B06,HY-17439,Salinomycin (sodium salt),Salinomycin sodium; Sodium salinomycin,55721-31-8,772.98,Antibiotic; Apoptosis; Autophagy; Bacterial; Parasite; Wnt; β-catenin,Anti-infection; Apoptosis; Autophagy; Stem Cell/Wnt,"Salinomycin sodium salt (Salinomycin sodium), an antibiotic potassium ionophore, is a potent inhibitor of Wnt/β-catenin signaling. Salinomycin sodium salt (Salinomycin sodium) acts on the Wnt/Fzd/LRP complex, blocks Wnt-induced LRP6 phosphorylation, and causes degradation of the LRP6 protein. Salinomycin sodium salt (Salinomycin sodium) shows selective activity against human cancer stem cells[1][2][3].",C42H69NaO11,DMSO : 100 mg/mL (129.37 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble),10mM,Cancer,No Development Reported,[H][C@]1([C@](C)(CC2)O[C@]32[C@H](O)C=C[C@]4(O[C@]([H])([C@@H](CC)C([C@@H](C)[C@@H](O)[C@H](C)[C@]5([H])O[C@]([C@@H](CC)C(O[Na])=O)([H])CC[C@@H]5C)=O)[C@@H](C)C[C@H]4C)O3)CC[C@@](CC)(O)[C@H](C)O1
,,,,,,,,,,,,,,,,sox2,atra,HY-L025-46,C02,HY-14649,Retinoic acid,Vitamin A acid; all-trans-Retinoic acid; ATRA,302-79-4,300.44,Autophagy; Endogenous Metabolite; PPAR; RAR/RXR,Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.",C20H28O2,DMSO : 50 mg/mL (166.42 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,CC1(C)C(/C=C/C(C)=C/C=C/C(C)=C/C(O)=O)=C(C)CCC1
,,,,,,,,,,,,,,,,sox2,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,sox2,dapt,HY-L025-31,F03,HY-13027,DAPT,GSI-IX,208255-80-5,432.46,Amyloid-β; Apoptosis; Autophagy; Notch; γ-secretase,Apoptosis; Autophagy; Neuronal Signaling; Stem Cell/Wnt,"DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment[1][2].",C23H26F2N2O4,DMSO : 62.5 mg/mL (144.52 mM; Need ultrasonic); Ethanol : 10 mg/mL (23.12 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,No Development Reported,FC1=CC(F)=CC(CC(N[C@H](C(N[C@H](C(OC(C)(C)C)=O)C2=CC=CC=C2)=O)C)=O)=C1
,,,,,,,,,,,,,,,,sox2,5 fu,HY-L025-65,C06,HY-90006,5-Fluorouracil,5-FU,51-21-8,130.08,Apoptosis; Endogenous Metabolite; HIV; Nucleoside Antimetabolite/Analog,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil induces apoptosis and can be used as a chemical sensitizer[1][2]. 5-Fluorouracil also inhibits HIV[3].,C4H3FN2O2,DMSO : 50 mg/mL (384.38 mM; Need ultrasonic); H2O : 16.67 mg/mL (128.15 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(N1)NC=C(F)C1=O
,,,,,,,,,,,,,,,,caspase 3 7,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
,,,,,,,,,,,,,,,,caspase 3 7,sp600125,HY-L025-22,G02,HY-12041,SP600125,,129-56-6,220.23,Apoptosis; Autophagy; Ferroptosis; JNK,Apoptosis; Autophagy; MAPK/ERK Pathway,"SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 inhibits autophagy and activates apoptosis[1][2][3].",C14H8N2O,DMSO : 12.5 mg/mL (56.76 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C3C(NN=C3C4=C1C=CC=C4)=CC=C2
,,,,,,,,,,,,,,,,caspase 3 7,nac,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,caspase 3 7,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,caspase 3 7,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,axl,r428,HY-L025-49,G04,HY-15150,Bemcentinib,R428; BGB324,1037624-75-1,506.64,TAM Receptor,Protein Tyrosine Kinase/RTK,Bemcentinib (R428) is a potent and selective inhibitor of Axl with an IC50 of 14 nM[2].,C30H34N8,DMSO : 25 mg/mL (49.34 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,NC1=NC(NC2=CC(CC[C@@H](N3CCCC3)CC4)=C4C=C2)=NN1C(N=N5)=CC6=C5C7=CC=CC=C7CCC6
,,,,,,,,,,,,,,,,axl,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,axl,tp 0903,HY-L025-31,A06,HY-12963,Dubermatinib,TP-0903,1341200-45-0,516.06,Apoptosis; TAM Receptor,Apoptosis; Protein Tyrosine Kinase/RTK,Dubermatinib (TP-0903) is a potent and selective Axl receptor tyrosine kinase inhibitor with an IC50 value of 27 nM.,C24H30ClN7O2S,DMSO : 3.33 mg/mL (6.45 mM; Need ultrasonic),2mM,Cancer,Phase 2,O=S(C1=CC=CC=C1NC2=NC(NC3=CC=C(CN4CCN(C)CC4)C=C3)=NC=C2Cl)(N(C)C)=O
,,,,,,,,,,,,,,,,axl,erlotinib,HY-L025-64,B08,HY-50896,Erlotinib,CP-358774; NSC 718781; OSI-774,183321-74-6,393.44,Autophagy; EGFR,Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer[1].",C22H23N3O4,DMSO : 3.94 mg/mL (10.01 mM; ultrasonic and warming and heat to 40°C),10mM,Cancer,Launched,C#CC1=CC=CC(NC2=NC=NC3=C2C=C(C(OCCOC)=C3)OCCOC)=C1
,,,,,,,,,,,,,,,,axl,sitravatinib,HY-L025-57,C08,HY-16961,Sitravatinib,MGCD516; MG-516,1123837-84-2,629.68,c-Kit; Discoidin Domain Receptor; FLT3; Trk Receptor; VEGFR,Neuronal Signaling; Protein Tyrosine Kinase/RTK,"Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM,  6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively[1]. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment[2].",C33H29F2N5O4S,DMSO : ≥ 32 mg/mL (50.82 mM),10mM,Cancer; Inflammation/Immunology,Phase 3,O=C(C1(C(NC2=CC=C(F)C=C2)=O)CC1)NC3=CC=C(OC4=C5C(C=C(C6=NC=C(CNCCOC)C=C6)S5)=NC=C4)C(F)=C3
,,,,,,,,,,,,,,,,axl,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,axl,s49076,HY-L025-31,A08,HY-12965,S49076,,1265965-22-7,438.5,c-Met/HGFR; FGFR,Protein Tyrosine Kinase/RTK,"S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM.",C22H22N4O4S,DMSO : ≥ 31 mg/mL (70.70 mM),10mM,Cancer,No Development Reported,O=C(N1CC2=CC3=C(NC(/C3=C\C4=CC(CN5CCOCC5)=CN4)=O)C=C2)SCC1=O
,,,,,,,,,,,,,,,,axl,quercetin,HY-L025-72,F04,HY-N0146,Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.63 mM; Need ultrasonic); H2O : 1 mg/mL (2.96 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
,,,,,,,,,,,,,,,,axl,mp470,HY-L025-7,C06,HY-10206,Amuvatinib,MP470; HPK 56,850879-09-3,447.51,Apoptosis; c-Kit; c-Met/HGFR; FLT3; PDGFR; RAD51; RET,Apoptosis; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK,"Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair[1][2][3]. Antineoplastic activity[4].",C23H21N5O3S,DMSO : 50 mg/mL (111.73 mM; Need ultrasonic),10mM,Cancer,Phase 2,S=C(N1CCN(C2=C3OC4=CC=CC=C4C3=NC=N2)CC1)NCC5=CC=C6OCOC6=C5
,,,,,,,,,,,,,,,,axl,foretinib,HY-L025-8,F07,HY-10338,Foretinib,XL880; GSK1363089; GSK089; EXEL-2880,849217-64-7,632.65,c-Met/HGFR; VEGFR,Protein Tyrosine Kinase/RTK,Foretinib is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR. ,C34H34F2N4O6,DMSO : 75 mg/mL (118.55 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC=C(C(F)=C1)OC2=C3C=C(C(OCCCN4CCOCC4)=CC3=NC=C2)OC)C5(CC5)C(NC6=CC=C(C=C6)F)=O
,,,,,,,,,,,,,,,,axl,bgb324,HY-L025-49,G04,HY-15150,Bemcentinib,R428; BGB324,1037624-75-1,506.64,TAM Receptor,Protein Tyrosine Kinase/RTK,Bemcentinib (R428) is a potent and selective inhibitor of Axl with an IC50 of 14 nM[2].,C30H34N8,DMSO : 25 mg/mL (49.34 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,NC1=NC(NC2=CC(CC[C@@H](N3CCCC3)CC4)=C4C=C2)=NN1C(N=N5)=CC6=C5C7=CC=CC=C7CCC6
,,,,,,,,,,,,,,,,axl,cabozantinib,HY-L025-31,D08,HY-13016,Cabozantinib,XL184; BMS-907351,849217-68-1,501.51,Apoptosis; c-Kit; c-Met/HGFR; FLT3; TAM Receptor; VEGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis[1][2].",C28H24FN3O5,DMSO : 25 mg/mL (49.85 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,O=C(C1(CC1)C(NC2=CC=C(F)C=C2)=O)NC3=CC=C(C=C3)OC4=C5C=C(OC)C(OC)=CC5=NC=C4
,,,,,,,,,,,,,,,,axl,gilteritinib,HY-L025-26,E07,HY-12432,Gilteritinib,ASP2215,1254053-43-4,552.71,FLT3; TAM Receptor,Protein Tyrosine Kinase/RTK,"Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.",C29H44N8O3,Ethanol : 100 mg/mL (180.93 mM; ultrasonic and adjust pH to 2 with HCl); DMSO : 2 mg/mL (3.62 mM; Need ultrasonic),2mM,Cancer,Launched,NC(C1=NC(CC)=C(NC2CCOCC2)N=C1NC3=CC(OC)=C(N4CCC(N5CCN(C)CC5)CC4)C=C3)=O
,,,,,,,,,,,,,,,,axl,bemcentinib,HY-L025-49,G04,HY-15150,Bemcentinib,R428; BGB324,1037624-75-1,506.64,TAM Receptor,Protein Tyrosine Kinase/RTK,Bemcentinib (R428) is a potent and selective inhibitor of Axl with an IC50 of 14 nM[2].,C30H34N8,DMSO : 25 mg/mL (49.34 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,NC1=NC(NC2=CC(CC[C@@H](N3CCCC3)CC4)=C4C=C2)=NN1C(N=N5)=CC6=C5C7=CC=CC=C7CCC6
,,,,,,,,,,,,,,,,chk1,rabusertib,HY-L025-46,H04,HY-14720,Rabusertib,LY2603618; IC-83,911222-45-2,436.3,Autophagy; Checkpoint Kinase (Chk),Autophagy; Cell Cycle/DNA Damage,Rabusertib (LY2603618) is a potent and selective inhibitor of Chk1 with an IC50 of 7 nM.,C18H22BrN5O3,DMSO : 31.25 mg/mL (71.63 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,BrC(C=C1NC(NC2=NC=C(N=C2)C)=O)=C(C=C1OC[C@H]3OCCNC3)C
,,,,,,,,,,,,,,,,chk1,panobinostat,HY-L025-7,E05,HY-10224,Panobinostat,LBH589; NVP-LBH589,404950-80-7,349.43,Apoptosis; Autophagy; HDAC; HIV,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].",C21H23N3O2,DMSO : ≥ 100 mg/mL (286.18 mM),10mM,Cancer,Launched,O=C(/C=C/C1=CC=C(CNCCC2=C(NC3=C2C=CC=C3)C)C=C1)NO
,,,,,,,,,,,,,,,,chk1,sch900776,HY-L025-52,G04,HY-15532B,SCH900776 (S-isomer),MK-8776 S-isomer,891494-64-7,376.25,Others,Others,"SCH900776 S-isomer is the S-isomer of SCH900776. SCH900776 is a potent, selective and orally bioavailable inhibitor of checkpoint kinase1 (Chk1) with IC50 of 3 nM.",C15H18BrN7,DMSO : ≥ 100 mg/mL (265.78 mM),10mM,Cancer,Phase 2,NC1=C(Br)C([C@@H]2CNCCC2)=NC3=C(C4=CN(C)N=C4)C=NN13
,,,,,,,,,,,,,,,,chk1,olaparib,HY-L025-6,B03,HY-10162,Olaparib,AZD2281; KU0059436,763113-22-0,434.46,Autophagy; Mitophagy; PARP,Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].",C24H23FN4O3,DMSO : 100 mg/mL (230.17 mM; Need ultrasonic); DMF : 50 mg/mL (115.09 mM; Need ultrasonic); Ethanol : 3.12 mg/mL (7.18 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CC(CC(C2=C3C=CC=C2)=NNC3=O)=CC=C1F)N4CCN(C(C5CC5)=O)CC4
,,,,,,,,,,,,,,,,chk1,gdc 0575,HY-L025-17,B09,HY-112167A,GDC-0575 (dihydrochloride),ARRY-575 (dihydrochloride); RG7741 (dihydrochloride),1657014-42-0,451.19,Checkpoint Kinase (Chk),Cell Cycle/DNA Damage,"GDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is an orally bioavailable CHK1 inhibitor, with an IC50 of 1.2 nM, and has antitumor activity.",C16H22BrCl2N5O,DMSO : 65 mg/mL (144.06 mM; Need ultrasonic); H2O : 25 mg/mL (55.41 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(C1CC1)NC2=CNC3=NC=C(Br)C(N4C[C@H](N)CCC4)=C32.[H]Cl.[H]Cl
,,,,,,,,,,,,,,,,chk1,ve 821,HY-L025-47,B04,HY-14731,VE-821,,1232410-49-9,368.41,ATM/ATR,Cell Cycle/DNA Damage; PI3K/Akt/mTOR,VE-821 is a potent ATP-competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM.,C18H16N4O3S,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 50 mg/mL (135.72 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C(NC1=CC=CC=C1)C2=NC(C3=CC=C(C=C3)S(=O)(C)=O)=CN=C2N
,,,,,,,,,,,,,,,,chk1,cct244747,HY-L025-59,B02,HY-18175,CCT244747,,1404095-34-6,408.46,Checkpoint Kinase (Chk),Cell Cycle/DNA Damage,"CCT244747 is a potent, orally bioavailable and highly selective CHK1 inhibitor, with an IC50 of 7.7 nM; CCT244747 also abrogates G2 checkpoint with an IC50 of 29 nM.",C20H24N8O2,DMSO : 50 mg/mL (122.41 mM; Need ultrasonic),10mM,Cancer,No Development Reported,N#CC1=NC=C(NC2=NC=C(C3=CN(C)N=C3)C(OC)=C2)N=C1O[C@H](C)CN(C)C
,,,,,,,,,,,,,,,,chk1,chir 124,HY-L025-33,F05,HY-13263,CHIR-124,,405168-58-3,419.91,Apoptosis; Checkpoint Kinase (Chk); FLT3; PDGFR,Apoptosis; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK,"CHIR-124 is a potent and selective Chk1 inhibitor with IC50 of 0.3 nM, and also potently targets PDGFR and FLT3 with IC50s of 6.6 nM and 5.8 nM.",C23H22ClN5O,DMSO : 7.14 mg/mL (17.00 mM; Need ultrasonic),10mM,Cancer,No Development Reported,ClC1=CC2=C(NC(C(C3=NC4=C(C=CC=C4)N3)=C2N[C@@H]5CN6CCC5CC6)=O)C=C1
,,,,,,,,,,,,,,,,chk1,sar 020106,HY-L025-1,D10,HY-100195,SAR-020106,,1184843-57-9,382.85,Checkpoint Kinase (Chk),Cell Cycle/DNA Damage,"SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC50 of 13.3 nM for human CHK1. SAR-020106 shows excellent selectivity over CHK2. SAR-020106 significantly enhances the cell killing of Gemcitabine and SN38 by 3- to 29-fold in several colon tumor lines and in a p53-dependent fashion. SAR-020106 can enhance antitumor activity with selected anticancer agents[1][2].",C19H19ClN6O,DMSO : 5 mg/mL (13.06 mM; Need ultrasonic),10mM,Cancer,No Development Reported,N#CC1=NC=C(NC2=CC3=C(C=N2)C(Cl)=CC=C3)N=C1O[C@H](C)CN(C)C
,,,,,,,,,,,,,,,,chk1,mk 1775,HY-L025-14,D02,HY-10993,Adavosertib,AZD1775; MK-1775,955365-80-7,500.6,Wee1,Cell Cycle/DNA Damage,Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC50 of 5.2 nM.,C27H32N8O2,DMSO : 125 mg/mL (249.70 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1N(N(C2=NC(NC3=CC=C(C=C3)N4CCN(CC4)C)=NC=C21)C5=NC(C(O)(C)C)=CC=C5)CC=C
,,,,,,,,,,,,,,,,chk1,ly2603618,HY-L025-46,H04,HY-14720,Rabusertib,LY2603618; IC-83,911222-45-2,436.3,Autophagy; Checkpoint Kinase (Chk),Autophagy; Cell Cycle/DNA Damage,Rabusertib (LY2603618) is a potent and selective inhibitor of Chk1 with an IC50 of 7 nM.,C18H22BrN5O3,DMSO : 31.25 mg/mL (71.63 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,BrC(C=C1NC(NC2=NC=C(N=C2)C)=O)=C(C=C1OC[C@H]3OCCNC3)C
,,,,,,,,,,,,,,,,chk1,ly2606368,HY-L025-59,A11,HY-18174E,Prexasertib (dimesylate),LY2606368 (dimesylate),1234015-58-7,557.6,Apoptosis; Checkpoint Kinase (Chk),Apoptosis; Cell Cycle/DNA Damage,"Prexasertib dimesylate (LY2606368 dimesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib dimesylate inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib dimesylate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dimesylate shows potent anti-tumor activity[1][2].",C20H27N7O8S2,DMSO : 100 mg/mL (179.34 mM; Need ultrasonic); H2O : 50 mg/mL (89.67 mM; Need ultrasonic),10mM,Cancer,Phase 2,N#CC1=NC=C(NC2=NNC(C3=C(OC)C=CC=C3OCCCN)=C2)N=C1.CS(=O)(O)=O.CS(=O)(O)=O
,,,,,,,,,,,,,,,,chk1,pf 477736,HY-L025-1,G04,HY-10032,PF 477736,PF 00477736,952021-60-2,419.48,Aurora Kinase; CDK; c-Fms; Checkpoint Kinase (Chk); FGFR; FLT3; RET; Src; VEGFR,Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK,"PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a Ki of 0.49 nM, it is also a Chk2 inhibitor, with a Ki of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, Yes, Aurora-A, FGFR3, Flt3,  and Ret (IC50=8 (Ki), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo[1][2].",C22H25N7O2,DMSO : 125 mg/mL (297.99 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C([C@@H](C1CCCCC1)N)NC2=CC3=C(C(C=NNC4=O)=C(N3)C5=CN(N=C5)C)C4=C2
,,,,,,,,,,,,,,,,chk1,pf 00477736,HY-L025-1,G04,HY-10032,PF 477736,PF 00477736,952021-60-2,419.48,Aurora Kinase; CDK; c-Fms; Checkpoint Kinase (Chk); FGFR; FLT3; RET; Src; VEGFR,Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK,"PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a Ki of 0.49 nM, it is also a Chk2 inhibitor, with a Ki of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, Yes, Aurora-A, FGFR3, Flt3,  and Ret (IC50=8 (Ki), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo[1][2].",C22H25N7O2,DMSO : 125 mg/mL (297.99 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C([C@@H](C1CCCCC1)N)NC2=CC3=C(C(C=NNC4=O)=C(N3)C5=CN(N=C5)C)C4=C2
,,,,,,,,,,,,,,,,bak,obatoclax,HY-L025-14,B09,HY-10969,Obatoclax (Mesylate),GX15-070 (Mesylate),803712-79-0,413.49,Autophagy; Bcl-2 Family; Parasite,Anti-infection; Apoptosis; Autophagy,"Obatoclax Mesylate (GX15-070 Mesylate), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a Ki of 220 nM for BCL-2[1][2]. Obatoclax Mesylate induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax Mesylate has anti-cancer and broad-spectrum antiparasitic activity[3][4].",C21H23N3O4S,DMSO : 12.5 mg/mL (30.23 mM; Need ultrasonic),10mM,Cancer; Infection,Phase 3,COC1=CC(C2=CC3=C(C=CC=C3)N2)=N/C1=C\C4=C(C=C(N4)C)C.CS(=O)(O)=O
,,,,,,,,,,,,,,,,bak,abt 737,HY-L025-64,C06,HY-50907,ABT-737,,852808-04-9,813.43,Apoptosis; Autophagy; Bcl-2 Family; Mitophagy,Apoptosis; Autophagy,"ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research[1][2][3].",C42H45ClN6O5S2,DMSO : 50 mg/mL (61.47 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(CC[C@@H](NC1=CC=C(C=C1[N+]([O-])=O)S(NC(C2=CC=C(C=C2)N3CCN(CC3)CC4=CC=CC=C4C5=CC=C(C=C5)Cl)=O)(=O)=O)CSC6=CC=CC=C6)C
,,,,,,,,,,,,,,,,bak,dioscin,HY-L025-72,E02,HY-N0124,Dioscin,Collettiside III; CCRIS 4123,19057-60-4,869.04,Apoptosis; Autophagy,Apoptosis; Autophagy,"Dioscin(CCRIS 4123; Collettiside III) is a natural steroid saponin derived from several plants, showing potent anti-cancer effect against a variety of tumor cell lines. 
IC50 value:
Target: Anticancer agent
in vitro: dioscin (1, 2 and 4 μmol/L) could significantly inhibit the viability of LNCaP cells in a time- and concentration-dependent manner. Flow cytometry revealed that the apoptosis rate was increased after treatment of LNCaP cells with dioscin for 24 h, indicating that apoptosis was an important mechanism by which dioscin inhibited cancer [1]. dioscin abrogated AKT phosphorylation, which subsequently impaired RANKL-induced nuclear factor-kappaB (NF-κB) signaling pathway and inhibited NFATc1 transcriptional activity. Moreover, in vivo studies further verified the bone protection activity of dioscin in osteolytic animal model [2]. Dioscin reduced cell death and lactate dehydrogenase (LDH) release in cells subjected to I/R. I/R induced apoptosis and cytochrome c release from mitochondria to the cytosol and this was prevented by dioscin. In support, dioscin decreased Bax but increased Bcl-2 mRNA expression. Dioscin prevented I/R induced dissipation of ΔΨm [3].",C45H72O16,DMSO : ≥ 100 mg/mL (115.07 mM),10mM,Cancer,Launched,O[C@@H]1[C@@H](O)[C@H](C)O[C@@]([H])(O[C@H]2[C@H](O)[C@@H](O[C@]3([H])O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@](O[C@@H]4CC5=CC[C@]([C@]([H])(C[C@@]6([H])[C@]7([H])[C@H](C)[C@]8(OC[C@H](C)CC8)O6)[C@]7(C)CC9)([H])[C@@]9([H])[C@@]5(C)CC4)([H])O[C@@H]2CO)[C@@H]1O
,,,,,,,,,,,,,,,,sqstm1,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,sqstm1,chloroquine,HY-L025-58,G04,HY-17589A,Chloroquine,,54-05-7,319.87,Antibiotic; Autophagy; HIV; Parasite; SARS-CoV; Toll-like Receptor (TLR),Anti-infection; Autophagy; Immunology/Inflammation,Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].,C18H26ClN3,Ethanol : 100 mg/mL (312.63 mM; Need ultrasonic); DMSO : 50 mg/mL (156.31 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,CC(NC1=CC=NC2=CC(Cl)=CC=C12)CCCN(CC)CC
,,,,,,,,,,,,,,,,dnmt1,procainamide,HY-L025-65,F09,HY-A0084A,Procainamide,Procaine amide; SP 100,51-06-9,235.33,DNA Methyltransferase,Epigenetics,Procainamide is a specific and potent inhibitor of DNA methyltransferase 1 (DNMT1). Procainamide is a Class 1A antiarrhythmic agent. Procainamide has the potential for the research of cancer and arrhythmias[1][2].,C13H21N3O,DMSO : 50 mg/mL (212.47 mM; Need ultrasonic),10mM,Cancer; Cardiovascular Disease,Launched,O=C(NCCN(CC)CC)C1=CC=C(N)C=C1
,,,,,,,,,,,,,,,,dnmt1,azacitidine,HY-L025-10,H06,HY-10586,5-Azacytidine,Azacitidine; 5-AzaC; Ladakamycin,320-67-2,244.2,Antibiotic; Autophagy; Bacterial; DNA Methyltransferase; Nucleoside Antimetabolite/Analog,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Epigenetics,5-Azacytidine (Azacitidine; 5-AzaC; Ladakamycin) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation. 5-Azacytidine is incorporated into DNA to covalently trap DNA methyltransferases and contributes to reverse epigenetic changes[1][2]. 5-Azacytidine induces cell autophagy[4].,C8H12N4O5,DMSO : ≥ 31 mg/mL (126.95 mM); H2O : 33.33 mg/mL (136.49 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)N=C2)=O)O1
,,,,,,,,,,,,,,,,dnmt1,vorinostat,HY-L025-7,E02,HY-10221,Vorinostat,SAHA; Suberoylanilide hydroxamic acid,149647-78-9,264.32,Apoptosis; Autophagy; Filovirus; HDAC; HPV; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].",C14H20N2O3,DMSO : ≥ 100 mg/mL (378.33 mM),10mM,Cancer; Infection,Launched,O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O
,,,,,,,,,,,,,,,,dnmt1,decitabine,HY-L025-65,D02,HY-A0004,Decitabine,5-Aza-2'-deoxycytidine; 5-AZA-CdR; NSC 127716,2353-33-5,228.21,Apoptosis; DNA Methyltransferase; Nucleoside Antimetabolite/Analog,Apoptosis; Cell Cycle/DNA Damage; Epigenetics,Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and a DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell apoptosis. Decitabine has potent anticancer activity[1][2].,C8H12N4O4,H2O : 20 mg/mL (87.64 mM; Need ultrasonic); DMSO : ≥ 50 mg/mL (219.10 mM),10mM,Cancer,Launched,O[C@H]1C[C@H](N2C(N=C(N)N=C2)=O)O[C@@H]1CO
,,,,,,,,,,,,,,,,dnmt1,hydralazine,HY-L025-68,D04,HY-B0464,Hydralazine (hydrochloride),,304-20-1,196.64,HIF/HIF Prolyl-Hydroxylase,Metabolic Enzyme/Protease,"Hydralazine hydrochloride is a orally active antihypertensive agent, reduces peripheral resistance directly by relaxing the smooth muscle cell layer in arterial vessel. Hydralazine hydrochloride has antioxidant activity, as well as inhibits ROS release and O2·- generation with an IC50 value of 9.53 mM and 1.19 mM, respectively[1][2].",C8H9ClN4,H2O : 25 mg/mL (127.14 mM; Need ultrasonic); DMSO : 25 mg/mL (127.14 mM; ultrasonic and adjust pH to 11 with NaOH),10mM,Cardiovascular Disease; Cancer,Launched,NNC1=NN=CC2=C1C=CC=C2.Cl
,,,,,,,,,,,,,,,,dnmt1,zebularine,HY-L025-34,G10,HY-13420,Zebularine,NSC309132; 4-Deoxyuridine,10/6/90,228.2,Autophagy; DNA Methyltransferase,Autophagy; Epigenetics,Zebularine (NSC309132; 4-Deoxyuridine) is a DNA methyltransferase inhibitor. Zebularine also inhibits cytidine deaminase with a Ki of 0.95 μM.,C9H12N2O5,DMSO : ≥ 100 mg/mL (438.21 mM); H2O : 50 mg/mL (219.11 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=CC=C2)=O)O1
,,,,,,,,,,,,,,,,dnmt1,rg108,HY-L025-38,A03,HY-13642,RG108,N-Phthalyl-L-tryptophan,48208-26-0,334.33,DNA Methyltransferase,Epigenetics,"RG108 (N-Phthalyl-L-tryptophan) is a non-nucleoside DNA methyltransferases (DNMTs) inhibitor (IC50=115 nM) that blocks the DNMTs active site. RG108 (N-Phthalyl-L-tryptophan) causes demethylation and reactivation of tumor suppressor genes, but it does not affect the methylation of centromeric satellite sequences[1][2][3].",C19H14N2O4,H2O : < 0.1 mg/mL (insoluble); DMSO : 100 mg/mL (299.11 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C(N1[C@H](C(O)=O)CC2=CNC3=C2C=CC=C3)C4=CC=CC=C4C1=O
,,,,,,,,,,,,,,,,dnmt1,tsa,HY-L025-49,F10,HY-15144,Trichostatin A,TSA,58880-19-6,302.37,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].",C17H22N2O3,DMSO : 25 mg/mL (82.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
,,,,,,,,,,,,,,,,dnmt1,5 azacytidine,HY-L025-10,H06,HY-10586,5-Azacytidine,Azacitidine; 5-AzaC; Ladakamycin,320-67-2,244.2,Antibiotic; Autophagy; Bacterial; DNA Methyltransferase; Nucleoside Antimetabolite/Analog,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Epigenetics,5-Azacytidine (Azacitidine; 5-AzaC; Ladakamycin) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation. 5-Azacytidine is incorporated into DNA to covalently trap DNA methyltransferases and contributes to reverse epigenetic changes[1][2]. 5-Azacytidine induces cell autophagy[4].,C8H12N4O5,DMSO : ≥ 31 mg/mL (126.95 mM); H2O : 33.33 mg/mL (136.49 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)N=C2)=O)O1
,,,,,,,,,,,,,,,,dnmt1,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,dnmt1,sgi 1027,HY-L025-42,C08,HY-13962,SGI-1027,,1020149-73-8,461.52,Apoptosis; DNA Methyltransferase,Apoptosis; Epigenetics,"SGI-1027 is a DNA methyltransferase (DNMT) inhibitor, with IC50s of 7.5 μM, 8 μM, and 12.5 μM for DNMT3B, DNMT3A, and DNMT1 with poly(dI-dC) as substrate.",C27H23N7O,DMSO : 27 mg/mL (58.50 mM; Need ultrasonic and warming),10mM,Cancer,No Development Reported,O=C(NC1=CC=C(NC2=NC(N)=NC(C)=C2)C=C1)C3=CC=C(NC4=CC=NC5=CC=CC=C45)C=C3
,,,,,,,,,,,,,,,,taz,dasatinib,HY-L025-6,D08,HY-10181B,Dasatinib (monohydrate),BMS-354825 (monohydrate),863127-77-9,506.02,Apoptosis; Autophagy; Bcr-Abl; Src,Apoptosis; Autophagy; Protein Tyrosine Kinase/RTK,"Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively.  Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively[1]. Dasatinib monohydrate also induces apoptosis and autophagy.",C22H28ClN7O3S,10 mM in DMSO,10mM,Cancer,Launched,O=C(C1=CN=C(NC2=NC(C)=NC(N3CCN(CCO)CC3)=C2)S1)NC4=C(C)C=CC=C4Cl.[H]O[H]
,,,,,,,,,,,,,,,,taz,fluvastatin,HY-L025-46,D05,HY-14664A,Fluvastatin (sodium),XU 62-320,93957-55-2,433.45,Autophagy; Ferroptosis; HMG-CoA Reductase (HMGCR),Apoptosis; Autophagy; Metabolic Enzyme/Protease,"Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin sodium protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1][2][3].",C24H25FNNaO4,H2O : 50 mg/mL (115.35 mM; Need ultrasonic); DMSO : 50 mg/mL (115.35 mM; Need ultrasonic),10mM,Cardiovascular Disease; Cancer,Launched,O=C(O[Na])C[C@H](O)C[C@H](O)/C=C/C(N1C(C)C)=C(C2=CC=C(F)C=C2)C3=C1C=CC=C3
,,,,,,,,,,,,,,,,taz,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,taz,verteporfin,HY-L025-66,F07,HY-B0146,Verteporfin,CL 318952,129497-78-5,718.79,Apoptosis; Autophagy; YAP,Apoptosis; Autophagy; Stem Cell/Wnt,Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis[1]. Verteporfinis an autophagy inhibitor that blocks?autophagy?at an early stage by inhibiting autophagosome formation[3].,C41H42N4O8,DMF : 10 mg/mL (13.91 mM; ultrasonic and warming and heat to 60°C); DMSO : 100 mg/mL (139.12 mM; Need ultrasonic),10mM,Cancer,Launched,C[C@]1(/C2=C/C(N3)=C4C)C(C(/C=C(C(C)=C/5C=C)\NC5=C/C6=N/C(C(CCC(OC)=O)=C6C)=C\C3=C4CCC(O)=O)=N2)=CC=C(C(OC)=O)[C@H]1C(OC)=O.C[C@]7(/C8=C/C(N9)=C%10C)C(C(/C=C(C(C)=C/%11C=C)\NC%11=C/C%12=N/C(C(CCC(O)=O)=C%12C)=C\C9=C%10CCC(OC)=O)=N8)=CC=C(C(OC)=O)[C@H]7C(OC)=O
,,,,,,,,,,,,,,,,plk1,gsk461364a,HY-L025-64,A11,HY-50877,GSK461364,GSK461364A,929095-18-1,543.6,Polo-like Kinase (PLK),Cell Cycle/DNA Damage,"GSK461364 is a selective, reversible and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with a Ki value of 2.2 nM.",C27H28F3N5O2S,DMSO : 50 mg/mL (91.98 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(C(SC(N1C=NC2=CC=C(C=C12)CN3CCN(CC3)C)=C4)=C4O[C@@H](C5=CC=CC=C5C(F)(F)F)C)N
,,,,,,,,,,,,,,,,plk1,mk 5108,HY-L025-33,D11,HY-13252,MK-5108,VX-689,1010085-13-8,461.94,Aurora Kinase; Autophagy,Autophagy; Cell Cycle/DNA Damage; Epigenetics,MK-5108 is a highly potent and specific inhibitor of Aurora A kinase with an IC50 value of 0.064 nM.,C22H21ClFN3O3S,DMSO : 12.5 mg/mL (27.06 mM; Need ultrasonic),10mM,Cancer,Phase 1,FC(C(Cl)=CC=C1)=C1O[C@H](CC2)CC[C@@]2(C(O)=O)CC3=CC=CC(NC4=NC=CS4)=N3
,,,,,,,,,,,,,,,,plk1,poloxin,HY-L025-23,F04,HY-12134,Poloxin,,321688-88-4,297.35,Polo-like Kinase (PLK),Cell Cycle/DNA Damage,"Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain, with an IC50 of appr 4.8 μM.",C18H19NO3,DMSO : 14.29 mg/mL (48.06 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C(C(C(C)C)=C/1)C=C(C)C1=N/OC(C2=CC=CC=C2C)=O
,,,,,,,,,,,,,,,,plk1,genistein,HY-L025-45,H04,HY-14596,Genistein,NPI 031L,446-72-0,270.24,Apoptosis; Autophagy; EGFR; Endogenous Metabolite,Apoptosis; Autophagy; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,"Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.",C15H10O5,DMSO : ≥ 100 mg/mL (370.04 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 4,OC1=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,plk1,tak 960,HY-L025-49,H10,HY-15160B,TAK-960 (dihydrochloride),,,634.52,Polo-like Kinase (PLK),Cell Cycle/DNA Damage,"TAK-960 dihydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. TAK-960 dihydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 dihydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts[1].",C27H36Cl2F3N7O3,DMSO : 3.23 mg/mL (5.09 mM; Need ultrasonic); H2O : 10 mg/mL (15.76 mM; Need ultrasonic),10mM,Cancer,Phase 1,[H]Cl.O=C(NC1CCN(C)CC1)C2=CC(OC)=C(NC3=NC=C(N4C)C(N(C5CCCC5)CC(F)(F)C4=O)=N3)C=C2F.[H]Cl
,,,,,,,,,,,,,,,,plk1,azd1775,HY-L025-14,D02,HY-10993,Adavosertib,AZD1775; MK-1775,955365-80-7,500.6,Wee1,Cell Cycle/DNA Damage,Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC50 of 5.2 nM.,C27H32N8O2,DMSO : 125 mg/mL (249.70 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1N(N(C2=NC(NC3=CC=C(C=C3)N4CCN(CC4)C)=NC=C21)C5=NC(C(O)(C)C)=CC=C5)CC=C
,,,,,,,,,,,,,,,,plk1,wortmannin,HY-L025-6,H04,HY-10197,Wortmannin,SL-2052; KY-12420,19545-26-7,428.43,Antibiotic; Autophagy; PI3K; Polo-like Kinase (PLK),Anti-infection; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively[1][2][3].",C23H24O8,DMSO : ≥ 50 mg/mL (116.71 mM),10mM,Cancer,No Development Reported,O=C1C([C@@](CC2)([H])[C@@]3(C)C2=O)=C([C@H](OC(C)=O)C3)[C@]4(C)C5=C1OC=C5C(O[C@@H]4COC)=O
,,,,,,,,,,,,,,,,plk1,gsk461364,HY-L025-64,A11,HY-50877,GSK461364,GSK461364A,929095-18-1,543.6,Polo-like Kinase (PLK),Cell Cycle/DNA Damage,"GSK461364 is a selective, reversible and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with a Ki value of 2.2 nM.",C27H28F3N5O2S,DMSO : 50 mg/mL (91.98 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(C(SC(N1C=NC2=CC=C(C=C12)CN3CCN(CC3)C)=C4)=C4O[C@@H](C5=CC=CC=C5C(F)(F)F)C)N
,,,,,,,,,,,,,,,,plk1,onvansertib,HY-L025-54,D06,HY-15828,Onvansertib,NMS-1286937; NMS-P937,1034616-18-6,532.52,Apoptosis; Polo-like Kinase (PLK),Apoptosis; Cell Cycle/DNA Damage,"NMS-1286937 is a potent, selective and orally available PLK1 inhibitor, with an IC50 of 2 nM.",C24H27F3N8O3,DMSO : 21 mg/mL (39.44 mM; Need ultrasonic and warming),10mM,Cancer,Phase 2,O=C(C1=NN(CCO)C2=C1CCC3=CN=C(NC4=CC(N5CCN(C)CC5)=CC=C4OC(F)(F)F)N=C23)N
,,,,,,,,,,,,,,,,plk1,ro3280,HY-L025-49,H11,HY-15161,Ro3280,,1062243-51-9,543.61,Polo-like Kinase (PLK),Cell Cycle/DNA Damage,"Ro3280 is a potent, highly selective inhibitor of PLK1 with an IC50 and a Kd of 3 nM and 0.09 nM, respectively, and nearly has no effect on PLK2 and PLK3.",C27H35F2N7O3,DMSO : 100 mg/mL (183.96 mM; Need ultrasonic),10mM,Cancer,No Development Reported,COC1=C(NC2=NC(N(C3CCCC3)CC(F)(F)C(N4C)=O)=C4C=N2)C=CC(C(NC5CCN(C)CC5)=O)=C1
,,,,,,,,,,,,,,,,plk1,sbe13,HY-L025-49,H06,HY-15158,SBE13 (Hydrochloride),,1052532-15-6,479.4,Apoptosis; Autophagy; Polo-like Kinase (PLK),Apoptosis; Autophagy; Cell Cycle/DNA Damage,"SBE13 Hydrochloride is a potent and selective Plk1 inhibitor, with an IC50 of 200 pM; SBE13 Hydrochloride poorly inhibits Plk2 (IC50>66?μM) or Plk3 (IC50=875?nM).",C24H28Cl2N2O4,DMSO : ≥ 100 mg/mL (208.59 mM); H2O : 5 mg/mL (10.43 mM; Need ultrasonic),10mM,Cancer,No Development Reported,COC1=CC=C(CCNCC2=CC=C(OCC3=CC=C(Cl)N=C3)C(OC)=C2)C=C1OC.[H]Cl
,,,,,,,,,,,,,,,,plk1,volasertib,HY-L025-23,F07,HY-12137,Volasertib,BI 6727,755038-65-4,618.81,Apoptosis; Polo-like Kinase (PLK),Apoptosis; Cell Cycle/DNA Damage,"Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models[1][2].",C34H50N8O3,DMSO : 50 mg/mL (80.80 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=CC=C(C(OC)=C1)NC2=NC=C(N(C3=O)C)C(N([C@@H]3CC)C(C)C)=N2)N[C@H]4CC[C@@H](CC4)N5CCN(CC5)CC6CC6
,,,,,,,,,,,,,,,,plk1,bi 2536,HY-L025-63,G06,HY-50698,BI 2536,,755038-02-9,521.65,Apoptosis; Epigenetic Reader Domain; Polo-like Kinase (PLK),Apoptosis; Cell Cycle/DNA Damage; Epigenetics,"BI 2536 is a dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively[1]. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription[4].",C28H39N7O3,DMSO : 65 mg/mL (124.60 mM; Need ultrasonic); 0.1 M HCL : 25 mg/mL (47.92 mM; ultrasonic and adjust pH to 4 with HCl),10mM,Cancer,Phase 2,O=C1[C@H](N(C2=C(N1C)C=NC(NC3=CC=C(C(NC4CCN(C)CC4)=O)C=C3OC)=N2)C5CCCC5)CC
,,,,,,,,,,,,,,,,plk1,rigosertib,HY-L025-22,F04,HY-12037,Rigosertib (sodium),ON-01910 (sodium),592542-60-4,473.47,Apoptosis; PI3K; Polo-like Kinase (PLK),Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3K/Akt pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle[1][2]. Rigosertib sodium is a selective and non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM[3].",C21H24NNaO8S,H2O : ≥ 52 mg/mL (109.83 mM); DMSO : 150 mg/mL (316.81 mM; Need ultrasonic),10mM,Cancer,Phase 3,COC1=CC=C(C=C1NCC(O[Na])=O)CS(/C=C/C2=C(C=C(C=C2OC)OC)OC)(=O)=O
,,,,,,,,,,,,,,,,plk1,nms p937,HY-L025-54,D06,HY-15828,Onvansertib,NMS-1286937; NMS-P937,1034616-18-6,532.52,Apoptosis; Polo-like Kinase (PLK),Apoptosis; Cell Cycle/DNA Damage,"NMS-1286937 is a potent, selective and orally available PLK1 inhibitor, with an IC50 of 2 nM.",C24H27F3N8O3,DMSO : 21 mg/mL (39.44 mM; Need ultrasonic and warming),10mM,Cancer,Phase 2,O=C(C1=NN(CCO)C2=C1CCC3=CN=C(NC4=CC(N5CCN(C)CC5)=CC=C4OC(F)(F)F)N=C23)N
,,,,,,,,,,,,,,,,plk1,bi 6727,HY-L025-23,F07,HY-12137,Volasertib,BI 6727,755038-65-4,618.81,Apoptosis; Polo-like Kinase (PLK),Apoptosis; Cell Cycle/DNA Damage,"Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models[1][2].",C34H50N8O3,DMSO : 50 mg/mL (80.80 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=CC=C(C(OC)=C1)NC2=NC=C(N(C3=O)C)C(N([C@@H]3CC)C(C)C)=N2)N[C@H]4CC[C@@H](CC4)N5CCN(CC5)CC6CC6
,,,,,,,,,,,,,,,,plk1,gw843682x,HY-L025-14,E03,HY-11003,GW843682X,GW843682,660868-91-7,477.46,Polo-like Kinase (PLK),Cell Cycle/DNA Damage,"GW843682X is a selective, ATP-competitive inhibitor of PLK1 and PLK3, with IC50s of 2.2 nM and 9.1 nM, respectively, and is also >100-fold selective against ～30 other kinases.",C22H18F3N3O4S,DMSO : 33.33 mg/mL (69.81 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C(C1=C(OCC2=CC=CC=C2C(F)(F)F)C=C(N3C4=CC(OC)=C(OC)C=C4N=C3)S1)N
,,,,,,,,,,,,,,,,puma,pifithrin α,HY-L025-52,D04,HY-15484,Pifithrin-α (hydrobromide),Pifithrin hydrobromide; PFTα hydrobromide,63208-82-2,367.3,Apoptosis; Aryl Hydrocarbon Receptor; Ferroptosis; MDM-2/p53,Apoptosis; Immunology/Inflammation,Pifithrin-α hydrobromide is a p53 inhibitor which blocks its transcriptional activity and prevents cells from apoptosis. Pifithrin-α hydrobromide is also an aryl hydrocarbon receptor (AhR) agonist.,C16H19BrN2OS,DMSO : ≥ 50 mg/mL (136.13 mM); H2O : 1.25 mg/mL (3.40 mM; Need ultrasonic),10mM,Cancer,No Development Reported,N=C1SC2=C(CCCC2)N1CC(C3=CC=C(C)C=C3)=O.[H]Br
,,,,,,,,,,,,,,,,puma,sp600125,HY-L025-22,G02,HY-12041,SP600125,,129-56-6,220.23,Apoptosis; Autophagy; Ferroptosis; JNK,Apoptosis; Autophagy; MAPK/ERK Pathway,"SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 inhibits autophagy and activates apoptosis[1][2][3].",C14H8N2O,DMSO : 12.5 mg/mL (56.76 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C2=C3C(NN=C3C4=C1C=CC=C4)=CC=C2
,,,,,,,,,,,,,,,,puma,nac,HY-L025-67,B05,HY-B0215,Acetylcysteine,N-Acetylcysteine; N-Acetyl-L-cysteine; NAC,616-91-1,163.19,Apoptosis; Endogenous Metabolite; Ferroptosis; Influenza Virus; Reactive Oxygen Species,Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].",C5H9NO3S,H2O : 163 mg/mL (998.81 mM; ultrasonic and adjust pH to 7 with NaOH); DMSO : ≥ 100 mg/mL (612.76 mM),10mM,Infection; Neurological Disease; Cancer,Launched,SC[C@@H](C(O)=O)NC(C)=O
,,,,,,,,,,,,,,,,gli1,salinomycin,HY-L025-58,B06,HY-17439,Salinomycin (sodium salt),Salinomycin sodium; Sodium salinomycin,55721-31-8,772.98,Antibiotic; Apoptosis; Autophagy; Bacterial; Parasite; Wnt; β-catenin,Anti-infection; Apoptosis; Autophagy; Stem Cell/Wnt,"Salinomycin sodium salt (Salinomycin sodium), an antibiotic potassium ionophore, is a potent inhibitor of Wnt/β-catenin signaling. Salinomycin sodium salt (Salinomycin sodium) acts on the Wnt/Fzd/LRP complex, blocks Wnt-induced LRP6 phosphorylation, and causes degradation of the LRP6 protein. Salinomycin sodium salt (Salinomycin sodium) shows selective activity against human cancer stem cells[1][2][3].",C42H69NaO11,DMSO : 100 mg/mL (129.37 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble),10mM,Cancer,No Development Reported,[H][C@]1([C@](C)(CC2)O[C@]32[C@H](O)C=C[C@]4(O[C@]([H])([C@@H](CC)C([C@@H](C)[C@@H](O)[C@H](C)[C@]5([H])O[C@]([C@@H](CC)C(O[Na])=O)([H])CC[C@@H]5C)=O)[C@@H](C)C[C@H]4C)O3)CC[C@@](CC)(O)[C@H](C)O1
,,,,,,,,,,,,,,,,gli1,forskolin,HY-L025-51,G04,HY-15371,Forskolin,Coleonol; Colforsin; HL 362,66575-29-9,410.5,Adenylate Cyclase; Autophagy; FXR,Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease,"Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC50 of 41 nM and an EC50 of 0.5 μM for type I adenylyl cyclase[1]. Forskolin is also an inducer of intracellular cAMP formation[2]. Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR[3]. Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy[4][5].",C22H34O7,DMSO : 100 mg/mL (243.61 mM; Need ultrasonic),10mM,Cancer; Endocrinology; Metabolic Disease; Inflammation/Immunology,No Development Reported,O=C1[C@@]2(O)[C@]([C@@H](OC(C)=O)[C@@H](O)[C@@]3([H])C(C)(C)CC[C@H](O)[C@@]32C)(C)O[C@@](C)(C=C)C1
,,,,,,,,,,,,,,,,gli1,perifosine,HY-L025-64,C07,HY-50909,Perifosine,KRX-0401; NSC 639966; D21266,157716-52-4,461.66,Akt; Apoptosis; Autophagy,Apoptosis; Autophagy; PI3K/Akt/mTOR,Perifosine is an oral Akt inhibitor which inhibits proliferation of different tumor cell lines with IC50s of 0.6-8.9 μM.,C25H52NO4P,H2O : 100 mg/mL (216.61 mM; Need ultrasonic); DMSO : < 1 mg/mL (insoluble or slightly soluble); DMF : 1 mg/mL (2.17 mM; Need ultrasonic),10mM,Cancer,Phase 3,[O-]P(OC1CC[N+](C)(CC1)C)(OCCCCCCCCCCCCCCCCCC)=O
,,,,,,,,,,,,,,,,gli1,itraconazole,HY-L025-58,E06,HY-17514,Itraconazole,R51211,84625-61-6,705.63,Antibiotic; Autophagy; Bacterial; Cytochrome P450; Fungal; Hedgehog,Anti-infection; Autophagy; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor[1][2][3][4].",C35H38Cl2N8O4,DMSO : 6.25 mg/mL (8.86 mM; Need ultrasonic),2mM,Infection; Cancer,Launched,ClC1=C(C=CC(Cl)=C1)[C@@]2(O[C@@H](COC3=CC=C(N4CCN(C5=CC=C(N(C=NN6C(C)CC)C6=O)C=C5)CC4)C=C3)CO2)CN7C=NC=N7
,,,,,,,,,,,,,,,,gli1,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,gli1,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,gli1,glabrescione b,HY-L025-24,D08,HY-122590,Glabrescione B,,65893-94-9,450.52,Gli,Stem Cell/Wnt,"Glabrescione B is the first compound that binds the Hedgehog (Hh) modulator Gli1. Glabrescione B impairs its activity by interfering with Gli1-DNA interaction. Glabrescione B inhibits the growth of Hedgehog-dependent tumor cells, the self-renewal ability, and clonogenicity of tumor-derived stem cells[1][2].",C27H30O6,DMSO : 100 mg/mL (221.97 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C(C2=CC=C(OC/C=C(C)/C)C(OC/C=C(C)/C)=C2)=COC3=CC(OC)=CC(OC)=C13
,,,,,,,,,,,,,,,,gli1,genistein,HY-L025-45,H04,HY-14596,Genistein,NPI 031L,446-72-0,270.24,Apoptosis; Autophagy; EGFR; Endogenous Metabolite,Apoptosis; Autophagy; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,"Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.",C15H10O5,DMSO : ≥ 100 mg/mL (370.04 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 4,OC1=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,gli1,gant 61,HY-L025-41,C05,HY-13901,GANT 61,NSC 136476,500579-04-4,429.6,Autophagy; Gli,Autophagy; Stem Cell/Wnt,GANT 61 is an inhibitor of Gli1 and Gli2 targeting the Hedgehog/GLI pathway.,C27H35N5,DMSO : 25 mg/mL (58.19 mM; Need ultrasonic); Ethanol : 66.67 mg/mL (155.19 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C)C1=CC=CC=C1CN2C(C3=CC=NC=C3)N(CC4=CC=CC=C4N(C)C)CCC2
,,,,,,,,,,,,,,,,gli1,gdc 0449,HY-L025-10,A09,HY-10440,Vismodegib,GDC-0449,879085-55-9,421.3,Autophagy; Hedgehog,Autophagy; Stem Cell/Wnt,"Vismodegib (GDC-0449) is an orally active hedgehog pathway inhibitor with an IC50 of 3 nM. Vismodegib also inhibits P-gp, ABCG2 with IC50 values of 3.0 μM and 1.4 μM, respectively[1][2].",C19H14Cl2N2O3S,DMSO : 50 mg/mL (118.68 mM; Need ultrasonic); Ethanol : 3.33 mg/mL (7.90 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CC=C(C=C1Cl)S(=O)(C)=O)NC2=CC=C(C(C3=NC=CC=C3)=C2)Cl
,,,,,,,,,,,,,,,,gli1,vismodegib,HY-L025-10,A09,HY-10440,Vismodegib,GDC-0449,879085-55-9,421.3,Autophagy; Hedgehog,Autophagy; Stem Cell/Wnt,"Vismodegib (GDC-0449) is an orally active hedgehog pathway inhibitor with an IC50 of 3 nM. Vismodegib also inhibits P-gp, ABCG2 with IC50 values of 3.0 μM and 1.4 μM, respectively[1][2].",C19H14Cl2N2O3S,DMSO : 50 mg/mL (118.68 mM; Need ultrasonic); Ethanol : 3.33 mg/mL (7.90 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CC=C(C=C1Cl)S(=O)(C)=O)NC2=CC=C(C(C3=NC=CC=C3)=C2)Cl
,,,,,,,,,,,,,,,,gli1,cyclopamine,HY-L025-57,F03,HY-17024,Cyclopamine,11-Deoxojervine,4449-51-8,411.62,Endogenous Metabolite; Hedgehog; Smo,Metabolic Enzyme/Protease; Stem Cell/Wnt,Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay. Cyclopamine is also a selective Smo inhibitor.,C27H41NO2,DMSO : 10 mg/mL (24.29 mM; ultrasonic and warming and heat to 80°C); Ethanol : 20 mg/mL (48.59 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CC1=C2[C@@]([C@@]3([H])[C@]([C@@]4(C(C[C@@H](O)CC4)=CC3)C)([H])C2)([H])CC[C@@]15[C@@H]([C@@]6([H])[C@](C[C@H](C)CN6)([H])O5)C
,,,,,,,,,,,,,,,,nanog,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,nanog,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,nanog,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,nanog,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,aurka,mln8054,HY-L025-6,D04,HY-10180,MLN8054,,869363-13-3,476.86,Aurora Kinase,Cell Cycle/DNA Damage; Epigenetics,"MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC50 of 4 nM.",C25H15ClF2N4O2,DMSO : 20.83 mg/mL (43.68 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 1,O=C(C1=CC=C(NC2=NC3=C(CN=C(C4=C3C=CC(Cl)=C4)C5=C(F)C=CC=C5F)C=N2)C=C1)O
,,,,,,,,,,,,,,,,aurka,reversine,HY-L025-46,G02,HY-14711,Reversine,,656820-32-5,393.49,Aurora Kinase; Autophagy,Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Reversine is a novel class of ATP-competitive Aurora kinase inhibitor with IC50s of 400, 500 and 400 nM for Aurora A, Aurora B and Aurora C, respectively.",C21H27N7O,DMSO : 20 mg/mL (50.83 mM; Need ultrasonic),10mM,Cancer,No Development Reported,C1(NC2=CC=C(N3CCOCC3)C=C2)=NC(NC4CCCCC4)=C5C(NC=N5)=N1
,,,,,,,,,,,,,,,,aurka,alisertib,HY-L025-14,B10,HY-10971,Alisertib,MLN 8237,1028486-01-2,518.92,Apoptosis; Aurora Kinase; Autophagy,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity[1][2][3].",C27H20ClFN4O4,DMSO : 25 mg/mL (48.18 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(C1=CC=C(C=C1OC)NC2=NC=C3CN=C(C4=CC(Cl)=CC=C4C3=N2)C5=C(C=CC=C5F)OC)O
,,,,,,,,,,,,,,,,epcam,dapt,HY-L025-31,F03,HY-13027,DAPT,GSI-IX,208255-80-5,432.46,Amyloid-β; Apoptosis; Autophagy; Notch; γ-secretase,Apoptosis; Autophagy; Neuronal Signaling; Stem Cell/Wnt,"DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment[1][2].",C23H26F2N2O4,DMSO : 62.5 mg/mL (144.52 mM; Need ultrasonic); Ethanol : 10 mg/mL (23.12 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,No Development Reported,FC1=CC(F)=CC(CC(N[C@H](C(N[C@H](C(OC(C)(C)C)=O)C2=CC=CC=C2)=O)C)=O)=C1
,,,,,,,,,,,,,,,,epcam,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,klf4,kenpaullone,HY-L025-25,B09,HY-12302,Kenpaullone,9-Bromopaullone; NSC-664704,142273-20-9,327.18,CDK; GSK-3,Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"Kenpaullone is a potent inhibitor of CDK1/cyclin B and GSK-3β, with IC50s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC50s of 0.68 μM, 7.5 μM, 0.85 μM, respectively. Kenpaullone, a small molecule inhibitor of KLF4, reduces self-renewal of breast cancer stem cells and cell motility in vitro.",C16H11BrN2O,DMSO : ≥ 35 mg/mL (106.97 mM),10mM,Cancer,No Development Reported,O=C1NC2=CC=CC=C2C(NC3=C4C=C(Br)C=C3)=C4C1
,,,,,,,,,,,,,,,,foxm1,dim,HY-L025-54,A02,HY-15758,"3,3'-Diindolylmethane",DIM; Arundine; HB 236,5/4/68,246.31,Androgen Receptor; Autophagy,Autophagy; Vitamin D Related/Nuclear Receptor,"3,3'-Diindolylmethane is a strong, pure androgen receptor (AR) antagonist.",C17H14N2,DMSO : ≥ 100 mg/mL (405.99 mM),10mM,Cancer,Phase 4,C1(CC2=CNC3=C2C=CC=C3)=CNC4=C1C=CC=C4
,,,,,,,,,,,,,,,,foxm1,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,foxm1,fdi 6,HY-L025-18,C03,HY-112721,FDI-6,,313380-27-7,437.43,Others,Others,"FDI-6 is an inhibitor of FOXM1. FDI-6 binds directly to FOXM1 protein, to displace FOXM1 from genomic targets in MCF-7 breast cancer cells, and induce concomitant transcriptional down-regulation.",C19H11F4N3OS2,DMSO : 41.67 mg/mL (95.26 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C(C1=C(N)C2=C(C(F)(F)F)C=C(C3=CC=CS3)N=C2S1)NC4=CC=C(F)C=C4
,,,,,,,,,,,,,,,,foxm1,bortezomib,HY-L025-7,E07,HY-10227,Bortezomib,PS-341; LDP-341; NSC 681239,179324-69-7,384.24,Apoptosis; Autophagy; NF-κB; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].",C19H25BN4O4,DMSO : 50 mg/mL (130.13 mM; Need ultrasonic); Ethanol : 66.67 mg/mL (173.51 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
,,,,,,,,,,,,,,,,wee1,mk 1775,HY-L025-14,D02,HY-10993,Adavosertib,AZD1775; MK-1775,955365-80-7,500.6,Wee1,Cell Cycle/DNA Damage,Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC50 of 5.2 nM.,C27H32N8O2,DMSO : 125 mg/mL (249.70 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1N(N(C2=NC(NC3=CC=C(C=C3)N4CCN(CC4)C)=NC=C21)C5=NC(C(O)(C)C)=CC=C5)CC=C
,,,,,,,,,,,,,,,,wee1,pd0166285,HY-L025-41,F09,HY-13925,PD0166285,,185039-89-8,512.43,Apoptosis; Wee1,Apoptosis; Cell Cycle/DNA Damage,"PD0166285, a substrate of P-gp, is a WEE1 inhibitor and a weak Myt1 inhibitor with IC50 values of 24 and 72 nM, respectively. PD0166285 exhibits an IC50 of 3.433 μM for Chk1[1].",C26H27Cl2N5O2,DMSO : 50 mg/mL (97.57 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1N(C)C2=NC(NC3=CC=C(OCCN(CC)CC)C=C3)=NC=C2C=C1C4=C(Cl)C=CC=C4Cl
,,,,,,,,,,,,,,,,wee1,adavosertib,HY-L025-14,D02,HY-10993,Adavosertib,AZD1775; MK-1775,955365-80-7,500.6,Wee1,Cell Cycle/DNA Damage,Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC50 of 5.2 nM.,C27H32N8O2,DMSO : 125 mg/mL (249.70 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1N(N(C2=NC(NC3=CC=C(C=C3)N4CCN(CC4)C)=NC=C21)C5=NC(C(O)(C)C)=CC=C5)CC=C
,,,,,,,,,,,,,,,,wee1,azd1775,HY-L025-14,D02,HY-10993,Adavosertib,AZD1775; MK-1775,955365-80-7,500.6,Wee1,Cell Cycle/DNA Damage,Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC50 of 5.2 nM.,C27H32N8O2,DMSO : 125 mg/mL (249.70 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1N(N(C2=NC(NC3=CC=C(C=C3)N4CCN(CC4)C)=NC=C21)C5=NC(C(O)(C)C)=CC=C5)CC=C
,,,,,,,,,,,,,,,,ddr,minocycline,HY-L025-58,A05,HY-17412,Minocycline (hydrochloride),,13614-98-7,493.94,Antibiotic; Apoptosis; Bacterial; Calcium Channel; HIF/HIF Prolyl-Hydroxylase; MDM-2/p53; Potassium Channel,Anti-infection; Apoptosis; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling,"Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect[1][2][3][4][5][6][7].",C23H28ClN3O7,DMSO : 19.23 mg/mL (38.93 mM; Need ultrasonic); H2O : 10 mg/mL (20.25 mM; Need ultrasonic),10mM,Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease,Launched,OC1=C(C(N)=O)C([C@@]2(O)C(O)=C3C(C4=C(O)C=CC(N(C)C)=C4C[C@@]3([H])C[C@@]2([H])[C@@H]1N(C)C)=O)=O.Cl
,,,,,,,,,,,,,,,,ddr,imatinib,HY-L025-64,D06,HY-50946,Imatinib (Mesylate),STI571 (Mesylate); CGP-57148B (Mesylate),220127-57-1,589.71,Autophagy; Bcr-Abl; c-Kit; PDGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.",C30H35N7O4S,DMSO : 125 mg/mL (211.97 mM; Need ultrasonic); H2O : ≥ 50 mg/mL (84.79 mM),10mM,Cancer,Launched,O=S(O)(C)=O.O=C(NC1=CC=C(C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)C)C4=CC=C(CN5CCN(CC5)C)C=C4
,,,,,,,,,,,,,,,,smo,lde225,HY-L025-56,D11,HY-16582A,Sonidegib,Erismodegib; LDE225; NVP-LDE225,956697-53-3,485.5,Smo,Stem Cell/Wnt,"Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively[1].",C26H26F3N3O3,DMSO : 50 mg/mL (102.99 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=C(C)C(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)NC3=CC=C(N=C3)N4C[C@@H](C)O[C@@H](C)C4
,,,,,,,,,,,,,,,,smo,gant 61,HY-L025-41,C05,HY-13901,GANT 61,NSC 136476,500579-04-4,429.6,Autophagy; Gli,Autophagy; Stem Cell/Wnt,GANT 61 is an inhibitor of Gli1 and Gli2 targeting the Hedgehog/GLI pathway.,C27H35N5,DMSO : 25 mg/mL (58.19 mM; Need ultrasonic); Ethanol : 66.67 mg/mL (155.19 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C)C1=CC=CC=C1CN2C(C3=CC=NC=C3)N(CC4=CC=CC=C4N(C)C)CCC2
,,,,,,,,,,,,,,,,smo,salinomycin,HY-L025-58,B06,HY-17439,Salinomycin (sodium salt),Salinomycin sodium; Sodium salinomycin,55721-31-8,772.98,Antibiotic; Apoptosis; Autophagy; Bacterial; Parasite; Wnt; β-catenin,Anti-infection; Apoptosis; Autophagy; Stem Cell/Wnt,"Salinomycin sodium salt (Salinomycin sodium), an antibiotic potassium ionophore, is a potent inhibitor of Wnt/β-catenin signaling. Salinomycin sodium salt (Salinomycin sodium) acts on the Wnt/Fzd/LRP complex, blocks Wnt-induced LRP6 phosphorylation, and causes degradation of the LRP6 protein. Salinomycin sodium salt (Salinomycin sodium) shows selective activity against human cancer stem cells[1][2][3].",C42H69NaO11,DMSO : 100 mg/mL (129.37 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble),10mM,Cancer,No Development Reported,[H][C@]1([C@](C)(CC2)O[C@]32[C@H](O)C=C[C@]4(O[C@]([H])([C@@H](CC)C([C@@H](C)[C@@H](O)[C@H](C)[C@]5([H])O[C@]([C@@H](CC)C(O[Na])=O)([H])CC[C@@H]5C)=O)[C@@H](C)C[C@H]4C)O3)CC[C@@](CC)(O)[C@H](C)O1
,,,,,,,,,,,,,,,,smo,nvp lde225,HY-L025-56,D11,HY-16582A,Sonidegib,Erismodegib; LDE225; NVP-LDE225,956697-53-3,485.5,Smo,Stem Cell/Wnt,"Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively[1].",C26H26F3N3O3,DMSO : 50 mg/mL (102.99 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=C(C)C(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)NC3=CC=C(N=C3)N4C[C@@H](C)O[C@@H](C)C4
,,,,,,,,,,,,,,,,smo,gdc 0449,HY-L025-10,A09,HY-10440,Vismodegib,GDC-0449,879085-55-9,421.3,Autophagy; Hedgehog,Autophagy; Stem Cell/Wnt,"Vismodegib (GDC-0449) is an orally active hedgehog pathway inhibitor with an IC50 of 3 nM. Vismodegib also inhibits P-gp, ABCG2 with IC50 values of 3.0 μM and 1.4 μM, respectively[1][2].",C19H14Cl2N2O3S,DMSO : 50 mg/mL (118.68 mM; Need ultrasonic); Ethanol : 3.33 mg/mL (7.90 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CC=C(C=C1Cl)S(=O)(C)=O)NC2=CC=C(C(C3=NC=CC=C3)=C2)Cl
,,,,,,,,,,,,,,,,smo,bms 833923,HY-L025-40,B09,HY-13809,BMS-833923,XL-139,1059734-66-5,473.57,Apoptosis; Smo,Apoptosis; Stem Cell/Wnt,"BMS-833923 (XL-139) is an orally bioavailable small-molecule inhibitor of Smoothened  with potential antineoplastic activity;  inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner with an IC50 of 21 nM.
IC50 Value: 6-35 nM [1]
Target: Smoothened
SMO antagonist BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway.
in vitro: In vitro, BMS-833923 inhibits the expression of downstream effectors in the HH pathway (GLI1 and PTCH1) in cell lines that express wild-type SMO and those which express activated mutant forms of SMO (IC50values of 6-35 nM). In FACS-based binding assays, BMS-833923 inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner with an IC50 of 21 nM [1]. 
in vivo: Pharmacodynamic studies show that BMS-833923 robustly inhibits HH pathway activity with along duration of action after a single oral dose in medulloblastoma and pancreatic carcinoma xenograft models. The pharmacodynamic effects of BMS-833923 observed in these models translate into tumor growth inhibition at well-tolerated doses [1].
Clinical trial: Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923). Phase 2",C30H27N5O,DMSO : 50 mg/mL (105.58 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC(CNC)=CC=C1C)C2=CC=C(NC3=NC(C4=CC=CC=C4)=C5C=CC=CC5=N3)C=C2
,,,,,,,,,,,,,,,,smo,sonidegib,HY-L025-56,D11,HY-16582A,Sonidegib,Erismodegib; LDE225; NVP-LDE225,956697-53-3,485.5,Smo,Stem Cell/Wnt,"Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively[1].",C26H26F3N3O3,DMSO : 50 mg/mL (102.99 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=C(C)C(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)NC3=CC=C(N=C3)N4C[C@@H](C)O[C@@H](C)C4
,,,,,,,,,,,,,,,,smo,vismodegib,HY-L025-10,A09,HY-10440,Vismodegib,GDC-0449,879085-55-9,421.3,Autophagy; Hedgehog,Autophagy; Stem Cell/Wnt,"Vismodegib (GDC-0449) is an orally active hedgehog pathway inhibitor with an IC50 of 3 nM. Vismodegib also inhibits P-gp, ABCG2 with IC50 values of 3.0 μM and 1.4 μM, respectively[1][2].",C19H14Cl2N2O3S,DMSO : 50 mg/mL (118.68 mM; Need ultrasonic); Ethanol : 3.33 mg/mL (7.90 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CC=C(C=C1Cl)S(=O)(C)=O)NC2=CC=C(C(C3=NC=CC=C3)=C2)Cl
,,,,,,,,,,,,,,,,smo,itraconazole,HY-L025-58,E06,HY-17514,Itraconazole,R51211,84625-61-6,705.63,Antibiotic; Autophagy; Bacterial; Cytochrome P450; Fungal; Hedgehog,Anti-infection; Autophagy; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor[1][2][3][4].",C35H38Cl2N8O4,DMSO : 6.25 mg/mL (8.86 mM; Need ultrasonic),2mM,Infection; Cancer,Launched,ClC1=C(C=CC(Cl)=C1)[C@@]2(O[C@@H](COC3=CC=C(N4CCN(C5=CC=C(N(C=NN6C(C)CC)C6=O)C=C5)CC4)C=C3)CO2)CN7C=NC=N7
,,,,,,,,,,,,,,,,smo,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,smo,cyclopamine,HY-L025-57,F03,HY-17024,Cyclopamine,11-Deoxojervine,4449-51-8,411.62,Endogenous Metabolite; Hedgehog; Smo,Metabolic Enzyme/Protease; Stem Cell/Wnt,Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay. Cyclopamine is also a selective Smo inhibitor.,C27H41NO2,DMSO : 10 mg/mL (24.29 mM; ultrasonic and warming and heat to 80°C); Ethanol : 20 mg/mL (48.59 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CC1=C2[C@@]([C@@]3([H])[C@]([C@@]4(C(C[C@@H](O)CC4)=CC3)C)([H])C2)([H])CC[C@@]15[C@@H]([C@@]6([H])[C@](C[C@H](C)CN6)([H])O5)C
,,,,,,,,,,,,,,,,smo,jervine,HY-L025-76,F06,HY-N0836,Jervine,11-Ketocyclopamine,469-59-0,425.6,Hedgehog; Smo,Stem Cell/Wnt,Jervine (11-Ketocyclopamine) is a potent Hedgehog (Hh) inhibitor with an IC50 of 500-700 nM[1]. Jervine is a natural teratogenic sterodial alkaloid from rhizomes of Veratrum nigrum. Jervine has anti-inflammatory and antioxidant properties[2].,C27H39NO3,DMSO : 1 mg/mL (2.35 mM; Need ultrasonic),2mM,Cancer; Inflammation/Immunology,No Development Reported,O=C1[C@]2([H])[C@]3(C)C(C[C@@H](O)CC3)=CC[C@@]2([H])[C@]4([H])CC[C@]5(O[C@@]6([H])[C@@]([C@H]5C)([H])NC[C@@H](C)C6)C(C)=C41
,,,,,,,,,,,,,,,,smo,hhantag,HY-L025-51,G11,HY-15412,HhAntag,,496794-70-8,450.92,Smo,Stem Cell/Wnt,"HhAntag is a specific, potent and orally active small molecule SMO antagonist of the Hh pathway[1].",C24H23ClN4O3,DMSO : ≥ 100 mg/mL (221.77 mM),10mM,Cancer,No Development Reported,O=C(NC1=CC=C(Cl)C(C2=NC3=CC=C(N(C)C)C=C3N2)=C1)C4=CC(OC)=CC(OC)=C4
,,,,,,,,,,,,,,,,twist1,harmine,HY-L025-76,A07,HY-N0737A,Harmine,Telepathine,442-51-3,212.25,5-HT Receptor; DYRK,GPCR/G Protein; Neuronal Signaling; Protein Tyrosine Kinase/RTK,"Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK)  inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT2A serotonin receptor, with an Ki of 397 nM[1].",C13H12N2O,DMSO : ≥ 30 mg/mL (141.34 mM),10mM,Cancer; Neurological Disease,Phase 1,CC1=NC=CC2=C1NC3=C2C=CC(OC)=C3
,,,,,,,,,,,,,,,,twist1,metformin,HY-L025-69,A07,HY-B0627,Metformin,"1,1-Dimethylbiguanide",657-24-9,129.16,AMPK; Autophagy; Mitophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy[1].",C4H11N5,H2O : 50 mg/mL (387.12 mM; Need ultrasonic); DMSO : 20.83 mg/mL (161.27 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
,,,,,,,,,,,,,,,,twist1,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,cmyc,jq1,HY-L025-31,F06,HY-13030,(+)-JQ-1,JQ1,1268524-70-4,456.99,Autophagy; Epigenetic Reader Domain; Ligands for Target Protein for PROTAC,Autophagy; Epigenetics; PROTAC,"(+)-JQ-1 (JQ1) is a potent, specific, and reversible BET bromodomain inhibitor, with IC50s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2))[1]. (+)-JQ-1 also activates autophagy[2].",C23H25ClN4O2S,DMSO : ≥ 45 mg/mL (98.47 mM),10mM,Cancer,No Development Reported,O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C
,,,,,,,,,,,,,,,,skp2,bortezomib,HY-L025-7,E07,HY-10227,Bortezomib,PS-341; LDP-341; NSC 681239,179324-69-7,384.24,Apoptosis; Autophagy; NF-κB; Proteasome,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].",C19H25BN4O4,DMSO : 50 mg/mL (130.13 mM; Need ultrasonic); Ethanol : 66.67 mg/mL (173.51 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
,,,,,,,,,,,,,,,,skp2,imatinib,HY-L025-64,D06,HY-50946,Imatinib (Mesylate),STI571 (Mesylate); CGP-57148B (Mesylate),220127-57-1,589.71,Autophagy; Bcr-Abl; c-Kit; PDGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.",C30H35N7O4S,DMSO : 125 mg/mL (211.97 mM; Need ultrasonic); H2O : ≥ 50 mg/mL (84.79 mM),10mM,Cancer,Launched,O=S(O)(C)=O.O=C(NC1=CC=C(C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)C)C4=CC=C(CN5CCN(CC5)C)C=C4
,,,,,,,,,,,,,,,,skp2,ly294002,HY-L025-4,F05,HY-10108,LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
,,,,,,,,,,,,,,,,skp2,szl p1 41,HY-L025-1,F10,HY-100237,SZL P1-41,,222716-34-9,420.52,Apoptosis; E1/E2/E3 Enzyme,Apoptosis; Metabolic Enzyme/Protease,"SZL P1-41 is a specific Skp2 inhibitor, binds to the F-box domain of Skp2 to prevent Skp1 association and Skp2 SCF complex formation. SZL P1-41, like Skp2 deficiency, augments p27-mediated apoptosis/senescence, while it impairs Akt-driven glycolysis. Anti-tumor activities[1][2].",C24H24N2O3S,DMSO : 2.5 mg/mL (5.95 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C1C(C2=NC3=CC=CC=C3S2)=COC4=C(CN5CCCCC5)C(O)=C(CC)C=C14
,,,,,,,,,,,,,,,,skp2,smip004,HY-L025-53,E05,HY-15694,SMIP004,,143360-00-3,205.3,Apoptosis; E1/E2/E3 Enzyme,Apoptosis; Metabolic Enzyme/Protease,"SMIP004 is a SKP2 E3 ligase inhibitor, which downregulates SKP2 and to stabilise p27. SMIP004 is a cancer cell selective apoptosis inducer of human prostate cancer cells[1][2].",C13H19NO,DMSO : ≥ 100 mg/mL (487.09 mM),10mM,Cancer,No Development Reported,CC1=C(NC(C)=O)C=CC(CCCC)=C1
,,,,,,,,,,,,,,,,skp2,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,skp2,troglitazone,HY-L025-64,D02,HY-50935,Troglitazone,CS-045,97322-87-7,441.54,Apoptosis; Autophagy; Ferroptosis; PPAR,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor,"Troglitazone is a PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine?PPARγ receptor, respectively.",C24H27NO5S,DMSO : 125 mg/mL (283.10 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(SC1CC(C=C2)=CC=C2OCC3(C)OC(C(CC3)=C4C)=C(C)C(C)=C4O)NC1=O
,,,,,,,,,,,,,,,,skp2,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,yap taz,verteporfin,HY-L025-66,F07,HY-B0146,Verteporfin,CL 318952,129497-78-5,718.79,Apoptosis; Autophagy; YAP,Apoptosis; Autophagy; Stem Cell/Wnt,Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis[1]. Verteporfinis an autophagy inhibitor that blocks?autophagy?at an early stage by inhibiting autophagosome formation[3].,C41H42N4O8,DMF : 10 mg/mL (13.91 mM; ultrasonic and warming and heat to 60°C); DMSO : 100 mg/mL (139.12 mM; Need ultrasonic),10mM,Cancer,Launched,C[C@]1(/C2=C/C(N3)=C4C)C(C(/C=C(C(C)=C/5C=C)\NC5=C/C6=N/C(C(CCC(OC)=O)=C6C)=C\C3=C4CCC(O)=O)=N2)=CC=C(C(OC)=O)[C@H]1C(OC)=O.C[C@]7(/C8=C/C(N9)=C%10C)C(C(/C=C(C(C)=C/%11C=C)\NC%11=C/C%12=N/C(C(CCC(O)=O)=C%12C)=C\C9=C%10CCC(OC)=O)=N8)=CC=C(C(OC)=O)[C@H]7C(OC)=O
,,,,,,,,,,,,,,,,klf5,ml264,HY-L025-63,A07,HY-19994,ML264,,1550008-55-3,384.88,KLF,MAPK/ERK Pathway,ML264 is an antitumor agent that potently and selectively inhibits Krüppel-like factor five (KLF5) expression.,C17H21ClN2O4S,DMSO : ≥ 100 mg/mL (259.82 mM),10mM,Cancer,No Development Reported,O=C(NCC(N(C)C(CC1)CCS1(=O)=O)=O)/C=C/C2=CC=CC(Cl)=C2
,,,,,,,,,,,,,,,,iap,bv6,HY-L025-56,G10,HY-16701,BV6,,1001600-56-1,1205.57,IAP,Apoptosis,"BV6 is an antagonist of cIAP1 and XIAP, members of the inhibitors of apoptosis (IAP) family.",C70H96N10O8,DMSO : ≥ 58 mg/mL (48.11 mM),10mM,Cancer,No Development Reported,O=C(NCCCCCCNC([C@@H](NC([C@H](CCC1)N1C([C@H](C2CCCCC2)NC([C@H](C)NC)=O)=O)=O)C(C3=CC=CC=C3)C4=CC=CC=C4)=O)[C@@H](NC([C@H](CCC5)N5C([C@H](C6CCCCC6)NC([C@H](C)NC)=O)=O)=O)C(C7=CC=CC=C7)C8=CC=CC=C8
,,,,,,,,,,,,,,,,iap,birinapant,HY-L025-56,E06,HY-16591,Birinapant,TL32711,1260251-31-7,806.94,Apoptosis; HIV; IAP,Anti-infection; Apoptosis,"Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist for XIAP and cIAP1 with Kds of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in intact cells, which results in formation of a RIPK1: caspase-8 complex, caspase-8 activation, and induction of tumor cell death. Birinapant (TL32711) targets TRAF2-associated cIAPs and abrogates TNF-induced NF-κB activation.",C42H56F2N8O6,DMSO : 125 mg/mL (154.91 mM; Need ultrasonic),10mM,Cancer,Phase 2,FC1=CC2=C(C=C1)C(C[C@H]3N(C([C@@H](NC([C@@H](NC)C)=O)CC)=O)C[C@@H](O)C3)=C(C(N4)=C(C[C@H]5N(C([C@@H](NC([C@@H](NC)C)=O)CC)=O)C[C@@H](O)C5)C6=C4C=C(F)C=C6)N2
,,,,,,,,,,,,,,,,iap,azd5582,HY-L025-28,B10,HY-12600,AZD5582,,1258392-53-8,1015.29,Apoptosis; IAP,Apoptosis,"AZD5582 is an antagonist of the inhibitor of apoptosis proteins (IAPs), which binds to the BIR3 domains cIAP1, cIAP2, and XIAP with IC50s of 15, 21, and 15 nM, respectively. AZD5582 induces apoptosis[1].",C58H78N8O8,DMSO : ≥ 66.25 mg/mL (65.25 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,No Development Reported,CN[C@@H](C)C(N[C@H](C(N1[C@H](C(N[C@H]2C3=CC=CC=C3C[C@H]2OCC#CC#CCO[C@H]4[C@@H](NC([C@@H]5CCCN5C([C@@H](NC([C@H](C)NC)=O)C6CCCCC6)=O)=O)C(C=CC=C7)=C7C4)=O)CCC1)=O)C8CCCCC8)=O
,,,,,,,,,,,,,,,,iap,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,iap,at 406,HY-L025-52,A11,HY-15454,Xevinapant,AT-406; Debio 1143; SM-406,1071992-99-8,561.71,Apoptosis; IAP,Apoptosis,"Xevinapant (AT-406) is a potent and orally bioavailable Smac mimetic and an antagonist of IAPs, and it binds to XIAP, cIAP1, and cIAP2 proteins with Ki of 66.4, 1.9, and 5.1 nM, respectively.",C32H43N5O4,DMSO : 100 mg/mL (178.03 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C([C@@H]1CC[C@@](CCN(C(CC(C)C)=O)C[C@@H]2NC([C@@H](NC)C)=O)([H])N1C2=O)NC(C3=CC=CC=C3)C4=CC=CC=C4
,,,,,,,,,,,,,,,,iap,lcl161,HY-L025-52,F05,HY-15518,LCL161,,1005342-46-0,500.63,IAP,Apoptosis,"LCL161 is a IAP inhibitor which inhibits XIAP in HEK293 cell and cIAP1 in MDA-MB-231 cell with IC50s of 35 and 0.4 nM, respectively.",C26H33FN4O3S,DMSO : 100 mg/mL (199.75 mM; Need ultrasonic),10mM,Cancer,Phase 2,C[C@H](NC)C(N[C@@H](C1CCCCC1)C(N2[C@H](C3=NC(C(C4=CC=C(F)C=C4)=O)=CS3)CCC2)=O)=O
,,,,,,,,,,,,,,,,iap,gdc 0152,HY-L025-37,H09,HY-13638,GDC-0152,,873652-48-3,498.64,IAP,Apoptosis,"GDC-0152 is a potent IAPs inhibitor, and binds to the BIR3 domains of XIAP, cIAP1, cIAP2 and the BIR domain of ML-IAP with Ki values of 28 nM, 17 nM, 43 nM and 14 nM, respectively.",C25H34N6O3S,Ethanol : 50 mg/mL (100.27 mM; Need ultrasonic); DMSO : 50 mg/mL (100.27 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(N1[C@H](C(NC2=C(C3=CC=CC=C3)N=NS2)=O)CCC1)[C@H](C4CCCCC4)NC([C@H](C)NC)=O
,,,,,,,,,,,,,,,,foxp3,melatonin,HY-L025-66,B09,HY-B0075,Melatonin,N-Acetyl-5-methoxytryptamine,73-31-4,232.28,Apoptosis; Autophagy; Endogenous Metabolite; Melatonin Receptor; Mitophagy,Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling,Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties[1][2][3]. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation[4]. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress[5].,C13H16N2O2,DMSO : 100 mg/mL (430.51 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (53.81 mM; Need ultrasonic); H2O : 1.1 mg/mL (4.74 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,CC(NCCC1=CNC2=C1C=C(OC)C=C2)=O
,,,,,,,,,,,,,,,,foxp3,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,foxp3,dapt,HY-L025-31,F03,HY-13027,DAPT,GSI-IX,208255-80-5,432.46,Amyloid-β; Apoptosis; Autophagy; Notch; γ-secretase,Apoptosis; Autophagy; Neuronal Signaling; Stem Cell/Wnt,"DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment[1][2].",C23H26F2N2O4,DMSO : 62.5 mg/mL (144.52 mM; Need ultrasonic); Ethanol : 10 mg/mL (23.12 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,No Development Reported,FC1=CC(F)=CC(CC(N[C@H](C(N[C@H](C(OC(C)(C)C)=O)C2=CC=CC=C2)=O)C)=O)=C1
,,,,,,,,,,,,,,,,foxp3,baicalin,HY-L025-73,B03,HY-N0197,Baicalin,Baicalein 7-O-β-D-glucuronide,21967-41-9,446.36,Autophagy; HIV; NF-κB,Anti-infection; Autophagy; NF-κB,"Baicalin, as a flavonoid glycoside, is an allosteric carnitine palmityl transferase 1 (CPT1) activator. Baicalin reduces the expression of NF-κB[1][2][3].",C21H18O11,DMSO : ≥ 100 mg/mL (224.03 mM); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Inflammation/Immunology; Cancer,Launched,O[C@H]([C@H]([C@@H]([C@@H](C(O)=O)O1)O)O)[C@@H]1OC2=C(O)C(O)=C3C(C=C(C4=CC=CC=C4)OC3=C2)=O
,,,,,,,,,,,,,,,,foxp3,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,foxp3,rapamycin,HY-L025-7,D11,HY-10219,Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 125 mg/mL (136.74 mM; Need ultrasonic); Ethanol : 50 mg/mL (54.69 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
,,,,,,,,,,,,,,,,smoothened,sonidegib,HY-L025-56,D11,HY-16582A,Sonidegib,Erismodegib; LDE225; NVP-LDE225,956697-53-3,485.5,Smo,Stem Cell/Wnt,"Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively[1].",C26H26F3N3O3,DMSO : 50 mg/mL (102.99 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=C(C)C(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)NC3=CC=C(N=C3)N4C[C@@H](C)O[C@@H](C)C4
,,,,,,,,,,,,,,,,smoothened,bms 833923,HY-L025-40,B09,HY-13809,BMS-833923,XL-139,1059734-66-5,473.57,Apoptosis; Smo,Apoptosis; Stem Cell/Wnt,"BMS-833923 (XL-139) is an orally bioavailable small-molecule inhibitor of Smoothened  with potential antineoplastic activity;  inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner with an IC50 of 21 nM.
IC50 Value: 6-35 nM [1]
Target: Smoothened
SMO antagonist BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway.
in vitro: In vitro, BMS-833923 inhibits the expression of downstream effectors in the HH pathway (GLI1 and PTCH1) in cell lines that express wild-type SMO and those which express activated mutant forms of SMO (IC50values of 6-35 nM). In FACS-based binding assays, BMS-833923 inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner with an IC50 of 21 nM [1]. 
in vivo: Pharmacodynamic studies show that BMS-833923 robustly inhibits HH pathway activity with along duration of action after a single oral dose in medulloblastoma and pancreatic carcinoma xenograft models. The pharmacodynamic effects of BMS-833923 observed in these models translate into tumor growth inhibition at well-tolerated doses [1].
Clinical trial: Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923). Phase 2",C30H27N5O,DMSO : 50 mg/mL (105.58 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC(CNC)=CC=C1C)C2=CC=C(NC3=NC(C4=CC=CC=C4)=C5C=CC=CC5=N3)C=C2
,,,,,,,,,,,,,,,,smoothened,lde225,HY-L025-56,D11,HY-16582A,Sonidegib,Erismodegib; LDE225; NVP-LDE225,956697-53-3,485.5,Smo,Stem Cell/Wnt,"Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively[1].",C26H26F3N3O3,DMSO : 50 mg/mL (102.99 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=C(C)C(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)NC3=CC=C(N=C3)N4C[C@@H](C)O[C@@H](C)C4
,,,,,,,,,,,,,,,,smoothened,glasdegib,HY-L025-56,A02,HY-16391,Glasdegib,PF-04449913,1095173-27-5,374.44,Smo,Stem Cell/Wnt,Glasdegib (PF-04449913) is a potent and orally bioavailable smoothened inhibitor. Glasdegib (PF-04449913) binds to human SMO (amino acids 181-787) with an IC50 of 4 nM[1].,C21H22N6O,DMSO : ≥ 83.33 mg/mL (222.55 mM),10mM,Cancer,Launched,O=C(NC1=CC=C(C#N)C=C1)N[C@H]2C[C@H](C3=NC4=CC=CC=C4N3)N(C)CC2
,,,,,,,,,,,,,,,,smoothened,itraconazole,HY-L025-58,E06,HY-17514,Itraconazole,R51211,84625-61-6,705.63,Antibiotic; Autophagy; Bacterial; Cytochrome P450; Fungal; Hedgehog,Anti-infection; Autophagy; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor[1][2][3][4].",C35H38Cl2N8O4,DMSO : 6.25 mg/mL (8.86 mM; Need ultrasonic),2mM,Infection; Cancer,Launched,ClC1=C(C=CC(Cl)=C1)[C@@]2(O[C@@H](COC3=CC=C(N4CCN(C5=CC=C(N(C=NN6C(C)CC)C6=O)C=C5)CC4)C=C3)CO2)CN7C=NC=N7
,,,,,,,,,,,,,,,,smoothened,gdc 0449,HY-L025-10,A09,HY-10440,Vismodegib,GDC-0449,879085-55-9,421.3,Autophagy; Hedgehog,Autophagy; Stem Cell/Wnt,"Vismodegib (GDC-0449) is an orally active hedgehog pathway inhibitor with an IC50 of 3 nM. Vismodegib also inhibits P-gp, ABCG2 with IC50 values of 3.0 μM and 1.4 μM, respectively[1][2].",C19H14Cl2N2O3S,DMSO : 50 mg/mL (118.68 mM; Need ultrasonic); Ethanol : 3.33 mg/mL (7.90 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CC=C(C=C1Cl)S(=O)(C)=O)NC2=CC=C(C(C3=NC=CC=C3)=C2)Cl
,,,,,,,,,,,,,,,,smoothened,vismodegib,HY-L025-10,A09,HY-10440,Vismodegib,GDC-0449,879085-55-9,421.3,Autophagy; Hedgehog,Autophagy; Stem Cell/Wnt,"Vismodegib (GDC-0449) is an orally active hedgehog pathway inhibitor with an IC50 of 3 nM. Vismodegib also inhibits P-gp, ABCG2 with IC50 values of 3.0 μM and 1.4 μM, respectively[1][2].",C19H14Cl2N2O3S,DMSO : 50 mg/mL (118.68 mM; Need ultrasonic); Ethanol : 3.33 mg/mL (7.90 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CC=C(C=C1Cl)S(=O)(C)=O)NC2=CC=C(C(C3=NC=CC=C3)=C2)Cl
,,,,,,,,,,,,,,,,smoothened,cyclopamine,HY-L025-57,F03,HY-17024,Cyclopamine,11-Deoxojervine,4449-51-8,411.62,Endogenous Metabolite; Hedgehog; Smo,Metabolic Enzyme/Protease; Stem Cell/Wnt,Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay. Cyclopamine is also a selective Smo inhibitor.,C27H41NO2,DMSO : 10 mg/mL (24.29 mM; ultrasonic and warming and heat to 80°C); Ethanol : 20 mg/mL (48.59 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CC1=C2[C@@]([C@@]3([H])[C@]([C@@]4(C(C[C@@H](O)CC4)=CC3)C)([H])C2)([H])CC[C@@]15[C@@H]([C@@]6([H])[C@](C[C@H](C)CN6)([H])O5)C
,,,,,,,,,,,,,,,,notch3,dapt,HY-L025-31,F03,HY-13027,DAPT,GSI-IX,208255-80-5,432.46,Amyloid-β; Apoptosis; Autophagy; Notch; γ-secretase,Apoptosis; Autophagy; Neuronal Signaling; Stem Cell/Wnt,"DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment[1][2].",C23H26F2N2O4,DMSO : 62.5 mg/mL (144.52 mM; Need ultrasonic); Ethanol : 10 mg/mL (23.12 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,No Development Reported,FC1=CC(F)=CC(CC(N[C@H](C(N[C@H](C(OC(C)(C)C)=O)C2=CC=CC=C2)=O)C)=O)=C1
,,,,,,,,,,,,,,,,pk,staurosporine,HY-L025-49,F07,HY-15141,Staurosporine,Antibiotic AM-2282; STS; AM-2282,62996-74-1,466.53,Antibiotic; Apoptosis; Bacterial; Fungal; PKA; PKC,Anti-infection; Apoptosis; Epigenetics; Stem Cell/Wnt; TGF-beta/Smad,"Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC50s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase respectively. Staurosporine also inhibits TAOK2 with an IC50 of 3 μM. Staurosporine is an apoptosis inducer[1][2][3][4][5].",C28H26N4O3,DMSO : 62.5 mg/mL (133.97 mM; Need ultrasonic),10mM,Cancer; Infection,No Development Reported,O=C(NC1)C2=C1C3=C(C4=C2C5=C(C=CC=C5)N4[C@H]6C[C@@H](NC)[C@@H](OC)[C@]7(C)O6)N7C8=CC=CC=C83
,,,,,,,,,,,,,,,,dnmts,zebularine,HY-L025-34,G10,HY-13420,Zebularine,NSC309132; 4-Deoxyuridine,10/6/90,228.2,Autophagy; DNA Methyltransferase,Autophagy; Epigenetics,Zebularine (NSC309132; 4-Deoxyuridine) is a DNA methyltransferase inhibitor. Zebularine also inhibits cytidine deaminase with a Ki of 0.95 μM.,C9H12N2O5,DMSO : ≥ 100 mg/mL (438.21 mM); H2O : 50 mg/mL (219.11 mM; Need ultrasonic),10mM,Cancer,No Development Reported,OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=CC=C2)=O)O1
,,,,,,,,,,,,,,,,dnmts,decitabine,HY-L025-65,D02,HY-A0004,Decitabine,5-Aza-2'-deoxycytidine; 5-AZA-CdR; NSC 127716,2353-33-5,228.21,Apoptosis; DNA Methyltransferase; Nucleoside Antimetabolite/Analog,Apoptosis; Cell Cycle/DNA Damage; Epigenetics,Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and a DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell apoptosis. Decitabine has potent anticancer activity[1][2].,C8H12N4O4,H2O : 20 mg/mL (87.64 mM; Need ultrasonic); DMSO : ≥ 50 mg/mL (219.10 mM),10mM,Cancer,Launched,O[C@H]1C[C@H](N2C(N=C(N)N=C2)=O)O[C@@H]1CO
,,,,,,,,,,,,,,,,dnmts,tsa,HY-L025-49,F10,HY-15144,Trichostatin A,TSA,58880-19-6,302.37,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].",C17H22N2O3,DMSO : 25 mg/mL (82.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
,,,,,,,,,,,,,,,,dnmts,resveratrol,HY-L025-56,C11,HY-16561,Resveratrol,trans-Resveratrol; SRT501,501-36-0,228.24,Antibiotic; Apoptosis; Autophagy; Bacterial; Fungal; IKK; Keap1-Nrf2; Mitophagy; Sirtuin,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; NF-κB,"Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].",C14H12O3,DMSO : 100 mg/mL (438.14 mM; Need ultrasonic); Ethanol : 50 mg/mL (219.07 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,OC1=CC=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1
,,,,,,,,,,,,,,,,dnmts,trichostatin a,HY-L025-49,F10,HY-15144,Trichostatin A,TSA,58880-19-6,302.37,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].",C17H22N2O3,DMSO : 25 mg/mL (82.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
,,,,,,,,,,,,,,,,dnmts,egcg,HY-L025-38,C03,HY-13653,(-)-Epigallocatechin Gallate,EGCG; Epigallocatechol Gallate,989-51-5,458.37,Apoptosis; Endogenous Metabolite,Apoptosis; Metabolic Enzyme/Protease,"(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].",C22H18O11,DMSO : ≥ 30 mg/mL (65.45 mM); H2O : 20 mg/mL (43.63 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
,,,,,,,,,,,,,,,,dnmts,genistein,HY-L025-45,H04,HY-14596,Genistein,NPI 031L,446-72-0,270.24,Apoptosis; Autophagy; EGFR; Endogenous Metabolite,Apoptosis; Autophagy; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,"Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.",C15H10O5,DMSO : ≥ 100 mg/mL (370.04 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 4,OC1=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=CC(O)=C1
,,,,,,,,,,,,,,,,dnmts,5 azacytidine,HY-L025-10,H06,HY-10586,5-Azacytidine,Azacitidine; 5-AzaC; Ladakamycin,320-67-2,244.2,Antibiotic; Autophagy; Bacterial; DNA Methyltransferase; Nucleoside Antimetabolite/Analog,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Epigenetics,5-Azacytidine (Azacitidine; 5-AzaC; Ladakamycin) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation. 5-Azacytidine is incorporated into DNA to covalently trap DNA methyltransferases and contributes to reverse epigenetic changes[1][2]. 5-Azacytidine induces cell autophagy[4].,C8H12N4O5,DMSO : ≥ 31 mg/mL (126.95 mM); H2O : 33.33 mg/mL (136.49 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)N=C2)=O)O1
,,,,,,,,,,,,,,,,dnmts,rg108,HY-L025-38,A03,HY-13642,RG108,N-Phthalyl-L-tryptophan,48208-26-0,334.33,DNA Methyltransferase,Epigenetics,"RG108 (N-Phthalyl-L-tryptophan) is a non-nucleoside DNA methyltransferases (DNMTs) inhibitor (IC50=115 nM) that blocks the DNMTs active site. RG108 (N-Phthalyl-L-tryptophan) causes demethylation and reactivation of tumor suppressor genes, but it does not affect the methylation of centromeric satellite sequences[1][2][3].",C19H14N2O4,H2O : < 0.1 mg/mL (insoluble); DMSO : 100 mg/mL (299.11 mM; Need ultrasonic),10mM,Cancer,No Development Reported,O=C(N1[C@H](C(O)=O)CC2=CNC3=C2C=CC=C3)C4=CC=CC=C4C1=O
,,,,,,,,,,,,,,,,dnmts,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,hh,cyclopamine,HY-L025-57,F03,HY-17024,Cyclopamine,11-Deoxojervine,4449-51-8,411.62,Endogenous Metabolite; Hedgehog; Smo,Metabolic Enzyme/Protease; Stem Cell/Wnt,Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay. Cyclopamine is also a selective Smo inhibitor.,C27H41NO2,DMSO : 10 mg/mL (24.29 mM; ultrasonic and warming and heat to 80°C); Ethanol : 20 mg/mL (48.59 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CC1=C2[C@@]([C@@]3([H])[C@]([C@@]4(C(C[C@@H](O)CC4)=CC3)C)([H])C2)([H])CC[C@@]15[C@@H]([C@@]6([H])[C@](C[C@H](C)CN6)([H])O5)C
,,,,,,,,,,,,,,,,hh,bms 833923,HY-L025-40,B09,HY-13809,BMS-833923,XL-139,1059734-66-5,473.57,Apoptosis; Smo,Apoptosis; Stem Cell/Wnt,"BMS-833923 (XL-139) is an orally bioavailable small-molecule inhibitor of Smoothened  with potential antineoplastic activity;  inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner with an IC50 of 21 nM.
IC50 Value: 6-35 nM [1]
Target: Smoothened
SMO antagonist BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway.
in vitro: In vitro, BMS-833923 inhibits the expression of downstream effectors in the HH pathway (GLI1 and PTCH1) in cell lines that express wild-type SMO and those which express activated mutant forms of SMO (IC50values of 6-35 nM). In FACS-based binding assays, BMS-833923 inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner with an IC50 of 21 nM [1]. 
in vivo: Pharmacodynamic studies show that BMS-833923 robustly inhibits HH pathway activity with along duration of action after a single oral dose in medulloblastoma and pancreatic carcinoma xenograft models. The pharmacodynamic effects of BMS-833923 observed in these models translate into tumor growth inhibition at well-tolerated doses [1].
Clinical trial: Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923). Phase 2",C30H27N5O,DMSO : 50 mg/mL (105.58 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC(CNC)=CC=C1C)C2=CC=C(NC3=NC(C4=CC=CC=C4)=C5C=CC=CC5=N3)C=C2
,,,,,,,,,,,,,,,,hh,curcumin,HY-L025-71,F04,HY-N0005,Curcumin,Diferuloylmethane; Natural Yellow 3; Turmeric yellow,458-37-7,368.38,Autophagy; Epigenetic Reader Domain; Ferroptosis; Histone Acetyltransferase; Influenza Virus; Keap1-Nrf2; Mitophagy,Anti-infection; Apoptosis; Autophagy; Epigenetics; NF-κB,"Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.",C21H20O6,DMSO : 100 mg/mL (271.46 mM; Need ultrasonic),10mM,Cancer,Phase 4,O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2
,,,,,,,,,,,,,,,,hh,lde225,HY-L025-56,D11,HY-16582A,Sonidegib,Erismodegib; LDE225; NVP-LDE225,956697-53-3,485.5,Smo,Stem Cell/Wnt,"Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively[1].",C26H26F3N3O3,DMSO : 50 mg/mL (102.99 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=C(C)C(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)NC3=CC=C(N=C3)N4C[C@@H](C)O[C@@H](C)C4
,,,,,,,,,,,,,,,,hh,nvp lde225,HY-L025-56,D11,HY-16582A,Sonidegib,Erismodegib; LDE225; NVP-LDE225,956697-53-3,485.5,Smo,Stem Cell/Wnt,"Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively[1].",C26H26F3N3O3,DMSO : 50 mg/mL (102.99 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=C(C)C(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)NC3=CC=C(N=C3)N4C[C@@H](C)O[C@@H](C)C4
,,,,,,,,,,,,,,,,hh,sonidegib,HY-L025-56,D11,HY-16582A,Sonidegib,Erismodegib; LDE225; NVP-LDE225,956697-53-3,485.5,Smo,Stem Cell/Wnt,"Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively[1].",C26H26F3N3O3,DMSO : 50 mg/mL (102.99 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=C(C)C(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)NC3=CC=C(N=C3)N4C[C@@H](C)O[C@@H](C)C4
,,,,,,,,,,,,,,,,hh,forskolin,HY-L025-51,G04,HY-15371,Forskolin,Coleonol; Colforsin; HL 362,66575-29-9,410.5,Adenylate Cyclase; Autophagy; FXR,Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease,"Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC50 of 41 nM and an EC50 of 0.5 μM for type I adenylyl cyclase[1]. Forskolin is also an inducer of intracellular cAMP formation[2]. Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR[3]. Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy[4][5].",C22H34O7,DMSO : 100 mg/mL (243.61 mM; Need ultrasonic),10mM,Cancer; Endocrinology; Metabolic Disease; Inflammation/Immunology,No Development Reported,O=C1[C@@]2(O)[C@]([C@@H](OC(C)=O)[C@@H](O)[C@@]3([H])C(C)(C)CC[C@H](O)[C@@]32C)(C)O[C@@](C)(C=C)C1
,,,,,,,,,,,,,,,,hh,glasdegib,HY-L025-56,A02,HY-16391,Glasdegib,PF-04449913,1095173-27-5,374.44,Smo,Stem Cell/Wnt,Glasdegib (PF-04449913) is a potent and orally bioavailable smoothened inhibitor. Glasdegib (PF-04449913) binds to human SMO (amino acids 181-787) with an IC50 of 4 nM[1].,C21H22N6O,DMSO : ≥ 83.33 mg/mL (222.55 mM),10mM,Cancer,Launched,O=C(NC1=CC=C(C#N)C=C1)N[C@H]2C[C@H](C3=NC4=CC=CC=C4N3)N(C)CC2
,,,,,,,,,,,,,,,,hh,gdc 0449,HY-L025-10,A09,HY-10440,Vismodegib,GDC-0449,879085-55-9,421.3,Autophagy; Hedgehog,Autophagy; Stem Cell/Wnt,"Vismodegib (GDC-0449) is an orally active hedgehog pathway inhibitor with an IC50 of 3 nM. Vismodegib also inhibits P-gp, ABCG2 with IC50 values of 3.0 μM and 1.4 μM, respectively[1][2].",C19H14Cl2N2O3S,DMSO : 50 mg/mL (118.68 mM; Need ultrasonic); Ethanol : 3.33 mg/mL (7.90 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CC=C(C=C1Cl)S(=O)(C)=O)NC2=CC=C(C(C3=NC=CC=C3)=C2)Cl
,,,,,,,,,,,,,,,,hh,gant 61,HY-L025-41,C05,HY-13901,GANT 61,NSC 136476,500579-04-4,429.6,Autophagy; Gli,Autophagy; Stem Cell/Wnt,GANT 61 is an inhibitor of Gli1 and Gli2 targeting the Hedgehog/GLI pathway.,C27H35N5,DMSO : 25 mg/mL (58.19 mM; Need ultrasonic); Ethanol : 66.67 mg/mL (155.19 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C)C1=CC=CC=C1CN2C(C3=CC=NC=C3)N(CC4=CC=CC=C4N(C)C)CCC2
,,,,,,,,,,,,,,,,hh,itraconazole,HY-L025-58,E06,HY-17514,Itraconazole,R51211,84625-61-6,705.63,Antibiotic; Autophagy; Bacterial; Cytochrome P450; Fungal; Hedgehog,Anti-infection; Autophagy; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor[1][2][3][4].",C35H38Cl2N8O4,DMSO : 6.25 mg/mL (8.86 mM; Need ultrasonic),2mM,Infection; Cancer,Launched,ClC1=C(C=CC(Cl)=C1)[C@@]2(O[C@@H](COC3=CC=C(N4CCN(C5=CC=C(N(C=NN6C(C)CC)C6=O)C=C5)CC4)C=C3)CO2)CN7C=NC=N7
,,,,,,,,,,,,,,,,hh,vismodegib,HY-L025-10,A09,HY-10440,Vismodegib,GDC-0449,879085-55-9,421.3,Autophagy; Hedgehog,Autophagy; Stem Cell/Wnt,"Vismodegib (GDC-0449) is an orally active hedgehog pathway inhibitor with an IC50 of 3 nM. Vismodegib also inhibits P-gp, ABCG2 with IC50 values of 3.0 μM and 1.4 μM, respectively[1][2].",C19H14Cl2N2O3S,DMSO : 50 mg/mL (118.68 mM; Need ultrasonic); Ethanol : 3.33 mg/mL (7.90 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CC=C(C=C1Cl)S(=O)(C)=O)NC2=CC=C(C(C3=NC=CC=C3)=C2)Cl
,,,,,,,,,,,,,,,,deubiquitinase,wp1130,HY-L025-33,F06,HY-13264,Degrasyn,WP1130,856243-80-6,384.27,Apoptosis; Autophagy; Bcr-Abl; Deubiquitinase,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK,"Degrasyn (WP1130) is a cell-permeable deubiquitinase (DUB) inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37. Degrasyn has been shown to downregulate the antiapoptotic proteins Bcr-Abl and JAK2.",C19H18BrN3O,DMSO : 100 mg/mL (260.23 mM; Need ultrasonic),10mM,Cancer,No Development Reported,BrC1=CC=CC(/C=C(C(N[C@H](C2=CC=CC=C2)CCC)=O)\C#N)=N1
,,,,,,,,,,,,,,,,deubiquitinase,pr 619,HY-L025-40,C02,HY-13814,PR-619,,2645-32-1,223.28,Apoptosis; Autophagy; Deubiquitinase,Apoptosis; Autophagy; Cell Cycle/DNA Damage,"PR-619 is a broad-range and reversible DUB inhibitor with EC50s of 3.93, 4.9, 6.86, 7.2, and 8.61 μM for USP4, USP8, USP7, USP2, and USP5, respectively. PR-619 induces ER Stress and ER-Stress related apoptosis[1][2][3][4].",C7H5N5S2,DMSO : ≥ 21 mg/mL (94.05 mM),10mM,Cancer,No Development Reported,NC1=C(SC#N)C=C(SC#N)C(N)=N1
,,,,,,,,,,,,,,,,treg,lenalidomide,HY-L025-65,C11,HY-A0003B,Lenalidomide (hemihydrate),CC-5013 hemihydrate,847871-99-2,268.27,Apoptosis; Ligands for E3 Ligase; Molecular Glues,Apoptosis; PROTAC,"Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].",C13H14N3O3.5,DMSO : 50 mg/mL (186.38 mM; Need ultrasonic); H2O : 0.1 mg/mL (0.37 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1N(C2C(NC(CC2)=O)=O)CC3=C(N)C=CC=C31.[0.5 H2O]
,,,,,,,,,,,,,,,,treg,sunitinib,HY-L025-7,F10,HY-10255A,Sunitinib,SU 11248,557795-19-4,398.47,Apoptosis; Autophagy; IRE1; Mitophagy; PDGFR; VEGFR,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK,"Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].",C22H27FN4O2,DMSO : 20.83 mg/mL (52.27 mM; ultrasonic and warming and heat to 80°C),10mM,Cancer,Launched,O=C(NCCN(CC)CC)C1=C(NC(/C=C2C(NC3=C\2C=C(C=C3)F)=O)=C1C)C
,,,,,,,,,,,,,,,,treg,baicalin,HY-L025-73,B03,HY-N0197,Baicalin,Baicalein 7-O-β-D-glucuronide,21967-41-9,446.36,Autophagy; HIV; NF-κB,Anti-infection; Autophagy; NF-κB,"Baicalin, as a flavonoid glycoside, is an allosteric carnitine palmityl transferase 1 (CPT1) activator. Baicalin reduces the expression of NF-κB[1][2][3].",C21H18O11,DMSO : ≥ 100 mg/mL (224.03 mM); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Inflammation/Immunology; Cancer,Launched,O[C@H]([C@H]([C@@H]([C@@H](C(O)=O)O1)O)O)[C@@H]1OC2=C(O)C(O)=C3C(C=C(C4=CC=CC=C4)OC3=C2)=O
,,,,,,,,,,,,,,,,hdac2,theophylline,HY-L025-69,F08,HY-B0809,Theophylline,"1,3-Dimethylxanthine; Theo-24",58-55-9,180.16,Adenosine Receptor; Apoptosis; Endogenous Metabolite; HDAC; Interleukin Related; Phosphodiesterase (PDE); TNF Receptor,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease,"Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research[1][2][3][4][5].",C7H8N4O2,H2O : 5 mg/mL (27.75 mM; Need ultrasonic); DMSO : 11.11 mg/mL (61.67 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(N1C)N(C)C2=C(N=CN2)C1=O
,,,,,,,,,,,,,,,,hdac2,trichostatin a,HY-L025-49,F10,HY-15144,Trichostatin A,TSA,58880-19-6,302.37,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].",C17H22N2O3,DMSO : 25 mg/mL (82.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
,,,,,,,,,,,,,,,,hdac2,ms 275,HY-L025-23,G06,HY-12163,Entinostat,MS-275; SNDX-275,209783-80-2,376.41,Apoptosis; Autophagy; HDAC,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Entinostat is an oral and selective class I HDAC inhibitor, with IC50s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively.",C21H20N4O3,DMSO : 50 mg/mL (132.83 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,O=C(NCC1=CC=C(C=C1)C(NC2=CC=CC=C2N)=O)OCC3=CC=CN=C3
,,,,,,,,,,,,,,,,hdac2,vorinostat,HY-L025-7,E02,HY-10221,Vorinostat,SAHA; Suberoylanilide hydroxamic acid,149647-78-9,264.32,Apoptosis; Autophagy; Filovirus; HDAC; HPV; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].",C14H20N2O3,DMSO : ≥ 100 mg/mL (378.33 mM),10mM,Cancer; Infection,Launched,O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O
,,,,,,,,,,,,,,,,hdac2,saha,HY-L025-7,E02,HY-10221,Vorinostat,SAHA; Suberoylanilide hydroxamic acid,149647-78-9,264.32,Apoptosis; Autophagy; Filovirus; HDAC; HPV; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].",C14H20N2O3,DMSO : ≥ 100 mg/mL (378.33 mM),10mM,Cancer; Infection,Launched,O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O
,,,,,,,,,,,,,,,,hdac2,tsa,HY-L025-49,F10,HY-15144,Trichostatin A,TSA,58880-19-6,302.37,HDAC,Cell Cycle/DNA Damage; Epigenetics,"Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC[1].",C17H22N2O3,DMSO : 25 mg/mL (82.68 mM; Need ultrasonic),10mM,Cancer,No Development Reported,CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C
,,,,,,,,,,,,,,,,hdac2,suberoylanilide hydroxamic acid,HY-L025-7,E02,HY-10221,Vorinostat,SAHA; Suberoylanilide hydroxamic acid,149647-78-9,264.32,Apoptosis; Autophagy; Filovirus; HDAC; HPV; Mitophagy,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].",C14H20N2O3,DMSO : ≥ 100 mg/mL (378.33 mM),10mM,Cancer; Infection,Launched,O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O
,,,,,,,,,,,,,,,,aldehyde dehydrogenase,pargyline,HY-L025-65,F11,HY-A0091A,Pargyline,,555-57-7,159.23,Monoamine Oxidase,Neuronal Signaling,"Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline has antihypertensive and anticancer activities[1][2][3].",C11H13N,DMSO : 100 mg/mL (628.02 mM; Need ultrasonic),10mM,Cancer; Cardiovascular Disease,Launched,C#CCN(C)CC1=CC=CC=C1
,,,,,,,,,,,,,,,,aldehyde dehydrogenase,disulfiram,HY-L025-67,C08,HY-B0240,Disulfiram,Tetraethylthiuram disulfide; TETD,97-77-8,296.54,Aldehyde Dehydrogenase (ALDH); Apoptosis; Interleukin Related; Pyroptosis,Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease,"Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of?aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram?+?Cu2+ increases intracellular ROS levels triggering apoptosis of ovarian cancer stem cells[1-6].",C10H20N2S4,DMSO : 75 mg/mL (252.92 mM; Need ultrasonic),10mM,Metabolic Disease; Cancer,Launched,S=C(SSC(N(CC)CC)=S)N(CC)CC
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,